url	PharmGKB ID	Name	Source	Biomarker Flag	Testing Level	Has Prescribing Info	Has Dosing Info	Has Alternate Drug	Has Other Prescribing Guidance	Cancer Genome	Prescribing	Chemicals	Genes	Variants/Haplotypes	Latest History Date (YYYY-MM-DD)	Extracted Summary
https://www.pharmgkb.org/labelAnnotation/PA166269401	PA166269401	Annotation of EMA Label for nateglinide and CYP2C9	EMA									nateglinide	CYP2C9		11/21/2023	Nateglinide (STARLIX) was withdrawn from use in the European Union.
https://www.pharmgkb.org/labelAnnotation/PA166269701	PA166269701	Annotation of EMA Label for glycerol phenylbutyrate and ARG1, ASL, ASS1, CPS1, OTC	EMA		Testing Required							glycerol phenylbutyrate	ARG1; ASL; ASS1; CPS1; OTC		8/7/2024	Glycerol phenylbutyrate (RAVICTI) is a nitrogen-binding agent indicated for chronic management of patients with urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS1), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS1)), argininosuccinate lyase (ASL), arginase I (ARG1) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.
https://www.pharmgkb.org/labelAnnotation/PA166273281	PA166273281	Annotation of EMA Label for nusinersen and SMN2	EMA									nusinersen	SMN2		8/17/2023	Nusinersen is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide EMA-indicated for the treatment of the treatment of 5q Spinal Muscular Atrophy.
https://www.pharmgkb.org/labelAnnotation/PA166273261	PA166273261	Annotation of EMA Label for ospemifene and CYP2C9	EMA									ospemifene	CYP2C9		8/16/2024	The EMA product information contains information about drug-drug interactions and contraindicates strong/moderate CYP3A4 inhibitors in patients who are known or suspected CYP2C9 poor metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166271261	PA166271261	Annotation of EMA Label for tegafur / gimeracil / oteracil and DPYD	EMA		Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	tegafur / gimeracil / oteracil	DPYD	DPYD c.1129-5923C>G, c.1236G>A (HapB3); DPYD c.1679T>G (*13); DPYD c.1905+1G>A (*2A); DPYD c.2846A>T		The EMA-approved label for tegafur/gimeracil/oteracil (Teysuno) notes that patients who have complete dihydropyrimidine dehydrogenase (DPD) deficiency are at high risk of life-threatening or fatal toxicity, and patients who have partial DPD deficiency are at increased risk of severe and potentially life-threatening toxicity. Phenotype and/or genotype testing prior to initiation of treatment with Teysuno is recommended.
https://www.pharmgkb.org/labelAnnotation/PA166273521	PA166273521	Annotation of EMA Label for ipilimumab and ALK, CD274, EGFR	EMA		Testing Required					Cancer Genome		ipilimumab	ALK; CD274; EGFR		4/21/2024	Ipilimumab (Yervoy) is an anti-CTLA-4 monoclonal antibody, EMA indicated for treatment of various cancers including metastatic non-small cell lung cancer in adults whose tumors have no sensitising EGFR mutation or ALK translocation and melanoma with low PD-L1 (CD274) expression and unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumor cell PD-L1 expression ≥ 1%.
https://www.pharmgkb.org/labelAnnotation/PA166273423	PA166273423	Annotation of EMA Label for lutetium (177Lu) oxodotreotide and SSTR1, SSTR2, SSTR3, SSTR4, SSTR5	EMA		Testing Required					Cancer Genome		lutetium (177Lu) oxodotreotide	SSTR1; SSTR2; SSTR3; SSTR4; SSTR5		8/8/2024	Lutetium (177Lu) oxodotreotide is a radiopharmaceutical EMA indicated to treat gastroenteropancreatic neuroendocrine tumors that overexpress somatostatin receptors (which are coded for by the SSTR family of genes). The overexpression of somatostatin receptors in tumor tissues must be confirmed before starting treatment.
https://www.pharmgkb.org/labelAnnotation/PA166273501	PA166273501	Annotation of EMA Label for ipilimumab and CTLA4, HLA-A	EMA		No Clinical PGx							ipilimumab	CTLA4; HLA-A	HLA-A*02:01	8/7/2024	Ipilimumab (Yervoy) is an anti-CTLA-4 monoclonal antibody EMA indicated for treatment of various cancers. The product information also has information about HLA-A*02:01 in trials and lack of implication in adverse reactions.
https://www.pharmgkb.org/labelAnnotation/PA166272241	PA166272241	Annotation of HCSC Label for upadacitinib and CYP2D6	HCSC		No Clinical PGx							upadacitinib	CYP2D6			Upadacitinib (Rinvoq) is indicated for moderate to severe active rheumatoid arthritis or active psoriatic arthritis in adults, or refractory moderate to severe atopic dermatitis in adults and adolescents 12 years of age and older. The HCSC labels states that upadacitinib is metabolized by CYP3A4 with a minor contribution from CYP2D6. However, CYP2D6 metabolic phenotype had no effect on upadacitinib pharmacokinetics.
https://www.pharmgkb.org/labelAnnotation/PA166272321	PA166272321	Annotation of HCSC Label for tipiracil / trifluridine and ERBB2, KRAS	HCSC							Cancer Genome		tipiracil / trifluridine	ERBB2; KRAS		8/27/2023	The HCSC label for tipiracil / trifluridine (Lonsurf) states that it is indicated for patients who have failed other targeted therapies including those for KRAS negative metastatic colorectal cancer and HER2 positive (ERBB2) metastatic gastric or gastroesophageal junction cancers. Therefore testing was required for those prior therapies.
https://www.pharmgkb.org/labelAnnotation/PA166271361	PA166271361	Annotation of HCSC Label for capmatinib and MET	HCSC		Testing Required					Cancer Genome		capmatinib	MET		4/16/2024	The HCSC label for capmatinib (TABRECTA) states that capmatinib is indicated for treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations as detected by a validated test prior to treatment.
https://www.pharmgkb.org/labelAnnotation/PA166272581	PA166272581	Annotation of HCSC Label for sotorasib and KRAS	HCSC		Testing Required					Cancer Genome		sotorasib	KRAS	rs121913530	8/13/2024	Sotorasib (LUMAKRAS) is HCSC indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received at least one prior systemic therapy. Presence of the KRAS G12C mutation must be confirmed using a validated test prior to initiation of therapy.
https://www.pharmgkb.org/labelAnnotation/PA166272601	PA166272601	Annotation of EMA Label for sotorasib and KRAS	EMA		Testing Required					Cancer Genome		sotorasib	KRAS	rs121913530	8/13/2024	Sotorasib is EMA indicated for the treatment of adults with advanced non-small cell lung cancer (NSCLC) where KRAS G12C mutation have been confirmed using a validated test.
https://www.pharmgkb.org/labelAnnotation/PA166271481	PA166271481	Annotation of HCSC Label for escitalopram and CYP2C19	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	escitalopram	CYP2C19		8/14/2024	The HCSC-approved drug label for escitalopram (ACH-ESCITALOPRAM) notes that the metabolism of escitalopram is mainly mediated by CYP2C19. For patients who are known to be poor metabolizers with respect to CYP2C19, an initial dose of 5 mg daily is recommended. Depending on the individual response, the dose may be increased to a maximum of 10 mg.
https://www.pharmgkb.org/labelAnnotation/PA166184114	PA166184114	Annotation of Swissmedic Label for capecitabine and DPYD	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	capecitabine	DPYD		2/28/2023	The Swiss drug label for capecitabine (Xeloda) states that capecitabine is contraindicated in patients with low or no DPYD activity. Patients with partial DPYD deficiency may be given capecitabine at a significantly reduced dose if the benefit of the drug is deemed to outweigh the risks.
https://www.pharmgkb.org/labelAnnotation/PA166184117	PA166184117	Annotation of Swissmedic Label for carbasalate calcium and G6PD	Swissmedic		Actionable PGx							carbasalate calcium	G6PD		9/30/2022	The Swiss drug label for carbasalate calcium (Alcacyl) states that carbasalate calcium should be used with caution in patients with G6PD deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166184126	PA166184126	Annotation of Swissmedic Label for codeine and CYP2D6	Swissmedic		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	codeine	CYP2D6			"The Swiss drug label for codeine (Codein Knoll) states that codeine is contraindicated in patients with a CYP2D6 ultrarapid metabolizer phenotype.CYP2D6 ""slow metabolizers"" may experience reduced or no analgesia from codeine."
https://www.pharmgkb.org/labelAnnotation/PA166184405	PA166184405	Annotation of Swissmedic Label for brexpiprazole and CYP2D6	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	brexpiprazole	CYP2D6			The Swiss drug label for brexpiprazole (REXULTI) states that extensive CYP2D6 metabolizers receiving both CYP3A4 and CYP2D6 inhibitors, or slow CYP2D6 metabolizers receiving strong CYP3A4 inhibitors, are expected to have a 4-5-fold increase in brexpiprazole concentrations. Therefore, the dosage of REXULTI in these cases should be reduced to a quarter of the recommended dose.
https://www.pharmgkb.org/labelAnnotation/PA166184116	PA166184116	Annotation of Swissmedic Label for carbamazepine and HLA-B	Swissmedic		Testing Required	Prescribing Info		Alternate Drug			Prescribing	carbamazepine	HLA-B	HLA-B*15:02	2/28/2023	The Swiss drug label for carbamazepine (Tegretol) states that patients from certain ancestries should be tested for the presence of the HLA-B*15:02 allele prior to beginning carbamazepine therapy. Patients carrying the HLA-B*15:02 allele should not be treated with carbamazepine unless the benefits greatly outweigh the risks.
https://www.pharmgkb.org/labelAnnotation/PA166272701	PA166272701	Annotation of EMA Label for rimegepant and CYP2C9	EMA		No Clinical PGx							rimegepant	CYP2C9		8/24/2023	N/A
https://www.pharmgkb.org/labelAnnotation/PA166272721	PA166272721	Annotation of EMA Label for risdiplam and SMN1, SMN2	EMA		Testing Required							risdiplam	SMN1; SMN2		8/13/2024	Risdiplam is EMA indicated for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies.
https://www.pharmgkb.org/labelAnnotation/PA166271541	PA166271541	Annotation of EMA Label for sacituzumab govitecan and UGT1A1	EMA		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	sacituzumab govitecan	UGT1A1	UGT1A1*28	8/13/2024	The EMA label for sacituzumab govitecan-hziy (TRODELVY) states that patients with known reduced UGT1A1 activity should be closely monitored for adverse reactions.
https://www.pharmgkb.org/labelAnnotation/PA166273981	PA166273981	Annotation of HCSC Label for asciminib and ABL1, BCR	HCSC		Testing Required					Cancer Genome		asciminib	ABL1; BCR		8/26/2024	The HCSC-approved drug label for asciminib (SCEMBLIX) states that it is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with two or more tyrosine kinase inhibitors.
https://www.pharmgkb.org/labelAnnotation/PA166184506	PA166184506	Annotation of Swissmedic Label for dolutegravir / abacavir / lamivudine and HLA-B	Swissmedic		Testing Required	Prescribing Info					Prescribing	dolutegravir / abacavir / lamivudine	HLA-B	HLA-B*57:01	2/28/2023	The Swiss drug label for dolutegravir / abacavir / lamivudine (Triumeq) states that patients should be screened for the presence of HLA-B*57:01 prior to starting treatment with abacavir. Triumeq is contraindicated in carriers of the HLA-B*57:01 allele.
https://www.pharmgkb.org/labelAnnotation/PA166184122	PA166184122	Annotation of Swissmedic Label for ciprofloxacin and G6PD	Swissmedic		Actionable PGx							ciprofloxacin	G6PD			The Swiss drug label for ciprofloxacin (Ciproxin) states that ciprofloxacin should be used with caution in patients with G6PD deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166184124	PA166184124	Annotation of Swissmedic Label for clomipramine and CYP2D6	Swissmedic		Actionable PGx							clomipramine	CYP2D6			The Swiss drug label for clomipramine (Anafranil) states that patients with reduced CYP2D6 activity may have high plasma concentrations of desmethylclomipramine, a metabolite of clomipramine.
https://www.pharmgkb.org/labelAnnotation/PA166184133	PA166184133	Annotation of Swissmedic Label for dexlansoprazole and CYP2C19	Swissmedic		Actionable PGx							dexlansoprazole	CYP2C19			The Swiss drug label for dexlansoprazole (Dexilant) states that CYP2C19 poor metabolizers have increased exposure to dexlansoprazole compared to normal metabolizers. CYP2C19 metabolizer phenotype can also affect the nature of some drug-drug interactions involving dexlansoprazole.
https://www.pharmgkb.org/labelAnnotation/PA166184134	PA166184134	Annotation of Swissmedic Label for dextromethorphan and CYP2D6	Swissmedic		Actionable PGx							dextromethorphan	CYP2D6			"The Swiss drug label for dextromethorphan (Bexin) states that metabolism and elimination of dextromethorphan are delayed in CYP2D6 ""slow metabolizers""."
https://www.pharmgkb.org/labelAnnotation/PA166184442	PA166184442	Annotation of Swissmedic Label for duloxetine and CYP2D6	Swissmedic		Actionable PGx							duloxetine	CYP2D6			The Swiss drug label for duloxetine (Cymbalta) states that CYP2D6 metabolizer status contributes to inter-individual differences in pharmacokinetics.
https://www.pharmgkb.org/labelAnnotation/PA166184449	PA166184449	Annotation of Swissmedic Label for flucytosine and DPYD	Swissmedic		Testing Recommended							flucytosine	DPYD			The Swiss drug label for flucytosine (Ancotil) cautions about risk for toxicity of flucytosine in patients with DPYD deficiency if nucleoside analogues have been given and states that DPYD testing is indicated. It does not discuss testing in patients receiving flucytosine only.
https://www.pharmgkb.org/labelAnnotation/PA166183786	PA166183786	Annotation of Swissmedic Label for amlodipine / atorvastatin / perindopril arginine and G6PD, SLCO1B1	Swissmedic		Actionable PGx							amlodipine / atorvastatin / perindopril arginine	G6PD; SLCO1B1	rs4149056		The Swiss drug label for amlodipine, atorvastatin and perindopril arginine (Triveram) states that patients with G6PD deficiency may experience hemolytic anemia. Additionally, patients with the SLCO1B1 rs4149056 CC genotype may have higher atorvastatin exposure which may increase the risk of rhabdomyolysis.
https://www.pharmgkb.org/labelAnnotation/PA166271561	PA166271561	Annotation of HCSC Label for sacituzumab govitecan and UGT1A1	HCSC		Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	sacituzumab govitecan	UGT1A1	UGT1A1*28	8/13/2024	The HCSC label for sacituzumab govitecan-hziy (TRODELVY) states that patients homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are at increased risk for neutropenia, febrile neutropenia, and anemia; and may be at increased risk for other adverse reactions when treated with TRODELVY, and close monitoring are recommended for patients with known reduced UGT1A1 activity for adverse reactions.
https://www.pharmgkb.org/labelAnnotation/PA166274002	PA166274002	Annotation of HCSC Label for blinatumomab and ABL1, BCR, CD19	HCSC							Cancer Genome		blinatumomab	ABL1; BCR; CD19		5/21/2024	The HCSC-approved drug label for blinatumomab (BLINCYTO) states that it is indicated for the treatment of adult patients with B-cell precursor acute lymphoblastic leukemia (ALL) and pediatric patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL.
https://www.pharmgkb.org/labelAnnotation/PA166272781	PA166272781	Annotation of EMA Label for selpercatinib and RET	EMA		Testing Required					Cancer Genome		selpercatinib	RET		8/13/2024	Selpercatinib is EMA indicated for cancers with a RET gene fusion (NSCLC and non-medullary thyroid cancer) or mutation (medullary thyroid cancer). The presence of a RET gene fusion or mutation should be confirmed by a validated test prior to initiation of treatment.
https://www.pharmgkb.org/labelAnnotation/PA166272801	PA166272801	Annotation of EMA Label for setmelanotide and LEPR, PCSK1, POMC	EMA		Testing Required							setmelanotide	LEPR; PCSK1; POMC		8/13/2024	Setmelanotide is EMA indicated for the treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above.
https://www.pharmgkb.org/labelAnnotation/PA166272821	PA166272821	Annotation of EMA Label for siponimod and CYP2C9	EMA		Testing Required	Prescribing Info	Dosing Info				Prescribing	siponimod	CYP2C9	CYP2C9*1; CYP2C9*11; CYP2C9*2; CYP2C9*3; CYP2C9*5; CYP2C9*6; CYP2C9*8		Siponimod is contraindicated for individuals with CYP2C9*3/*3 genotype and does adjustments are provided for some genotypes, other genotypes are discussed but no dosing advice given.
https://www.pharmgkb.org/labelAnnotation/PA166272841	PA166272841	Annotation of EMA Label for sodium oxybate and ALDH5A1	EMA		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	sodium oxybate	ALDH5A1		8/14/2024	Sodium oxybate is EMA indicated for treatment of narcolepsy with cataplexy in adult patients, adolescents and children from the age of 7 years. It is contraindicated in patients with succinic semialdehyde dehydrogenase deficiency, a rare metabolic disorder caused by homozygous or compound heterozygous mutation in the ALDH5A1 gene see OMIM:271980.
https://www.pharmgkb.org/labelAnnotation/PA166273101	PA166273101	Annotation of EMA Label for pitolisant and CYP2D6	EMA		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	pitolisant	CYP2D6			Pitolisant is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA). There is information about dosage adjustments in CYP2D6 poor metabolizers and CYP2D6 rapid metabolizers. CYP2D6 genotypes are not specified.
https://www.pharmgkb.org/labelAnnotation/PA166278442	PA166278442	Annotation of HCSC Label for cemiplimab-rwlc and ALK, CD274, EGFR, ROS1	HCSC		Testing Required					Cancer Genome		cemiplimab-rwlc	ALK; CD274; EGFR; ROS1		4/16/2024	The HCSC-approved drug label for cemiplimab (LIBTAYO) states that it is indicated for the first-line treatment of patients with non-small cell lung cancer whose tumors express PD-L1 in more than 50% of tumor cells, with no EGFR, ALK or ROS1 aberrations. PD-L1 is encoded by the CD274 gene.
https://www.pharmgkb.org/labelAnnotation/PA166278601	PA166278601	Annotation of HCSC Label for selpercatinib and RET	HCSC		Testing Required					Cancer Genome		selpercatinib	RET		8/13/2024	Selpercatinib is HCSC approved for certain RET-fusion positive or RET-mutant cancers. The presence of a RET gene fusion (for patients with NSCLC or thyroid cancer) or a RET gene mutation (for patients with MTC) should be confirmed using a validated test before starting treatment with RETEVMO.
https://www.pharmgkb.org/labelAnnotation/PA166184157	PA166184157	Annotation of Swissmedic Label for ofloxacin and G6PD	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	ofloxacin	G6PD		2/28/2023	The Swiss drug label for ofloxacin (Tarivid) states that ofloxacin should be used with caution in patients with G6PD deficiency due to increased risk of hemolytic reactions.
https://www.pharmgkb.org/labelAnnotation/PA166184173	PA166184173	Annotation of Swissmedic Label for oxcarbazepine and HLA-B	Swissmedic		Testing Required	Prescribing Info		Alternate Drug			Prescribing	oxcarbazepine	HLA-B	HLA-B*15:02	2/28/2023	"The Swiss label for oxcarbazepine (Apydan® extent) states that patients who have an increased risk of SJS/TEN should be tested for the presence of the allele HLA-B*1502 before starting treatment with Apydan extent. ""In case of a positive result, Apydan extent should not be used unless the benefit is clearly greater than the risk. It should be considered that HLA-B*1502 is also a risk factor for other antiepileptic drugs""."
https://www.pharmgkb.org/labelAnnotation/PA166184120	PA166184120	Annotation of Swissmedic Label for quinine and G6PD	Swissmedic		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	quinine	G6PD		2/28/2023	The Swiss drug label for quinine (Chininsulfat 250 Hänseler) states that quinine is contraindicated in patients with G6PD deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166184403	PA166184403	Annotation of Swissmedic Label for rasburicase and G6PD	Swissmedic		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	rasburicase	G6PD		2/28/2023	The Swiss drug label for rasburicase (Fasturtec) states that rasburicase is contraindicated in patients with G6PD deficiency due to risk of hemolytic anaemia.
https://www.pharmgkb.org/labelAnnotation/PA166184450	PA166184450	Annotation of Swissmedic Label for fluorouracil and DPYD	Swissmedic		Testing Required							fluorouracil	DPYD			The Swiss drug label for fluorouracil (Efudix) requires DPYD testing in patients receiving fluorouracil who have also been treated with brivudine or other nucleoside analogues.
https://www.pharmgkb.org/labelAnnotation/PA166184452	PA166184452	Annotation of Swissmedic Label for fluoxetine and CYP2D6	Swissmedic		Informative PGx							fluoxetine	CYP2D6			The Swiss drug label for fluoxetine (Fluctine) states that the sum of fluoxetine and active metabolites is comparable between CYP2D6 extensive and poor metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166184461	PA166184461	Annotation of Swissmedic Label for hydroxychloroquine and G6PD	Swissmedic		Actionable PGx							hydroxychloroquine	G6PD			The Swiss drug label for hydroxychloroquine (Plaquenil) states that this drug is contraindicated in patients with G6PD deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166183900	PA166183900	Annotation of Swissmedic Label for moclobemide and CYP2C19	Swissmedic		Actionable PGx							moclobemide	CYP2C19			The Swiss drug label for moclobemid (Aurorix) states that the metabolism of moclobemide may be affected in genetically induced or drug-induced slow metabolisers. Caution is recommended when using moclobemide with drugs that are metabolized by CYP2C19 as moclobemide inhibits this enzyme.
https://www.pharmgkb.org/labelAnnotation/PA166183910	PA166183910	Annotation of Swissmedic Label for nebivolol and CYP2D6	Swissmedic		Informative PGx							nebivolol	CYP2D6			The Swiss drug label for nebivolol (Nebilet) states that nebivolol is metabolized by CYP2D6. However, the active metabolites achieve a similar effect in the rapidly and slowly metabolizing patients.
https://www.pharmgkb.org/labelAnnotation/PA166184221	PA166184221	Annotation of Swissmedic Label for palonosetron and CYP2D6	Swissmedic		Informative PGx							palonosetron	CYP2D6			The Swiss drug label for palonosetron (Aloxi) states that the CYP2D6 genetic polymorphism does not significantly influence the overall body clearance of palonosetron compared to healthy individuals and no dose adjustment is necessary.
https://www.pharmgkb.org/labelAnnotation/PA166184268	PA166184268	Annotation of Swissmedic Label for pazopanib and HLA-B	Swissmedic		Actionable PGx							pazopanib	HLA-B	HLA-B*15:02		The Swiss drug label for pazopanib (Votrient) states that patients who carry the HLA-B*57:01 allele may have a higher risk of votrient-induced ALT elevation.
https://www.pharmgkb.org/labelAnnotation/PA166184395	PA166184395	Annotation of Swissmedic Label for propafenone and CYP2D6	Swissmedic		Actionable PGx							propafenone	CYP2D6			The Swiss drug label for propafenone (Rytmonorm) states that propafenone may be metabolized more slowly in patients with CYP2D6 variants where the 5-hydroxy metabolite is not produced or is produced minimally.
https://www.pharmgkb.org/labelAnnotation/PA166184388	PA166184388	Annotation of Swissmedic Label for losartan and CYP2C9, CYP3A4	Swissmedic		Actionable PGx							losartan	CYP2C9; CYP3A4			The Swiss drug label for losartan (Cosaar) gives information on CYP2C9 and CYP3A4 involvement in formation of active metabolites of losartan.
https://www.pharmgkb.org/labelAnnotation/PA166184390	PA166184390	Annotation of Swissmedic Label for sulfamethoxazole / trimethoprim and G6PD	Swissmedic		Actionable PGx							sulfamethoxazole / trimethoprim	G6PD			The Swiss drug label for sulfamethoxazole and trimethoprim (Bactrim) cautions about use of the drug in patients with G6PD deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166281081	PA166281081	Annotation of EMA Label for eculizumab and AQP4, CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE	EMA									eculizumab	AQP4; CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE		9/28/2023	"Eculizumab (Soliris) is a terminal complement inhibitor that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9.
Soliris is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uremic syndrome (aHUS). Soliris is indicated in adults for the treatment of refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive and neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease.
The presence of antibodies against the AQP4 protein and AchR proteins are biomarkers for treatment indication."
https://www.pharmgkb.org/labelAnnotation/PA166129526	PA166129526	Annotation of HCSC Label for ceritinib and ALK	HCSC		Testing Required					Cancer Genome		ceritinib	ALK		4/16/2024	Ceritinib (ZYKADIA) is indicated as a monotherapy for patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer who have progressed on or were intolerant to crizotinib.
https://www.pharmgkb.org/labelAnnotation/PA166129527	PA166129527	Annotation of HCSC Label for ponatinib and ABI1, BCR	HCSC		Testing Required					Cancer Genome		ponatinib	ABI1; BCR		4/21/2024	Ponatinib (ICLUSIG) is indicated for adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), including CML or Ph+ ALL that is T315I mutation positive. The majority of patients with CML are positive for the Philadelphia chromosome (BCR-ABL1 gene fusion). The T315I mutation is known to cause resistance to other BCR-ABL kinase inhibitors.
https://www.pharmgkb.org/labelAnnotation/PA166129525	PA166129525	Annotation of HCSC Label for carglumic acid and NAGS	HCSC									carglumic acid	NAGS		8/5/2024	Carglumic acid (Carbaglu) indicated for patients for the treatment of acute or chronic hyperammonemia due to deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS).
https://www.pharmgkb.org/labelAnnotation/PA166281722	PA166281722	Annotation of HCSC Label for pralsetinib and RET	HCSC		Testing Required					Cancer Genome		pralsetinib	RET	rs74799832; rs77709286	8/13/2024	Pralsetinib is indicated for the treatment of adult patients with rearranged during transfection (RET) fusion-positive locally advanced unresectable or metastatic non-small cell lung cancer. A validated test is required prior to treatment to identify RET fusion-positive status.
https://www.pharmgkb.org/labelAnnotation/PA166281761	PA166281761	Annotation of HCSC Label for paliperidone and CYP2D6	HCSC		No Clinical PGx							paliperidone	CYP2D6			The HCSC product monograph for paliperidone states that no dose adjustment is needed based on CYP2D6 metabolizer status.
https://www.pharmgkb.org/labelAnnotation/PA166283201	PA166283201	Annotation of HCSC Label for mivacurium and BCHE	HCSC		Actionable PGx							mivacurium	BCHE			The HCSC product monograph for Mivacurium contraindicates use in patients who are known or suspected to be homozygotes for the atypical plasma cholinesterase gene, BCHE.
https://www.pharmgkb.org/labelAnnotation/PA166283221	PA166283221	Annotation of HCSC Label for lumasiran and AGXT	HCSC									lumasiran	AGXT		8/8/2024	The product monograph for lumasiran (OXLUMO) implies that testing for AGXT gene mutation is required since the drug is only approved for treatment of primary hyperoxaluria type 1, a disorder resulting from variants in AGXT, in pediatric and adult patients.
https://www.pharmgkb.org/labelAnnotation/PA166284541	PA166284541	Annotation of EMA Label for encorafenib and HRAS, KRAS, NRAS	EMA		Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance	Cancer Genome	Prescribing	encorafenib	HRAS; KRAS; NRAS		8/14/2024	The product information for encorafenib states that, based on its mechanism of action, it may promote malignancies associated with activation of RAS through mutation or other mechanisms.
https://www.pharmgkb.org/labelAnnotation/PA166283241	PA166283241	Annotation of HCSC Label for lenvatinib	HCSC		Testing Required					Cancer Genome		lenvatinib			4/21/2024	The product monograph for lenvatinib states that it is indicated for patients with cancer that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).
https://www.pharmgkb.org/labelAnnotation/PA166284681	PA166284681	Annotation of EMA Label for pembrolizumab and BRAF	EMA							Cancer Genome		pembrolizumab	BRAF	rs113488022	11/21/2023	Pembrolizumab is an anti-PD-L1 (CD274) antibody EMA indicated for a number of cancers including melanoma. In the section on clinical trials and melanoma, the participants BRAF V600E status is discussed.
https://www.pharmgkb.org/labelAnnotation/PA166283161	PA166283161	Annotation of HCSC Label for niraparib and BRCA1, BRCA2	HCSC		Informative PGx					Cancer Genome		niraparib	BRCA1; BRCA2		7/24/2024	THE HCSC label for niraparib (ZEJULA) discusses BRCA1 and BRCA2 variant status in the context of trials and mechanism of action but testing is not required as part of the indication.
https://www.pharmgkb.org/labelAnnotation/PA166284761	PA166284761	Annotation of HCSC Label for cabotegravir / rilpivirine and UGT1A1	HCSC		No Clinical PGx							cabotegravir / rilpivirine	UGT1A1		8/14/2023	Cabotegravir / rilpivirine (CABENUVA) is an injectable extended-release combination of antiviral drugs for the treatment of HIV. The HCSC label for cabotegravir / rilpivirine describes that cabotegravir is primarily metabolized by UGT1A1 but states that no dose adjustment is required in subjects with UGT1A1 polymorphisms.
https://www.pharmgkb.org/labelAnnotation/PA166284241	PA166284241	Annotation of HCSC Label for fosphenytoin and HLA-B	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	fosphenytoin	HLA-B	HLA-B*15:02	8/14/2024	The HCSC product monograph states that fosphenytoin should be avoided in patients with a positive test for the HLA-B*1502 allele and discusses some of the limitations of this test.
https://www.pharmgkb.org/labelAnnotation/PA166224081	PA166224081	Annotation of HCSC Label for oxcarbazepine and HLA-A	HCSC		Informative PGx							oxcarbazepine	HLA-A	HLA-A*31:01	7/26/2024	The product monograph for oxcarbazepine states that HLA-A*3101 may be a risk factor for the development of cutaneous adverse drug reactions such as SJS, TEN, DRESS, AGEP and maculopapular rash. However, there are insufficient data on patients treated with oxcarbazepine to support a recommendation for testing the presence of HLA-A*3101 allele in patients prior to initiating treatment with oxcarbazepine.
https://www.pharmgkb.org/labelAnnotation/PA166283802	PA166283802	Annotation of HCSC Label for givosiran and CPOX, HMBS, PPOX	HCSC									givosiran	CPOX; HMBS; PPOX		8/17/2023	Givosiran is HCSC indicated for the treatment of acute hepatic porphyria (AHP) in adults. The FDA table lists the genes CPOX, HMBS and PPOX which are associated with AHP however these are not specified in the HCSC product monograph.
https://www.pharmgkb.org/labelAnnotation/PA166284561	PA166284561	Annotation of HCSC Label for encorafenib and HRAS, KRAS, NRAS	HCSC		Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance	Cancer Genome	Prescribing	encorafenib	HRAS; KRAS; NRAS		8/14/2024	The product monograph for encorafenib states that, based on its mechanism of action, it may promote malignancies associated with activation of RAS through mutation or other mechanisms.
https://www.pharmgkb.org/labelAnnotation/PA166272361	PA166272361	Annotation of HCSC Label for tafamidis and TTR	HCSC									tafamidis	TTR		8/24/2023	Tafamidis is used to prevent TTR protein from breaking up and forming amyloid fibrils in the heart of patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
https://www.pharmgkb.org/labelAnnotation/PA166278561	PA166278561	Annotation of HCSC Label for sodium oxybate and ALDH5A1	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	sodium oxybate	ALDH5A1		7/21/2024	Sodium oxybate is HCSC indicated for the treatment of cataplexy in patients with narcolepsy. It is contraindicated in patients with succinic semialdehyde dehydrogenase deficiency, a rare metabolic disorder caused by homozygous or compound heterozygous mutation in the ALDH5A1 gene see OMIM:271980.
https://www.pharmgkb.org/labelAnnotation/PA166283821	PA166283821	Annotation of HCSC Label for ipilimumab and ALK, CD274, EGFR	HCSC		Testing Required					Cancer Genome		ipilimumab	ALK; CD274; EGFR		4/21/2024	Ipilimumab is HCSC indicated for several cancers, including NSCLC where testing is required for CD274 (also known as PD-L1) and exclusion of mutations in ALK and EGFR.
https://www.pharmgkb.org/labelAnnotation/PA166284721	PA166284721	Annotation of HCSC Label for nivolumab and ALK, CD274, EGFR, ERBB2	HCSC		Testing Required					Cancer Genome		nivolumab	ALK; CD274; EGFR; ERBB2		8/9/2024	"Nivolumab is HCSC indicated for several cancers including ERBB2 negative metastatic gastric cancer, metastatic esophageal squamous cell carcinoma expressing CD274, metastatic non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.
Select patients with metastatic NSCLC based on PD-L1 (CD274) expression using a test authorized by Health Canada; patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer should be selected for treatment based on MSI-H or dMMR tumor status as determined by an experienced laboratory using validated testing methods."
https://www.pharmgkb.org/labelAnnotation/PA166272341	PA166272341	Annotation of HCSC Label for tepotinib and MET	HCSC		Testing Required					Cancer Genome		tepotinib	MET		8/14/2024	The HCSC monograph for Tepotinib states it is indicated for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations.
https://www.pharmgkb.org/labelAnnotation/PA166281741	PA166281741	Annotation of HCSC Label for pitolisant and CYP2D6	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	pitolisant	CYP2D6			The HCSC product monograph for pitolisant recommends dose limitation and close monitoring for CYP2D6 poor metabolizers. It does not give testing information about which variants to test for.
https://www.pharmgkb.org/labelAnnotation/PA166273302	PA166273302	Annotation of EMA Label for nivolumab and BRAF	EMA							Cancer Genome		nivolumab	BRAF	rs113488022	8/17/2023	Nivolumab is EMA indicated for several types of cancers. The product information discusses trials that included BRAF mutation positive melanoma but testing is not discussed or required as part of the indication.
https://www.pharmgkb.org/labelAnnotation/PA166283961	PA166283961	Annotation of EMA Label for fosdenopterin and MOCS1	EMA		Testing Required							fosdenopterin	MOCS1		8/6/2024	Fosdenopterin is EMA indicated for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A. Patients with MoCD Type A have mutations in the Molybdenum Cofactor Synthesis 1 (MOCS1) gene. Patients with a presumptive diagnosis of MoCD Type A need to have a genetic test to confirm the diagnosis of MoCD Type A.
https://www.pharmgkb.org/labelAnnotation/PA166283941	PA166283941	Annotation of EMA Label for trastuzumab deruxtecan and ERBB2	EMA		Testing Required					Cancer Genome		trastuzumab deruxtecan	ERBB2		8/5/2024	Trastuzumab deruxtecan is an antibody-drug conjugate, EMA approved for the treatment of unresectable or metastatic ERBB2-positive breast cancer (HER-2 positive) who have received one or more prior anti-HER2-based regimens and for ERBB2 -positive gastric cancer. Patients treated with trastuzumab deruxtecan should have documented ERBB2-positive tumour status.
https://www.pharmgkb.org/labelAnnotation/PA166273481	PA166273481	Annotation of EMA Label for isatuximab and CD38	EMA							Cancer Genome		isatuximab	CD38		8/18/2023	Isatuximab is a monoclonal antibody, directed at CD38, and EMA indicated for treatment of multiple myeloma. The FDA table lists various chromosomal abnormalities (del(17p), t(4;14) and t(14;16)) that were observed during the clinical trials for isatuximab, these are also listed in the EMA product information however no alternative dosing or recommended action occurred.
https://www.pharmgkb.org/labelAnnotation/PA166283981	PA166283981	Annotation of EMA Label for evinacumab and LDLR	EMA									evinacumab	LDLR		8/20/2024	Evinacumab is a recombinant human monoclonal antibody, which specifically binds to and inhibits ANGPTL3 and reduces LDL-C independent of the presence of LDLR. Evinacumab is EMA indicated for treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (HoFH). Familial hypercholesterolemia is commonly caused by mutations in the LDLR gene. The label does not describe tests for HoFH but mentions LDLR null mutations in the context of patients in clinical trials.
https://www.pharmgkb.org/labelAnnotation/PA166284001	PA166284001	Annotation of EMA Label for enfortumab vedotin and NECTIN4	EMA							Cancer Genome		enfortumab vedotin	NECTIN4		11/21/2023	Enfortumab vedotin is EMA indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitor. Enfortumab vedotin is an antibody drug conjugate (ADC) targeting Nectin-4, an adhesion protein located on the surface of the urothelial cancer cells.
https://www.pharmgkb.org/labelAnnotation/PA166284021	PA166284021	Annotation of HCSC Label for enfortumab vedotin and NECTIN4	HCSC							Cancer Genome		enfortumab vedotin	NECTIN4		8/17/2023	Enfortumab vedotin is an antibody-drug conjugate directed against Nectin-4, an adhesion protein located on the surface of most urothelial cancer cells. PADCEV (enfortumab vedotin for injection) is HCSC indicated for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) who have previously received a platinum-containing chemotherapy and programmed death receptor-1 (PD-1) or programmed deathligand 1 (PD-L1) inhibitor therapy.
https://www.pharmgkb.org/labelAnnotation/PA166277761	PA166277761	Annotation of FDA Label for tebentafusp and HLA-A	FDA	On FDA Biomarker List	Testing Required							tebentafusp	HLA-A	HLA-A*02:01	8/21/2023	Tebentafusp is FDA indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
https://www.pharmgkb.org/labelAnnotation/PA166229941	PA166229941	Annotation of HCSC Label for atezolizumab and ALK, CD274, EGFR	HCSC		Testing Required					Cancer Genome		atezolizumab	ALK; CD274; EGFR		4/15/2024	The product monograph for atezolizumab (TECENTRIQ) states that it is a programmed death ligand 1 (PD-L1; encoded by CD274) monoclonal antibody indicated for the first-line treatment of unresectable or metastatic hepatocellular carcinoma, extensive-stage small cell lung cancer, locally advanced or metastatic triple-negative breast cancer, locally advanced or metastatic urothelial carcinoma, and, in patients without EGFR or ALK genetic tumor aberrations, locally advanced or metastatic non-small cell lung cancer. It is also indicated for patients with locally advanced or metastatic non-small cell lung cancer with EGFR or ALK aberrations who have had disease progression on EGFR- or ALK-targeted therapy.
https://www.pharmgkb.org/labelAnnotation/PA166284062	PA166284062	Annotation of HCSC Label for entrectinib and NTRK1, NTRK2, NTRK3, ROS1	HCSC		Testing Required					Cancer Genome		entrectinib	NTRK1; NTRK2; NTRK3; ROS1		4/16/2024	Entrectinib is HCSC indicated for the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options and patients with ROS1-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).
https://www.pharmgkb.org/labelAnnotation/PA166284081	PA166284081	Annotation of HCSC Label for erdafitinib and FGFR2, FGFR3	HCSC		Testing Required					Cancer Genome		erdafitinib	FGFR2; FGFR3		4/16/2024	Erdafitinib is HCSC indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC), whose tumors have susceptible fibroblast growth factor receptor (FGFR)2 or FGFR3 genetic alterations and who have disease progression during or following at least one line of prior chemotherapy, including within 12 months of neoadjuvant or adjuvant chemotherapy.
https://www.pharmgkb.org/labelAnnotation/PA166272641	PA166272641	Annotation of EMA Label for tepotinib and MET	EMA		Testing Required					Cancer Genome		tepotinib	MET		8/14/2024	Tepotinib is EMA indicated a treatment for patients with advanced non-small cell lung cancer that test positive for the METex14 skipping variant.
https://www.pharmgkb.org/labelAnnotation/PA166284101	PA166284101	Annotation of HCSC Label for erdafitinib and CYP2C9	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	erdafitinib	CYP2C9	CYP2C9*3	8/6/2024	The HCSC product monograph for erdafitinib states that erdafitinib plasma concentrations were predicted to be higher in patients with the CYP2C9*3/*3 genotype and to monitor for increased adverse reactions in patients who are known to have CYP2C9*3/*3 genotype.
https://www.pharmgkb.org/labelAnnotation/PA166278202	PA166278202	Annotation of EMA Label for azacitidine and KRAS, NRAS, PTPN11	EMA							Cancer Genome		azacitidine	KRAS; NRAS; PTPN11		8/14/2023	The EPAR for azacitidine includes mention of the genes PTPN11, NRAS, and KRAS when discussing the clinical studies of Juvenile Myelomonocytic Leukemia but not CBL, which is listed in the FDA table.
https://www.pharmgkb.org/labelAnnotation/PA166284261	PA166284261	Annotation of HCSC Label for fosphenytoin and CYP2C9	HCSC		No Clinical PGx							fosphenytoin	CYP2C9			The fosphenytoin HCSC product monograph discusses CYP2C9 and its role in metabolism but does not have information on variants or metabolizer phenotypes.
https://www.pharmgkb.org/labelAnnotation/PA166229921	PA166229921	Annotation of HCSC Label for amifampridine and NAT2	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	amifampridine	NAT2			The product monograph for amifampridine (RUZURGI) states that exposure is increased in patients who are N-acetyltransferase (NAT2) slow acetylators and that it should be initiated at the lowest recommended starting dose possible and patients should be monitored for adverse reactions. Information is not given on what genetic variants to test.
https://www.pharmgkb.org/labelAnnotation/PA166283901	PA166283901	Annotation of HCSC Label for inclisiran and APOB, LDLR, PCSK9	HCSC									inclisiran	APOB; LDLR; PCSK9		7/23/2024	Inclisiran is HCSC indicated for the treatment of heterozygous familial hypercholesterolemia (HeFH). In one of the studies discussed HeFH was diagnosed by genotyping but the genes tested were not discussed. Inclisiran acts by limiting the amount of PCSK9.
https://www.pharmgkb.org/labelAnnotation/PA166273462	PA166273462	Annotation of EMA Label for lenvatinib	EMA							Cancer Genome		lenvatinib			8/18/2023	The EMA product information for lenvatinib for renal cell carcinoma (Kisplyx) or thyroid cancer (Lenvima) does not have information about microsatelite or mismatch repair that is in the FDA label for lenvatinib or listed in the FDA biomarker table.
https://www.pharmgkb.org/labelAnnotation/PA166184172	PA166184172	Annotation of Swissmedic Label for Opium derivatives and expectorants and CYP2D6	Swissmedic		Actionable PGx							Opium derivatives and expectorants	CYP2D6			"The Swiss label for opium derivatives und expectorants (Codicalm Sirup) states that codeine metabolism is mediated by CYP2D6 and CYP2D6 ""ultra-fast metabolizers"" may show symptoms of overdose, such as dizziness, deep sedation, shortness of breath, nausea and vomiting, to respiratory and cardiac arrest."
https://www.pharmgkb.org/labelAnnotation/PA166184112	PA166184112	Annotation of Swissmedic Label for azathioprine and NUDT15, TPMT	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	azathioprine	NUDT15; TPMT			The Swiss drug label for azathioprine (Imurek) states that a dose reduction is generally required for patients carrying NUDT15 variants and notes that patients with TPMT deficiency are sensitive to the myelosuppressive effect of azathioprine.
https://www.pharmgkb.org/labelAnnotation/PA166184125	PA166184125	Annotation of Swissmedic Label for clopidogrel and CYP2C19	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	clopidogrel	CYP2C19	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*4; CYP2C19*5; CYP2C19*6; CYP2C19*7; CYP2C19*8	11/5/2019	"The Swiss drug label for clopidogrel (Plavix) states that clopidogrel has a reduced efficacy in CYP2C19 ""slow metatoblizers"" and a dose increase should be considered for these patients."
https://www.pharmgkb.org/labelAnnotation/PA166183181	PA166183181	Annotation of EMA Label for lesinurad and CYP2C9	EMA		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	lesinurad	CYP2C9	CYP2C9*1; CYP2C9*3	8/14/2024	The EMA European Public Assessment Report (EPAR) for lesinurad (Zurampic) states that patients who are known CYP2C9 poor metabolizers should be treated with caution due to an increased risk for renal-related adverse effects.
https://www.pharmgkb.org/labelAnnotation/PA166182948	PA166182948	Annotation of EMA Label for encorafenib and BRAF	EMA		Testing Required					Cancer Genome		encorafenib	BRAF	rs113488022	4/16/2024	The EMA European Public Assessment Report (EPAR) for encorafenib (Braftovi) states that it is indicated in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation or in combination with cetuximab for BRAF V600E colorectal cancer.
https://www.pharmgkb.org/labelAnnotation/PA166182952	PA166182952	Annotation of EMA Label for irinotecan and UGT1A1	EMA		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	irinotecan	UGT1A1	UGT1A1*28	5/31/2024	The EMA European Public Assessment Report (EPAR) for irinotecan (ONIVYDE) states that a reduced starting dose of 50 mg/m2 should be considered for patients with the UGT1A1*28/*28 genotype, with a dose increase to 70 mg/m2 if tolerated in subsequent cycles. Individuals with the UGT1A1*28/*28 genotype are at increased risk for neutropenia.
https://www.pharmgkb.org/labelAnnotation/PA166184121	PA166184121	Annotation of Swissmedic Label for chloroquine and G6PD	Swissmedic		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	chloroquine	G6PD		2/28/2023	The Swiss drug label for chloroquine (Nivaquine) states that chloroquine is contraindicated in patients with G6PD deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166184429	PA166184429	Annotation of Swissmedic Label for ezetimibe / simvastatin and SLCO1B1	Swissmedic		Testing Recommended	Prescribing Info	Dosing Info				Prescribing	ezetimibe / simvastatin	SLCO1B1	rs4149056	2/28/2023	"The Swiss drug label for ezetimibe/simvastatin (Inegy) states that patients with SLCO1B1 c.521T>C polymorphism are at risk of increased exposure to simvastatin acid, which may lead to an increased risk of rhabdomyolysis. ""Genotyping for the presence of the C allele should be considered as part of the benefit-risk assessment in individual patients before prescribing simvastatin 80 mg, and high doses should be avoided in identified carriers of the CC genotype."""
https://www.pharmgkb.org/labelAnnotation/PA166184502	PA166184502	Annotation of Swissmedic Label for lamivudine / abacavir and HLA-B	Swissmedic		Testing Required	Prescribing Info					Prescribing	lamivudine / abacavir	HLA-B	HLA-B*57:01	2/28/2023	The Swiss drug label for lamivudine / abacavir (Kivexa) states that patients should be screened for the presence of HLA-B*57:01 prior to starting treatment with abacavir. Kivexa is contraindicated in carriers of the HLA-B*57:01 allele.
https://www.pharmgkb.org/labelAnnotation/PA166184113	PA166184113	Annotation of Swissmedic Label for bisoprolol fumarate / perindopril arginine and G6PD	Swissmedic		Actionable PGx							bisoprolol fumarate / perindopril arginine	G6PD			The Swiss drug label for bisoprolol fumarate/perindopril arginine (Cosyrel) states that patients with G6PD deficiency may experience hemolytic anemia as a result of bisoprolol fumarate/perindopril arginine treatment.
https://www.pharmgkb.org/labelAnnotation/PA166184132	PA166184132	Annotation of Swissmedic Label for dasabuvir and IFNL3	Swissmedic		Actionable PGx							dasabuvir	IFNL3			The Swiss drug label for dasabuvir (Exviera) states that patients with an IFNL3 (IL28B) CC genotype have an increased sustained viral response than patients with the CC genotype.
https://www.pharmgkb.org/labelAnnotation/PA166184443	PA166184443	Annotation of Swissmedic Label for efavirenz and CYP2B6	Swissmedic		Actionable PGx							efavirenz	CYP2B6	CYP2B6*1; CYP2B6*6; rs3745274		The Swiss drug label for efavirenz (Stocrin) states that patients with elevated efavirenz concentrations, such as patients with CYP2B6 genotypes *1/*6 and *6/*6, have a higher risk of prolonging the QTc interval.
https://www.pharmgkb.org/labelAnnotation/PA166184446	PA166184446	Annotation of Swissmedic Label for escitalopram and CYP2D6	Swissmedic		Informative PGx							escitalopram	CYP2D6			The Swiss drug label for escitalopram (Cipralex) states that no significant changes in plasma levels were measured in poor CYP2D6 metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166184447	PA166184447	Annotation of Swissmedic Label for fesoterodine and CYP2D6	Swissmedic		Actionable PGx							fesoterodine	CYP2D6			The Swiss drug label for fesoterodine (Toviaz) cautions the increased likelihood of side effects in CYP2D6 poor metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166184451	PA166184451	Annotation of Swissmedic Label for fluorouracil and TYMS	Swissmedic		Actionable PGx							fluorouracil	TYMS	rs45445694		The Swiss drug label for fluorouracil (Fluorouracil Labatec) cautions about increased toxicity in patients with the 2R/2R and 2R/3R genotypes in the TYMS gene promoter relative to that of 3R/3R individuals.
https://www.pharmgkb.org/labelAnnotation/PA166184455	PA166184455	Annotation of Swissmedic Label for gefitinib and CYP2D6	Swissmedic		Actionable PGx							gefitinib	CYP2D6			The Swiss drug label for gefitinib (Iressa) states that CYP2D6 poor metabolizers had increased exposure compared to CYP2D6 extensive metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166184457	PA166184457	Annotation of Swissmedic Label for gliclazide and G6PD	Swissmedic		Actionable PGx							gliclazide	G6PD			The Swiss drug label for gliclazide (Diamicron) states that caution should be used when treating patients with G6PD deficiency with gliclazide as they are at increased risk for hemolytic anemia.
https://www.pharmgkb.org/labelAnnotation/PA166184374	PA166184374	Annotation of Swissmedic Label for ibrutinib and CYP2D6	Swissmedic		Informative PGx							ibrutinib	CYP2D6			The Swiss drug label for ibrutinib (IMBRUVICA) states that no precautions are required in patients with different CYP2D6 genotypes.
https://www.pharmgkb.org/labelAnnotation/PA166184383	PA166184383	Annotation of Swissmedic Label for lapatinib and HLA-DQA1, HLA-DRB1	Swissmedic		Actionable PGx							lapatinib	HLA-DQA1; HLA-DRB1	HLA-DQA1*02:01; HLA-DRB1*07:01		The Swiss drug label for lapatinib (Tyverb) cautions for increased risk of drug induced liver injury in carriers of the HLA alleles DQA1*02:01 and DRB1*07:01.
https://www.pharmgkb.org/labelAnnotation/PA166184427	PA166184427	Annotation of Swissmedic Label for ezetimibe / rosuvastatin and ABCG2, SLCO1B1	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	ezetimibe / rosuvastatin	ABCG2; SLCO1B1	rs2231142; rs4149056	8/13/2024	The Swiss drug label for ezetimibe/rosuvastatin (Ezetimib-Rosuvastatin-Mepha Kapseln) states that genetic polymorphisms in SLCO1B1 and ABCG2 may lead to an increase in rosuvastatin exposure, a reduction in the dosage is recommended.
https://www.pharmgkb.org/labelAnnotation/PA166184155	PA166184155	Annotation of Swissmedic Label for nitrofurantoin and G6PD	Swissmedic		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	nitrofurantoin	G6PD			The Swiss drug label for nitrofurantoin (Uvamin retard) states that breastfeeding of infants suspected or known to suffer from erythrocyte enzyme deficiency (including G6PD deficiency) should be avoided as traces of nitrofurantoin are found in breast milk.
https://www.pharmgkb.org/labelAnnotation/PA166184500	PA166184500	Annotation of Swissmedic Label for simvastatin and SLCO1B1	Swissmedic		Testing Recommended	Prescribing Info					Prescribing	simvastatin	SLCO1B1	rs4149056	2/28/2023	"The Swiss drug label for simvastatin (Zocor® 20 mg/40 mg/80 mg) states that patients with SLCO1B1 c.521T>C polymorphism are at risk of increased exposure to simvastatin acid, which may lead to an increased risk of rhabdomyolysis. ""Genotyping for the presence of the C allele should be considered as part of the benefit-risk assessment in individual patients before prescribing simvastatin 80 mg, and high doses should be avoided in identified carriers of the CC genotype."""
https://www.pharmgkb.org/labelAnnotation/PA166184160	PA166184160	Annotation of Swissmedic Label for ondansetron and CYP2D6	Swissmedic		Informative PGx							ondansetron	CYP2D6			The Swiss label for ondansetron (Zofran®/- Zydis®) states that CYP3A4, CYP2D6 and CYP1A2 are involved in ondansetron metabolism. However, the overall rate of ondansetron elimination will hardly be affected by the absence of one enzyme (e.g. genetic CYP2D6 deficiency).
https://www.pharmgkb.org/labelAnnotation/PA166184177	PA166184177	Annotation of Swissmedic Label for oxycodone and CYP2D6	Swissmedic		Actionable PGx							oxycodone	CYP2D6			The Swiss label for oxycodone (Oxycontin or Targin) states that genetic polymorphisms of CYP2D6 can alter the efficacy of oxycodone or lead to undesired effects.
https://www.pharmgkb.org/labelAnnotation/PA166184220	PA166184220	Annotation of Swissmedic Label for paliperidone and CYP2D6	Swissmedic		Informative PGx							paliperidone	CYP2D6			The Swiss label for paliperidon (Trevicta) states that no discernible difference between extensive metabolisers and slow metabolisers of CYP2D6 substrates with respect to apparent clearance of paliperidone after application of oral paliperidone.
https://www.pharmgkb.org/labelAnnotation/PA166184286	PA166184286	Annotation of Swissmedic Label for perindopril and G6PD	Swissmedic		Actionable PGx							perindopril	G6PD			The Swiss drug label for perindopril (COVERSUM N 5 mg/10 mg) states that patients with congenital G6PD deficiency may have risk for haemolytic anaemia.
https://www.pharmgkb.org/labelAnnotation/PA166184393	PA166184393	Annotation of Swissmedic Label for pitavastatin and SLCO1B1	Swissmedic		Actionable PGx							pitavastatin	SLCO1B1			The Swiss drug label for pitavastatin (Livazo) states that genetic variation in SLCO1B1 gene may impact pitavastatin concentration.
https://www.pharmgkb.org/labelAnnotation/PA166184396	PA166184396	Annotation of Swissmedic Label for rabeprazole and CYP2C19	Swissmedic		Actionable PGx							rabeprazole	CYP2C19			The Swiss drug label for rabeprazole (Pariet) states that CYP2C19 slow metabolizers may have higher concentration (AUC) as compared to extensive metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166184421	PA166184421	Annotation of Swissmedic Label for risperidone and CYP2D6	Swissmedic		Informative PGx							risperidone	CYP2D6			The Swiss label for risperidone (Risperdal) states that CYP2D6 plays a role in risperidone metabolism. However, no clinically relevant differences were observed in slow and fast metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166184389	PA166184389	Annotation of Swissmedic Label for sulfadiazine and G6PD	Swissmedic		Actionable PGx							sulfadiazine	G6PD			The Swiss drug labels for sulfadiazin-silber (Flammazine) and Sulfadiazin-Silber, Kombinationen (Ialugen Plus) has a caution for use in patients with known or suspected G6PD deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166184392	PA166184392	Annotation of Swissmedic Label for tamoxifen and CYP2D6	Swissmedic		Actionable PGx							tamoxifen	CYP2D6			The Swiss drug label for tamoxifen (Nolvadex) cautions about changes in efficacy in CYP2D6 poor metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166184391	PA166184391	Annotation of Swissmedic Label for sulfasalazine and G6PD	Swissmedic		Actionable PGx							sulfasalazine	G6PD			The Swiss drug label for sulfasalazine (Salazopyrin) states that the drug is contraindicated in patients with G6PD deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166184425	PA166184425	Annotation of Swissmedic Label for tolperisone and CYP2D6	Swissmedic		Actionable PGx							tolperisone	CYP2D6			The Swiss drug label for tolperisone (Mydocalm) suggests that tolperisone exposure may be increased in CYP2D6 poor metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166184236	PA166184236	Annotation of Swissmedic Label for umeclidinium / vilanterol and CYP2D6	Swissmedic		Informative PGx							umeclidinium / vilanterol	CYP2D6			The Swiss drug label for umeclidinium/vilanterol (Anoro® Ellipta®) states that umeclidinium exposure is not affected by CYP2D6 variants.
https://www.pharmgkb.org/labelAnnotation/PA166184239	PA166184239	Annotation of Swissmedic Label for vortioxetine and CYP2D6	Swissmedic		Actionable PGx							vortioxetine	CYP2D6			"The Swiss drug label for vortioxetine (Brintellix) states that plasma concentrations of vortioxetine are increased in CYP2D6 ""slow metabolizers"" compared to normal metabolizers."
https://www.pharmgkb.org/labelAnnotation/PA166184386	PA166184386	Annotation of Swissmedic Label for letermovir and SLCO1B1, UGT1A1	Swissmedic		Informative PGx							letermovir	SLCO1B1; UGT1A1	rs2306283; rs4148323; rs4149032; rs4149056; UGT1A1*28		The Swiss drug label for letermovir (Prevymis) gives information about variants in UGT1A1 and SLCO1B1 that were tested for association with letermovir pharmacokinetics although no clinically relevant effects were observed.
https://www.pharmgkb.org/labelAnnotation/PA166122967	PA166122967	Annotation of EMA Label for fesoterodine and CYP2D6	EMA		Informative PGx							fesoterodine	CYP2D6		8/7/2014	The EMA European Public Assessment Report (EPAR) for fesoterodine (Toviaz) states that Cmax and AUC of the active metabolite are 1.7 and 2-fold higher, respectively, in CYP2D6 poor metabolizers as compared to extensive metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166119823	PA166119823	Annotation of EMA Label for afatinib and EGFR	EMA		Testing Required					Cancer Genome		afatinib	EGFR		4/15/2024	The EMA European Public Assessment Report (EPAR) for afatinib (GIOTRIF) states that it is indicated for the treatment of EGFR TKI-naive adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGFR mutations, among other indications.
https://www.pharmgkb.org/labelAnnotation/PA166286161	PA166286161	Annotation of HCSC Label for allopurinol and HLA-B	HCSC		Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	allopurinol	HLA-B	HLA-B*58:01	6/18/2024	The HCSC product monograph for allopurinol states that screening for HLA-B*5801 should be considered before starting treatment in patient subgroups where the allele frequency is known to be high.
https://www.pharmgkb.org/labelAnnotation/PA166184422	PA166184422	Annotation of Swissmedic Label for tetrabenazine and CYP2D6	Swissmedic		Testing Required	Prescribing Info					Prescribing	tetrabenazine	CYP2D6			The Swiss drug label for tetrabenazine (Xenazine) states that patients should be tested for CYP2D6 poor metabolizer status prior to receiving daily doses above 50 mg.
https://www.pharmgkb.org/labelAnnotation/PA166127634	PA166127634	Annotation of HCSC Label for atorvastatin and LDLR	HCSC									atorvastatin	LDLR		9/26/2023	The product monograph for atorvastatin states that it is indicated for hyperlipidemic and dyslipidemic conditions, including homozygous and heterozygous familial hypercholesterolemia, genetically determined conditions caused by mutations in the low density lipoprotein receptor (LDLR)
https://www.pharmgkb.org/labelAnnotation/PA166122487	PA166122487	Annotation of EMA Label for propranolol and CYP2D6	EMA		No Clinical PGx							propranolol	CYP2D6		6/26/2014	The EMA European Public Assessment Report (EPAR) for propranolol hydrochloride (Hemangiol) gives information regarding the metabolism of the drug by three different routes which varies between individuals, but that no difference in oral clearance or elimination is observed between CYP2D6 extensive and poor metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166117941	PA166117941	Annotation of EMA Label for bosutinib and ABL1, BCR	EMA		Testing Required					Cancer Genome		bosutinib	ABL1; BCR		8/26/2024	The EMA European Public Assessment Report (EPAR) for bosutinib (Bosulif) states that it is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
https://www.pharmgkb.org/labelAnnotation/PA166104844	PA166104844	Annotation of EMA Label for erlotinib and EGFR	EMA		Testing Required					Cancer Genome		erlotinib	EGFR		4/16/2024	The EMA European Public Assessment Report (EPAR) for erlotinib (Tarceva) states that it is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations, and switch maintenance treatment in patients with locally advanced or metastatic NSCLC with EGFR activating mutations and stable disease after first-line chemotherapy, among other indications.
https://www.pharmgkb.org/labelAnnotation/PA166104834	PA166104834	Annotation of FDA Label for lenalidomide	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		lenalidomide			5/2/2024	Lenalidomide (REVLIMID) is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
https://www.pharmgkb.org/labelAnnotation/PA166104841	PA166104841	Annotation of EMA Label for clopidogrel and CYP2C19	EMA		Informative PGx							clopidogrel	CYP2C19	CYP2C19*2; CYP2C19*3; CYP2C19*4; CYP2C19*5; CYP2C19*6; CYP2C19*7; CYP2C19*8	7/17/2024	The EMA European Public Assessment Report (EPAR) for clopidogrel (Plavix) states that in patients who are CYP2C19 poor metabolizers, clopidogrel at recommended doses forms less of the active metabolite and has a smaller effect on platelet function. The EPAR also discusses literature on the effect of CYP2C19 metabolizer status on clopidogrel pharmacokinetics and antiplatelet response.
https://www.pharmgkb.org/labelAnnotation/PA166127706	PA166127706	Annotation of HCSC Label for rabeprazole and CYP2C19	HCSC		Informative PGx							rabeprazole	CYP2C19		7/22/2024	The product monograph for rabeprazole states that individuals with CYP2C19 deficiency have reduced metabolism of rabeprazole.
https://www.pharmgkb.org/labelAnnotation/PA166122547	PA166122547	Annotation of EMA Label for trastuzumab emtansine and ERBB2	EMA		Testing Required					Cancer Genome		trastuzumab emtansine	ERBB2		4/21/2024	The EMA European Public Assessment Report (EPAR) for trastuzumab emtansine (Kadcyla) contains information regarding indication of the drug in patients with HER2-positive (encoded by the ERBB2 gene) breast cancer due to its mechanism of action, and HER2 positive status should be tested for by a validated method.
https://www.pharmgkb.org/labelAnnotation/PA166127702	PA166127702	Annotation of HCSC Label for primaquine and CYB5R1, CYB5R2, CYB5R3, CYB5R4, CYP2D6	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	primaquine	CYB5R1; CYB5R2; CYB5R3; CYB5R4; CYP2D6		7/25/2024	The product monograph for primaquine states that caution should be used in individuals with NADH methemoglobin reductase (CYB5R1-4) deficiency due to the risk of methemoglobinemia. In case of treatment failure, after checking patient’s compliance to treatment, it may be useful to assess the patient’s CYP2D6 status.
https://www.pharmgkb.org/labelAnnotation/PA166127707	PA166127707	Annotation of HCSC Label for rasburicase and G6PD	HCSC		Testing Recommended							rasburicase	G6PD			The product monograph for rasburicase (FASTURTEC) states that patients at higher risk for G6PD deficiency (e.g. those of African or Mediterranean ancestry) be screened prior to starting treatment, due to the risk of severe hemolytic anemia.
https://www.pharmgkb.org/labelAnnotation/PA166114481	PA166114481	Annotation of EMA Label for trastuzumab and ERBB2	EMA		Testing Required					Cancer Genome		trastuzumab	ERBB2		4/21/2024	The EMA European Public Assessment Report (EPAR) for trastuzumab (Herceptin) requires testing of tumours for HER2 overexpression or gene amplification prior to initiating therapy. Trastuzumab (Herceptin) targets human epidermal growth factor receptor 2 (HER2) to inhibit growth of HER2 overexpressing cancer cells.
https://www.pharmgkb.org/labelAnnotation/PA166127633	PA166127633	Annotation of HCSC Label for atomoxetine and CYP2D6	HCSC		Informative PGx							atomoxetine	CYP2D6			The product monograph for atomoxetine notes that CYP2D6 poor metabolizers (PMs) have a 10-fold higher area under the curve (AUC) and a 5-fold higher peak concentration of the drug as compared to extensive metabolizers (EM); this leads to a higher rate of some adverse events for PMs compared to EMs.
https://www.pharmgkb.org/labelAnnotation/PA166104920	PA166104920	Annotation of FDA Label for trastuzumab and ERBB2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		trastuzumab	ERBB2		9/1/2023	Trastuzumab (Herceptin) is used for the treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Select patients for therapy based on an FDA-approved companion diagnostic for Herceptin.
https://www.pharmgkb.org/labelAnnotation/PA166104902	PA166104902	Annotation of FDA Label for sulfadiazine and G6PD	FDA	On FDA Biomarker List	Informative PGx							sulfadiazine	G6PD		10/25/2013	Sulfadiazine (SILVADENE) is an antimicrobial topical drug used to prevent and treat wound sepsis in second and third degree burns. A link between sulfadiazine-induced hemolytic anemia and G6PD deficiency is highlighted in the Warnings section of the label.
https://www.pharmgkb.org/labelAnnotation/PA166104881	PA166104881	Annotation of FDA Label for glyburide and G6PD	FDA	Formerly on FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	glyburide	G6PD		8/25/2023	The FDA-approved drug label for glibenclamide (glyburide; GLYNASE PresTab) notes that caution should be used in patients with G6PD deficiency and a non-sulfonylurea alternative should be considered.
https://www.pharmgkb.org/labelAnnotation/PA166104793	PA166104793	Annotation of FDA Label for risperidone and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							risperidone	CYP2D6		8/22/2023	The FDA-approved drug label for risperidone (PERSERIS) states that exposure to the total active moiety is similar in CYP2D6 extensive, intermediate and poor metabolizers, supporting no need for dose adjustment based on CYP2D6 genotype.
https://www.pharmgkb.org/labelAnnotation/PA166159707	PA166159707	Annotation of HCSC Label for atazanavir and CYP2C19	HCSC		Informative PGx							atazanavir	CYP2C19		5/30/2024	Atazanavir is a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. The HCSC-approved product monograph for atazanavir contains pharmacogenetic information related to co-treatment with voriconazole and ritonavir. The use of voriconazole in patients with a functional CYP2C19 allele and receiving atazanavir with ritonavir is not recommended unless an assessment of the benefit/risk to the patient justifies the use of voriconazole.
https://www.pharmgkb.org/labelAnnotation/PA166182931	PA166182931	Annotation of EMA Label for brigatinib and ALK	EMA		Testing Required					Cancer Genome		brigatinib	ALK		4/16/2024	The EMA European Public Assessment Report (EPAR) for brigatinib (Alunbrig) states that it is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer previously treated with crizotinib.
https://www.pharmgkb.org/labelAnnotation/PA166115435	PA166115435	Annotation of EMA Label for timolol and CYP2D6	EMA									timolol	CYP2D6		8/24/2023	The EMA EPAR for timolol contains information regarding potentiated beta-blockade when treatment is combined with CYP2D6 inhibitors. No pharmacogenetic information was found in the label.
https://www.pharmgkb.org/labelAnnotation/PA166114913	PA166114913	Annotation of FDA Label for dabrafenib and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	dabrafenib	G6PD		5/14/2024	The drug label for dabrafenib (TAFINLAR) states that it is indicated, as a single agent or in combination with trametinib, for patients with certain types of cancer. The label also notes that patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency have a risk for developing hemolytic anemia, and that these patients should be closely observed when taking dabrafenib.
https://www.pharmgkb.org/labelAnnotation/PA166114378	PA166114378	Annotation of EMA Label for telaprevir and IFNL3	EMA		Informative PGx							telaprevir	IFNL3		10/28/2013	The EMA European Public Assessment Report (EPAR) for telaprevir (Incivo) contains a table showing higher SVR rates for patients with the IL28B (IFNL3) CC genotype compared to those with CT or TT when treated with the telaprevir, peginterferon alfa-2a and ribavirin drug combination, though this is not discussed further in the main text. Please note that as of September 2016 telaprevir (Incivo) has been withdrawn from use in the European Union.
https://www.pharmgkb.org/labelAnnotation/PA166122066	PA166122066	Annotation of EMA Label for pertuzumab and ERBB2	EMA		Testing Required					Cancer Genome		pertuzumab	ERBB2		4/21/2024	The EMA European Public Assessment Report (EPAR) for pertuzumab (Perjeta) states that it is indicated for HER2-positive early or metastatic breast cancer.
https://www.pharmgkb.org/labelAnnotation/PA166122969	PA166122969	Annotation of EMA Label for vardenafil	EMA									vardenafil			8/29/2023	The EMA European Public Assessment Report (EPAR) for vardenafil (Levitra) contains genetic information regarding its contraindication in patients with hereditary retinal degenerative disorders. It also mentions that the drug is metabolized primarily by CYP3A4 and that concomitant use of potent CYP3A4 inhibitors is contraindicated, or dose adjustments should be made when prescribed with moderate CYP3A4 inhibitors.
https://www.pharmgkb.org/labelAnnotation/PA166119826	PA166119826	Annotation of EMA Label for dabrafenib and BRAF	EMA		Testing Required					Cancer Genome		dabrafenib	BRAF		5/14/2024	The EMA European Public Assessment Report (EPAR) for dabrafenib (Tafinlar) states that it is indicated for the treatment of adult patients with the BRAF V600 mutation and unresectable or metastatic melanoma, advanced non-small cell lung cancer, and for the adjuvant treatment of adult patients with Stage III melanoma.
https://www.pharmgkb.org/labelAnnotation/PA166122826	PA166122826	Annotation of EMA Label for voriconazole and CYP2C19, CYP2C9, CYP3A4	EMA									voriconazole	CYP2C19; CYP2C9; CYP3A4		8/29/2023	The EMA European Public Assessment Report (EPAR) for voriconazole (VFEND) does not contain pharmacogenetic information. It contains warning information regarding the co-administration of drugs that are substrates, inhibitors or activators of CYP3A4, CYP2C9 or CYP2C19 due to drug-drug interactions.
https://www.pharmgkb.org/labelAnnotation/PA166127701	PA166127701	Annotation of HCSC Label for phenytoin and HLA-B	HCSC		Testing Recommended							phenytoin	HLA-B			The product monograph for phenytoin (DILANTIN) notes that individuals with the HLA-B*15:02 allele have an increased risk of developing Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) when receiving the drug. It further notes that this allele is common in individuals of Asian ancestry, and HLA-B genotyping should be considered as a screening tool in these patients. The use of phenytoin should be avoided in patients who test positive for the HLA-B*15:02 allele.
https://www.pharmgkb.org/labelAnnotation/PA166127700	PA166127700	Annotation of HCSC Label for pertuzumab and ERBB2	HCSC		Testing Required					Cancer Genome		pertuzumab	ERBB2		4/21/2024	The product monograph for pertuzumab (PERJETA) states that it is indicated in combination with trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer.
https://www.pharmgkb.org/labelAnnotation/PA166127635	PA166127635	Annotation of HCSC Label for azathioprine and TPMT	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	azathioprine	TPMT		7/18/2024	The product monograph for azathioprine notes that individuals with an inherited deficiency of the thiopurine methyltransferase (TPMT) enzyme may be at risk for developing myelosuppression when treated with the drug, and that close monitoring of blood counts is necessary.
https://www.pharmgkb.org/labelAnnotation/PA166127647	PA166127647	Annotation of HCSC Label for celecoxib and CYP2C9	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	celecoxib	CYP2C9	CYP2C9*3	7/19/2024	The product monograph for celecoxib (pmsc-CELECOXIB) notes that patients who are CYP2C9 poor metabolizers should be administered celecoxib with caution. It further states that the drug should be introduced at half the lowest recommended dose in these individuals, with a maximum recommended dose of 100 mg/day. However, the product monograph does not discuss CYP2C9 genotyping prior to treatment.
https://www.pharmgkb.org/labelAnnotation/PA166127650	PA166127650	Annotation of HCSC Label for citalopram and CYP2C19	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	citalopram	CYP2C19		7/19/2024	The product monograph for citalopram (CELEXA) recommends that patients who are CYP2C19 poor metabolizers receive an initial dose of 10 mg daily during the first two weeks of treatment, and should not receive a dose of greater than 20 mg/day. However, it makes no statements regarding genetic testing of CYP2C19 prior to treatment.
https://www.pharmgkb.org/labelAnnotation/PA166127705	PA166127705	Annotation of HCSC Label for quinine and G6PD	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	quinine	G6PD		7/22/2024	The product monograph for quinine states that it is contraindicated in patients with G6PD deficiency. However, it makes no statements regarding testing for G6PD deficiency prior to treatment.
https://www.pharmgkb.org/labelAnnotation/PA166105321	PA166105321	Annotation of EMA Label for prasugrel and CYP2B6, CYP2C19, CYP2C9, CYP3A5	EMA		No Clinical PGx							prasugrel	CYP2B6; CYP2C19; CYP2C9; CYP3A5		10/27/2013	The EMA European Public Assessment Report (EPAR) for prasugrel (Efient) contains information regarding the lack of effect of genetic variants in the CYP3A5, CYP2B6, CYP2C9 and CYP2C19 genes on the pharmacokinetics of prasugrel or response.
https://www.pharmgkb.org/labelAnnotation/PA166127704	PA166127704	Annotation of HCSC Label for propafenone and CYP2D6	HCSC		Informative PGx							propafenone	CYP2D6			The product monograph for propafenone notes that individuals with reduced CYP2D6 activity may have higher plasma concentrations of the drug as compared to those who do not have reduced CYP2D6 activity.
https://www.pharmgkb.org/labelAnnotation/PA166127646	PA166127646	Annotation of HCSC Label for carvedilol and CYP2D6	HCSC		Informative PGx							carvedilol	CYP2D6		7/19/2024	The product monograph for carvedilol notes that CYP2D6 poor metabolizers exhibit 2- to 3-fold higher plasma concentrations of R( + )-carvedilol compared to extensive metabolizers. Plasma levels of S( - )-carvedilol are increased only about 20 - 25% in poor metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166104786	PA166104786	Annotation of FDA Label for chloroquine and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	chloroquine	G6PD		9/27/2023	The FDA-approved drug label for chloroquine (ARALAN) states that it may cause hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. However, CDC guidelines from 2019 recommend chloroquine for malaria prophylaxis in patients who cannot be treated with primaquine or tafenoquine due to G6PD deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166104887	PA166104887	Annotation of FDA Label for iloperidone and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	iloperidone	CYP2D6		10/25/2013	The FDA-approved drug label for iloperidone (FANAPT) states that CYP2D6 poor metabolizers have higher exposure to iloperidone compared with extensive metabolizers, and they should have their dose reduced by one half.
https://www.pharmgkb.org/labelAnnotation/PA166127709	PA166127709	Annotation of HCSC Label for rosuvastatin and LDLR	HCSC									rosuvastatin	LDLR		7/22/2024	The product monograph for rosuvastatin states that it is indicated for hyperlipidemic and dyslipidemic conditions, including homozygous familial hypercholesterolemia, a genetically determined condition caused by mutations in the low density lipoprotein receptor (LDLR)
https://www.pharmgkb.org/labelAnnotation/PA166127708	PA166127708	Annotation of HCSC Label for risperidone and CYP2D6	HCSC		No Clinical PGx							risperidone	CYP2D6			The product monograph for risperidone notes that since CYP2D6 is responsible for the metabolism of risperidone to 9-hydroxyrisperidone, the levels of each differ between CYP2D6 poor and extensive metabolizers. However, the concentration of risperidone and 9-hydroxyrisperidone combined does not differ substantially between poor and extensive metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166104785	PA166104785	Annotation of FDA Label for erlotinib and EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		erlotinib	EGFR	rs121434568	9/1/2023	Erlotinib (TARCEVA) is a kinase inhibitor indicated for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
https://www.pharmgkb.org/labelAnnotation/PA166114903	PA166114903	Annotation of FDA Label for afatinib and EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		afatinib	EGFR	rs121434568	8/1/2024	Afatinib (GILOTRIF) is indicated for patients with metastatic non-small cell lung cancer (NSCLC) who have tumors with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test.
https://www.pharmgkb.org/labelAnnotation/PA166104872	PA166104872	Annotation of EMA Label for boceprevir and IFNL3	EMA		No Clinical PGx							boceprevir	IFNL3		8/14/2023	The EMA European Public Assessment Report (EPAR) for boceprevir (Victrelis) contains pharmacogenetic information regarding a genetic variant within the IL28B gene that is associated with response to treatment with peginterferon alfa-2b/ribavirin (drugs taken concomitantly with boceprevir), but highlight caveats in studies carried out so far and that the association with boceprevir is currently being investigated further. Please note that as of June 2018 boceprevir (Victrelis) has been withdrawn from use in the European Union.
https://www.pharmgkb.org/labelAnnotation/PA166104835	PA166104835	Annotation of FDA Label for fluoxetine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info					Prescribing	fluoxetine	CYP2D6		9/7/2023	Fluoxetine (PROZAC) is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder, obsessive compulsive disorder, bulimia nervosa, and panic disorder. Fluoxetine is primarily metabolized by CYP2D6. It should be used used with caution in patients with congenital long QT syndrome; a previous history of QT prolongation and other conditions that predispose to QT prolongation and ventricular arrhythmia (which include conditions that predispose to increased fluoxetine exposure (overdose, hepatic impairment, use of CYP2D6 inhibitors, CYP2D6 poor metabolizer status, or use of other highly protein-bound drugs).
https://www.pharmgkb.org/labelAnnotation/PA166104884	PA166104884	Annotation of FDA Label for clobazam and CYP2C19	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	clobazam	CYP2C19		4/23/2019	In patients known to be CYP2C19 poor metabolizers, the drug label states that the initial dose of clobazam (ONFI) should be 5 mg/day, and that dose titration should be proceed slowly according to weight.
https://www.pharmgkb.org/labelAnnotation/PA166104880	PA166104880	Annotation of FDA Label for nefazodone and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							nefazodone	CYP2D6		8/15/2023	The FDA-approved drug label for nefazodone states that treatment adjustment is not required based on CYP2D6 metabolizer status.
https://www.pharmgkb.org/labelAnnotation/PA166104791	PA166104791	Annotation of FDA Label for lapatinib and ERBB2, ESR1, ESR2, PGR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		lapatinib	ERBB2; ESR1; ESR2; PGR		8/26/2024	"Lapatinib (TYKERB) is indicated for patients with breast cancer whose tumors overexpress HER2 (ERBB2). The FDA-approved drug label for lapatinib notes that the HLA-DQA1*02:01 and HLA-DRB1*07:01 alleles have been associated with hepatotoxicity in individuals received the drug, but does not discuss genetic testing for these alleles.
The lapatinib label mentions testing for HER2 positivity in the context of clinical trials."
https://www.pharmgkb.org/labelAnnotation/PA166104782	PA166104782	Annotation of FDA Label for azathioprine and NUDT15, TPMT	FDA	On FDA Biomarker List	Testing Recommended	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	azathioprine	NUDT15; TPMT		8/22/2023	The FDA-approved drug label for azathioprine (IMURAN) states to consider genotyping or phenotyping patients for TPMT deficiency and genotyping for NUDT15 deficiency in patients with severe myelosuppression. Alternative therapy in patients with homozygous TPMT or NUDT15 deficiency and reduced dosages in patients with heterozygous deficiency should be considered.
https://www.pharmgkb.org/labelAnnotation/PA166104775	PA166104775	Annotation of FDA Label for atorvastatin and LDLR	FDA	Formerly on FDA Biomarker List								atorvastatin	LDLR		12/4/2023	Although the atorvastatin (LIPITOR) drug label does not specifically mention genetic testing, one of the indications listed is for the treatment of familial hypercholesterolemia, a genetically determined condition caused by mutations in the low density lipoprotein receptor (LDLR); one of the drug's mechanisms of action is increasing LDLR cell surface expression.
https://www.pharmgkb.org/labelAnnotation/PA166104830	PA166104830	Annotation of FDA Label for tiotropium and CYP2D6	FDA	Formerly on FDA Biomarker List								tiotropium	CYP2D6		8/27/2023	Tiotropium (SPIRIVA RESPIMAT) is an inhalation powder used daily for the treatment of bronchospasms associated with chronic obstructive pulmonary disease (COPD) and maintenance treatment of asthma. It is believed to be metabolized in part by CYP2D6.
https://www.pharmgkb.org/labelAnnotation/PA166104794	PA166104794	Annotation of FDA Label for sodium benzoate / sodium phenylacetate and ARG1, ASL, ASS1, CPS1, NAGS, OTC	FDA	Formerly on FDA Biomarker List								sodium benzoate / sodium phenylacetate	ARG1; ASL; ASS1; CPS1; NAGS; OTC		9/28/2023	Sodium phenylacetate and sodium benzoate (AMMONUL) provides an alternate vehicle to urea for waste nitrogen excretion in patients with urea cycle disorders. Urea cycle disorders may be caused by mutations in the genes NAGS, CPS1, OTC, ASS1, ASL and ARG1.
https://www.pharmgkb.org/labelAnnotation/PA166122546	PA166122546	Annotation of EMA Label for rituximab and MS4A1	EMA							Cancer Genome		rituximab	MS4A1		9/28/2023	The EMA European Public Assessment Report (EPAR) for rituximab (MabThera) contains information regarding one of the indications of the drug in patients with CD20-positive diffuse large V cell non-Hodgkin's lymphoma in combination with CHOP chemotherapy regimen. The drug targets CD20 (MS4A1) expressing B cells to induce cell lysis.
https://www.pharmgkb.org/labelAnnotation/PA166104822	PA166104822	Annotation of FDA Label for terbinafine and CYP2D6	FDA	Formerly on FDA Biomarker List								terbinafine	CYP2D6		8/24/2023	The FDA-approved drug label for terbinafine (LAMISIL) states that the drug is an inhibitor of the CYP2D6 enzyme, and therefore may convert CYP2D6 extensive metabolizers to poor metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166104779	PA166104779	Annotation of EMA Label for indacaterol and UGT1A1	EMA		No Clinical PGx							indacaterol	UGT1A1		8/18/2023	The EMA European Public Assessment Report (EPAR) for indacaterol (Hirobriz Breezhaler) does not contain pharmacogenetic information, but does contain information regarding the pharmacodynamics of the drug as a beta2-adrenoceptor (ADRB2) agonist and also contains information regarding the pharmacokinetics of indacaterol involving UGT1A1, CYP3A4 and ABCB1.
https://www.pharmgkb.org/labelAnnotation/PA166104869	PA166104869	Annotation of FDA Label for galantamine and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							galantamine	CYP2D6		8/22/2023	The FDA-approved drug label for galantamine (RAZADYNE) states dosage adjustment of galantamine is not necessary in patients identified as CYP2D6 poor metabolizers as the dose is individually titrated to tolerability.
https://www.pharmgkb.org/labelAnnotation/PA166104850	PA166104850	Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2	FDA	On FDA Biomarker List	Informative PGx							isoniazid / pyrazinamide / rifampin	NAT2		7/23/2024	"The FDA-approved drug label for rifampin, isoniazid and pyrazinamide (RIFATER) states that 'slow inactivators' of isoniazid may be more susceptible to drug toxicity due to higher blood concentrations of the drug in these individuals. Acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene. However, the label never mentions any specific gene with regard to inactivator or acetylator status.
Note: As of July 2024, the Marketing Status of this drug combination is Discontinued, but the drug combination remains on the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling."
https://www.pharmgkb.org/labelAnnotation/PA166104896	PA166104896	Annotation of EMA Label for abacavir and HLA-B	EMA		Testing Required	Prescribing Info		Alternate Drug			Prescribing	abacavir	HLA-B	HLA-B*57:01	10/15/2013	The EMA European Public Assessment Report (EPAR) for abacavir (Ziagen) states that screening for the HLA-B*5701 allele should be performed in any HIV-infected patient, and that the drug should not be used in patient's with the HLA-B*57:01 allele.
https://www.pharmgkb.org/labelAnnotation/PA166104891	PA166104891	Annotation of FDA Label for nalidixic acid and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	nalidixic acid	G6PD		12/18/2013	Nalidixic acid (NegGram) is used to treat urinary tract infections due to gram-negative bacteria. Although the nalidixic acid drug label does not specifically mention genetic testing, the FDA highlight precaution prior to initiating treatment with nalidixic acid for G6PD deficient individuals due to an association with hemolytic anemia.
https://www.pharmgkb.org/labelAnnotation/PA166104825	PA166104825	Annotation of FDA Label for valproic acid and OTC	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	valproic acid	OTC		2/16/2023	The FDA-approved drug label for valproic acid (Depakene) notes that it is contraindicated in patients with known urea cycle disorders (UCDs), a group of uncommon genetic abnormalities, particularly ornithine transcarbamylase (OTC) deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166104805	PA166104805	Annotation of FDA Label for thioridazine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	thioridazine	CYP2D6		10/25/2013	Thioridazine is used to treat schizophrenia, but has been associated with Torsades de pointes and sudden death. Due to the potentially fatal side effects, it is typically reserved for patients who do not respond well to other anti-psychotics. This drug is contraindicated in patients with reduced CYP2D6 activity.
https://www.pharmgkb.org/labelAnnotation/PA166104862	PA166104862	Annotation of FDA Label for desipramine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							desipramine	CYP2D6		10/25/2013	The FDA-approved drug label for desipramine (NORPRAMIN) notes that CYP2D6 poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs), such as desipramine, when given typical doses. Additionally, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. It is therefore desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be a CYP2D6 inhibitor.
https://www.pharmgkb.org/labelAnnotation/PA166104928	PA166104928	Annotation of EMA Label for ivacaftor and CFTR	EMA		Testing Required							ivacaftor	CFTR	rs121908755; rs121908757; rs121909005; rs121909013; rs121909041; rs193922525; rs267606723; rs74503330; rs75527207; rs78655421; rs80282562	4/21/2024	The EMA European Public Assessment Report (EPAR) states that ivacaftor (Kalydeco) is indicated for cystic fibrosis patients who have one of the following variants in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, R117H. Treatment in patients who do not have one of these variants is not recommended, and if a patient's genotype is not known, testing should be carried out before treatment.
https://www.pharmgkb.org/labelAnnotation/PA166104889	PA166104889	Annotation of FDA Label for pertuzumab and ERBB2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		pertuzumab	ERBB2		9/1/2023	Pertuzumab (PERJETA) is a targeted antibody drug designed to bind to ERBB2 (HER2). Detection of HER2 protein overexpression is necessary for selection of patients appropriate for PERJETA therapy because these are the only patients studied and for whom benefit has been shown.
https://www.pharmgkb.org/labelAnnotation/PA166104916	PA166104916	Annotation of FDA Label for codeine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	codeine	CYP2D6		9/18/2020	The FDA-approved drug label for codeine states in a black box warning that respiratory depression and death have occurred in children who received codeine following a tonsillectomy and/or adenoidectomy and who had evidence of being CYP2D6 ultra-rapid metabolizers. The label also states that individuals who are CYP2D6 ultra-rapid metabolizers should not use codeine.
https://www.pharmgkb.org/labelAnnotation/PA166104814	PA166104814	Annotation of FDA Label for drospirenone / ethinyl estradiol and CYP2C19	FDA	On FDA Biomarker List								drospirenone / ethinyl estradiol	CYP2C19		8/15/2023	The FDA-approved drug label for drospirenone and ethinyl estradiol (Yaz) notes that drospirenone did not affect the clearance of omeprazole, suggesting that it does not inhibit the CYP2C19 enzyme.
https://www.pharmgkb.org/labelAnnotation/PA166104853	PA166104853	Annotation of FDA Label for cisplatin and TPMT	FDA	On FDA Biomarker List	Informative PGx							cisplatin	TPMT		7/26/2024	The FDA-approved drug label for cisplatin states that genetic factors, such as variants in the TPMT gene, may contribute to cisplatin-induced ototoxicity. However, this association has not be consistent across populations and study designs.
https://www.pharmgkb.org/labelAnnotation/PA166104905	PA166104905	Annotation of EMA Label for capecitabine and DPYD	EMA		Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	capecitabine	DPYD	DPYD c.1129-5923C>G, c.1236G>A (HapB3); DPYD c.1679T>G (*13); DPYD c.1905+1G>A (*2A); DPYD c.2846A>T	6/3/2022	The EMA European Public Assessment Report (EPAR) for capecitabine (Medac) states that it is contraindicated in patients with complete absence of DPD activity, and that genotyping for certain alleles is recommended to identify patients at increased risk for severe toxicity. It also states that a reduction in starting dose in patients with partial DPD deficiency should be considered to avoid serious toxicity.
https://www.pharmgkb.org/labelAnnotation/PA166104922	PA166104922	Annotation of FDA Label for flurbiprofen and CYP2C9	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	flurbiprofen	CYP2C9		10/25/2013	The FDA-approved drug label for flurbiprofen (ANSAID) states that patients known or suspected to be CYP2C9 poor metabolizers should receive a reduced dose of flurbiprofen to avoid abnormally high plasma levels.
https://www.pharmgkb.org/labelAnnotation/PA166104870	PA166104870	Annotation of FDA Label for pimozide and CYP2D6	FDA	On FDA Biomarker List	Testing Required	Prescribing Info	Dosing Info				Prescribing	pimozide	CYP2D6		8/28/2023	The FDA-approved drug label for pimozide (ORAP) states that CYP2D6 genotyping should be performed at doses above 0.05mg/kg/day in children or above 4 mg/day in adults. In poor CYP2D6 metabolizers, pimozide doses should not exceed 0.05mg/kg/day in children or 4 mg/day in adults and doses should not be increased earlier than 14 days.
https://www.pharmgkb.org/labelAnnotation/PA166104883	PA166104883	Annotation of FDA Label for denileukin diftitox and IL2RA	FDA	On FDA Biomarker List						Cancer Genome		denileukin diftitox	IL2RA		8/6/2024	The FDA-approved drug label for denileukin diftitox (Ontak) notes that it is indicated for patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor. On the most recent drug label, testing for CD25 expression is only mentioned in the context of clinical trials.
https://www.pharmgkb.org/labelAnnotation/PA166104876	PA166104876	Annotation of FDA Label for primaquine and G6PD	FDA	On FDA Biomarker List	Testing Required	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	primaquine	G6PD		11/9/2017	The FDA-approved drug label for primaquine states that G6PD testing has to be performed before using the drug, and that it should not be prescribed for patients with severe G6PD deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166114908	PA166114908	Annotation of FDA Label for carglumic acid and NAGS	FDA	On FDA Biomarker List								carglumic acid	NAGS		8/5/2024	Carglumic acid (Carbaglu) is a synthetic structural analogue of N-acetylglutamate (NAG), and is indicated as adjunctive therapy for the treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency or maintenance therapy for treatment of chronic hyperammonemia due to NAGS deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166104898	PA166104898	Annotation of FDA Label for lansoprazole and CYP2C19	FDA	On FDA Biomarker List								lansoprazole	CYP2C19		8/18/2023	The FDA-approved drug label for lansoprazole (PREVACID) states that it is metabolized mainly by CYP3A and CYP2C19 isozymes. Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19
https://www.pharmgkb.org/labelAnnotation/PA166104899	PA166104899	Annotation of EMA Label for aripiprazole and CYP2D6	EMA		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	aripiprazole	CYP2D6		12/11/2023	The EMA European Public Assessment Report (EPAR) for aripiprazole (Abilify Maintena) states that the starting and maintenance dose should be 300 mg in known CYP2D6 poor metabolizers. The EMA EPAR for aripiprazole (ABILIFY) states that the mean elimination half-life for the drug is approximately 75 hours in CYP2D6 extensive metabolizers and 146 hours in CYP2D6 poor metabolizers, but does not provide any dosing advice based on CYP2D6 metabolizer status.
https://www.pharmgkb.org/labelAnnotation/PA166104904	PA166104904	Annotation of EMA Label for brentuximab vedotin and TNFRSF8	EMA							Cancer Genome		brentuximab vedotin	TNFRSF8		8/5/2024	The EMA European Public Assessment Report (EPAR) for brentuximab vedotin (ADCETRIS) states that it is indicated for adult patients with CD30+ Hodgkin lymphoma (HL) or CD30+ cutaneous T-cell lymphoma (CTCL), among other indications. CD30 is encoded by the TNFRSF8 gene.
https://www.pharmgkb.org/labelAnnotation/PA166123048	PA166123048	Annotation of EMA Label for cabazitaxel and CYP3A4	EMA									cabazitaxel	CYP3A4		8/14/2023	The EMA European Public Assessment Report (EPAR) for cabazitaxel (Jevtana) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A, and coadministration of strong CYP3A inhibitors or inducers should be avoided.
https://www.pharmgkb.org/labelAnnotation/PA166104832	PA166104832	Annotation of FDA Label for carisoprodol and CYP2C19	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	carisoprodol	CYP2C19		10/25/2013	Carisoprodol (SOMA) should be used with caution in patients with reduced CYP2C19 activity. Published studies indicate that patients who are poor CYP2C19 metabolizers have a 4-fold increase in exposure to carisoprodol and a 50% decreased exposure to meprobamate (a metabolite of carisoprodol) compared to normal CYP2C19 metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166104843	PA166104843	Annotation of FDA Label for celecoxib and CYP2C9	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	celecoxib	CYP2C9	CYP2C9*3	2/5/2021	The FDA-approved drug label for celecoxib (CELEBREX) states that in adult patients known or suspected to be poor CYP2C9 metabolizers, treatment should be initiated with half of the lowest recommended dose. In patients with juvenile rheumatoid arthritis (JRA) known or suspected to be poor CYP2C9 metabolizers, alternative treatments should be considered.
https://www.pharmgkb.org/labelAnnotation/PA166104908	PA166104908	Annotation of EMA Label for cetuximab and EGFR, KRAS, NRAS	EMA		Testing Required					Cancer Genome		cetuximab	EGFR; KRAS; NRAS		4/16/2024	The EMA European Public Assessment Report (EPAR) for cetuximab (Erbitux) states that it is indicated for patients with EGFR-expressing, RAS wild-type metastatic colorectal cancer, among other indications.
https://www.pharmgkb.org/labelAnnotation/PA166104930	PA166104930	Annotation of EMA Label for gefitinib and EGFR	EMA		Testing Required					Cancer Genome		gefitinib	EGFR		4/16/2024	The EMA European Public Assessment Report (EPAR) for gefitinib (IRESSA) states that it is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK.
https://www.pharmgkb.org/labelAnnotation/PA166104890	PA166104890	Annotation of FDA Label for ivacaftor and CFTR	FDA	On FDA Biomarker List	Testing Required							ivacaftor	CFTR	rs113993958; rs115545701; rs11971167; rs121908752; rs121908753; rs121908755; rs121908757; rs121909013; rs121909020; rs121909041; rs141033578; rs150212784; rs186045772; rs193922525; rs200321110; rs202179988; rs267606723; rs368505753; rs397508256; rs397508288; rs397508387; rs397508442; rs397508513; rs397508537; rs397508761; rs74503330; rs74551128; rs75039782; rs75527207; rs75541969; rs76151804; rs77834169; rs77932196; rs78655421; rs78769542; rs80224560; rs80282562	4/21/2024	Ivacaftor (KALYDECO) is indicated for the treatment of patients with cystic fibrosis (CF) who have a mutation in the CFTR gene that is responsive to ivacaftor based on clinical or in vitro data. Genetic testing is required prior to initiating treatment with ivacaftor if a patient's CFTR genotype is not known.
https://www.pharmgkb.org/labelAnnotation/PA166104927	PA166104927	Annotation of EMA Label for lenalidomide	EMA		Testing Required					Cancer Genome		lenalidomide			5/2/2024	The EMA European Public Assessment Report (EPAR) for lenalidomide (Revlimid) states that, among other indications, lenalidomide as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.
https://www.pharmgkb.org/labelAnnotation/PA166104894	PA166104894	Annotation of EMA Label for rasburicase and G6PD	EMA		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	rasburicase	G6PD		2/22/2023	The EMA European Public Assessment Report (EPAR) for rasburicase (Fasturtec) states that it is contraindicated in patients with G6PD deficiency due to a risk of hemolytic anemia or methemoglobinemia. Testing or screening for G6PD deficiency is not mentioned.
https://www.pharmgkb.org/labelAnnotation/PA166119824	PA166119824	Annotation of EMA Label for belimumab and TNFSF13B	EMA									belimumab	TNFSF13B		8/14/2023	The EMA European Public Assessment Report (EPAR) for belimumab (Benlysta) contains information regarding its mechanism of action for use in the treatment of systemuc lupus erythematosus (SLE). It is a human IgG1lambda that blocks binding of TNFSF13B to its receptor to inhibit B cell survival and reduce differentiation.
https://www.pharmgkb.org/labelAnnotation/PA166122488	PA166122488	Annotation of EMA Label for regorafenib and KRAS	EMA		Informative PGx					Cancer Genome		regorafenib	KRAS		7/5/2022	The EMA European Public Assessment Report (EPAR) for regorafenib (Stivarga) states that the hazard ratios for overall survival and progression-free survival were lower in patients with KRAS wild-type tumors as compared to KRAS mutant tumors. However, the EPAR does not comment on the significance of this difference.
https://www.pharmgkb.org/labelAnnotation/PA166114382	PA166114382	Annotation of EMA Label for ticagrelor and CYP2C19	EMA		Informative PGx							ticagrelor	CYP2C19		7/19/2024	The EMA European Public Assessment Report (EPAR) for ticagrelor (Brilique) contains information regarding a study in which CYP2C19 and ABCB1 genotyping was carried out (PLATO - platelet inhibition and patient outcomes). In patients with one or more CYP2C19 loss of function allele, non-coronary artery by-pass grafting (non-CABG) PLATO major bleeding was increased when treated with ticagrelor compared to clopidogrel, but was similar in patients with no loss of function alleles.
https://www.pharmgkb.org/labelAnnotation/PA166105240	PA166105240	Annotation of FDA Label for rituximab and MS4A1	FDA	On FDA Biomarker List						Cancer Genome		rituximab	MS4A1		8/24/2023	Rituximab (Rituxan) is used to treat patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis or granulomatosis polyangiitis and microscopic polyangiitis. The drug is a CD20-directed cytolytic monoclonal antibody, but there is no association with genetic variation within the coding gene, MS4A1, and therefore no mention of genetic testing in the drug label.
https://www.pharmgkb.org/labelAnnotation/PA166119825	PA166119825	Annotation of EMA Label for carglumic acid and NAGS	EMA									carglumic acid	NAGS		8/5/2024	The EMA European Public Assessment Report (EPAR) for carglumic acid (Carbaglu) states that it is indicated in the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) primary deficiency, among other indications.
https://www.pharmgkb.org/labelAnnotation/PA166121246	PA166121246	Annotation of EMA Label for ibritumomab and MS4A1	EMA							Cancer Genome		ibritumomab	MS4A1		9/28/2023	The EMA European Public Assessment Report (EPAR) for ibritumomab (Zevalin) contains information regarding the indication of the drug for the treatment of CD20+ (MS4A1) follicular B-cell non-Hodgkin's lymphoma due to its mechanism of action.
https://www.pharmgkb.org/labelAnnotation/PA166121251	PA166121251	Annotation of EMA Label for mercaptopurine and NUDT15, TPMT	EMA		Testing Recommended	Prescribing Info	Dosing Info				Prescribing	mercaptopurine	NUDT15; TPMT	rs116855232	7/24/2024	The EMA European Public Assessment Report (EPAR) for mercaptopurine (Xaluprine) states that starting or target doses should be lower in patients with reduced or absent TPMT enzyme activity, and that patients with mutated NUDT15 gene also generally require a dose reduction.
https://www.pharmgkb.org/labelAnnotation/PA166151881	PA166151881	Annotation of FDA Label for rasburicase and G6PD	FDA	On FDA Biomarker List	Testing Required	Prescribing Info		Alternate Drug			Prescribing	rasburicase	G6PD		3/21/2016	The FDA-approved drug label for rasburicase (Elitek) states that patients at higher risk for G6PD deficiency, such as those of African or Mediterranean ancestry, should be screened prior to starting treatment, as rasburicase is contraindicated in patients with G6PD deficiency. The label also states that It is unclear whether patients with NADH cytochrome b5 reductase (CYB5R1, 2, 3, 4) deficiency are at risk for methemoglobinemia or hemolytic anemia.
https://www.pharmgkb.org/labelAnnotation/PA166159064	PA166159064	Annotation of FDA Label for elosulfase alfa and GALNS	FDA	On FDA Biomarker List	Testing Required							elosulfase alfa	GALNS		8/21/2023	Elosulfase alfa (VIMIZIM) is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with mucopolysaccharidosis type IVA, also known as Morquio A syndrome. This disease results from deficiency or marked reduction of the galactosamine (N-acetyl)-6-sulfatase (GALNS) enzyme.
https://www.pharmgkb.org/labelAnnotation/PA166185194	PA166185194	Annotation of FDA Label for raloxifene and ESR1, ESR2	FDA	On FDA Biomarker List						Cancer Genome		raloxifene	ESR1; ESR2		9/7/2023	The FDA label for raloxifene (EVISTA) states that EVISTA is indicated for the treatment and prevention of osteoporosis in postmenopausal women, for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer. The label notes the percentages of patients in clinical studies who had estrogen receptor (ER) positive disease.
https://www.pharmgkb.org/labelAnnotation/PA166159938	PA166159938	Annotation of HCSC Label for belimumab and TNFSF13B	HCSC									belimumab	TNFSF13B		8/14/2023	Belimumab (BENLYSTA) is a human IgG1λ monoclonal antibody, indicated for use in adults with active, autoantibody-positive, systemic lupus erythematosus who are receiving standard therapy. It acts by blocking binding of soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B-cell survival factor, to its receptors on B cells.
https://www.pharmgkb.org/labelAnnotation/PA166160288	PA166160288	Annotation of HCSC Label for brentuximab vedotin and TNFRSF8	HCSC							Cancer Genome		brentuximab vedotin	TNFRSF8		8/5/2024	Brentuximab vedotin (Adcetris) is an antibody-drug conjugate (ADC) directed at TNFRSF8 (CD30), and its anti-cancer mechanism of action is by binding to CD30-expressing cells and then releasing a small molecule that disrupts microtubules.
https://www.pharmgkb.org/labelAnnotation/PA166160289	PA166160289	Annotation of HCSC Label for brivaracetam and CYP2C19	HCSC		Informative PGx							brivaracetam	CYP2C19		7/15/2024	The drug label for brivaracetam (BRIVLERA) states that individuals with ineffective mutations of CYP2C19 had decreased production of the hydroxy metabolite and increased concentrations of brivaracetam.
https://www.pharmgkb.org/labelAnnotation/PA166183246	PA166183246	Annotation of EMA Label for osimertinib and EGFR	EMA		Testing Required					Cancer Genome		osimertinib	EGFR	rs121434568; rs121434569	8/12/2024	The EMA European Public Assessment Report (EPAR) for osimertinib (TAGRISSO) states that it is indicated for the treatment of adult patients with non-small cell lung cancer with activating EGFR mutations or EGFR T790M mutation. Robust, reliable and sensitive tests with demonstrated utility for the determination of EGFR mutation status should be used to confirm the EGFR mutation-positive status prior to treatment.
https://www.pharmgkb.org/labelAnnotation/PA166182744	PA166182744	Annotation of FDA Label for lorlatinib and ALK	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		lorlatinib	ALK		12/5/2023	The FDA-approved drug label for lorlatinib (LORBRENA) states that it is indicated for the treatment of treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
https://www.pharmgkb.org/labelAnnotation/PA166182727	PA166182727	Annotation of FDA Label for ivosidenib and IDH1	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		ivosidenib	IDH1		8/31/2023	The FDA-approved drug label for ivosidenib (TIBSOVO) states that it is indicated for the treatment of acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.
https://www.pharmgkb.org/labelAnnotation/PA166182940	PA166182940	Annotation of EMA Label for cholic acid and AKR1D1, HSD3B7	EMA									cholic acid	AKR1D1; HSD3B7		8/5/2024	The EMA European Public Assessment Report (EPAR) for cholic acid (Orphacol) states that it is indicated for the treatment of inborn errors in primary bile acid synthesis due to 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency or Δ4-3-Oxosteroid-5β-reductase deficiency, which can be caused by deficiencies in the proteins encoded by the HSD3B7 and AKR1D1 genes.
https://www.pharmgkb.org/labelAnnotation/PA166182726	PA166182726	Annotation of FDA Label for rivaroxaban and F5	FDA	On FDA Biomarker List								rivaroxaban	F5		8/24/2023	Rivaroxaban (XARELTO) is an anticoagulant with several indications, including for the reduction of risk of recurrence of deep vein thrombosis (DVT) or pulmonary embolism (PE). In a study of the efficacy of rivaroxaban in reducing the risk of recurrence of DVT or PE, mutations in F5 are mentioned as a risk factor for recurrence of DVT or PE.
https://www.pharmgkb.org/labelAnnotation/PA166160121	PA166160121	Annotation of FDA Label for nivolumab and BRAF, ERBB2	FDA	On FDA Biomarker List						Cancer Genome		nivolumab	BRAF; ERBB2	rs113488022	12/4/2023	The FDA-approved drug label for nivolumab (OPDIVO) previously stated that it is indicated for the treatment of patients with BRAF V600 wild-type or BRAF V600 mutation-positive unresectable or metastatic melanoma as a single agent, among other indications. The label now indicates for unresectable or metastatic melanoma and does not define by BRAF mutation, although there is discussion of BRAF in the different clinical studies. The label also mentions that patients with ERBB2 (HER2) positive cancers were excluded from some clinical studies of nivolumab.
https://www.pharmgkb.org/labelAnnotation/PA166182725	PA166182725	Annotation of FDA Label for eribulin and ERBB2, ESR1, ESR2, PGR	FDA	On FDA Biomarker List						Cancer Genome		eribulin	ERBB2; ESR1; ESR2; PGR		8/17/2023	The FDA-approved label for eribulin (HALAVEN) states that it is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease and unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.
https://www.pharmgkb.org/labelAnnotation/PA166182750	PA166182750	Annotation of FDA Label for toremifene and ESR1, ESR2	FDA	On FDA Biomarker List						Cancer Genome		toremifene	ESR1; ESR2		8/6/2024	The FDA-approved drug label for toremifene (FARESTON) states that it is indicated for the treatment of estrogen-receptor positive or unknown metastatic breast cancer.
https://www.pharmgkb.org/labelAnnotation/PA166182787	PA166182787	Annotation of FDA Label for tolbutamide and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	tolbutamide	G6PD		8/25/2023	The FDA-approved drug label for tolbutamide states that, due to the risk of hemolytic anemia, caution should be used when administering tolbutamide to patients with G6PD deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166182941	PA166182941	Annotation of EMA Label for cobimetinib and BRAF	EMA		Testing Required					Cancer Genome		cobimetinib	BRAF		4/16/2024	The EMA European Public Assessment Report (EPAR) for cobimetinib (Cotellic) states that it is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutations.
https://www.pharmgkb.org/labelAnnotation/PA166182944	PA166182944	Annotation of EMA Label for duloxetine and CYP2D6	EMA		Informative PGx							duloxetine	CYP2D6			The EMA European Public Assessment Report (EPAR) for duloxetine (Cymbalta) states that the pharmacokinetics of the drug have large intersubject variability partly due to gender, age, smoking status and CYP2D6 metabolizer status. Limited data suggests that concentrations of duloxetine are higher in CYP2D6 poor metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166182943	PA166182943	Annotation of EMA Label for dolutegravir and UGT1A1	EMA		Informative PGx							dolutegravir	UGT1A1			The EMA European Public Assessment Report (EPAR) for dolutegravir (Tivicay) states that subjects with UGT1A1 genotypes that confer poor dolutegravir metabolism had a 32% lower clearance and 46% higher AUC as compared to subjects with UGT1A1 genotypes that confer normal dolutegravir metabolism.
https://www.pharmgkb.org/labelAnnotation/PA166129528	PA166129528	Annotation of HCSC Label for sodium nitrite and G6PD	HCSC		Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	sodium nitrite	G6PD		7/21/2024	Sodium nitrite is indicated for sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning judged to be life-threatening. Patients with G6PD deficiency are at increased risk for hemolytic crisis when administered sodium nitrite; the product monograph notes that alternative therapeutic approaches should be considered in these patients.
https://www.pharmgkb.org/labelAnnotation/PA166183621	PA166183621	Annotation of Swissmedic Label for mefloquine and G6PD	Swissmedic		Informative PGx							mefloquine	G6PD			The Swiss drug label for mefloquine (Mephaquin Lactab) states that there's no in vitro or in vivo evidence to suggest hemolysis to be associated with glucose-6-phosphate dehydrogenase deficiency in patients treated with mefloquine.
https://www.pharmgkb.org/labelAnnotation/PA166183593	PA166183593	Annotation of Swissmedic Label for acenocoumarol and CYP2C9	Swissmedic		Actionable PGx							acenocoumarol	CYP2C9	CYP2C9*2; CYP2C9*3		The Swiss drug label for acenocoumarol (Sintrom) states that patients with the CYP2C9*2 or *3 variants have reduced clearance of acenocoumarol.
https://www.pharmgkb.org/labelAnnotation/PA166182752	PA166182752	Annotation of FDA Label for talazoparib and ERBB2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		talazoparib	ERBB2		8/26/2024	The FDA-approved label for talazoparib (TALZENNA) states that it is indicated for use in patients with deleterious or suspected deleterious germline BRCA mutations and HER2-negative locally advanced or metastatic breast cancer, and in combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCPRC). Select patients for the treatment with talazoparib based on the presence of alterations in genes directly or indirectly involved in HRR.
https://www.pharmgkb.org/labelAnnotation/PA166160051	PA166160051	Annotation of FDA Label for alectinib and ALK	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		alectinib	ALK		8/19/2024	The FDA-approved drug label for alectinib (ALECENSA) states that it is indicated for the treatment of patients with ALK-positive non-small cell lung cancer, as detected by an FDA-approved test.
https://www.pharmgkb.org/labelAnnotation/PA166184238	PA166184238	Annotation of Swissmedic Label for voriconazole and CYP2C19	Swissmedic		Actionable PGx							voriconazole	CYP2C19			The Swiss drug label for voriconazole (Vfend) states that voriconazole levels are increased in patients who are CYP2C19 intermediate or poor metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166184404	PA166184404	Annotation of Swissmedic Label for tamsulosin and CYP2D6, CYP3A4	Swissmedic		Actionable PGx							tamsulosin	CYP2D6; CYP3A4			The Swiss drug label for tamsulosin (Pradif) and tamsulosin and dutasteride (Duodart) states that since CYP3A4 inhibitors can significantly influence exposure to tamsulosin in CYP2D6 poor metabolizers, all tamsulosin treated patients should avoid strong CYP3A4 inhibitors.
https://www.pharmgkb.org/labelAnnotation/PA166151974	PA166151974	Annotation of HCSC Label for nilotinib and UGT1A1	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	nilotinib	UGT1A1		7/23/2024	The product monograph for nilotinib (TASIGNA) notes that patients homozygous for the UGT1A1*28 allele (rs8175347; (TA)7) may be at risk for hyperbilirubinemia when receiving nilotinib. This drug is indicated for patients with Philadelphia chromosome positive (BCR-ABL1 fusion) chronic myeloid leukemia, though individuals with the BCR-ABL T315I mutation are highly resistant to the drug.
https://www.pharmgkb.org/labelAnnotation/PA166160010	PA166160010	Annotation of FDA Label for dolutegravir and UGT1A1	FDA	On FDA Biomarker List	Informative PGx							dolutegravir	UGT1A1			The FDA-approved drug label for TIVICAY (dolutegravir) states that subjects with UGT1A1 genotypes that result in poor metabolism of the drug have decreased clearance and increased AUC as compared to those who have UGT1A1 genotypes that result in normal dolutegravir metabolism. The label does not mention specific UGT1A1 variants or genetic testing.
https://www.pharmgkb.org/labelAnnotation/PA166183590	PA166183590	Annotation of Swissmedic Label for maraviroc and CYP3A5	Swissmedic		Actionable PGx							maraviroc	CYP3A5	CYP3A5*1		The Swiss drug label for maraviroc (Celsentri) states that CYP3A5 genotypes may affect the exposure to maraviroc.
https://www.pharmgkb.org/labelAnnotation/PA166182949	PA166182949	Annotation of EMA Label for erlotinib and UGT1A1	EMA		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	erlotinib	UGT1A1		8/6/2024	The EMA European Public Assessment Report (EPAR) for erlotinib (Tarceva) states that patients with low expression levels of UGT1A1 or genetic glucuronidation disorders such as Gilbert's disease may have increased concentrations of bilirubin and should be treated with caution.
https://www.pharmgkb.org/labelAnnotation/PA166183219	PA166183219	Annotation of EMA Label for mirabegron and CYP2D6	EMA		No Clinical PGx							mirabegron	CYP2D6		8/15/2023	The EMA European Public Assessment Report (EPAR) for mirabegron (Betmiga) states that CYP2D6 genetic polymporphisms have a minimal impact on exposure to mirabegron and no dose adjustment is needed when administered to patients who are CYP2D6 poor metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166183563	PA166183563	Annotation of Swissmedic Label for abacavir and HLA-B	Swissmedic		Testing Required	Prescribing Info		Alternate Drug			Prescribing	abacavir	HLA-B	HLA-B*57:01	2/28/2023	The Swiss drug label for abacavir (Ziagen) states that patients should be screened for the presence of HLA-B*57:01 prior to starting treatment with abacavir. Ziagen is contraindicated in carriers of the HLA-B*57:01 allele.
https://www.pharmgkb.org/labelAnnotation/PA166161536	PA166161536	Annotation of PMDA Label for atazanavir and CYP2C19	PMDA		Actionable PGx							atazanavir	CYP2C19			The PMDA package insert for atazanavir (Reyataz) contains pharmacogenetic information related to co-treatment with voriconazole and ritonavir: atazanavir exposure is expected to be decreased and voriconazole exposure is expected to be increased in patients who are CYP2C19 poor metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166182766	PA166182766	Annotation of FDA Label for fosphenytoin and CYP2C19, CYP2C9, HLA-B	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	fosphenytoin	CYP2C19; CYP2C9; HLA-B	CYP2C9*2; CYP2C9*3; HLA-B*15:02	8/23/2023	The FDA label for fosphenytoin (CEREBYX) states that limited evidence suggests that the HLA-B*15:02 and CYP2C9*3 alleles may increase the risk of severe cutaneous adverse reactions in patients of Asian ancestry who are treated with phenytoin and that prescribers should consider avoiding fosphenytoin as an alternative to carbamazepine in these patients. It also notes that the phenytoin derived from fosphenytoin is metabolized by CYP2C9 and CYP2C19 and that patients who are known to be CYP2C9 intermediate or poor metabolizers may have lower fosphenytoin dose requirements.
https://www.pharmgkb.org/labelAnnotation/PA166183441	PA166183441	Annotation of EMA Label for umeclidinium and CYP2D6	EMA		No Clinical PGx							umeclidinium	CYP2D6			The EMA European Public Assessment Report (EPAR) for umeclidinium (Incruse Ellipta) states that there is no evidence of any clinically significant effect of CYP2D6 genetic polymorphism on systemic exposure to umeclidinium.
https://www.pharmgkb.org/labelAnnotation/PA166182928	PA166182928	Annotation of EMA Label for binimetinib and BRAF	EMA		Testing Required					Cancer Genome		binimetinib	BRAF	rs113488022	4/16/2024	The EMA European Public Assessment Report (EPAR) for binimetinib (Mektovi) states that it is indicated in combination with encorafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
https://www.pharmgkb.org/labelAnnotation/PA166177479	PA166177479	Annotation of FDA Label for cariprazine and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							cariprazine	CYP2D6		8/15/2023	Cariprazine (VRAYLAR) is an atypical antipsychotic used for the treatment of schizophrenia and bipolar disorder. The label notes that CYP2D6 poor metabolizer status does not have a clinically relevant effect on cariprazine pharmacokinetics.
https://www.pharmgkb.org/labelAnnotation/PA166182942	PA166182942	Annotation of EMA Label for dacomitinib and EGFR	EMA		Testing Required					Cancer Genome		dacomitinib	EGFR		4/16/2024	The EMA European Public Assessment Report (EPAR) for dacomitinib (Vizimpro) states that it is indicated for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-activating mutations,
https://www.pharmgkb.org/labelAnnotation/PA166182953	PA166182953	Annotation of EMA Label for ivacaftor / lumacaftor and CFTR	EMA		Testing Required							ivacaftor / lumacaftor	CFTR	rs113993960	4/21/2024	The EMA European Public Assessment Report (EPAR) for ivacaftor and lumacaftor (Orkambi) states that it is indicated for the treatment of cystic fibrosis in patients aged 6 years and older who are homozygous for the F508del mutation in the CFTR gene.
https://www.pharmgkb.org/labelAnnotation/PA166183423	PA166183423	Annotation of EMA Label for rucaparib and BRCA1, BRCA2	EMA		Testing Required					Cancer Genome		rucaparib	BRCA1; BRCA2		4/21/2024	The EMA European Public Assessment Report (EPAR) for rucaparib (Rubraca) states that testing must confirm deleterious germline or somatic mutations in BRCA1 and BRCA2 prior to treatment for relapsed or progressive high-grade epithelial ovarian cancer (EOC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) although there is no need to test for maintenance treatment of adult patients with relapsed high-grade epithelial ovarian cancer (EOC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) who are in a complete or partial response to platinum-based chemotherapy.
https://www.pharmgkb.org/labelAnnotation/PA166182934	PA166182934	Annotation of EMA Label for cerliponase alfa and TPP1	EMA									cerliponase alfa	TPP1		8/5/2024	The EMA European Public Assessment Report (EPAR) for cerliponase alfa (Brineura) states that it is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166182932	PA166182932	Annotation of EMA Label for brivaracetam and CYP2C19	EMA		Informative PGx							brivaracetam	CYP2C19		7/15/2024	The EMA European Public Assessment Report (EPAR) for brivaracetam (Briviact) states that individuals with ineffective mutations of CYP2C19 had decreased production of the hydroxy metabolite and increased concentrations of brivaracetam.
https://www.pharmgkb.org/labelAnnotation/PA166170937	PA166170937	Annotation of FDA Label for trametinib and G6PD	FDA	On FDA Biomarker List								trametinib	G6PD		8/29/2023	Trametinib (MEKINIST) is indicated for use in patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, or metastatic non-small cell lung cancer with BRAF V600E mutation, as detected by an FDA-approved test. The label also notes that patients with a known history of G6PD deficiency were excluded from some clinical trials.
https://www.pharmgkb.org/labelAnnotation/PA166184917	PA166184917	Annotation of FDA Label for avatrombopag and CYP2C9	FDA	On FDA Biomarker List	Informative PGx							avatrombopag	CYP2C9	CYP2C9*2; CYP2C9*3	7/11/2024	The FDA-approved drug label for avatrombopag (DOPTELET) states that avatrombopag is primarily metabolized by CYP2C9 and CYP3A4, and that the CYP2C9*2 and CYP2C9*3 loss-of-function polymorphisms result in reduced CYP2C9 enzymatic activity and higher drug exposure in heterozygous and homozygous carriers.
https://www.pharmgkb.org/labelAnnotation/PA166160668	PA166160668	Annotation of PMDA Label for allopurinol and HLA-B	PMDA		Informative PGx							allopurinol	HLA-B	HLA-B*58:01		The PMDA package insert for allopurinol (TEVA) notes that the HLA-B*58:01 allele was present at a high frequency in patients with Stevens-Johnson syndrome or toxic epidermal necrolysis who came from Han Chinese, Japanese or European populations.
https://www.pharmgkb.org/labelAnnotation/PA166183200	PA166183200	Annotation of EMA Label for midostaurin and FLT3	EMA		Testing Required					Cancer Genome		midostaurin	FLT3		4/21/2024	The EMA European Public Assessment Report (EPAR) for midostaurin (Rydapt) states that it is indicated for treatment of adults with acute myeloid leukemia who are FLT3 mutation-positive.
https://www.pharmgkb.org/labelAnnotation/PA166183184	PA166183184	Annotation of EMA Label for lorlatinib and ALK	EMA		Testing Required					Cancer Genome		lorlatinib	ALK		5/24/2024	The EMA European Public Assessment Report (EPAR) for lorlatinib (Lorviqua) states that it is indicated as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) not previously treated with an ALK inhibitor. Detection of ALK-positive NSCLC is necessary for selection of patients for treatment with lorlatinib because these are the only patients for whom benefit has been shown.
https://www.pharmgkb.org/labelAnnotation/PA166177516	PA166177516	Annotation of FDA Label for neratinib and ERBB2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		neratinib	ERBB2		8/31/2023	Neratinib (NERLYNX) is indicated for the treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.
https://www.pharmgkb.org/labelAnnotation/PA166159586	PA166159586	Annotation of HCSC Label for aliskiren and ABCB1	HCSC									aliskiren	ABCB1		8/14/2023	The HCSC product monograph for aliskiren (Rasilez HCT) does not contain pharmacogenetic information. It contains information regarding the role of ABCB1 (Pgp, MDR1) in intestinal absorption of aliskiren, and concomitant use of aliskiren with potent P-gp inhibitors is contraindicated.
https://www.pharmgkb.org/labelAnnotation/PA166183784	PA166183784	Annotation of Swissmedic Label for amifampridine phosphate and NAT2	Swissmedic		Actionable PGx							amifampridine phosphate	NAT2			The Swiss drug label for amifampridine (Firdapse) states that patients who are NAT2 slow acetylators may have higher exposure to the drug and more adverse effects as compared to fast acetylators
https://www.pharmgkb.org/labelAnnotation/PA166183782	PA166183782	Annotation of Swissmedic Label for aspirin and G6PD	Swissmedic		Actionable PGx							aspirin	G6PD			The Swiss drug label for aspirin (Aspirin Cardio 100/300, Aspirin, Aspirin-C) states that acetylsalicylic acid could induce hemolysis or hemolytic anemia in patients with G6PD deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166184232	PA166184232	Annotation of Swissmedic Label for venlafaxine and CYP2D6	Swissmedic		Actionable PGx							venlafaxine	CYP2D6			The Swiss drug label for venlafaxine (Efexor ER) states that CYP2D6 poor metabolizers experience a greater increase in the AUCs of venlafaxine and O-desmethylvenlafaxine when treated with concomitant ketoconazole compared to normal metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166159584	PA166159584	Annotation of HCSC Label for afutuzumab and MS4A1	HCSC							Cancer Genome		afutuzumab	MS4A1		8/11/2023	Afutuzumab (GAZYVA; obinutuzumab) is used in combination with chlorambucil in patients with chronic lymphocytic leukemia who are previously untreated. The drug is a CD20-directed cytolytic monoclonal antibody, but there is no association with genetic variation within the coding gene, MS4A1, and therefore no mention of genetic testing in the drug label.
https://www.pharmgkb.org/labelAnnotation/PA166183249	PA166183249	Annotation of EMA Label for pembrolizumab and ALK, CD274, EGFR, ERBB2	EMA		Testing Required					Cancer Genome		pembrolizumab	ALK; CD274; EGFR; ERBB2		4/21/2024	The EMA European Public Assessment Report (EPAR) for pembrolizumab (KEYTRUDA) states that it is indicated for the treatment of certain cancers with documented expression of PD-L1 (CD274) and do not have mutations in ALK, EGFR or ERBB2 (listed as HER-2 in the label).
https://www.pharmgkb.org/labelAnnotation/PA166170930	PA166170930	Annotation of FDA Label for dabrafenib and HRAS, KRAS, NRAS	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance	Cancer Genome	Prescribing	dabrafenib	HRAS; KRAS; NRAS		11/30/2023	The drug label for dabrafenib (TAFINLAR) states that it is indicated, as a single agent or in combination with trametinib, for patients with certain types of cancer. The label also notes that the drug may promote growth and development of malignancies with activation of RAS.
https://www.pharmgkb.org/labelAnnotation/PA166183251	PA166183251	Annotation of EMA Label for raltegravir and UGT1A1	EMA		No Clinical PGx							raltegravir	UGT1A1		8/23/2023	The EMA European Public Assessment Report (EPAR) for raltegravir (ISENTRESS) states that the geometric mean ratio of AUC was 1.41 in patients with the UGT1A1*28/*28 genotype and 1.91 in patients with the UGT1A1 wild-type genotype, and that dose adjustment is not necessary based on UGT1A1 genotype.
https://www.pharmgkb.org/labelAnnotation/PA166183248	PA166183248	Annotation of EMA Label for palonosetron and CYP2D6	EMA		No Clinical PGx							palonosetron	CYP2D6			The EMA European Public Assessment Report (EPAR) for palonosetron (Aloxi) states that pharmacokinetic parameters are not significantly different between CYP2D6 poor and extensive metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166169877	PA166169877	Annotation of FDA Label for avelumab and CD274	FDA	On FDA Biomarker List						Cancer Genome		avelumab	CD274		8/5/2024	The FDA-approved drug label for avelumab (BAVENCIO) states that it is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of metastatic Merkel cell carcinoma and locally advanced or metastatic urothelial carcinoma. PD-L1 is encoded by the CD274 gene.
https://www.pharmgkb.org/labelAnnotation/PA166183783	PA166183783	Annotation of Swissmedic Label for allopurinol and HLA-B	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	allopurinol	HLA-B	HLA-B*58:01	2/28/2023	The Swiss drug label for allopurinol (Zyloric) states that in patients with the HLA-B*58:01 allele, use of allopurinol may be considered if the benefits are considered greater than the risks. However, increased attention to signs of hypersensitivity reaction or SJS/TEN is required.
https://www.pharmgkb.org/labelAnnotation/PA166163433	PA166163433	Annotation of FDA Label for eteplirsen and DMD	FDA	On FDA Biomarker List	Testing Required							eteplirsen	DMD		8/21/2023	The FDA-approved drug label for eteplirsen (EXONDYS 51) states that it is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.
https://www.pharmgkb.org/labelAnnotation/PA166183172	PA166183172	Annotation of EMA Label for lapatinib and HLA-DQA1, HLA-DRB1	EMA		Informative PGx							lapatinib	HLA-DQA1; HLA-DRB1	HLA-DQA1*02:01; HLA-DRB1*07:01		The EMA European Public Assessment Report (EPAR) for lapatinib (Tyverb) states that patients with the HLA-DQA1*02:01 and HLA-DRB1*07:01 alleles have an increased risk of hepatotoxicity.
https://www.pharmgkb.org/labelAnnotation/PA166183220	PA166183220	Annotation of EMA Label for neratinib and ERBB2, ESR1, ESR2, PGR	EMA		Testing Required					Cancer Genome		neratinib	ERBB2; ESR1; ESR2; PGR		4/21/2024	The EMA European Public Assessment Report (EPAR) for neratinib (Nerlynx) states that it is indicated for the treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.
https://www.pharmgkb.org/labelAnnotation/PA166160153	PA166160153	Annotation of PMDA Label for celecoxib and CYP2C9	PMDA		Actionable PGx							celecoxib	CYP2C9			The PMDA package insert for celecoxib (Celecox) notes that individuals with the CYP2C9 *1/*3 or *3/*3 genotypes had increased AUC or Cmax of celecoxib as compared to those with the *1/*1 genotype.
https://www.pharmgkb.org/labelAnnotation/PA166160226	PA166160226	Annotation of PMDA Label for codeine and CYP2D6	PMDA		Actionable PGx							codeine	CYP2D6			The PMDA package insert for codeine notes that CYP2D6 ultrarapid metabolizers are at increased risk of developing side effects due to high serum levels of morphine, and that they may also have higher morphine levels in breast milk.
https://www.pharmgkb.org/labelAnnotation/PA166160683	PA166160683	Annotation of PMDA Label for dapsone and G6PD	PMDA		Actionable PGx							dapsone	G6PD			The PMDA package insert for dapsone (PROTOGEN) states that hemolysis may occur in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166160162	PA166160162	Annotation of PMDA Label for efavirenz and CYP2B6	PMDA		Actionable PGx							efavirenz	CYP2B6			The PMDA package insert for efavirenz (STOCRIN) notes that patients with the CYP2B6 rs3745274 TT genotype may have an increased AUC as compared to those with the GG genotype.
https://www.pharmgkb.org/labelAnnotation/PA166160712	PA166160712	Annotation of PMDA Label for fesoterodine and CYP2D6	PMDA		Actionable PGx							fesoterodine	CYP2D6			The PMDA package insert for fesoterodine (Toviaz) states that CYP2D6 poor metabolizers had increased Cmax and AUC of the active metabolite (5-HMT) as compared to extensive metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166160717	PA166160717	Annotation of PMDA Label for letrozole and CYP2A6	PMDA		Actionable PGx							letrozole	CYP2A6			The PMDA package insert for letrozole notes that CYP2A6 slow metabolizers were found to have 2-fold higher mean plasma trough concentrations as compared to extensive metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166160719	PA166160719	Annotation of PMDA Label for nalidixic acid and G6PD	PMDA		Actionable PGx							nalidixic acid	G6PD			The PMDA package insert for nalidixic acid states that patients with G6PD deficiency are at increased risk of hemolytic anemia.
https://www.pharmgkb.org/labelAnnotation/PA166160845	PA166160845	Annotation of PMDA Label for perphenazine and CYP2D6	PMDA		Actionable PGx							perphenazine	CYP2D6			The PMDA package insert for perphenazine states that individuals who are deficient in CYP2D6 may have higher serum levels of the drug.
https://www.pharmgkb.org/labelAnnotation/PA166160846	PA166160846	Annotation of PMDA Label for rabeprazole and CYP2C19	PMDA		Actionable PGx							rabeprazole	CYP2C19			The PMDA package insert for rabeprazole states that CYP2C19 and CYP3A4 are involved in the metabolism of the drug, and provides data showing that CYP2C19 poor metabolizers have increased Cmax, AUC and half-life time as compared to extensive metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166160847	PA166160847	Annotation of PMDA Label for sulfadiazine and G6PD	PMDA		Actionable PGx							sulfadiazine	G6PD			The PMDA package insert for sulfadiazine (GEBEN) states that hemolysis may occur in patients with G6PD deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166160848	PA166160848	Annotation of PMDA Label for sulfamethoxazole / trimethoprim and G6PD	PMDA		Actionable PGx							sulfamethoxazole / trimethoprim	G6PD			The PMDA package insert for sulfamethoxazole and trimethoprim (DAIPHEN) states that hemolysis may occur in patients with G6PD deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166160849	PA166160849	Annotation of PMDA Label for sulfasalazine and G6PD	PMDA		Actionable PGx							sulfasalazine	G6PD			The PMDA package insert for sulfasalazine (Azulfidine) states that hemolysis may occur in patients with G6PD deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166160850	PA166160850	Annotation of PMDA Label for tetrabenazine and CYP2D6	PMDA		Actionable PGx							tetrabenazine	CYP2D6			The PMDA package insert for tetrabenazine states that CYP2D6 poor metabolizers and intermediate metabolizer are at increased risk of developing side effects due to higher levels of the active metabolite, and that caution should be used in treating these patients.
https://www.pharmgkb.org/labelAnnotation/PA166160854	PA166160854	Annotation of PMDA Label for moviprep and G6PD	PMDA		Actionable PGx							moviprep	G6PD			MoviPrep, a solution containing Vitamin C, is a laxative used for colon cleansing in preparation for a colonoscopy. Because it contains Vitamin C (ascorbic acid), the PMDA package insert warns that hemolytic reactions are possible in those with G6PD deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166160856	PA166160856	Annotation of PMDA Label for voriconazole and CYP2C19	PMDA		Actionable PGx							voriconazole	CYP2C19			The PMDA package insert for voriconazole (VFEND) notes that it is metabolized by CYP2C19 (as well as CYP2C9 and CYP3A4) and provides tables showing the difference in pharmacokinetic metrics between extensive metabolizers (EM), intermediate metabolizers (also known as heterozygous extensive metabolizers (HEM)) and poor metabolizers (PM) in adults and pediatrics.
https://www.pharmgkb.org/labelAnnotation/PA166160709	PA166160709	Annotation of PMDA Label for eliglustat and CYP2D6	PMDA		Testing Required							eliglustat	CYP2D6			The PMDA package insert for eliglustat (CERDELGA) states that a patient's CYP2D6 genotype should be established prior to treatment, and that the drug is not recommended in CYP2D6 poor or ultrarapid metabolizers, or those who CYP2D6 metabolizer status cannot be determined.
https://www.pharmgkb.org/labelAnnotation/PA166160710	PA166160710	Annotation of PMDA Label for erlotinib and EGFR	PMDA		Testing Required							erlotinib	EGFR			The PMDA package insert for erlotinib states that it is indicated for recurrent and/or advanced inoperable non-small cell lung cancer that is positive for an EGFR gene mutation and has not been previously treated with chemotherapy.
https://www.pharmgkb.org/labelAnnotation/PA166160851	PA166160851	Annotation of PMDA Label for vemurafenib and BRAF	PMDA		Testing Required							vemurafenib	BRAF			The PMDA package insert for vemurafenib (ZELBORAF) states that it is indicated for patients with unresectable, refractory melanoma with BRAF gene mutation.
https://www.pharmgkb.org/labelAnnotation/PA166160669	PA166160669	Annotation of PMDA Label for escitalopram and CYP2C19, CYP2D6	PMDA		Actionable PGx							escitalopram	CYP2C19; CYP2D6			The PMDA package insert for escitalopram notes that the recommended maximum dose is 10 mg in patients with genetically absent CYP2C19 activity (poor metabolizers), due to an increased risk for developing QT prolongation and other side effects from the increased plasma concentrations.
https://www.pharmgkb.org/labelAnnotation/PA166152939	PA166152939	Annotation of FDA Label for ivacaftor / lumacaftor and CFTR	FDA	On FDA Biomarker List	Testing Required							ivacaftor / lumacaftor	CFTR	rs113993960	10/5/2023	The FDA-approved drug label for ivacaftor and lumacaftor combination (ORKAMBI) states that it is indicated for treatment of cystic fibrosis in patients aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene.
https://www.pharmgkb.org/labelAnnotation/PA166179870	PA166179870	Annotation of FDA Label for binimetinib and BRAF	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		binimetinib	BRAF	rs113488022	10/25/2023	The FDA-approved drug label for binimetinib (MEKTOVI) states that it is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, or for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.
https://www.pharmgkb.org/labelAnnotation/PA166183881	PA166183881	Annotation of Swissmedic Label for mivacurium and BCHE	Swissmedic		Actionable PGx							mivacurium	BCHE		11/15/2022	The Swiss drug label for mivacurium chlorid (Mivacron) states that BCHE genotypes may affect the response to mivacurium chlorid.
https://www.pharmgkb.org/labelAnnotation/PA166184130	PA166184130	Annotation of Swissmedic Label for dapoxetine and CYP2D6	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	dapoxetine	CYP2D6			"The Swiss drug label for dapoxetine (Priligy) states that dapoxetine should be used with caution in CYP2D6 ""slow metabolizers"" and that the dose of dapoxetine should not be increased to 60mg in these patients."
https://www.pharmgkb.org/labelAnnotation/PA166184115	PA166184115	Annotation of Swissmedic Label for carbamazepine and HLA-A	Swissmedic		Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	carbamazepine	HLA-A	HLA-A*31:01	2/28/2023	The Swiss drug label for carbamazepine (Tegretol) recommends that patients of certain ancestries be tested for the presence of the HLA-A*31:01 allele before beginning carbamazepine therapy. Carbamazepine should be avoided in patients carrying the HLA-A*31:01 allele unless the benefits clearly outweigh the risks.
https://www.pharmgkb.org/labelAnnotation/PA166184445	PA166184445	Annotation of Swissmedic Label for escitalopram and CYP2C19	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	escitalopram	CYP2C19		2/28/2023	The Swiss drug label for escitalopram (Cipralex) states that care should be used in dosing in CYP2C19 metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166184378	PA166184378	Annotation of Swissmedic Label for irinotecan and UGT1A1	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	irinotecan	UGT1A1	UGT1A1*28	2/28/2023	The Swiss drug label for irinotecan (Onivyde) gives dosing changes for patients homozygous for UGT1A1*28.
https://www.pharmgkb.org/labelAnnotation/PA166183901	PA166183901	Annotation of Swissmedic Label for moxifloxacin and G6PD	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	moxifloxacin	G6PD		2/28/2023	The Swiss drug label for moxifloxacin (Avalox) states that moxifloxacin should be used with caution in patients with G6PD deficiency. .
https://www.pharmgkb.org/labelAnnotation/PA166184082	PA166184082	Annotation of Swissmedic Label for nicorandil and G6PD	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	nicorandil	G6PD		2/28/2023	The Swiss drug label for nicorendil (Dancor 10/20) states that patients with glucose-6-phosphate dehydrogenase deficiency should use Dancor with caution.
https://www.pharmgkb.org/labelAnnotation/PA166184128	PA166184128	Annotation of Swissmedic Label for acetaminophen / codeine and G6PD	Swissmedic		Actionable PGx							acetaminophen / codeine	G6PD			The Swiss drug label for acetaminophen/codeine (Co-Dafalgan) states that acetaminophen (paracetamol) should be used with caution in patients with G6PD deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166184109	PA166184109	Annotation of Swissmedic Label for aripiprazole and CYP2D6	Swissmedic		Actionable PGx							aripiprazole	CYP2D6			The Swiss drug label for aripiprazole (Abilify) states that CYP2D6 poor metabolizers who take aripiprazole with a concomitant strong CYP3A4 inhibitor may have increased plasma concentrations of aripiprazole compared to CYP2D6 normal metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166184119	PA166184119	Annotation of Swissmedic Label for celecoxib and CYP2C9	Swissmedic		Actionable PGx							celecoxib	CYP2C9	CYP2C9*1; CYP2C9*3		"The Swiss drug label for celecoxib (Celebrex) states that celecoxib should be used with caution in patients who are known or suspected to be CYP2C9 ""slow metabolizers""."
https://www.pharmgkb.org/labelAnnotation/PA166184131	PA166184131	Annotation of Swissmedic Label for darifenacin and CYP2D6	Swissmedic		Actionable PGx							darifenacin	CYP2D6			The Swiss drug label for darifenacin (Emselex) states that CYP2D6 poor metabolizers who are taking darifenacin with a concomitant strong CYP3A4 inhibitor may have significantly increased exposure to darifenacin.
https://www.pharmgkb.org/labelAnnotation/PA166184444	PA166184444	Annotation of Swissmedic Label for eletriptan and CYP2D6	Swissmedic		Informative PGx							eletriptan	CYP2D6			The Swiss drug label for eletriptan (Relpax) states that CYP2D6 polymorphisms have no clinically relevant effect on eletriptan pharmacokinetics.
https://www.pharmgkb.org/labelAnnotation/PA166184448	PA166184448	Annotation of Swissmedic Label for flucloxacillin and HLA-B	Swissmedic		Actionable PGx							flucloxacillin	HLA-B	HLA-B*57:01		The Swiss drug label for flucloxacillin (Floxapen) states that patients carrying the HLA-B*5701 allele have increased risk for drug-induced liver damage although routine testing is not required due to the low positive predictive value.
https://www.pharmgkb.org/labelAnnotation/PA166184108	PA166184108	Annotation of Swissmedic Label for fluorouracil / salicylic acid and DPYD	Swissmedic		Testing Recommended							fluorouracil / salicylic acid	DPYD			The Swiss drug labels for fluorouracil/salicylic acid (Actikerall and Verrumal) state that, where appropriate, DPYD activity levels should be determined prior to fluorouracil treatment.
https://www.pharmgkb.org/labelAnnotation/PA166184453	PA166184453	Annotation of Swissmedic Label for fluvoxamine and CYP2D6	Swissmedic		Actionable PGx							fluvoxamine	CYP2D6			The Swiss drug label for fluvoxamine (Floxyfral) states that the pharmacological properties and relative proportions of metabolites of fluvoxamine are altered in CYP2D6 poor metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166184458	PA166184458	Annotation of Swissmedic Label for glimepiride and G6PD	Swissmedic		Actionable PGx							glimepiride	G6PD			The Swiss drug label for glimepiride (Amaryl) states that caution should be used when treating patients with G6PD deficiency with glimepiride as they are at increased risk for hemolytic anemia.
https://www.pharmgkb.org/labelAnnotation/PA166184377	PA166184377	Annotation of Swissmedic Label for indacaterol and UGT1A1	Swissmedic		Informative PGx							indacaterol	UGT1A1	UGT1A1*28		The Swiss drug labels for indacaterol (Onbrez Breezhaler) and indacaterol and glycopyrronium bromide (Ultibro Breezhaler) states that the UGT1A1 (TA)7(TA)7 genotype is associated with marginally increased exposure to indacaterol.
https://www.pharmgkb.org/labelAnnotation/PA166184382	PA166184382	Annotation of Swissmedic Label for lansoprazole and CYP2C19	Swissmedic		Actionable PGx							lansoprazole	CYP2C19			The Swiss drug label for lansoprazole (Agopton) states that CYP2C19 poor metabolizers have increased exposure to lansoprazole compared to normal metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166184385	PA166184385	Annotation of Swissmedic Label for lesinurad and CYP2C9	Swissmedic		Informative PGx							lesinurad	CYP2C9	CYP2C9*1; CYP2C9*3		The Swiss drug label for lesinurad (Zurampic) gives information about CYP2C9 slow metabolizers and pharmacokinetics.
https://www.pharmgkb.org/labelAnnotation/PA166183790	PA166183790	Annotation of Swissmedic Label for metoprolol and CYP2D6	Swissmedic		Actionable PGx							metoprolol	CYP2D6			The Swiss drug label for metoprolol (Beloc ZOK, Logimax) states that CYP2D6 genotypes may affect the plasma concentration of metoprolol.
https://www.pharmgkb.org/labelAnnotation/PA166183810	PA166183810	Annotation of Swissmedic Label for mirabegron and CYP2D6	Swissmedic		Informative PGx							mirabegron	CYP2D6			The Swiss drug label for mirabegron (Betmiga) states that CYP2D6 genetic polymorphism has minimal effect on mean plasma exposure to mirabegron.
https://www.pharmgkb.org/labelAnnotation/PA166184118	PA166184118	Annotation of Swissmedic Label for carvedilol and CYP2D6	Swissmedic		Informative PGx							carvedilol	CYP2D6		8/15/2023	"The Swiss drug label for carvedilol (Dilatrend) states that CYP2D6 ""slow metabolizers"" have increased plasma concentrations of R- S-carvedilol. However, this is thought to be of limited clinical significance."
https://www.pharmgkb.org/labelAnnotation/PA166184127	PA166184127	Annotation of Swissmedic Label for acetaminophen / codeine and CYP2D6	Swissmedic		Testing Required	Prescribing Info		Alternate Drug			Prescribing	acetaminophen / codeine	CYP2D6		4/15/2024	The Swiss drug label for acetaminophen/codeine (Co-Dafalgan) states that CYP2D6 genotyping should be carried out in breastfeeding mothers prior to analgesic therapy as acetaminophen/codeine is contraindicated in patients with a CYP2D6 ultrarapid metabolizer phenotype. Patients with a CYP2D6 poor metabolizer phenotype do not experience an analgesic effect from codeine.
https://www.pharmgkb.org/labelAnnotation/PA166182947	PA166182947	Annotation of EMA Label for elosulfase alfa and GALNS	EMA		Testing Required							elosulfase alfa	GALNS		4/16/2024	The EMA European Public Assessment Report (EPAR) for elosulfase alfa (Vimizim) states that it is indicated for patients with mucopolysaccharidosis type IVA, also known as Morquio A syndrome. This disease results from deficiency or marked reduction of the galactosamine (N-acetyl)-6-sulfatase (GALNS) enzyme.
https://www.pharmgkb.org/labelAnnotation/PA166182929	PA166182929	Annotation of EMA Label for binimetinib and UGT1A1	EMA		No Clinical PGx							binimetinib	UGT1A1		8/14/2023	The EMA European Public Assessment Report (EPAR) for binimetinib (Mektovi) states that it is indicated in combination with encorafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. The EPAR also states that there is no apparent relationship observed between binimetinib exposure and UGT1A1 mutation status.
https://www.pharmgkb.org/labelAnnotation/PA166184156	PA166184156	Annotation of Swissmedic Label for norfloxacin and G6PD	Swissmedic		Actionable PGx							norfloxacin	G6PD			The Swiss drug label for norfloxacin (Norsol) states that patients with G6PD deficiency may experience hemolytic anemia.
https://www.pharmgkb.org/labelAnnotation/PA166184459	PA166184459	Annotation of Swissmedic Label for nitroglycerin and G6PD	Swissmedic		Actionable PGx							nitroglycerin	G6PD			The Swiss drug label for Glyceroltrinitrat (Deponit) states that caution should be used when treating patients with G6PD deficiency with glycerol trinitrate (also known as nitroglycerin) due to reduced metabolism.
https://www.pharmgkb.org/labelAnnotation/PA166184159	PA166184159	Annotation of Swissmedic Label for omeprazole and CYP2C19	Swissmedic		Actionable PGx							omeprazole	CYP2C19			The Swiss label for omeprazole (Antramups®, Tabletten) states that CYP2C19 is involved in the metabolism of the drug, and that slow metabolizers have a greater systemic exposure to omeprazole than that of fast metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166184222	PA166184222	Annotation of Swissmedic Label for pantoprazole and CYP2C19	Swissmedic		Informative PGx							pantoprazole	CYP2C19			The Swiss label for pantoprazole (Pantozol 20/40/- i.v.) states that individuals with CYP2C19 enzyme deficiency (poor metabolizers) may have increased pantoprazole concentration as compared to individuals with intact CYP2C19 enzyme activity (extensive metabolizers).
https://www.pharmgkb.org/labelAnnotation/PA166182930	PA166182930	Annotation of EMA Label for brexpiprazole and CYP2D6	EMA		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	brexpiprazole	CYP2D6			The EMA European Public Assessment Report (EPAR) for brexpiprazole (RXULTI) states that known CYP2D6 poor metabolizers should receive half the recommended dose, and known CYP2D6 poor metabolizers taking strong or moderate CYP3A4 inhibitors should receive a quarter of the recommended dose.
https://www.pharmgkb.org/labelAnnotation/PA166184402	PA166184402	Annotation of Swissmedic Label for ranolazine and CYP2D6	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	ranolazine	CYP2D6			The Swiss drug label for ranolazine (Ranexa) states that CYP2D6 poor metabolizers may have higher risk for adverse events.
https://www.pharmgkb.org/labelAnnotation/PA166184373	PA166184373	Annotation of Swissmedic Label for piroxicam and CYP2C9	Swissmedic		Actionable PGx							piroxicam	CYP2C9	CYP2C9*2; CYP2C9*3		The Swiss label for piroxicam (Felden) states that CYP2C9 variants may impact the systemic exposure and elimination half-life of piroxicam.
https://www.pharmgkb.org/labelAnnotation/PA166184381	PA166184381	Annotation of Swissmedic Label for prilocaine and G6PD	Swissmedic		Actionable PGx							prilocaine	G6PD			The Swiss drug label for prilocaine (Oraqix) cautions that patients with G6PD may be at increased risk for methemoglobinemia.
https://www.pharmgkb.org/labelAnnotation/PA166184234	PA166184234	Annotation of Swissmedic Label for vernakalant and CYP2D6	Swissmedic		Informative PGx							vernakalant	CYP2D6			"The Swiss drug label for vernakalant (Brinavess) outlines the differences in venlafaxine metabolism and clearance between CYP2D6 normal metabolizers and ""weak metabolizers"" but states that these differences do not require a dose adjustment to be made."
https://www.pharmgkb.org/labelAnnotation/PA166184504	PA166184504	Annotation of Swissmedic Label for zidovudine / lamivudine / abacavir and HLA-B	Swissmedic		Testing Required	Prescribing Info					Prescribing	zidovudine / lamivudine / abacavir	HLA-B	HLA-B*57:01	2/28/2023	The Swiss drug label for zidovudine / lamivudine / abacavir (Trizivir) states that patients should be screened for the presence of HLA-B*57:01 prior to starting treatment with abacavir. Trizivir is contraindicated in carriers of the HLA-B*57:01 allele.
https://www.pharmgkb.org/labelAnnotation/PA166184110	PA166184110	Annotation of Swissmedic Label for vitamin c and G6PD	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	vitamin c	G6PD		2/28/2023	The Swiss drug labels for vitamin C (Streuli, Callimon and Revitalose) state that high doses of vitamin C should be avoided in patients with G6PD deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166182926	PA166182926	Annotation of EMA Label for atezolizumab and CD274	EMA		Testing Required					Cancer Genome		atezolizumab	CD274		4/15/2024	The EMA European Public Assessment Report (EPAR) for atezolizumab (Tecentriq) states that it is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) after prior platinum-containing chemotherapy or who are considered cisplatin ineligible, and whose tumors have a PD-L1 expression >= 5%, among other indications.
https://www.pharmgkb.org/labelAnnotation/PA166184441	PA166184441	Annotation of Swissmedic Label for dolutegravir and CYP3A4, CYP3A5, NR1I2, UGT1A1	Swissmedic		Informative PGx							dolutegravir	CYP3A4; CYP3A5; NR1I2; UGT1A1		8/15/2023	The Swiss drug label for dolutegravir (Julica) states that there is no evidence that gene variants of UGT1A1, CYP3A4, CYP3A5 and NR1I2 have clinically relevant effects.
https://www.pharmgkb.org/labelAnnotation/PA166182924	PA166182924	Annotation of EMA Label for alectinib and ALK	EMA		Testing Required					Cancer Genome		alectinib	ALK		4/15/2024	The EMA European Public Assessment Report (EPAR) for alectinib (Alecensa) states that it is indicated for the first-line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC), or ALK-positive advanced NSCLC previously treated with crizotinib.
https://www.pharmgkb.org/labelAnnotation/PA166182951	PA166182951	Annotation of EMA Label for glyburide and G6PD	EMA		Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	glyburide	G6PD		7/22/2024	The EMA European Public Assessment Report (EPAR) for glibenclamide (AMGLIDIA) states that it should not be prescribed in patients with G6PD deficiency, and that use of an alternative treatment is strongly recommended.
https://www.pharmgkb.org/labelAnnotation/PA166183183	PA166183183	Annotation of EMA Label for lidocaine / prilocaine and CYB5R3, G6PD	EMA		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	lidocaine / prilocaine	CYB5R3; G6PD		7/23/2024	The EMA European Public Assessment Report (EPAR) for lidocaine and prilocaine (Fortacin) states that patients or their partner with G6PD deficiency are more susceptible to methemoglobinemia, and caution should be exercised.
https://www.pharmgkb.org/labelAnnotation/PA166182950	PA166182950	Annotation of EMA Label for gefitinib and CYP2D6	EMA		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	gefitinib	CYP2D6		8/7/2024	The EMA European Public Assessment Report (EPAR) for gefitinib (IRESSA) states that no specific dose adjustment is recommended in patients with known CYP2D6 poor metabolizer genotype, but these patients should be closely monitored for adverse events. The EPAR also states that mean exposure to gefitinib was 2-fold higher in poor metabolizers as compared to extensive metabolizers, and that these higher exposures may be clinically relevant.
https://www.pharmgkb.org/labelAnnotation/PA166182945	PA166182945	Annotation of EMA Label for efavirenz and CYP2B6	EMA		Informative PGx							efavirenz	CYP2B6	CYP2B6*1; CYP2B6*6; rs3745274		The EMA European Public Assessment Report (EPAR) for efavirenz (Sustiva) states that patients with the CYP2B6*6/*6 genotype had higher Cmax as compared to patients with the CYP2B6*1/*1 genotype, and the mean QTc prolongation was 8.7 ms. The label also notes that plasma exposure may be increased in patients with the rs3745274 TT genotype (G516T).
https://www.pharmgkb.org/labelAnnotation/PA166183171	PA166183171	Annotation of EMA Label for lacosamide and CYP2C19	EMA		No Clinical PGx							lacosamide	CYP2C19			The EMA European Public Assessment Report (EPAR) for lacosamide (Vimpat) states that no clinically relevant difference in lacosamide exposure was seen when comparing CYP2C19 extensive metabolizers and CYP2C19 poor metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166183247	PA166183247	Annotation of EMA Label for palbociclib and ERBB2, ESR1, ESR2, PGR	EMA		Testing Required					Cancer Genome		palbociclib	ERBB2; ESR1; ESR2; PGR		4/21/2024	The EMA European Public Assessment Report (EPAR) for palbociclib (IBRANCE) states that it is indicated for the treatment of hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer.
https://www.pharmgkb.org/labelAnnotation/PA166105319	PA166105319	Annotation of EMA Label for panitumumab and KRAS, NRAS	EMA		Testing Required					Cancer Genome		panitumumab	KRAS; NRAS		4/21/2024	The EMA European Public Assessment Report (EPAR) for panitumumab (Vectibix) states that it is indicated for adult patients with wild-type RAS metastatic colorectal cancer.
https://www.pharmgkb.org/labelAnnotation/PA166122067	PA166122067	Annotation of EMA Label for ponatinib and ABL1, BCR	EMA		Testing Required					Cancer Genome		ponatinib	ABL1; BCR		4/21/2024	The EMA European Public Assessment Report (EPAR) for ponatinib (Iclusig) states that indications of the drug include patients with Philadelphia chromosome positive (BCR-ABL1 gene fusion) acute lymphoblastic leukemia who are resistant or intolerant to dasatinib or patients who have the BCR-ABL T315I mutation, due to its mechanism of action as an inhibitor of BCR-ABL and inhibitor of mutant forms of the ABL kinase.
https://www.pharmgkb.org/labelAnnotation/PA166277781	PA166277781	Annotation of EMA Label for tebentafusp and HLA-A	EMA		Testing Required							tebentafusp	HLA-A	HLA-A*02:01	8/14/2024	Tebentafusp is EMA indicated as monotherapy for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. Patients treated with tebentafusp must have HLA-A*02:01 genotype determined by any validated HLA genotyping assay.
https://www.pharmgkb.org/labelAnnotation/PA166272661	PA166272661	Annotation of HCSC Label for abemaciclib and ERBB2, ESR1, ESR2	HCSC		Testing Required					Cancer Genome		abemaciclib	ERBB2; ESR1; ESR2		8/26/2024	Abemaciclib is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
https://www.pharmgkb.org/labelAnnotation/PA166184123	PA166184123	Annotation of Swissmedic Label for citalopram and CYP2C19, CYP2D6	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	citalopram	CYP2C19; CYP2D6		2/28/2023	The Swiss drug label for citalopram (Seropram) states that variants in both CYP2D6 and CYP2C19 can affect metabolism of citalopram. Patients who have reduced CYP2C19 metabolism should be given a reduced dose of citalopram.
https://www.pharmgkb.org/labelAnnotation/PA166184345	PA166184345	Annotation of Swissmedic Label for phenytoin and CYP2C9, HLA-B	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	phenytoin	CYP2C9; HLA-B	HLA-B*15:02	2/28/2023	The Swiss drug label for phenytoin (Phenytoin-Gerot) states that HLA-B*1502 may be associated with an increased risk of Stevens-Johnson syndrome (SJS) in individuals of Thai or Han Chinese descent treated with phenytoin and the use of phenytoin should only be considered if the benefit is considered higher than the risks for these patients known to carry HLA-B*5102.
https://www.pharmgkb.org/labelAnnotation/PA166184424	PA166184424	Annotation of Swissmedic Label for thioguanine and TPMT	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	thioguanine	TPMT		2/28/2023	The Swiss drug label for thioguanine (Lanvis) cautions about use in patients with a congenital deficiency of the enzyme thiopurine methyltransferase (TPMT).
https://www.pharmgkb.org/labelAnnotation/PA166160039	PA166160039	Annotation of FDA Label for evolocumab	FDA	On FDA Biomarker List								evolocumab			9/7/2023	The FDA-approved drug label for evolocumab (REPATHA) states that it is indicated for the treatment of heterozygous familial hypercholesterolemia (HeFH) or homozygous familial hypercholesterolemia (HoFH). Familial hypercholesterolemia is commonly caused by mutations in the LDLR gene, it can also be due to variants in PCSK9 which is the target of evolocumab.
https://www.pharmgkb.org/labelAnnotation/PA166293361	PA166293361	Annotation of FDA Label for desmopressin and F8	FDA	On FDA Biomarker List	Testing Required							desmopressin	F8		8/21/2023	Desmopressin is a synthetic vasopressin analog that is FDA approved to increase plasma levels of factor VIII activity in patients with hemophilia A (F8 deficiency) and von Willebrand’s disease Type I (VWF) during surgery or reduce bleeding from injury. Tests are required prior to treatment to measure F8 capacity to respond.
https://www.pharmgkb.org/labelAnnotation/PA166293681	PA166293681	Annotation of FDA Label for trastuzumab deruxtecan and ESR1, ESR2	FDA	On FDA Biomarker List						Cancer Genome		trastuzumab deruxtecan	ESR1; ESR2		9/28/2023	The FDA table lists ESR as biomarker for trastuzumab deruxtecan as hormone receptor status is mentioned in the label in the clinical studies section.
https://www.pharmgkb.org/labelAnnotation/PA166163412	PA166163412	Annotation of FDA Label for ombitasvir / paritaprevir / ritonavir and IFNL3	FDA	On FDA Biomarker List								ombitasvir / paritaprevir / ritonavir	IFNL3		9/7/2023	Technivie (ombitasvir, paritaprevir and ritonavir) is indicated in combination with ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis. Within the clinical studies section, the label mentions frequency of the rs12979860 non-CC genotype.
https://www.pharmgkb.org/labelAnnotation/PA166163435	PA166163435	Annotation of FDA Label for olaratumab and PDGFRA	FDA	On FDA Biomarker List						Cancer Genome		olaratumab	PDGFRA		8/23/2023	Olaratumab (LARTRUVO) is a platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.
https://www.pharmgkb.org/labelAnnotation/PA166235881	PA166235881	Annotation of FDA Label for margetuximab and ERBB2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		margetuximab	ERBB2		8/31/2023	Margetuximab (MARGENZA) is FDA-approved for treatment of adult patients with metastatic HER2-positive breast cancer. HER2 is a name for the product of the gene ERBB2.
https://www.pharmgkb.org/labelAnnotation/PA166293742	PA166293742	Annotation of FDA Label for mirvetuximab soravtansine and FOLR1	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		mirvetuximab soravtansine	FOLR1		8/31/2023	Mirvetuximab soravtansine is an antibody-drug conjugate, indicated for treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer based on the presence of folate receptor alpha (FOLR1) tumor expression as measured by an FDA-approved test.
https://www.pharmgkb.org/labelAnnotation/PA166293921	PA166293921	Annotation of FDA Label for olutasidenib and IDH1	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		olutasidenib	IDH1	rs121913499; rs121913500	8/31/2023	Olutasidenib is a small molecule inhibitor indicated for patients with AML with susceptible mutations in IDH1 as assessed by an FDA- approved test.
https://www.pharmgkb.org/labelAnnotation/PA166294401	PA166294401	Annotation of HCSC Label for evolocumab	HCSC									evolocumab			8/14/2024	Evolocumab is an antibody targeted to PCSK9, indicated for the treatment of heterozygous familial hypercholesterolemia (HeFH) or homozygous familial hypercholesterolemia (HoFH). Familial hypercholesterolemia is commonly caused by mutations in the LDLR gene, it can also be due to variants in PCSK9.
https://www.pharmgkb.org/labelAnnotation/PA166293301	PA166293301	Annotation of FDA Label for betaine and CBS, MMADHC, MTHFR	FDA	On FDA Biomarker List								betaine	CBS; MMADHC; MTHFR		8/5/2024	Betaine is indicated for homocystinurea including when caused by genetic variants in CBS, MTHFR and MMADHC (as listed in the FDA table of biomarkers).
https://www.pharmgkb.org/labelAnnotation/PA166293961	PA166293961	Annotation of HCSC Label for betaine and CBS, MMADHC, MTHFR	HCSC									betaine	CBS; MMADHC; MTHFR		8/5/2024	Betaine is indicated for treatment of homocystinurea including when caused by genetic variants in CBS (cystathionine beta-synthase), MTHFR (methylene-tetrahydrofolate reductase) and MMADHC (cobalamin cofactor metabolism).
https://www.pharmgkb.org/labelAnnotation/PA166293981	PA166293981	Annotation of HCSC Label for desmopressin and F8	HCSC		Testing Required							desmopressin	F8		4/16/2024	Desmopressin is HCSC indicated for prophylaxis of mild hemophilia A and mild von Willebrand’s disease Type I.
https://www.pharmgkb.org/labelAnnotation/PA166293941	PA166293941	Annotation of EMA Label for betaine and CBS, MMADHC, MTHFR	EMA									betaine	CBS; MMADHC; MTHFR		8/5/2024	Betaine is indicated for treatment of homocystinurea including when caused by genetic variants in CBS (cystathionine beta-synthase), MTHFR (methylene-tetrahydrofolate reductase) and MMADHC (cobalamin cofactor metabolism).
https://www.pharmgkb.org/labelAnnotation/PA166294041	PA166294041	Annotation of EMA Label for durvalumab and CD274	EMA		Testing Required					Cancer Genome		durvalumab	CD274		5/10/2024	Durvalumab is EMA indicated for the treatment of locally advanced, unresectable NSCLC in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy. PD-L1 is encoded by the CD274 gene.
https://www.pharmgkb.org/labelAnnotation/PA166294981	PA166294981	Annotation of EMA Label for pemigatinib and FGFR2	EMA		Testing Required					Cancer Genome		pemigatinib	FGFR2			Pemigatinib is a kinase inhibitor indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
https://www.pharmgkb.org/labelAnnotation/PA166295001	PA166295001	Annotation of HCSC Label for pemigatinib and FGFR2	HCSC		Testing Required					Cancer Genome		pemigatinib	FGFR2			PEMAZYRE™ (pemigatinib) is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.
https://www.pharmgkb.org/labelAnnotation/PA166104811	PA166104811	Annotation of FDA Label for quinidine and CYP2D6	FDA	On FDA Biomarker List								quinidine	CYP2D6		9/7/2023	The FDA-approved drug label for quinidine states that the drug inhibits the action of CYP2D6, effectively converting CYP2D6 extensive metabolizers into poor metabolizers. The drug label advises caution whenever quinidine is prescribed together with drugs metabolized by CYP2D6.
https://www.pharmgkb.org/labelAnnotation/PA166104845	PA166104845	Annotation of FDA Label for dapsone and CYB5R3	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	dapsone	CYB5R3		7/19/2024	The FDA-approved label for dapsone gel (ACZONE) states that some subjects with G6PD deficiency using ACZONE developed laboratory changes suggestive of hemolysis. The label states that dapsone gel (ACZONE) should be avoided in patients with congenital methemoglobinemia, which is associated with variants in CYB5R3.
https://www.pharmgkb.org/labelAnnotation/PA166295822	PA166295822	Annotation of FDA Label for teclistamab	FDA	On FDA Biomarker List						Cancer Genome		teclistamab			8/24/2023	"Teclistamab is a bispecific B-cell maturation antigen-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
The FDA biomarker table entries for teclistamab mention Chromosome 17p, Chromosome 4p;14q, and Chromosome 14q;16q."
https://www.pharmgkb.org/labelAnnotation/PA166104788	PA166104788	Annotation of FDA Label for fluoxetine / olanzapine and CYP2D6	FDA		Informative PGx							fluoxetine / olanzapine	CYP2D6		12/17/2013	The FDA-approved drug label for fluoxetine and olanzapine (SYMBYAX) states that individuals who are CYP2D6 poor metabolizers metabolized S-fluoxetine at a slower rate and achieved higher concentrations.
https://www.pharmgkb.org/labelAnnotation/PA166104789	PA166104789	Annotation of FDA Label for gefitinib and EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		gefitinib	EGFR	rs121434568	9/1/2023	The FDA-approved drug label for gefinitib (IRESSA) states that it is indicated for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
https://www.pharmgkb.org/labelAnnotation/PA166104833	PA166104833	Annotation of FDA Label for abacavir and HLA-B	FDA	On FDA Biomarker List	Testing Required	Prescribing Info		Alternate Drug			Prescribing	abacavir	HLA-B	HLA-B*57:01	5/8/2019	The FDA-approved label for abacavir (ZIAGEN) states that genetic testing for the HLA-B*5701 allele is required prior to initiating or reinitiating treatment with abacavir in patients of unknown HLA-B*5701 status. Abacavir is contraindicated in patients with the HLA-B*5701 allele due to risk for abacavir hypersensitivity reactions.
https://www.pharmgkb.org/labelAnnotation/PA166104812	PA166104812	Annotation of FDA Label for protriptyline and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							protriptyline	CYP2D6		10/25/2013	Protriptyline hydrochloride is an antidepressant agent and belongs to the class of tricyclic antidepressants. CYP2D6 poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
https://www.pharmgkb.org/labelAnnotation/PA166104806	PA166104806	Annotation of FDA Label for tolterodine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							tolterodine	CYP2D6		10/25/2013	Tolterodine (DETROL) is used for the treatment of overactive bladder and is primarily metabolized by CYP2D6. Poor metabolizers may have greater plasma concentrations of the drug which could possibly have an effect QT interval.
https://www.pharmgkb.org/labelAnnotation/PA166104826	PA166104826	Annotation of FDA Label for cetuximab and BRAF, EGFR, KRAS, NRAS	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		cetuximab	BRAF; EGFR; KRAS; NRAS		9/1/2023	Cetuximab (ERBITUX) is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of head and neck cancer, as well metastatic colorectal cancer that is EGFR-expressing, has no Ras mutations as determined by an FDA-approved text but is indicated for BRAF V600E Mutation-Positive colorectal cancers.
https://www.pharmgkb.org/labelAnnotation/PA166104784	PA166104784	Annotation of FDA Label for diazepam and CYP2C19	FDA	On FDA Biomarker List	Informative PGx							diazepam	CYP2C19		12/11/2023	The FDA-approved drug label for diazepam (Diastat) notes that the drug is metabolized by CYP2C19 and CYP3A4, and that inter-individual variation in clearance of the drug is likely attributable genetic polymorphism of CYP2C19 and CYP3A4.
https://www.pharmgkb.org/labelAnnotation/PA166104831	PA166104831	Annotation of FDA Label for irinotecan and UGT1A1	FDA	On FDA Biomarker List	Testing Recommended	Prescribing Info	Dosing Info		Other Prescribing Guidance		Prescribing	irinotecan	UGT1A1	UGT1A1*28; UGT1A1*6	8/30/2024	The FDA-approved drug label for irinotecan (CAMPTOSAR) states that a reduction in the starting dose by at least one level of CAMPTOSAR should be considered for patients known to be homozygous for the UGT1A1*28 allele, the UGT1A1*6 allele or compound heterozygotes. The label recommends to consider UGT1A1 genotype testing for the *28 and *6 alleles to determine UGT1A1 metabolizer status. The FDA-approved drug label for irinotecan liposome injection (ONIVYDE) contains language regarding starting dose reduction in patients who are homozygous for the UGT1A1*28 allele, but does not have a genotype testing recommendation.
https://www.pharmgkb.org/labelAnnotation/PA166104828	PA166104828	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2	FDA	On FDA Biomarker List	Informative PGx							hydralazine / isosorbide dinitrate	NAT2		9/8/2023	Hydralazine hydrochloride and isosorbide dinitrate (BiDil) is metabolized by acetylation, and individuals who are 'fast acetylators' may have decreased exposure to the drug, whereas individuals who are 'slow acetylators' may have increased drug bioavailability. Acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene. However, the label never mentions any specific gene with regard to acetylator status.
https://www.pharmgkb.org/labelAnnotation/PA166104777	PA166104777	Annotation of FDA Label for clopidogrel and CYP2C19	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	clopidogrel	CYP2C19		7/17/2024	The FDA-approved drug label for clopidogrel (Plavix) states that in patients who are CYP2C19 poor metabolizers, clopidogrel at recommended doses has a reduced effect on platelet activity, and that use of another platelet P2Y12 inhibitor should be considered.
https://www.pharmgkb.org/labelAnnotation/PA166104813	PA166104813	Annotation of FDA Label for carvedilol and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							carvedilol	CYP2D6		10/25/2013	The FDA-approved drug label for carvedilol (COREG) states that it is affected by the poor metabolizers of debrisoquin (a marker for cytochrome P450 2D6) resulting in higher plasma concentrations of R( + )-carvedilol. Additionally, CYP2D6 poor metabolizers had a higher rate of dizziness during up-titration.
https://www.pharmgkb.org/labelAnnotation/PA166104851	PA166104851	Annotation of FDA Label for ticagrelor and CYP2C19	FDA	On FDA Biomarker List	No Clinical PGx							ticagrelor	CYP2C19		3/16/2017	Ticagrelor (BRILINTA) is a platelet inhibitor used to reduce the risk of thrombotic cardiovascular events for patients with acute coronary syndrome. The FDA-approved drug label notes that thrombotic cardiovascular events did not depend on CYP2C19 loss of function status.
https://www.pharmgkb.org/labelAnnotation/PA166104816	PA166104816	Annotation of FDA Label for esomeprazole and CYP2C19	FDA	On FDA Biomarker List	No Clinical PGx							esomeprazole	CYP2C19		7/26/2024	The FDA-approved drug label for esomeprazole (NEXIUM) notes that individuals who are CYP2C19 poor metabolizers may have increased exposure to esomeprazole compared to extensive metabolizers. This change in exposure is not considered clinically meaningful.
https://www.pharmgkb.org/labelAnnotation/PA166104863	PA166104863	Annotation of FDA Label for dexlansoprazole and CYP2C19	FDA	On FDA Biomarker List	Informative PGx							dexlansoprazole	CYP2C19		10/25/2013	The FDA-approved drug label for dexlansoprazole (DEXILANT) notes that systemic exposure of the drug is generally higher in CYP2C19 intermediate and poor metabolizers, as compared to extensive metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166104799	PA166104799	Annotation of FDA Label for tramadol and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	tramadol	CYP2D6		5/1/2017	The FDA-approved label for tramadol (ULTRAM) states that individuals who are CYP2D6 ultra-rapid metabolizers convert tramadol into its active metabolite more rapidly than other people, and that even at labeled dosage regimens they may have life-threatening or fatal respiratory depression; these individuals should not use tramadol.
https://www.pharmgkb.org/labelAnnotation/PA166104859	PA166104859	Annotation of FDA Label for crizotinib and ALK, ROS1	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		crizotinib	ALK; ROS1		9/1/2023	The FDA-approved drug label for crizotinib (XALKORI) states that it is indicated for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ALK or ROS1-positive as detected by an FDA-approved test.
https://www.pharmgkb.org/labelAnnotation/PA166104808	PA166104808	Annotation of FDA Label for nelfinavir and CYP2C19, CYP3A4, CYP3A5	FDA	Formerly on FDA Biomarker List								nelfinavir	CYP2C19; CYP3A4; CYP3A5		8/29/2024	The FDA-approved drug label for nelfinavir (VIRACEPT) states that coadministration of nelfinavir and drugs that induce CYP3A or CYP2C19 may decrease nelfinavir plasma concentrations and reduce its therapeutic effect. Coadministration of nelfinavir and drugs that inhibit CYP3A or CYP2C19 may increase nelfinavir plasma concentrations.
https://www.pharmgkb.org/labelAnnotation/PA166104797	PA166104797	Annotation of FDA Label for letrozole and ESR1, ESR2, PGR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		letrozole	ESR1; ESR2; PGR		9/1/2023	Letrozole (Femara) is indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. It is also indicated as a first-line treatment for advanced breast cancer in postmenopausal women with hormone receptor positive or unknown tumors, or for extended adjuvant treatment of post-menopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy.
https://www.pharmgkb.org/labelAnnotation/PA166104781	PA166104781	Annotation of FDA Label for dasatinib and ABL1, BCR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		dasatinib	ABL1; BCR		8/26/2024	The FDA-approved drug label for dasatinib (SPRYCEL) notes that it is intended for adults or children with Philadelphia chromosome-positive chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (Ph+ ALL).
https://www.pharmgkb.org/labelAnnotation/PA166104836	PA166104836	Annotation of FDA Label for metoprolol and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							metoprolol	CYP2D6		9/7/2023	The FDA-approved drug label for metoprolol (TOPROL-XL) states that is metabolized predominantly by CYP2D6, and that poor metabolizers of CYP2D6 will have increased (several-fold) metoprolol blood levels, decreasing metoprolol's cardioselectivity.
https://www.pharmgkb.org/labelAnnotation/PA166104818	PA166104818	Annotation of FDA Label for voriconazole and CYP2C19	FDA	On FDA Biomarker List	Informative PGx							voriconazole	CYP2C19		10/25/2013	The FDA-approved drug label for voriconazole (VFEND) states that CYP2C19 poor metabolizers have, on average, 4-fold higher voriconazole exposure as compared to normal metabolizers, while intermediate metabolizers have 2-fold higher exposure as compared to normal metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166104820	PA166104820	Annotation of FDA Label for doxepin and CYP2C19, CYP2D6	FDA	On FDA Biomarker List	Informative PGx							doxepin	CYP2C19; CYP2D6		10/25/2013	The FDA-approved drug label for doxepin (Silenor) notes that CYP2D6 and CYP2C19 poor metabolizers have higher than expected plasma levels of the drug when given typical doses. The FDA-approved drug label for doxepin cream (ZONALON) notes the genetic variability of the CYP2D6 enzyme and its effect on tricyclic antidepressants (TCAs).
https://www.pharmgkb.org/labelAnnotation/PA166104842	PA166104842	Annotation of FDA Label for nilotinib and ABL1, BCR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		nilotinib	ABL1; BCR		9/1/2023	Nilotinib (Tasigna) is indicated for use in patients diagnosed with Philadelphia chromosome positive (presence of a BCR-ABL1 gene fusion) chronic myeloid leukemia, due to its mechanism of action.
https://www.pharmgkb.org/labelAnnotation/PA166104854	PA166104854	Annotation of FDA Label for fluvoxamine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	fluvoxamine	CYP2D6		7/22/2024	The FDA-approved drug label for fluvoxamine (LUVOX) states that it appears to be metabolized, at least in part, by CYP2D6, and that caution should be used in treating patients with reduced CYP2D6 activity.
https://www.pharmgkb.org/labelAnnotation/PA166104858	PA166104858	Annotation of FDA Label for vemurafenib and BRAF	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		vemurafenib	BRAF	rs113488022	9/1/2023	Vemurafenib (ZELBORAF) is a kinase inhibitor used to treat patients with unresectable or metastatic melanoma in cases where the BRAF V600E mutation is found by an FDA-approved test. In vitro evidence points to BRAF wild-type cells proliferation with exposure to BRAF inhibitors. Therefore, testing is required.
https://www.pharmgkb.org/labelAnnotation/PA166104796	PA166104796	Annotation of FDA Label for trastuzumab emtansine and ERBB2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		trastuzumab emtansine	ERBB2		9/1/2023	The FDA-approved label for trastuzumab emtansine (KADCYLA) states that test results demonstrating HER2 protein overexpression are required prior to initiating therapy with trastuzumab emtansine using FDA-approved tests by laboratories with demonstrated proficiency.
https://www.pharmgkb.org/labelAnnotation/PA166104857	PA166104857	Annotation of FDA Label for trimipramine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							trimipramine	CYP2D6		7/19/2024	Trimipramine (SURMONTIL) is a tricyclic antidepressant used to treat depression. Like many antidepressants, it has a black box warning for increased risk of suicidal thoughts and behavior. Trimipramine is metabolized by CYP2D6 and poor metabolizers may experience higher plasma concentrations of the drug at typical doses.
https://www.pharmgkb.org/labelAnnotation/PA166104798	PA166104798	Annotation of FDA Label for propranolol and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							propranolol	CYP2D6		10/25/2013	The FDA-approved drug label for propranolol (INNOPRAN XL) states that no difference in clearance of the drug was observed between CYP2D6 extensive and poor metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166104802	PA166104802	Annotation of FDA Label for capecitabine and DPYD	FDA	On FDA Biomarker List	Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	capecitabine	DPYD		12/19/2022	"The FDA-approved label for capecitabine (XELODA) notes that patients with certain homozygous or compound heterozygous variants in the DPYD gene are at increased risk for acute early-onset toxicity and serious, including fatal, adverse reactions due to XELODA. FDA states ""Consider testing for genetic variants of DPYD prior to initiating XELODA to reduce the risk of serious adverse reactions if the patient’s clinical status permits and based on clinical judgement""."
https://www.pharmgkb.org/labelAnnotation/PA166104815	PA166104815	Annotation of FDA Label for clozapine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	clozapine	CYP2D6		8/23/2023	The FDA-approved drug label for clozapine (CLOZARIL) states that it may be necessary to reduce the dose in patients who are CYP2D6 poor metabolizers, as these individuals may develop higher than expected plasma concentrations of clozapine when given usual doses.
https://www.pharmgkb.org/labelAnnotation/PA166104848	PA166104848	Annotation of FDA Label for rabeprazole and CYP2C19	FDA	On FDA Biomarker List	Informative PGx							rabeprazole	CYP2C19		10/10/2019	The FDA-approved drug label for rabeprazole (ACIPHEX) provides evidence from a study showing that gastric acid suppression was higher in CYP2C19 poor metabolizers as compared to extensive metabolizers, possibly due to higher rabeprazole levels in poor metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166104800	PA166104800	Annotation of FDA Label for indacaterol and UGT1A1	FDA	On FDA Biomarker List	No Clinical PGx							indacaterol	UGT1A1		10/25/2013	The FDA-approved drug label for indacaterol (ARCAPTA NEOHALER) states that steady-state AUC and Cmax of indacaterol were 1.2-fold higher in patients with the (TA)7/(TA)7 (*28/*28) genotype than in patients with the (TA)6/(TA)6 (*1/*1) genotype, suggesting no relevant effect of UGT1A1 genotype of indacaterol exposure.
https://www.pharmgkb.org/labelAnnotation/PA166104810	PA166104810	Annotation of FDA Label for mercaptopurine and NUDT15, TPMT	FDA	On FDA Biomarker List	Testing Recommended	Prescribing Info	Dosing Info				Prescribing	mercaptopurine	NUDT15; TPMT	NUDT15*2; NUDT15*3; TPMT*2; TPMT*3A; TPMT*3C	6/6/2024	"The FDA-approved drug labels for mercaptopurine (PURIXAN and PURINETHOL) state that patients with severe myelosuppression should be evaluated for TPMT or NUDT15 deficiency, and that patients with homozygous TPMT or NUDT15 deficiency may require dose reductions.
The FDA Table of Pharmacogenomic Biomarkers in Drug Labeling lists two different labels for mercaptopurine, mercaptopurine oral suspension (PURIXAN) and mercaptopurine tablets (PURINETHOL)."
https://www.pharmgkb.org/labelAnnotation/PA166104864	PA166104864	Annotation of FDA Label for paroxetine and CYP2D6	FDA	On FDA Biomarker List								paroxetine	CYP2D6		9/7/2023	The FDA-approved drug label for paroxetine (PEXEVA) states that it is both metabolized by and an inhibitor of CYP2D6. It also notes that when CYP2D6 extensive metabolizers were given paroxetine in combination with atomoxetine, atomoxetine steady state levels were higher than when the drug was given alone.
https://www.pharmgkb.org/labelAnnotation/PA166104855	PA166104855	Annotation of FDA Label for boceprevir and IFNL3	FDA	On FDA Biomarker List	No Clinical PGx							boceprevir	IFNL3	rs12979860	7/26/2024	"The FDA-approved drug label for boceprevir (Victrelis) contains information regarding a genetic variant near the IFNL3 gene (IL28B, rs12979860, a C to T change) which is a strong predictor of response to peginterferon alfa-2b (PegIntron) / ribavirin (Rebetol) treatment. Boceprevir must not be used as a monotherapy and should only be used in combination with these drugs for the treatment of chronic hepatitis C genotype 1.
July 2024: Please note that boceprevir is listed as discontinued by the FDA. However, this drug is still on the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. PharmGKB has therefore decided to keep this annotation active until the drug is removed from the FDA Biomarker table."
https://www.pharmgkb.org/labelAnnotation/PA166104783	PA166104783	Annotation of FDA Label for rasburicase and CYB5R1, CYB5R2, CYB5R3, CYB5R4	FDA	On FDA Biomarker List	No Clinical PGx							rasburicase	CYB5R1; CYB5R2; CYB5R3; CYB5R4		3/21/2016	The FDA-approved drug label for rasburicase (Elitek) states that is unclear whether patients with NADH cytochrome b5 reductase (CYB5R1, 2, 3, 4) deficiency are at risk for methemoglobinemia or hemolytic anemia. It also states that patients at higher risk for G6PD deficiency, such as those of African or Mediterranean ancestry, should be screened prior to starting treatment, as rasburicase is contraindicated in patients with G6PD deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166104803	PA166104803	Annotation of FDA Label for maraviroc and CCR5	FDA	Formerly on FDA Biomarker List								maraviroc	CCR5		8/18/2023	The drug labeling for maraviroc (SELZENTRY) is not related to genetic testing of the patient, rather testing of the HIV-1 strain that has infected the patient. The FDA-approved label states that HIV tropism testing be carried out before treatment with maraviroc. This drug is indicated only for CCR5-tropic HIV-1 infection, and due to its mechanism of action, is not effective against CXCR4-tropic and dual-tropic HIV-1.
https://www.pharmgkb.org/labelAnnotation/PA166104776	PA166104776	Annotation of FDA Label for warfarin and CYP2C9, PROC, PROS1, VKORC1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	warfarin	CYP2C9; PROC; PROS1; VKORC1	CYP2C9*1; CYP2C9*2; CYP2C9*3; rs9923231	12/12/2023	Warfarin (COUMADIN) is an anticoagulant used as a prophylaxis and to treat venous thrombosis, pulmonary embolism, thromboembolic complications from atrial fibrillation and cardiac valve replacement, and to reduce the recurrence of myocardial infarction. Pharmacogenomics-related dosing information for CYP2C9 and VKORC1 variants is provided within the label. The drug label notes that deficiency in protein C (PROC) or protein S (PROS1) have been associated with tissue necrosis following warfarin administration.
https://www.pharmgkb.org/labelAnnotation/PA166104906	PA166104906	Annotation of FDA Label for probenecid and G6PD	FDA	On FDA Biomarker List	Informative PGx							probenecid	G6PD		10/25/2013	Probenecid is used to treat chronic gouty arthritis. An association between probenecid-induced hemolytic anemia and G6PD deficiency is highlighted in the Adverse Reactions section of the probenecid label.
https://www.pharmgkb.org/labelAnnotation/PA166104877	PA166104877	Annotation of FDA Label for mycophenolic acid and HPRT1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	mycophenolic acid	HPRT1		10/25/2013	Mycophenolic acid (Myfortic) is an IMPDH Inhibitor that should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndrome.
https://www.pharmgkb.org/labelAnnotation/PA166104917	PA166104917	Annotation of FDA Label for prasugrel and CYP2B6, CYP2C19, CYP2C9, CYP3A5	FDA	On FDA Biomarker List	No Clinical PGx							prasugrel	CYP2B6; CYP2C19; CYP2C9; CYP3A5		10/25/2013	The FDA-approved drug label for prasugrel (Effient) contains information regarding a lack of effect of genetic variants on prasugrel pharmacokinetics.
https://www.pharmgkb.org/labelAnnotation/PA166104875	PA166104875	Annotation of FDA Label for clomipramine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							clomipramine	CYP2D6		10/25/2013	The FDA-approved drug label for clomipramine (Anafranil) notes that CYP2D6 poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs), such as clomipramine, when given typical doses.
https://www.pharmgkb.org/labelAnnotation/PA166105213	PA166105213	Annotation of FDA Label for oxcarbazepine and HLA-B	FDA	On FDA Biomarker List	Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	oxcarbazepine	HLA-B	HLA-B*15:02	4/16/2019	The FDA-approved drug label for oxcarbazepine (OXTELLAR XR) states that testing for the presence of the HLA-B*1502 allele should be considered in patients with ancestry in genetically at-risk populations prior to initiating treatment with the drug, due to the risk for Stevens-Johnson syndrome or toxic epidermal necrolysis.
https://www.pharmgkb.org/labelAnnotation/PA166105222	PA166105222	Annotation of FDA Label for piroxicam and CYP2C9	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	piroxicam	CYP2C9		8/23/2023	The FDA-approved drug label for piroxicam (FELDENE) states that CYP2C9 intermediate and poor metabolizers had higher systemic levels of piroxicam as compared to normal metabolizers, and that known or suspected CYP2C9 poor metabolizers should consider a dose reduction.
https://www.pharmgkb.org/labelAnnotation/PA166105023	PA166105023	Annotation of FDA Label for rosuvastatin and SLCO1B1	FDA	On FDA Biomarker List	Informative PGx							rosuvastatin	SLCO1B1	rs4149056	3/15/2017	The FDA-approved drug label for rosuvastatin (CRESTOR) states that higher plasma concentrations of the drug have been seen in small groups of patients homozygous for the SLCO1B1 rs4149056 variant.
https://www.pharmgkb.org/labelAnnotation/PA166104893	PA166104893	Annotation of FDA Label for perphenazine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							perphenazine	CYP2D6		10/25/2013	The FDA-approved drug label for perphenazine (TRILAFON) states that its metabolism is mediated by the CYP2D6 enzyme, and that CYP2D6 poor metabolizers will metabolize the drug more slowly and experience higher concentrations as compared with normal metabolizers. This may lead to greater side effects.
https://www.pharmgkb.org/labelAnnotation/PA166104921	PA166104921	Annotation of FDA Label for omeprazole and CYP2C19	FDA	On FDA Biomarker List	Informative PGx							omeprazole	CYP2C19		3/16/2017	The FDA-approved drug label for omeprazole (PRILOSEC) notes that CYP2C19 is involved in the metabolism of the drug, and that poor metabolizers have a greater systemic exposure to omeprazole, followed by intermediate and then extensive metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166105178	PA166105178	Annotation of FDA Label for lidocaine / prilocaine and CYB5R3, G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	lidocaine / prilocaine	CYB5R3; G6PD		7/23/2024	The FDA-approved drug label for ORAQIX (lidocaine and prilocaine) states that patients with G6PD deficiency or congenital or idiopathic methemoglobinemia are more susceptible to drug-induced methemoglobinemia. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.
https://www.pharmgkb.org/labelAnnotation/PA166104901	PA166104901	Annotation of FDA Label for pantoprazole and CYP2C19	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	pantoprazole	CYP2C19		8/21/2023	The FDA-approved drug label for pantoprazole (PROTONIX) states that pediatric patients who are CYP2C19 poor metabolizers exhibited ~10-fold lower clearance of the drug as compared to extensive metabolizers, and that a dose reduction should be considered in these patients. No dosage adjustment is needed in adult CYP2C19 poor metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166105028	PA166105028	Annotation of FDA Label for nebivolol and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							nebivolol	CYP2D6		8/15/2023	The FDA-approved drug label for nebivolol (BYSTOLIC) states that, though it is metabolized by CYP2D6, no dose adjustments are necessary for CYP2D6 poor metabolizers, as the clinical effect and safety profile was similar between poor and extensive metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166104867	PA166104867	Annotation of FDA Label for telaprevir and IFNL3	FDA	On FDA Biomarker List	Informative PGx							telaprevir	IFNL3	rs12979860	10/25/2013	Among both treatment-naïve and previous treatment failures patients with HCV genotype 1 infections, subjects of all IL28B genotypes appeared to have higher SVR rates with telaprevir (INCIVEK)-containing regimens compared to PEG-IFN alpha and RBV only. Patients with the favorable IFNL3 genotype (rs12979860 CC) tend to have higher response rates (SVR) as compared to patients with the CT or TT genotype with the protease inhibitor combination in treatment naïve patients.
https://www.pharmgkb.org/labelAnnotation/PA166114907	PA166114907	Annotation of FDA Label for bosutinib and ABL1, BCR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		bosutinib	ABL1; BCR		8/26/2024	The FDA-approved drug label for bosutinib (BOSULIF) notes that it is intended for adults with newly-diagnosed chronic phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) or chronic, accelerated or blast phase Ph+ CML with resistance or intolerance to prior therapy.
https://www.pharmgkb.org/labelAnnotation/PA166104868	PA166104868	Annotation of FDA Label for modafinil and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							modafinil	CYP2D6		10/25/2013	Modafinil (PROVIGIL), used to improve wakefulness, is metabolized by many cytochrome P450s. Patients that are poor metabolizers for CYP2D6 may need dose modifications for medications that have ancillary metabolism via CYP2C19, such as tricyclic antidepressants (TCAs).
https://www.pharmgkb.org/labelAnnotation/PA166104913	PA166104913	Annotation of FDA Label for everolimus and ERBB2, ESR1, ESR2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		everolimus	ERBB2; ESR1; ESR2		9/1/2023	Everolimus (AFINITOR) is indicated for treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole.
https://www.pharmgkb.org/labelAnnotation/PA166104886	PA166104886	Annotation of FDA Label for dextromethorphan / quinidine and CYP2D6	FDA	On FDA Biomarker List	Testing Recommended	Prescribing Info			Other Prescribing Guidance		Prescribing	dextromethorphan / quinidine	CYP2D6		10/24/2023	The quinidine component of NUEDEXTA is a CYP2D6 inhibitor used to increase the plasma availability of dextromethorphan, which is metabolized by CYP2D6. CYP2D6 poor metabolizers may be at risk of experiencing toxicity.
https://www.pharmgkb.org/labelAnnotation/PA166104912	PA166104912	Annotation of FDA Label for eltrombopag and F5, SERPINC1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	eltrombopag	F5; SERPINC1		7/19/2024	The FDA-approved drug label for eltrombopag (PROMACTA) notes that patients taking the drug have an increased risk of thromboembolism if they have antithrombin III deficiency (SERPINC1) or Factor V Leiden (F5). The label also mentions that when patients were evaluated for cytogenetic abnormalities in PROMACTA D1-M6 cohort, some patients had loss of chromosome 7 or deletion of chromosome 13.
https://www.pharmgkb.org/labelAnnotation/PA166114905	PA166114905	Annotation of FDA Label for belimumab and TNFSF13B	FDA	Formerly on FDA Biomarker List								belimumab	TNFSF13B		8/14/2023	Belimumab (BENLYSTA) is a human IgG1lambda monoclonal antibody, indicated for use in adults with active, autoantibody-positive, systemic lupus erythematosus who are receiving standard therapy. It acts by blocking binding of soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B-cell survival factor, to its receptors on B cells.
https://www.pharmgkb.org/labelAnnotation/PA166104888	PA166104888	Annotation of FDA Label for nortriptyline and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							nortriptyline	CYP2D6		7/23/2024	The FDA-approved drug label for nortriptyline (Pamelor), a tricyclic antidepressant (TCA), states that CYP2D6 poor metabolizers have higher than expected plasma concentrations of TCAs when given usual doses.
https://www.pharmgkb.org/labelAnnotation/PA166105059	PA166105059	Annotation of FDA Label for ofatumumab and MS4A1	FDA	Formerly on FDA Biomarker List						Cancer Genome		ofatumumab	MS4A1		8/17/2023	Ofatumumab (ARZERRA) is used to treat patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. The drug is a CD20-directed cytolytic monoclonal antibody, but there is no association with genetic variation within the coding gene, MS4A1, and therefore no mention of genetic testing in the drug label.
https://www.pharmgkb.org/labelAnnotation/PA166104866	PA166104866	Annotation of FDA Label for pravastatin and APOE	FDA	Formerly on FDA Biomarker List								pravastatin	APOE		9/7/2023	The FDA-approved drug label for pravastatin (PRAVACHOL) contains pharmacogenetic information regarding response results in patients with APOE genotype E2/E2 and Fredrickson Type III dysbetalipoproteinemia.
https://www.pharmgkb.org/labelAnnotation/PA166104892	PA166104892	Annotation of FDA Label for sulfasalazine and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	sulfasalazine	G6PD		8/16/2024	Sulfasalazine (Azulfidine) is used to treat and prolong remission for ulcerative colitis. The label warns that people with glucose-6 phosphate dehydrogenase deficiency are susceptible to hemolytic anemia on this drug. The label also notes that acetylator status may affect metabolism of the drug and risk for adverse events; acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene. However, the label never mentions any specific gene with regard to inactivator or acetylator status.
https://www.pharmgkb.org/labelAnnotation/PA166114912	PA166114912	Annotation of FDA Label for dabrafenib and BRAF	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		dabrafenib	BRAF	rs113488022	11/30/2023	The drug label for dabrafenib (TAFINLAR) states that it is indicated, as a single agent or in combination with trametinib, for patients with melanoma, non-small cell lung cancer (NSCLC) or anaplastic thyroid cancer (ATC) and the BRAF V600E or V600K mutations; the drug is not indicated for treatment of patients with wild-type BRAF solid tumors. It is also indicated for the treatment of adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options.
https://www.pharmgkb.org/labelAnnotation/PA166114928	PA166114928	Annotation of FDA Label for mipomersen and LDLR	FDA	Formerly on FDA Biomarker List								mipomersen	LDLR		8/20/2024	Mipomersen (KYNAMRO) is indicated as an adjunct to diet and lipid lowering treatments in patients with homozygous familial hypercholesterolemia (HoFH). Mutations in the LDL receptor gene (LDLR) are the most common cause of HoFH, however, mutations in other genes (such as APOB) can also lead to HoFH.
https://www.pharmgkb.org/labelAnnotation/PA166182751	PA166182751	Annotation of FDA Label for mepivacaine and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	mepivacaine	G6PD		10/3/2023	The FDA-approved drug label for mepivacaine states that patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency and congenital methemoglobinemia may be more susceptible to developing clinical manifestations of methemoglobinemia. Close monitoring for symptoms and signs of methemoglobinemia is recommended in this subset of patients.
https://www.pharmgkb.org/labelAnnotation/PA166179855	PA166179855	Annotation of FDA Label for avatrombopag and F2, F5, PROC, PROS1, SERPINC1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	avatrombopag	F2; F5; PROC; PROS1; SERPINC1	rs1799963; rs6025	7/17/2024	The FDA-approved drug label for avatrombopag (DOPTELET) states that the risk for thrombosis should be considered in patients with risk factors for thromboembolism, including genetic prothrombotic conditions such as Factor V Leiden (F5), Prothrombin 20210A (F2), Antithrombin deficiency (SERPINC1) or Protein C (PROC) or S (PROS1) deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166169878	PA166169878	Annotation of FDA Label for brigatinib and ALK	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		brigatinib	ALK		8/2/2024	Brigatinib (ALUNBRIG) is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
https://www.pharmgkb.org/labelAnnotation/PA166160009	PA166160009	Annotation of FDA Label for pembrolizumab and ALK, CD274, EGFR, ERBB2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		pembrolizumab	ALK; CD274; EGFR; ERBB2		11/30/2023	The FDA-approved drug label for pembrolizumab (KEYTRUDA) states that it is indicated for the treatment of patients with a variety of cancers whose tumors express PD-L1 (CD274) as detected by an FDA-approved test. Pembrolizumab is approved as first line therapy for patients with no EGFR and ALK genomic tumor aberrations and for patients with EGFR and ALK genomic tumor aberrations who have disease progression on FDA-approved therapies. It is also approved for the treatment of unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancers, Tumor Mutational Burden-High (TMB-H) Cancer and ERBB2 (HER2)-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.
https://www.pharmgkb.org/labelAnnotation/PA166177475	PA166177475	Annotation of FDA Label for abemaciclib and ERBB2, ESR1, ESR2, PGR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		abemaciclib	ERBB2; ESR1; ESR2; PGR		8/26/2024	Abemaciclib (VERZENIO) is indicated in combination with other medications or as a monotherapy for the treatment of women with hormone receptor-positive, HER2-negative breast cancer.
https://www.pharmgkb.org/labelAnnotation/PA166170936	PA166170936	Annotation of FDA Label for tamoxifen and F2, F5	FDA	On FDA Biomarker List	No Clinical PGx							tamoxifen	F2; F5			Tamoxifen (SOLTAMOX) is indicated for the treatment of breast cancer. A clinical trial showed no benefit of screening for Factor V Leiden (F5) or Prothrombin (F2) mutations when treating with tamoxifen.
https://www.pharmgkb.org/labelAnnotation/PA166153432	PA166153432	Annotation of FDA Label for flibanserin and CYP2C9, CYP2D6	FDA	On FDA Biomarker List	Informative PGx							flibanserin	CYP2C9; CYP2D6		7/22/2024	The FDA-approved drug label for flibanserin (ADDYI) notes the influence of CYP2D6 and CYP2C9 metabolizer phenotypes on flibanserin exposure.
https://www.pharmgkb.org/labelAnnotation/PA166151853	PA166151853	Annotation of FDA Label for nilotinib and UGT1A1	FDA	On FDA Biomarker List	Informative PGx							nilotinib	UGT1A1			Nilotinib (Tasigna) is indicated for use in patients diagnosed with Philadelphia chromosome positive (presence of a BCR-ABL1 gene fusion) chronic myeloid leukemia, due to its mechanism of action. Individuals with the UGT1A1*28 genotype (TA)7/(TA)7 (rs8175347) are at an increased risk of hyperbilirubinemia when taking nilotinib.
https://www.pharmgkb.org/labelAnnotation/PA166177509	PA166177509	Annotation of FDA Label for formoterol and CYP2C19, CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							formoterol	CYP2C19; CYP2D6			Formoterol (PERFOROMIST) is indicated in patients with chronic obstructive pulmonary disease (COPD). The label notes that the effect of patients with CYP2D6 or CYP2C19 deficiency on formoterol exposure has not been adequately explored.
https://www.pharmgkb.org/labelAnnotation/PA166182765	PA166182765	Annotation of FDA Label for flutamide and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	flutamide	G6PD		7/22/2024	The FDA-approved drug label for flutamide (Eulexin) states that in patients susceptible to aniline toxicity (e.g. persons with glucose-6-phosphate dehydrogenase deficiency, hemoglobin M disease and smokers), monitoring of methemoglobin levels should be considered.
https://www.pharmgkb.org/labelAnnotation/PA166180000	PA166180000	Annotation of FDA Label for meclizine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	meclizine	CYP2D6		10/21/2019	The FDA-approved drug label for meclizine (ANTIVERT) states that CYP2D6 is the dominant metabolizing enzyme and that genetic polymorphism of CYP2D6 could contribute to large variability in meclizine exposure
https://www.pharmgkb.org/labelAnnotation/PA166181925	PA166181925	Annotation of FDA Label for tamoxifen and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							tamoxifen	CYP2D6		10/9/2019	The FDA-approved drug label for tamoxifen (SOLTAMOX) states that the impact of CYP2D6 polymorphisms on the efficacy of tamoxifen is not well established, but that CYP2D6 poor metabolizers have lower endoxifen concentrations are compared to intermediate, normal or ultrarapid metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166129553	PA166129553	Annotation of FDA Label for belinostat and UGT1A1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	belinostat	UGT1A1		5/9/2019	The FDA-approved drug label for belinostat (BELEODAQ) states that the starting dose should be reduced to 750 mg/m2 in patients known to be homozygous for the UGT1A1*28 allele to minimize dose limiting toxicities. However, testing or screening for the *28 allele is not mentioned.
https://www.pharmgkb.org/labelAnnotation/PA166127663	PA166127663	Annotation of FDA Label for divalproex sodium and POLG	FDA	Formerly on FDA Biomarker List	Testing Required	Prescribing Info		Alternate Drug			Prescribing	divalproex sodium	POLG		8/22/2023	The FDA-approved drug label for divalproex states that it is contraindicated in individuals with known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG), and suspected POLG-related disorders in children under 2 years old.
https://www.pharmgkb.org/labelAnnotation/PA166182739	PA166182739	Annotation of FDA Label for tafenoquine and G6PD	FDA	On FDA Biomarker List	Testing Required	Prescribing Info		Alternate Drug			Prescribing	tafenoquine	G6PD			The FDA-approved drug label for tafenoquine states that G6PD testing must be performed before prescribing the drug, and that tafenoquine is contraindicated in patients with G6PD deficiency or of unknown G6PD status.
https://www.pharmgkb.org/labelAnnotation/PA166160021	PA166160021	Annotation of FDA Label for cabozantinib and RET	FDA	On FDA Biomarker List						Cancer Genome		cabozantinib	RET		8/15/2023	The FDA-approved drug label for cabozantinib (COMETRIQ) states that RET mutation status was determined in clinical studies of the drug, and that the drug inhibits the activity of the RET protein.
https://www.pharmgkb.org/labelAnnotation/PA166177512	PA166177512	Annotation of FDA Label for inotuzumab ozogamicin and ABL1, BCR	FDA	On FDA Biomarker List						Cancer Genome		inotuzumab ozogamicin	ABL1; BCR		8/18/2023	Inotuzumab ozogamicin (BESPONSA) is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The label notes that clinical studies included patients with Philadelphia chromosome-negative or -positive ALL.
https://www.pharmgkb.org/labelAnnotation/PA166182729	PA166182729	Annotation of FDA Label for amoxapine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							amoxapine	CYP2D6			The FDA-approved drug label for amoxapine contains information regarding the metabolism of tricyclic antidepressants by CYP2D6: CYP2D6 poor metabolizers may have higher plasma concentrations of tricyclic antidepressants, and the label suggests monitoring of plasma levels if this drug is co-administrered with a CYP2D6 inhibitor.
https://www.pharmgkb.org/labelAnnotation/PA166170957	PA166170957	Annotation of FDA Label for vemurafenib and HRAS, KRAS, NRAS	FDA	On FDA Biomarker List						Cancer Genome		vemurafenib	HRAS; KRAS; NRAS		8/29/2023	Vemurafenib (ZELBORAF) is a kinase inhibitor used to treat patients with unresectable or metastatic melanoma in cases where the BRAF V600E mutation is found by an FDA-approved test. The label notes that the drug may promote malignancies associated with activation of RAS (HRAS, KRAS, NRAS).
https://www.pharmgkb.org/labelAnnotation/PA166170048	PA166170048	Annotation of FDA Label for ribociclib and ERBB2, ESR1, ESR2, PGR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		ribociclib	ERBB2; ESR1; ESR2; PGR		8/31/2023	Ribociclib (KISQALI) is indicated in combination with an aromatase inhibitor for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
https://www.pharmgkb.org/labelAnnotation/PA166170932	PA166170932	Annotation of FDA Label for pembrolizumab and BRAF	FDA	On FDA Biomarker List						Cancer Genome		pembrolizumab	BRAF	rs113488022	11/30/2023	The FDA-approved drug label for pembrolizumab (KEYTRUDA) states that it is indicated for the treatment of patients with metastatic non-small cell lung cancer whose tumors express PD-L1 (CD274) as detected by an FDA-approved test. The label also mentions BRAF V600 mutations.
https://www.pharmgkb.org/labelAnnotation/PA166153492	PA166153492	Annotation of FDA Label for brivaracetam and CYP2C19	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	brivaracetam	CYP2C19		7/15/2024	The FDA-approved drug label for brivaracetam (BRIVIACT) states that CYP2C19 intermediate or poor metabolizers may have increased blood levels of brivaracetam, and that poor metabolizers may require a dose reduction.
https://www.pharmgkb.org/labelAnnotation/PA166160061	PA166160061	Annotation of FDA Label for dinutuximab and MYCN	FDA	On FDA Biomarker List						Cancer Genome		dinutuximab	MYCN		8/15/2023	The FDA-approved drug label for dinutuximab (UNITUXIN) provides information on the MYCN status of patients in a clinical study of the drug.
https://www.pharmgkb.org/labelAnnotation/PA166182760	PA166182760	Annotation of FDA Label for docetaxel and ESR1, ESR2, PGR	FDA	On FDA Biomarker List						Cancer Genome		docetaxel	ESR1; ESR2; PGR		8/15/2023	The FDA-approved drug label for docetaxel mentions subset analysis for Breast Cancer patients defined by positive estrogen and/or progesterone receptor status.
https://www.pharmgkb.org/labelAnnotation/PA166163422	PA166163422	Annotation of FDA Label for dronabinol and CYP2C9	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	dronabinol	CYP2C9			The FDA-approved drug label for dronabinol (SYNDROS) notes that patients who carry genetic variants that result in diminished CYP2C9 function may have a 2- to 3-fold higher dronabinol exposure.
https://www.pharmgkb.org/labelAnnotation/PA166115363	PA166115363	Annotation of FDA Label for succimer and G6PD	FDA	On FDA Biomarker List								succimer	G6PD		8/24/2023	Succimer (CHEMET) is used for treating lead poisoning in pediatric patients with blood lead levels greater than 45 mcg/dL. The drug label notes that succimer has been used to treat five patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency without any adverse reactions.
https://www.pharmgkb.org/labelAnnotation/PA166182768	PA166182768	Annotation of FDA Label for gilteritinib and FLT3	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		gilteritinib	FLT3		8/31/2023	The FDA-approved label for gilteritinib (XOSPATA) states that it is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.
https://www.pharmgkb.org/labelAnnotation/PA166114931	PA166114931	Annotation of FDA Label for ponatinib and ABL1, BCR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		ponatinib	ABL1; BCR	rs121913459	9/1/2023	The FDA-approved drug label for ponatinib (Iclusig) states that it is intended for adults with chronic, accelerated or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to prior tyrosine kinase inhibitor therapy, including those with the BCR-ABL T315I mutation. The majority of patients with CML are positive for the Philadelphia chromosome (BCR-ABL1 gene fusion).
https://www.pharmgkb.org/labelAnnotation/PA166163430	PA166163430	Annotation of FDA Label for isosorbide dinitrate and CYB5R1, CYB5R2, CYB5R3, CYB5R4	FDA	On FDA Biomarker List	Informative PGx							isosorbide dinitrate	CYB5R1; CYB5R2; CYB5R3; CYB5R4		7/30/2024	Isosorbide dinitrate (dilatrate-SR) is indicated for the prevention of angina pectoris due to coronary artery disease. The FDA-approved drug label provides information about patients with cytochrome b5 reductase activity and risk for methemoglobinemia.
https://www.pharmgkb.org/labelAnnotation/PA166114941	PA166114941	Annotation of FDA Label for pravastatin and LDLR	FDA	Formerly on FDA Biomarker List								pravastatin	LDLR		9/28/2023	The FDA-approved drug label for pravastatin (PRAVACHOL) states that the drug is intended for patients with familial hypercholesterolemia (Fredrickson Type IIa), among other indications. Familial hypercholesterolemia is commonly caused by mutations in the LDLR (low density lipoprotein receptor) gene; pravastatin has only been evaluated in patients with heterozygous familial hypercholesterolemia (i.e. patients with only one abnormal copy of the LDLR gene).
https://www.pharmgkb.org/labelAnnotation/PA166182724	PA166182724	Annotation of FDA Label for ixabepilone and ERBB2, ESR1, ESR2, PGR	FDA	On FDA Biomarker List						Cancer Genome		ixabepilone	ERBB2; ESR1; ESR2; PGR		8/18/2023	Ixabepilone (IXEMPRA) in combination with capecitabine is indicated for the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline and a taxane. IXEMPRA as monotherapy is indicated for the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline, a taxane, and capecitabine. The label notes the percentages of patients in clinical studies who are hormone receptor positive or negative.
https://www.pharmgkb.org/labelAnnotation/PA166163417	PA166163417	Annotation of FDA Label for sofosbuvir / velpatasvir and IFNL3	FDA	On FDA Biomarker List								sofosbuvir / velpatasvir	IFNL3	rs12979860	8/24/2023	EPCLUSA (sofosbuvir and velpatasvir) is indicated for the treatment of adult patients with chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis, or with decompensated cirrhosis for use in combination with ribavirin. Within the clinical studies section, the label mentions frequency of the rs12979860 non-CC genotype.
https://www.pharmgkb.org/labelAnnotation/PA166163420	PA166163420	Annotation of FDA Label for venetoclax and FLT3, IDH1, IDH2, NPM1, TP53	FDA	On FDA Biomarker List						Cancer Genome		venetoclax	FLT3; IDH1; IDH2; NPM1; TP53		8/29/2023	Venetoclax (VENCLEXTA) is a BCL-2 inhibitor indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without the 17p deletion, as detected by an FDA-approved test, who have received at least one prior therapy. The label also notes whether mutation analyses detected mutations in the TP53, IDH1, IDH2, FLT3 and NPM1 genes. The label states that the 11q deletion was detected in 32% of patients in the MURANO study.
https://www.pharmgkb.org/labelAnnotation/PA166182734	PA166182734	Annotation of FDA Label for larotrectinib and NTRK1, NTRK2, NTRK3	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		larotrectinib	NTRK1; NTRK2; NTRK3		5/24/2024	The FDA-approved drug label for larotrectinib (VITRAKVI) states that it is indicated for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.
https://www.pharmgkb.org/labelAnnotation/PA166170931	PA166170931	Annotation of FDA Label for midostaurin and KIT, NPM1	FDA	On FDA Biomarker List						Cancer Genome		midostaurin	KIT; NPM1		8/15/2023	The FDA-approved label for midostaurin (RYDAPT) states that it is indicated for the treatment of adult patients with acute myeloid leukemia that is FLT3 mutation-positive as detected by an FDA-approved test. The label also notes the percentage of patients with an NPM1 mutation or KIT D816V mutation in clinical studies.
https://www.pharmgkb.org/labelAnnotation/PA166163429	PA166163429	Annotation of FDA Label for atezolizumab and ALK, BRAF, CD274, EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		atezolizumab	ALK; BRAF; CD274; EGFR	rs113488022	8/31/2023	The FDA-approved drug label for atezolizumab (TECENTRIQ) states that it is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma or metastatic non-small cell lung cancer. PD-L1 is encoded by the CD274 gene. The FDA-approved drug label for atezolizumab (TECENTRIQ) also states that it is approved for use in patients with EGFR or ALK genomic tumor aberrations and disease progression on other FDA-approved therapy, and patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.
https://www.pharmgkb.org/labelAnnotation/PA166182757	PA166182757	Annotation of FDA Label for inotersen and TTR	FDA	On FDA Biomarker List								inotersen	TTR		8/18/2023	The FDA-approved drug label for inotersen (TEGSEDI) states that TEGSEDI is a transthyretin-directed antisense oligonucleotide indicated for treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
https://www.pharmgkb.org/labelAnnotation/PA166160046	PA166160046	Annotation of FDA Label for cobimetinib and BRAF	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		cobimetinib	BRAF	rs113488022	9/1/2023	The FDA-approved drug label for cobimetinib (COTELLIC) states that it is indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.
https://www.pharmgkb.org/labelAnnotation/PA166131627	PA166131627	Annotation of FDA Label for osimertinib and EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		osimertinib	EGFR	rs121434568; rs121434569	9/1/2023	The FDA-approved drug label for osimertinib (TAGRISSO) states that it is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, or those who have EGFR T790M mutations and whose disease has progressed on or after EGFR TKI therapy.
https://www.pharmgkb.org/labelAnnotation/PA166115365	PA166115365	Annotation of FDA Label for trametinib and BRAF	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		trametinib	BRAF	rs113488022	9/1/2023	Trametinib (MEKINIST) is indicated for use in patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, or metastatic non-small cell lung cancer with BRAF V600E mutation, as detected by an FDA-approved test.
https://www.pharmgkb.org/labelAnnotation/PA166163428	PA166163428	Annotation of FDA Label for ledipasvir / sofosbuvir and IFNL3	FDA	On FDA Biomarker List								ledipasvir / sofosbuvir	IFNL3		9/6/2023	HARVONI (ledipasvir and sofosbuvir) is indicated with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotype 1, 4, 5 or 6 infection. Within the clinical studies section, the label mentions frequency of the rs12979860 non-CC genotype.
https://www.pharmgkb.org/labelAnnotation/PA166169920	PA166169920	Annotation of FDA Label for niraparib and BRCA1, BRCA2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		niraparib	BRCA1; BRCA2		8/9/2024	The FDA-approved label for niraparib (ZEJULA) states that niraparib is also indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. These patients should be selected based on an FDA-approved companion diagnostic.
https://www.pharmgkb.org/labelAnnotation/PA166114944	PA166114944	Annotation of FDA Label for regorafenib and KRAS	FDA	On FDA Biomarker List						Cancer Genome		regorafenib	KRAS		8/26/2024	The FDA-approved drug label for regorafenib (STIVARGA) states that it is intended for patients with metastatic colorectal cancer who were previously given fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if they were RAS wild type, an anti-EGFR therapy.
https://www.pharmgkb.org/labelAnnotation/PA166163421	PA166163421	Annotation of FDA Label for daclatasvir and IFNL3	FDA	On FDA Biomarker List	No Clinical PGx							daclatasvir	IFNL3		8/15/2023	Daclatasvir (DAKLINZA) is indicated for use with sofosbuvir, with or without ribavirin, for the treatment of chronic HCV genotype 1 or 3 infection. Within the clinical studies section, the label mentions frequency of the rs12979860 non-CC genotype.
https://www.pharmgkb.org/labelAnnotation/PA166127644	PA166127644	Annotation of HCSC Label for capecitabine and DPYD	HCSC		Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	capecitabine	DPYD	DPYD c.1905+1G>A (*2A)	3/31/2023	The product monograph for capecitabine states that it is contraindicated in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. Testing for DPD deficiency should be considered prior to treatment, based on the local availability and current guidelines.
https://www.pharmgkb.org/labelAnnotation/PA166238981	PA166238981	Annotation of FDA Label for synthetic conjugated estrogens, A and PROC, PROS1, SERPINC1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	synthetic conjugated estrogens, A	PROC; PROS1; SERPINC1			The FDA-approved label for conjugated synthetic estrogens, A (CENESTIN) states that it is contraindicated for use in patients with protein C, protein S, or antithrombin deficiency. These proteins are encoded by PROC, PROS1, and SERPINC1, respectively.
https://www.pharmgkb.org/labelAnnotation/PA166293421	PA166293421	Annotation of FDA Label for pemigatinib and FGFR1, FGFR2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		pemigatinib	FGFR1; FGFR2			Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement or adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement.
https://www.pharmgkb.org/labelAnnotation/PA166190141	PA166190141	Annotation of FDA Label for enfortumab vedotin and NECTIN4	FDA	Formerly on FDA Biomarker List						Cancer Genome		enfortumab vedotin	NECTIN4		8/17/2023	Enfortumab vedotin-ejfv (PADCEV) is a Nectin-4-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. In clinical studies, an immunohistochemistry clinical trial assay was used to assess patients with tumor tissue available, and detected Nectin-4 expression in all patients tested.
https://www.pharmgkb.org/labelAnnotation/PA166185180	PA166185180	Annotation of FDA Label for nusinersen and SMN2	FDA	On FDA Biomarker List								nusinersen	SMN2		8/17/2023	The FDA-approved drug label for nusinersen (SPINRAZA) states that nusinersen is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
https://www.pharmgkb.org/labelAnnotation/PA166269301	PA166269301	Annotation of FDA Label for maralixibat and JAG1	FDA	On FDA Biomarker List								maralixibat	JAG1		8/18/2023	The FDA-approved drug label for maralixibat contains information about the JAG1 mutation status of pediatric clinical trial patients.
https://www.pharmgkb.org/labelAnnotation/PA166225042	PA166225042	Annotation of FDA Label for rimegepant and CYP2C9	FDA	On FDA Biomarker List	No Clinical PGx							rimegepant	CYP2C9		3/13/2024	The FDA label for rimegipant (NURTEC ODT) states that it is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults. The contribution of CYP2C9 to rimegepant metabolism is considered minor, and CYP2C9 polymorphism is not expected to significantly affect its exposure.
https://www.pharmgkb.org/labelAnnotation/PA166182769	PA166182769	Annotation of FDA Label for hydroxychloroquine and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	hydroxychloroquine	G6PD		9/27/2023	The FDA-approved drug label for hydroxychloroquine (PLAQUENIL) states that hemolysis was reported in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency and monitor for hemolytic anemia.
https://www.pharmgkb.org/labelAnnotation/PA166235601	PA166235601	Annotation of FDA Label for lonafarnib and LMNA, ZMPSTE24	FDA	On FDA Biomarker List	Testing Required							lonafarnib	LMNA; ZMPSTE24		8/8/2024	The FDA-approved drug label for lonafarnib (ZOKINVY) states that ZOKINVY is indicated to reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome and for the treatment of processing-deficient Progeroid Laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation or homozygous or compound heterozygous ZMPSTE24 mutations.
https://www.pharmgkb.org/labelAnnotation/PA166278281	PA166278281	Annotation of FDA Label for estradiol valerate	FDA	On FDA Biomarker List								estradiol valerate			8/17/2023	The FDA-approved label for estradiol valerate (DELESTROGEN) states that estradiol valerate is indicated for treatment of symptoms associated with menopause, treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure, and treatment of advanced androgen-dependent carcinoma of the prostate.
https://www.pharmgkb.org/labelAnnotation/PA166235441	PA166235441	Annotation of FDA Label for bupivacaine and CYB5R3, G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	bupivacaine	CYB5R3; G6PD		7/18/2024	The FDA-approved drug label for bupivacaine (MARCAINE SPINAL) states that individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency or congenital methemoglobinemia may be at increased risk for treatment-induced methemoglobinemia; close monitoring for symptoms of methemoglobinemia is recommended.
https://www.pharmgkb.org/labelAnnotation/PA166182886	PA166182886	Annotation of FDA Label for migalastat and GLA	FDA	On FDA Biomarker List	Testing Required							migalastat	GLA		8/9/2024	"The FDA-approved drug label for migalastat (GALAFOLD) states that it is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data. The label contains a list of ""amenable GLA variants"" in Table 2."
https://www.pharmgkb.org/labelAnnotation/PA166225101	PA166225101	Annotation of FDA Label for sacituzumab govitecan and UGT1A1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	sacituzumab govitecan	UGT1A1	UGT1A1*28	10/24/2023	The FDA label for sacituzumab govitecan-hziy (TRODELVY) states that patients who are homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are at increased risk for neutropenia and other adverse reactions following initiation of TRODELVY treatment. Closely monitor patients with reduced UGT1A1 activity for adverse reactions.
https://www.pharmgkb.org/labelAnnotation/PA166182890	PA166182890	Annotation of FDA Label for olaparib and ESR1, ESR2, PGR, PPP2R2A	FDA	On FDA Biomarker List						Cancer Genome		olaparib	ESR1; ESR2; PGR; PPP2R2A		8/17/2023	The FDA-approved drug label for olaparib (Lynparza) states that it is indicated for treatment of adult patients ovarian or breast cancer. The label also notes that patients with hormone receptor positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Although patients with PPP2R2A gene mutations were enrolled in the trial PROfound (NCT02987543), olaparib is not indicated for the treatment of patients with this gene mutation due to unfavorable risk-benefit.
https://www.pharmgkb.org/labelAnnotation/PA166190101	PA166190101	Annotation of FDA Label for elexacaftor / tezacaftor / ivacaftor and CFTR	FDA	On FDA Biomarker List	Testing Required							elexacaftor / tezacaftor / ivacaftor	CFTR	rs113993958; rs113993960; rs115545701; rs11971167; rs121908752; rs121908753; rs121908755; rs121908757; rs121909005; rs121909013; rs121909020; rs121909041; rs141033578; rs150212784; rs186045772; rs193922525; rs200321110; rs202179988; rs267606723; rs368505753; rs397508256; rs397508288; rs397508442; rs397508513; rs397508537; rs397508759; rs74503330; rs74551128; rs75527207; rs75541969; rs77834169; rs77932196; rs78655421; rs78769542; rs80282562	10/12/2023	Elexacaftor/tezacaftor/ivacaftor (TRIKAFTA) is a combination of ivacaftor, a CFTR potentiator, tezacaftor, and elexacaftor indicated for the treatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one F508del mutation in the CFTR gene or a mutation in the CFTR gene that is responsive based on in vitro data. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one F508del mutation or a mutation that is responsive based on in vitro data.
https://www.pharmgkb.org/labelAnnotation/PA166190761	PA166190761	Annotation of FDA Label for upadacitinib and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							upadacitinib	CYP2D6			Upadacitinib (RINVOQ) is a Janus kinase (JAK) inhibitor indicated for the treatment of moderately to severely active rheumatoid arthritis in adults who have had an inadequate response or intolerance to methotrexate. Upadacitinib is metabolized by CYP3A4 with a minor contribution from CYP2D6. However, CYP2D6 metabolic phenotype had not shown to have effect on upadacitinib pharmacokinetics.
https://www.pharmgkb.org/labelAnnotation/PA166190023	PA166190023	Annotation of FDA Label for luspatercept and HBB	FDA	On FDA Biomarker List								luspatercept	HBB		3/31/2024	Luspatercept-aamt (REBLOZYL) is an erythroid maturation agent indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. Beta thalassemia is caused by mutations in the HBB gene. Review of hemoglobin (Hgb) results is required prior to each administration.
https://www.pharmgkb.org/labelAnnotation/PA166225121	PA166225121	Annotation of FDA Label for selpercatinib and RET	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		selpercatinib	RET		8/13/2024	The FDA label for selpercatinib (RETEVMO) states that it is indicated for metastatic RET fusion-positive non-small cell lung cancer (NSCLC), advanced or metastatic RET-mutant medullary thyroid cancer (MTC) and advanced or metastatic RET fusion-positive thyroid cancer. Patients should be selected for treatment with RETEVMO based on the presence of a RET gene fusion (NSCLC or thyroid cancer) or specific RET gene mutation (MTC) in tumor specimens or plasma.
https://www.pharmgkb.org/labelAnnotation/PA166185168	PA166185168	Annotation of FDA Label for pitolisant and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	pitolisant	CYP2D6		2/11/2020	The FDA-approved drug label for pitolisant (WAKIX) states that dosage reduction is recommended in patients known to be poor CYP2D6 metabolizers because these patients have higher pitolisant concentrations than normal CYP2D6 metabolizers. The maximum recommended dosage is 17.8 mg once daily for poor metabolizers of CYP2D6.
https://www.pharmgkb.org/labelAnnotation/PA166225142	PA166225142	Annotation of FDA Label for tucatinib and ERBB2, HRAS, KRAS, NRAS	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		tucatinib	ERBB2; HRAS; KRAS; NRAS		10/24/2023	The FDA label for tucatinib (TUKYSA) states that TUKYSA is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. It is also indicated in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
https://www.pharmgkb.org/labelAnnotation/PA166190701	PA166190701	Annotation of FDA Label for givosiran and CPOX, HMBS, PPOX	FDA	On FDA Biomarker List								givosiran	CPOX; HMBS; PPOX		8/17/2023	Givosiran (GIVLAARI) is an aminolevulinate synthase 1-directed small interfering RNA indicated for the treatment of adults with acute hepatic porphyria (AHP). The efficacy of GIVLAARI was evaluated in the ENVISION trial in patients with acute intermittent porphyria (AIP), hereditary coproporphyria (HCP), and variegate porphyria (VP). Mutations in CPOX, HMBS and PPOX genes have been linked to these autosomal dominant disorders and are listed in the FDA table but not specified in the label itself.
https://www.pharmgkb.org/labelAnnotation/PA166224202	PA166224202	Annotation of FDA Label for capmatinib and MET	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		capmatinib	MET		8/31/2023	The FDA label for capmatinib (TABRECTA) states that capmatinib is a kinase inhibitor to treat adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
https://www.pharmgkb.org/labelAnnotation/PA166191501	PA166191501	Annotation of FDA Label for lenvatinib	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		lenvatinib			8/31/2023	Lenvatinib (LENVIMA) is a kinase inhibitor that is indicated for: 1) differentiated thyroid cancer, 2) renal cell carcinoma, 3) hepatocellular carcinoma, and 4) in combination with pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.
https://www.pharmgkb.org/labelAnnotation/PA166236521	PA166236521	Annotation of FDA Label for viltolarsen and DMD	FDA	On FDA Biomarker List	Testing Required							viltolarsen	DMD		8/21/2023	The FDA-approved label for viltolarsen (VILTEPSO) states that it is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.
https://www.pharmgkb.org/labelAnnotation/PA166236001	PA166236001	Annotation of FDA Label for sodium oxybate and ALDH5A1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	sodium oxybate	ALDH5A1		4/22/2022	The FDA-approved drug label for sodium oxybate (XYREM) states that it is a central nervous depressant indicated for treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy and that it is contraindicated for use in patients with succinic semialdehyde dehydrogenase deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166121327	PA166121327	Annotation of EMA Label for pegloticase and G6PD	EMA		Testing Required	Prescribing Info		Alternate Drug			Prescribing	pegloticase	G6PD		3/31/2023	The EMA European Public Assessment Report (EPAR) for pegloticase (Krystexxa) states that screening in patients at higher risk for G6PD deficiency should be carried out prior to pegloticase treatment. It is contraindicated in these patients due to a higher risk of hemolysis and methemoglobinemia. Please note that as of June 2016 pegloticase (Krystexxa) has been withdrawn from use in the European Union.
https://www.pharmgkb.org/labelAnnotation/PA166278321	PA166278321	Annotation of FDA Label for ganaxolone and CDKL5	FDA	On FDA Biomarker List	Testing Required							ganaxolone	CDKL5		8/21/2023	The FDA-approved label for ganaxolone (ZTALMY) states that it is a neuroactive steroid that functions as a positive modulator of GABA A receptor activity. Ganaxolone is indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder in patients who are 2 years of age or older.
https://www.pharmgkb.org/labelAnnotation/PA166169884	PA166169884	Annotation of FDA Label for durvalumab and ALK, CD274, EGFR, PDCD1	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		durvalumab	ALK; CD274; EGFR; PDCD1		8/31/2023	The FDA-approved drug label for durvalumab (IMFINZI) states that it is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of patients with various cancers including metastatic NSCLC without mutations in ALK or EGFR. PD-L1 is encoded by the CD274 gene and binds to the PDCD1 programmed cell death receptor.
https://www.pharmgkb.org/labelAnnotation/PA166191581	PA166191581	Annotation of FDA Label for ipilimumab and ALK, CD274, EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		ipilimumab	ALK; CD274; EGFR		12/4/2023	Ipilimumab (Yervoy) is a human cytotoxic T-lymphocyte antigen 4-blocking antibody indicated for several cancer types including microsatellte instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer, as well as metastatic non-small cell lung cancer expressing PD-L1 (≥1%), and metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy.
https://www.pharmgkb.org/labelAnnotation/PA166182719	PA166182719	Annotation of FDA Label for ipilimumab and HLA-A	FDA	On FDA Biomarker List	No Clinical PGx							ipilimumab	HLA-A	HLA-A*02:01	12/4/2023	Ipilimumab (Yervoy) is a human cytotoxic T-lymphocyte antigen 4-blocking antibody indicated for several cancer types. The label mentions a clinical trial which selected patients with a particular HLA-A variant.
https://www.pharmgkb.org/labelAnnotation/PA166123390	PA166123390	Annotation of EMA Label for fampridine and SLC22A2	EMA									fampridine	SLC22A2		8/17/2023	The EMA European Public Assessment Report (EPAR) for fampridine (Fampyra) does not contain pharmacogenetic information. It contains information regarding the role of OCT2 (SLC22A2) in the secretion of fampridine, and states that concomitant use of drugs that are inhibitors of OCT2 are contraindicated, and cautions the use of concomitant drugs that are substrates of OCT2.
https://www.pharmgkb.org/labelAnnotation/PA166123412	PA166123412	Annotation of EMA Label for sunitinib and CYP3A4	EMA									sunitinib	CYP3A4		8/24/2023	The EMA European Public Assessment Report (EPAR) for sunitinib (SUTENT) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4, and that potent CYP3A4 inhibitors or inducers should be avoided as they may affect sunitinib plasma levels.
https://www.pharmgkb.org/labelAnnotation/PA166123421	PA166123421	Annotation of EMA Label for atazanavir and CYP2C19	EMA		Informative PGx							atazanavir	CYP2C19		7/25/2024	The EMA European Public Assessment Report (EPAR) for atazanavir (REYATAZ) states that co-administration with voriconazole and ritonavir is not recommended, and that if voriconazole treatment is required a patient's CYP2C19 genotype should be performed if feasible. If the patient has at least one functional CYP2C19 allele, close clinical monitoring for a loss of voriconazole and atazanvir efficacy is recommended.
https://www.pharmgkb.org/labelAnnotation/PA166123528	PA166123528	Annotation of PMDA Label for atomoxetine and CYP2D6	PMDA		Actionable PGx							atomoxetine	CYP2D6			The PMDA package insert for atomoxetine (Strattera) states that individuals who are CYP2D6 poor metabolizers (PMs) and administered atomoxetine may have higher exposure to the drug and be at a greater risk of experiencing adverse events. The insert recommends dosing these patients with discretion.
https://www.pharmgkb.org/labelAnnotation/PA166123530	PA166123530	Annotation of PMDA Label for azathioprine and TPMT	PMDA		Actionable PGx							azathioprine	TPMT			The PMDA package insert for azathioprine notes that individuals with certain TPMT genetic variations may be at increased risk of developing myelotoxicity. The insert also notes that this myelotoxicity could be exacerbated by co-administration of drugs that inhibit TPMT, such as aminosalicylic acid derivatives.
https://www.pharmgkb.org/labelAnnotation/PA166123531	PA166123531	Annotation of PMDA Label for capecitabine and DPYD	PMDA		Actionable PGx							capecitabine	DPYD			The PMDA package insert for capecitabine states that severe adverse events have occurred in patients receiving the drug who are dihydropyrimidine dehydrogenase (DPD)-deficient. DPD is the enzyme responsible for the degradation of capecitabine and other fluoropyrimidines.
https://www.pharmgkb.org/labelAnnotation/PA166123535	PA166123535	Annotation of PMDA Label for clopidogrel and CYP2C19	PMDA		Actionable PGx							clopidogrel	CYP2C19			The PMDA package insert for clopidogrel states that in clinical pharmacological studies, CYP2C19 poor metabolizers had diminished inhibition of platelet aggregation.
https://www.pharmgkb.org/labelAnnotation/PA166123536	PA166123536	Annotation of PMDA Label for crizotinib and ALK	PMDA		Testing Required							crizotinib	ALK			Crizotinib is indicated for the treatment of patients with non-small cell lung cancer. The PMDA package insert for crizotinib states positive confirmation of the ALK fusion gene is necessary prior to treatment.
https://www.pharmgkb.org/labelAnnotation/PA166123538	PA166123538	Annotation of PMDA Label for eltrombopag and SERPINC1	PMDA		Actionable PGx							eltrombopag	SERPINC1			The PMDA package insert for eltrombopag notes that caution should be taken when administering the drug to patients with antithrombin III (AT III; SERPINC1 gene) deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166123539	PA166123539	Annotation of PMDA Label for fluorouracil and DPYD	PMDA		Actionable PGx							fluorouracil	DPYD			The PMDA package insert for fluorouracil states that severe adverse events have occurred in patients receiving the drug who are dihydropyrimidine dehydrogenase (DPD)-deficient. DPD is the enzyme responsible for the degradation of fluorouracil and other fluoropyrimidines.
https://www.pharmgkb.org/labelAnnotation/PA166123543	PA166123543	Annotation of PMDA Label for indacaterol and UGT1A1	PMDA		Actionable PGx							indacaterol	UGT1A1			The PMDA package insert for indacaterol (Onbrez) states that individuals who have low UGT1A1 expression have increased steady-state area under the concentration-time curve (AUC) and maximum plasma concentration (Cmax) as compared to UGT1A1 wild-type individuals.
https://www.pharmgkb.org/labelAnnotation/PA166123526	PA166123526	Annotation of PMDA Label for irinotecan and UGT1A1	PMDA		Testing Recommended							irinotecan	UGT1A1			The PMDA package insert for irinotecan states that it is for the treatment of refractory, inoperable pancreatic cancer and that patients should be selected for treatment based on their stage, general condition and UGT1A1 polymorphism.
https://www.pharmgkb.org/labelAnnotation/PA166123546	PA166123546	Annotation of PMDA Label for mycophenolic acid and HPRT1	PMDA		Actionable PGx							mycophenolic acid	HPRT1			The PMDA package insert for mycophenolic acid notes that caution should be used in patients with deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndromes, due to the risk for exacerbation of hyperuricemia.
https://www.pharmgkb.org/labelAnnotation/PA166123547	PA166123547	Annotation of PMDA Label for panitumumab and KRAS	PMDA		Testing Required							panitumumab	KRAS			The PMDA package insert for panitumumab (Vectibix) states that it is indicated for patients with wild-type KRAS colorectal cancer, and that patients should be selected based on RAS (KRAS and NRAS) mutation status.
https://www.pharmgkb.org/labelAnnotation/PA166123548	PA166123548	Annotation of PMDA Label for rasburicase and G6PD	PMDA		Actionable PGx							rasburicase	G6PD			The PMDA package insert for rasburicase notes that foreign clinical studies have shown that patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency can have severe hemolytic reactions when administered rasburicase, and patients should be carefully screened for a family history of G6PD deficiency or other red blood cell enzyme defects.
https://www.pharmgkb.org/labelAnnotation/PA166123550	PA166123550	Annotation of PMDA Label for trastuzumab and ERBB2	PMDA		Testing Required							trastuzumab	ERBB2			The PMDA package insert for trastuzumab states that it is indicated for patients with HER2-overexpressing breast or gastric cancers.
https://www.pharmgkb.org/labelAnnotation/PA166123537	PA166123537	Annotation of PMDA Label for dasatinib and ABL1, BCR	PMDA		Testing Required							dasatinib	ABL1; BCR			The PMDA package insert for dasatinib states that it is indicated for individuals with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
https://www.pharmgkb.org/labelAnnotation/PA166127722	PA166127722	Annotation of HCSC Label for trametinib and BRAF	HCSC		Testing Required					Cancer Genome		trametinib	BRAF		4/21/2024	The product monograph for trametinib (MEKINIST) states that it is indicated for patients with unresectable or metastatic melanoma, metastatic non-small cell lung cancer, or low-grade glioma with a BRAF V600 mutation. A validated test is required to identify BRAF V600 mutation status to select patients appropriate for treatment with trametinib.
https://www.pharmgkb.org/labelAnnotation/PA166127724	PA166127724	Annotation of HCSC Label for trastuzumab and ERBB2	HCSC		Testing Required					Cancer Genome		trastuzumab	ERBB2		4/21/2024	The product monograph for trastuzumab (HERCEPTIN) states that it is indicated for patients with early or metastatic breast cancer, or metastatic adenocarcinoma of the stomach or gastroesophageal junction, whose tumors are HER2 positive.
https://www.pharmgkb.org/labelAnnotation/PA166127721	PA166127721	Annotation of HCSC Label for tolterodine and CYP2D6	HCSC		Informative PGx							tolterodine	CYP2D6		7/26/2024	The product monograph for tolterodine (DETROL) notes that the effect of tolterodine on QTc interval appeared to be greater in CYP2D6 poor metabolizers than in CYP2D6 extensive metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166127725	PA166127725	Annotation of HCSC Label for tretinoin and PML, RARA	HCSC							Cancer Genome		tretinoin	PML; RARA		8/6/2024	Tretinoin (VESANOID) is a derivative of vitamin A (retinol) used for the treatment of skin conditions and acute promyelocytic leukemia (APL). APL is characterized by the translocation t(15;17) and PML/RAR alpha (RARA) fusion protein.
https://www.pharmgkb.org/labelAnnotation/PA166123408	PA166123408	Annotation of EMA Label for vortioxetine and CYP2D6	EMA		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	vortioxetine	CYP2D6		9/15/2014	The EMA European Public Assessment Report (EPAR) for vortioxetine (Brintellix) states that CYP2D6 poor metabolizers have higher concentrations of vortioxetine as compared to extensive metabolizers. Additionally, for CYP2D6 ultra-rapid metabolizers, a dose adjustment may be considered depending on individual patient response.
https://www.pharmgkb.org/labelAnnotation/PA166127723	PA166127723	Annotation of HCSC Label for trastuzumab emtansine and ERBB2	HCSC		Testing Required					Cancer Genome		trastuzumab emtansine	ERBB2		4/21/2024	The product monograph for trastuzumab emtansine (KADCYLA) states that it is indicated for patients with HER2-positive, metastatic breast cancer who received prior treatment with trastuzumab and a taxane, separately or in combination. Trastuzumab emtansine should only be used in patients with HER2 positive tumor status, defined as a score of 3+ by immunohistochemistry (IHC) or a ratio of = 2.0 by in situ hybridization (ISH) assessed by a validated test.
https://www.pharmgkb.org/labelAnnotation/PA166127731	PA166127731	Annotation of HCSC Label for vortioxetine and CYP2D6	HCSC		Informative PGx							vortioxetine	CYP2D6			The product monograph for vortioxetine (TRINTELLIX) states that the concentration of the drug is approximately 2 times higher in CYP2D6 poor metabolizers as compared to extensive metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166127728	PA166127728	Annotation of HCSC Label for vemurafenib and BRAF	HCSC		Testing Required					Cancer Genome		vemurafenib	BRAF		4/21/2024	The product monograph for vemurafenib (ZELBORAF) states that it is indicated for the treatment of patients with BRAF V600 mutation-positive melanoma, and that it should not be used in patients with BRAF wild-type melanoma. A validated test is required to detect BRAF V600 mutation-positive tumors in patients treated with vemurafenib.
https://www.pharmgkb.org/labelAnnotation/PA166127727	PA166127727	Annotation of HCSC Label for velaglucerase alfa and GBA	HCSC									velaglucerase alfa	GBA		8/6/2024	The product monograph for velaglucerase alfa (VPRIV) states that it is indicated for the treatment of type 1 Gaucher disease. Gaucher disease is caused by mutations in the GBA gene, resulting in a deficiency of the enzyme beta-glucocerebrosidase. Velaglucerase alfa is an enzyme replacement therapy.
https://www.pharmgkb.org/labelAnnotation/PA166127732	PA166127732	Annotation of HCSC Label for warfarin and CYP2C9, VKORC1	HCSC		Informative PGx							warfarin	CYP2C9; VKORC1			The product monograph for warfarin (COUMADIN) notes that patients carrying one or two copies of the CYP2C9*2 or *3 alleles may require a decreased mean daily warfarin dose, and have an increased bleeding risk, as compared to those homozygous for the CYP2C9*1 allele. Additionally, variations in the VKORC1 gene, such as -1639G>A, are also associated with changes in the dose requirement of warfarin.
https://www.pharmgkb.org/labelAnnotation/PA166127730	PA166127730	Annotation of HCSC Label for voriconazole and CYP2C19	HCSC		Informative PGx							voriconazole	CYP2C19			The product monograph for voriconazole notes that CYP2C19 poor metabolizers have, on average, 4-fold higher exposure to the drug as compared to extensive metabolizers. However, the product monograph does not make any statements regarding genetic testing of CYP2C19 prior to treatment.
https://www.pharmgkb.org/labelAnnotation/PA166127729	PA166127729	Annotation of HCSC Label for moviprep and G6PD	HCSC		Informative PGx							moviprep	G6PD		7/25/2024	MOVIPREP, a solution containing Vitamin C, is a laxative used for colon cleansing in preparation for a colonoscopy. Because it contains Vitamin C (ascorbic acid), the label warns that hemolytic reactions are possible in those with G6PD deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166129516	PA166129516	Annotation of HCSC Label for desflurane and CACNA1S, RYR1	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	desflurane	CACNA1S; RYR1		3/31/2023	"Desflurane (SUPRANE) is a potent (volatile) inhalational anesthetic used to induce or maintain general anesthesia. The HCSC-approved product monograph warns that individuals with a genetic predisposition to malignant hyperthermia, or patients with Duchenne Muscular Dystrophy, are at greater risk of developing malignant hyperthermia or hyperkaelemia, respectively, if administered desflurane.
Specific variants in the RYR1 and CACNA1S genes are associated with risk of malignant hyperthermia in individuals administered potent inhalational anesthetics, such as desflurane. Although the product monograph for desflurane (SUPRANE) does not specifically mention genetic testing, it states that desflurane is contraindicated in individuals with a genetic predisposition to malignant hyperthermia."
https://www.pharmgkb.org/labelAnnotation/PA166129515	PA166129515	Annotation of FDA Label for desflurane and CACNA1S, RYR1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	desflurane	CACNA1S; RYR1		3/31/2023	Desflurane (SUPRANE) is a potent (volatile) inhalational anesthetic used to induce or maintain general anesthesia. The FDA-approved label warns that individuals with a genetic predisposition to malignant hyperthermia, or patients with Duchenne Muscular Dystrophy, are at greater risk of developing malignant hyperthermia, or hyperkaelemia, respectively, if administered desflurane.
https://www.pharmgkb.org/labelAnnotation/PA166129449	PA166129449	Annotation of EMA Label for ceritinib and ALK	EMA		Testing Required					Cancer Genome		ceritinib	ALK		4/16/2024	The EMA European Public Assessment Report (EPAR) for ceritinib (Zykadia) states that it is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), including those previously treated with crizotinib.
https://www.pharmgkb.org/labelAnnotation/PA166129448	PA166129448	Annotation of EMA Label for ibrutinib	EMA							Cancer Genome		ibrutinib			8/7/2024	"The EMA European Public Assessment Report (EPAR) for ibrutinib (IMBRUVICA) states that is indicated as a single or combination therapy for the treatment of adult patients with refractory mantle cell lymphoma, chronic lymphocytic leukemia, or Waldenström’s macroglobulinaemia.
Patients with 17p or 11q deletions are mentioned in the context of clinical trials."
https://www.pharmgkb.org/labelAnnotation/PA166123422	PA166123422	Annotation of EMA Label for efavirenz / emtricitabine / tenofovir disoproxil and CYP2B6	EMA		Informative PGx							efavirenz / emtricitabine / tenofovir disoproxil	CYP2B6	CYP2B6*6; rs3745274	9/16/2014	The EMA European Public Assessment Report (EPAR) for efavirenz, emtricitabine and tenofovir disoproxil (Atripla) states that patients with the CYP2B6*6/*6 genotype had higher Cmax as compared to patients with the CYP2B6*1/*1 genotype, and the mean QTc prolongation was 8.7 ms. The label also notes that plasma exposure may be increased in patients with the rs3745274 TT genotype (G516T).
https://www.pharmgkb.org/labelAnnotation/PA166127665	PA166127665	Annotation of HCSC Label for divalproex sodium and POLG	HCSC		Testing Required							divalproex sodium	POLG			The product monograph for divalproex states that it is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG), and in children under two years of age who are suspected of having a POLG-related disorder.
https://www.pharmgkb.org/labelAnnotation/PA166129518	PA166129518	Annotation of HCSC Label for isoflurane and CACNA1S, RYR1	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	isoflurane	CACNA1S; RYR1		4/1/2023	Isoflurane is a potent (volatile) inhalational anesthetic used to induce or maintain general anesthesia. It is contraindicated in patients with known or suspected genetic susceptibility to malignant hyperthermia, or with a history of malignant hyperthermia.
https://www.pharmgkb.org/labelAnnotation/PA166127681	PA166127681	Annotation of HCSC Label for ibrutinib	HCSC							Cancer Genome		ibrutinib			8/7/2024	"The product monograph for ibrutinib (IMBRUVICA) states that it is indicated for single or combination therapy of patients with chronic lymphocytic leukemia, including those with a 17p deletion, and for patients with refractory mantle cell lymphoma, marginal zone lymphoma, Waldenström’s macroglobulinemia, or chronic graft versus host disease.
Patients with 11q deletions are mentioned in the context of clinical trials."
https://www.pharmgkb.org/labelAnnotation/PA166123409	PA166123409	Annotation of EMA Label for aliskiren and ABCB1	EMA									aliskiren	ABCB1		8/14/2023	The EMA European Public Assessment Report (EPAR) for aliskiren (Rasilez HCT) does not contain pharmacogenetic information. It contains information regarding the role of ABCB1 (P-gp, MDR1) in intestinal absorption and biliary secretion of aliskiren, and concomitant use of aliskiren with potent P-gp inhibitors is contraindicated.
https://www.pharmgkb.org/labelAnnotation/PA166123418	PA166123418	Annotation of EMA Label for posaconazole and CYP3A4	EMA									posaconazole	CYP3A4		8/23/2023	The EMA European Public Assessment Report (EPAR) for posaconazole (Noxafil) does not contain pharmacogenetic information. It contains information regarding metabolism drug-drug interactions with CYP3A4 substrates.
https://www.pharmgkb.org/labelAnnotation/PA166123419	PA166123419	Annotation of EMA Label for indinavir and CYP3A4	EMA									indinavir	CYP3A4		8/18/2023	The EMA European Public Assessment Report (EPAR) for indinavir (Crixivan) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4 and contraindicates concomitant use of drugs that are CYP3A4 substrates.
https://www.pharmgkb.org/labelAnnotation/PA166127630	PA166127630	Annotation of HCSC Label for anastrozole and ESR1, ESR2, PGR	HCSC							Cancer Genome		anastrozole	ESR1; ESR2; PGR		8/26/2024	The product monograph for anastrozole states that it is indicated for treatment of postmenopausal women with hormone receptor positive early breast cancer and for treatment of advanced breast cancer.
https://www.pharmgkb.org/labelAnnotation/PA166127675	PA166127675	Annotation of HCSC Label for galantamine and CYP2D6	HCSC		No Clinical PGx							galantamine	CYP2D6		8/17/2023	The product monograph for galantamine notes that CYP2D6 poor metabolizers have decreased clearance and increased AUC of galantamine as compared to extensive metabolizers. However, it also states that dosage adjustment based on CYP2D6 genotype is not necessary since the drug is individually titrated to tolerability.
https://www.pharmgkb.org/labelAnnotation/PA166127655	PA166127655	Annotation of HCSC Label for crizotinib and ALK	HCSC		Testing Required					Cancer Genome		crizotinib	ALK		4/16/2024	The product monograph for crizotinib (XALKORI) states that it is indicated for patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer.
https://www.pharmgkb.org/labelAnnotation/PA166127673	PA166127673	Annotation of HCSC Label for fesoterodine and CYP2D6	HCSC		Informative PGx							fesoterodine	CYP2D6			The product monograph for fesoterodine (TOVIAZ) states that CYP2D6 poor metabolizers have increased levels of the active metabolite of the drug as compared to extensive metabolizers. However, it makes no statements regarding genetic testing of CYP2D6.
https://www.pharmgkb.org/labelAnnotation/PA166127669	PA166127669	Annotation of HCSC Label for erlotinib and EGFR	HCSC		Testing Required					Cancer Genome		erlotinib	EGFR		4/16/2024	The product monograph for erlotinib (TARCEVA) states that it is indicated for patients with non-small cell lung cancer (NSCLC) who have a confirmed activating EGFR mutation.
https://www.pharmgkb.org/labelAnnotation/PA166127674	PA166127674	Annotation of HCSC Label for fluorouracil and DPYD	HCSC		Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	fluorouracil	DPYD		4/25/2024	"Fluorouracil injection is contraindicated in patients with known complete absence of dihydropyrimidine dehydrogenase (DPD) activity. Testing for DPD deficiency should be considered prior to treatment, based on local availability and current guidelines.
Fluorouracil is available as both an injection and a topical cream. These two formulations have different indications. Both HCSC-approved labels contain information about the potential for severe toxicity in patients with DPD deficiency."
https://www.pharmgkb.org/labelAnnotation/PA166127628	PA166127628	Annotation of HCSC Label for acetaminophen, tramadol and CYP2D6	HCSC		Informative PGx							acetaminophen; tramadol	CYP2D6		7/18/2024	The product monograph for tramadol and acetaminophen (AURO-TRAMADOL/ACETAMINOPHEN) notes that patients who are CYP2D6 ultrarapid metabolizers convert tramadol more rapidly into its more potent opioid metabolite O-desmethyltramadol, which could result in higher than expected opioid-like side effects including life-threatening or fatal respiratory depression or signs of overdose.
https://www.pharmgkb.org/labelAnnotation/PA166127627	PA166127627	Annotation of HCSC Label for abacavir and HLA-B	HCSC		Testing Required	Prescribing Info		Alternate Drug			Prescribing	abacavir	HLA-B	HLA-B*57:01	2/7/2024	The product monograph for abacavir (ZIAGEN) states that all patients should be screened for the HLA-B*5701 allele prior to initiating or re-initiating treatment with abacavir, due to the high risk of experiencing a hypersensitivity reaction (HSR) for patients carrying this allele.
https://www.pharmgkb.org/labelAnnotation/PA166127631	PA166127631	Annotation of HCSC Label for aripiprazole and CYP2D6	HCSC		Informative PGx							aripiprazole	CYP2D6			The product monograph for aripiprazole (ABILIFY) notes that CYP2D6 poor metabolizers have approximately an 80% increase in aripiprazole exposure and approximately a 30% decrease in exposure to the active metabolite compared to CYP2D6 extensive metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166127629	PA166127629	Annotation of HCSC Label for afatinib and EGFR	HCSC		Testing Required					Cancer Genome		afatinib	EGFR	rs121434568	5/10/2024	The product monograph for afatinib (GIOTRIF) states that it is indicated for the treatment of patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s), including exon 19 deletions and the exon 21 L858R point mutation. A validated test is required to identify EGFR mutation status.
https://www.pharmgkb.org/labelAnnotation/PA166127656	PA166127656	Annotation of HCSC Label for dabrafenib and BRAF	HCSC		Testing Required					Cancer Genome		dabrafenib	BRAF		5/14/2024	The product monograph for dabrafenib (TAFINLAR) states that confirmation of BRAF V600 mutation in a tumour biopsy using a validated test is required for selection of patients appropriate for treatment with dabrafenib.
https://www.pharmgkb.org/labelAnnotation/PA166127653	PA166127653	Annotation of HCSC Label for clopidogrel and CYP2C19	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	clopidogrel	CYP2C19	CYP2C19*2; CYP2C19*3; CYP2C19*4; CYP2C19*5; CYP2C19*6; CYP2C19*7; CYP2C19*8	7/17/2024	The product monograph for clopidogrel (PLAVIX) states that CYP2C19 poor metabolizers may be at increased risk for experiencing cardiovascular events when taking the drug at recommended doses as compared to normal CYP2C19 metabolizers, and that an alternative treatment or treatment strategies should be considered in these patients.
https://www.pharmgkb.org/labelAnnotation/PA166127654	PA166127654	Annotation of HCSC Label for codeine and CYP2D6	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	codeine	CYP2D6	CYP2D6*2x2	7/19/2024	The codeine (CODEINE 15, CODEINE 30) product monograph states that CYP2D6 ultra-rapid metabolizers may experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing at normal dosing regimens of codeine. Mothers who are ultra-rapid metabolizers and breast-feeding have higher-than-expected levels of morphine in breast milk and potentially dangerously high serum morphine levels in their breastfed infants.
https://www.pharmgkb.org/labelAnnotation/PA166127677	PA166127677	Annotation of HCSC Label for glyburide and G6PD	HCSC		Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	glyburide	G6PD		7/22/2024	Glyburide belongs to a class of drugs known as sulfonylurea agents. The product monograph for glyburide states that caution should be used when administering this drug to patients with G6PD deficiency due to the risk for hemolytic anemia, and that a nonsulfonylurea agent should be considered in these individuals.
https://www.pharmgkb.org/labelAnnotation/PA166127678	PA166127678	Annotation of HCSC Label for glimepiride and G6PD	HCSC		Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	glimepiride	G6PD		7/22/2024	Glimepiride belongs to a class of drugs known as sulfonylurea agents. The product monograph for glimepiride states that caution should be used when administering this drug to patients with G6PD deficiency due to the risk for hemolytic anemia, and that a nonsulfonylurea agent should be considered in these individuals.
https://www.pharmgkb.org/labelAnnotation/PA166127676	PA166127676	Annotation of HCSC Label for gefitinib and EGFR	HCSC		Testing Required					Cancer Genome		gefitinib	EGFR		8/7/2024	The product monograph for gefinitib (IRESSA) states that it is indicated for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer who have activating mutations of the EGFR-TK as assessed by a well-validated test.
https://www.pharmgkb.org/labelAnnotation/PA166127670	PA166127670	Annotation of HCSC Label for esomeprazole and CYP2C19	HCSC		No Clinical PGx							esomeprazole	CYP2C19		7/26/2024	The product monograph for esomeprazole (NEXIUM) states that CYP2C19 poor metabolizers have increased concentrations of the drug as compared to the rest of the population, but that dosage adjustment based on CYP2C19 genotype is not necessary.
https://www.pharmgkb.org/labelAnnotation/PA166127667	PA166127667	Annotation of HCSC Label for efavirenz / emtricitabine / tenofovir disoproxil and CYP2B6	HCSC		Informative PGx							efavirenz / emtricitabine / tenofovir disoproxil	CYP2B6			The product monograph for efavirenz, emtricitabine and tenofovir (ATRIPLA) states that patients homozygous for the G516T genetic variant in CYP2B6 may have increased plasma exposure of the drug. However, the effect of this increase on the occurrence of adverse events is unclear.
https://www.pharmgkb.org/labelAnnotation/PA166127661	PA166127661	Annotation of HCSC Label for dexlansoprazole and CYP2C19	HCSC		Informative PGx							dexlansoprazole	CYP2C19			The product monograph for dexlansoprazole (DEXILANT) notes that CYP2C19 intermediate and poor metabolizers generally have higher exposure to the drug as compared to extensive metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166127659	PA166127659	Annotation of HCSC Label for darifenacin and CYP2D6	HCSC		Informative PGx							darifenacin	CYP2D6			The product monograph for darifenacin notes that CYP2D6 poor metabolizers may have higher levels of the drug as compared to extensive metabolizers. However, it also notes that there are no special dosing requirements for poor metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166127657	PA166127657	Annotation of HCSC Label for dapsone and G6PD	HCSC		No Clinical PGx							dapsone	G6PD		7/19/2024	The product monograph for dapsone (ACZONE) notes that oral dapsone treatment can result in hemolysis and hemolytic anemia, particularly in patients who are glucose-6-phosphate dehydrogenase (G6PD)-deficient. However, for this topical formulation of the drug, a study showed no clinically relevant cases of hemolysis or anemia in G6PD-deficient individuals.
https://www.pharmgkb.org/labelAnnotation/PA166123416	PA166123416	Annotation of EMA Label for ivabradine and CYP3A4	EMA									ivabradine	CYP3A4		8/18/2023	The EMA European Public Assessment Report (EPAR) for ivabradine (Corlentor) does not contain pharmacogenetic information. It contains information regarding metabolism of ivabradine by CYP3A4, and that concomitant use of potent CYP3A4 inhibitors is contraindicated.
https://www.pharmgkb.org/labelAnnotation/PA166129447	PA166129447	Annotation of EMA Label for eliglustat and CYP2D6	EMA		Testing Required	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	eliglustat	CYP2D6			The EMA European Public Assessment Report (EPAR) for eliglustat (Cerdelga) states that it is indicated for adults with Gaucher disease type 1. CYP2D6 intermediate and extensive metabolizers have a recommended dose of 84 mg twice daily, while poor metabolizers have a recommended dose of 84 mg once daily. The label notes that eliglustat should not be used in patients who are CYP2D6 ultra-rapid metabolizers or indeterminate metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166127714	PA166127714	Annotation of HCSC Label for sulfadiazine and G6PD	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	sulfadiazine	G6PD		7/21/2024	The product monograph for sulfadiazine states that it should be used in caution in patients who are deficient for glucose-6-phosphate dehydrogenase (G6PD) due to the risk for hemolysis. However, the monograph makes no mention of testing for G6PD deficiency prior to treatment.
https://www.pharmgkb.org/labelAnnotation/PA166127688	PA166127688	Annotation of HCSC Label for lomitapide and LDLR	HCSC									lomitapide	LDLR		12/19/2023	Lomitapide (JUXTAPID) is indicated as an adjunct to a low-fat diet and other lipid lowering treatments in patients with homozygous familial hypercholesterolemia (HoFH). Mutations in the LDL receptor gene (LDLR) are the most common cause of HoFH, however, mutations in other genes (such as APOB) can also lead to HoFH. Diagnostic testing for LDL receptor alleles or function is only mentioned in the context of clinical trials.
https://www.pharmgkb.org/labelAnnotation/PA166127686	PA166127686	Annotation of HCSC Label for lenalidomide	HCSC		Testing Required					Cancer Genome		lenalidomide			5/2/2024	The product monograph for lenalidomide (REVLIMID) states that it is indicated for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
https://www.pharmgkb.org/labelAnnotation/PA166127684	PA166127684	Annotation of HCSC Label for ivacaftor and CFTR	HCSC		Testing Required							ivacaftor	CFTR	rs113993960; rs121908755; rs121908757; rs121909005; rs121909013; rs121909041; rs193922525; rs267606723; rs397508453; rs74503330; rs75527207; rs80282562	4/21/2024	Ivacaftor (KALYDECO) is indicated in cystic fibrosis patients 2 months and older who have one of the following variants in CFTR: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, G970R, or R117H. The product monograph also states that ivacaftor is not effective in patients homozygous for the F508del variant. An accurate and validated genotyping method should be performed to confirm the presence of an indicated mutation in at least one allele of the CFTR gene.
https://www.pharmgkb.org/labelAnnotation/PA166127683	PA166127683	Annotation of HCSC Label for irinotecan and UGT1A1	HCSC		Testing Recommended	Prescribing Info	Dosing Info				Prescribing	irinotecan	UGT1A1	UGT1A1*28; UGT1A1*6	5/30/2024	The HCSC-approved product monograph for irinotecan (IRINOTECAN HYDROCHLORIDE INJECTION USP) states that a reduction in the starting dose should be considered for patients known to be homozygous for UGT1A1*28 or *6 allele. It states that in order to identify patients at increased risk of experiencing neutropenia and diarrhea, UGT1A1 genotyping can be useful.
https://www.pharmgkb.org/labelAnnotation/PA166127696	PA166127696	Annotation of HCSC Label for norfloxacin and G6PD	HCSC		Informative PGx							norfloxacin	G6PD		7/23/2024	The product monograph for norfloxacin states that hemolytic reactions have occurred in patients with glucose-6-phosphate dehydrogenase deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166127698	PA166127698	Annotation of HCSC Label for omeprazole and CYP2C19	HCSC		No Clinical PGx							omeprazole	CYP2C19			The product monograph for omeprazole (LOSEC) states that CYP2C19 poor metabolizers have higher plasma concentrations of the drug as compared to extensive metabolizers. However, the monograph also notes that this has no implication on dosing of omeprazole.
https://www.pharmgkb.org/labelAnnotation/PA166127694	PA166127694	Annotation of HCSC Label for nitrofurantoin and G6PD	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	nitrofurantoin	G6PD		7/23/2024	The product monograph for nitrofurantoin states that individuals with a glucose-6-phosphate dehydrogenase (G6PD) deficiency may be at risk for hemolytic anemia when receiving the drug, and that it should be discontinued if the patient exhibits signs of hemolysis.
https://www.pharmgkb.org/labelAnnotation/PA166127715	PA166127715	Annotation of HCSC Label for sulfamethoxazole / trimethoprim and G6PD	HCSC		Informative PGx							sulfamethoxazole / trimethoprim	G6PD		7/22/2024	The product monograph for sulfamethoxazole and trimethoprim (SULFATRIM) states that hemolysis may occur in individuals taking the drug who are deficient in glucose-6-phosphate dehydrogenase (G6PD). However, it does not make any statements regarding testing for G6PD deficiency prior to treatment.
https://www.pharmgkb.org/labelAnnotation/PA166127690	PA166127690	Annotation of HCSC Label for mercaptopurine and NUDT15, TPMT	HCSC		Testing Recommended	Prescribing Info	Dosing Info				Prescribing	mercaptopurine	NUDT15; TPMT	rs116855232; TPMT*2; TPMT*3A; TPMT*3C	7/25/2024	The product monograph for mercaptopurine (PURINETHOL) states that individuals who are TPMT deficient are at risk of developing life-threatening bone marrow suppression when receiving the drug, and that substantial dose reductions are usually required for these individuals.
https://www.pharmgkb.org/labelAnnotation/PA166127692	PA166127692	Annotation of HCSC Label for mycophenolic acid and HPRT1	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	mycophenolic acid	HPRT1		7/25/2024	The product monograph for mycophenolic acid (MYFORTIC) states that it should be avoided in patients with hereditary deficiencies of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT, encoded by HPRT1), such as Lesch-Nyhan and Kelley-Seegmiller syndrome.
https://www.pharmgkb.org/labelAnnotation/PA166127718	PA166127718	Annotation of HCSC Label for tamoxifen and ESR1, ESR2, PGR	HCSC		Testing Required					Cancer Genome		tamoxifen	ESR1; ESR2; PGR		8/14/2024	The product monograph for tamoxifen states that it is indicated for treatment of early breast cancer in women with estrogen receptor positive tumors and the treatment of women with hormone responsive locally advanced / metastatic breast cancer. Estrogen and progesterone receptors status should be determined by a laboratory using a validated test.
https://www.pharmgkb.org/labelAnnotation/PA166127716	PA166127716	Annotation of HCSC Label for sulfasalazine and G6PD	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	sulfasalazine	G6PD		8/14/2024	The product monograph for sulfasalazine (SALAZOPYRIN) notes that patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency should be closely monitored for signs of hemolytic anemia when receiving the drug. However, no statement is made regarding testing for G6PD deficiency prior to treatment.
https://www.pharmgkb.org/labelAnnotation/PA166127697	PA166127697	Annotation of HCSC Label for nortriptyline and CYP2D6	HCSC		Informative PGx							nortriptyline	CYP2D6		7/24/2024	The product monograph for nortriptyline notes that individuals who are CYP2D6 poor metabolizers may have higher than expected levels of tricyclic antidepressants (of which nortriptyline is a member) when given usual doses.
https://www.pharmgkb.org/labelAnnotation/PA166123423	PA166123423	Annotation of EMA Label for tipranavir and CYP3A4	EMA									tipranavir	CYP3A4		8/27/2023	The EMA European Public Assessment Report (EPAR) for tipranavir (Aptivus) does not contain human pharmacogenetic information, but does contain pharmacogenetic information related to the genotype of the HIV virus. It contains information regarding metabolism of tipranavir by CYP3A4, and gives information regarding the coadministration of drugs that are CYP3A substrates, inhibitors or inducers.
https://www.pharmgkb.org/labelAnnotation/PA166129450	PA166129450	Annotation of EMA Label for trametinib and BRAF	EMA		Testing Required					Cancer Genome		trametinib	BRAF		4/21/2024	The EMA European Public Assessment Report (EPAR) for trametinib (Mekinist) states that it is indicated for the treatment of unresectable or metastatic melanoma with a BRAF V600 mutation, Stage III melanoma with a BRAF V600 mutation following complete resection, or advanced non-small cell lung cancer with a BRAF V600 mutation.
https://www.pharmgkb.org/labelAnnotation/PA166129520	PA166129520	Annotation of HCSC Label for sevoflurane and CACNA1S, RYR1	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	sevoflurane	CACNA1S; RYR1		4/1/2023	Sevoflurane is a potent (volatile) inhalational anesthetic used to induce or maintain general anesthesia.
https://www.pharmgkb.org/labelAnnotation/PA166182753	PA166182753	Annotation of FDA Label for meloxicam and CYP2C9	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info		Other Prescribing Guidance		Prescribing	meloxicam	CYP2C9	CYP2C9*3	8/24/2023	The FDA-approved drug label for meloxicam (QMIIZ ODT) states that in adult patients known or suspected to be poor CYP2C9 metabolizers, consider dose reduction, and monitor these patients for adverse effects.
https://www.pharmgkb.org/labelAnnotation/PA166127719	PA166127719	Annotation of HCSC Label for tetrabenazine and CYP2D6	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	tetrabenazine	CYP2D6		7/18/2024	The product monograph for tetrabenazine notes that the tetrabenazine active metabolite HTBZ is likely increased in CYP2D6 poor metabolizers as compared to extensive metabolizers, and that caution in dosing should be exercised.
https://www.pharmgkb.org/labelAnnotation/PA166127720	PA166127720	Annotation of HCSC Label for thioguanine and NUDT15, TPMT	HCSC		Testing Recommended	Prescribing Info	Dosing Info		Other Prescribing Guidance		Prescribing	thioguanine	NUDT15; TPMT	rs116855232; TPMT*2; TPMT*3A; TPMT*3B; TPMT*3C; TPMT*4	7/19/2024	The product monograph for thioguanine (LANVIS) recommends that patients undergo genotypic or phenotypic testing for TPMT and NUDT15 before beginning thioguanine treatment. Patients with reduced or no TPMT activity or carrying a NUDT15 variant should be given a dose reduction and their blood counts should be monitored.
https://www.pharmgkb.org/labelAnnotation/PA166190201	PA166190201	Annotation of FDA Label for entrectinib and NTRK1, NTRK2, NTRK3, ROS1	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		entrectinib	NTRK1; NTRK2; NTRK3; ROS1		4/16/2024	Entrectinib (ROZLYTREK) is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive and adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation. Select patients for treatment based on the presence of ROS1 rearrangements or NTRK gene fusion.
https://www.pharmgkb.org/labelAnnotation/PA166189821	PA166189821	Annotation of FDA Label for voxelotor and HBB	FDA	On FDA Biomarker List								voxelotor	HBB		3/31/2024	Voxelotor (OXBRYTA) is a hemoglobin S (HbS) polymerization inhibitor indicated for the treatment of sickle cell disease in adults and pediatric patients 12 years of age and older. Sickle cell disease is caused by mutations in the HBB gene. By increasing the affinity of hemoglobin for oxygen, voxelotor shows dose-dependent inhibition of HbS polymerization.
https://www.pharmgkb.org/labelAnnotation/PA166190741	PA166190741	Annotation of FDA Label for golodirsen and DMD	FDA	On FDA Biomarker List	Testing Required							golodirsen	DMD		8/21/2023	Golodirsen (VYONDYS 53) is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.
https://www.pharmgkb.org/labelAnnotation/PA166189982	PA166189982	Annotation of FDA Label for crizanlizumab-tmca and HBB	FDA	On FDA Biomarker List								crizanlizumab-tmca	HBB		3/31/2024	Crizanlizumab-tmca (ADAKVEO) is a selectin blocker indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. Sickle cell disease is caused by mutations in the HBB gene. The safety of this drug was evaluated in patients with sickle cell disease (any genotype including HbSS, HbSC, HbS beta0-thalassemia, HbSbeta+thalassemia, and others).
https://www.pharmgkb.org/labelAnnotation/PA166124617	PA166124617	Annotation of FDA Label for ceritinib and ALK	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		ceritinib	ALK		9/1/2023	The FDA-approved drug label for ceritinib (ZYKADIA) states that it is indicated for patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
https://www.pharmgkb.org/labelAnnotation/PA166115367	PA166115367	Annotation of FDA Label for velaglucerase alfa and GBA	FDA	Formerly on FDA Biomarker List								velaglucerase alfa	GBA		8/6/2024	Velaglucerase alfa (VPRIV) is indicated as a long-term enzyme replacement therapy for patients with type 1 Gaucher disease. Gaucher disease is caused by mutations in the GBA gene, resulting in a deficiency of the enzyme beta-glucocerebrosidase. Velaglucerase alfa has the same amino acid sequence as naturally occurring glucocerebrosidase.
https://www.pharmgkb.org/labelAnnotation/PA166114910	PA166114910	Annotation of FDA Label for chlorpropamide and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	chlorpropamide	G6PD		8/25/2023	The FDA-approved drug label for chlorpropamide (DIABINESE) states that caution should be used in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency due to the risk for hemolytic anemia, and that a non-sulfonylurea alternative should be considered in this subset of patients.
https://www.pharmgkb.org/labelAnnotation/PA166104787	PA166104787	Annotation of FDA Label for cevimeline and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	cevimeline	CYP2D6		10/25/2013	The FDA-approved drug label for cevimeline (EVOXAC) states that CYP2D6, CYP3A3 and CYP3A4 are responsible for the metabolism of cevimeline, and that cevimeline should be used with caution in individuals known or suspected to be CYP2D6 poor metabolizers, as they may be at a higher risk of adverse events.
https://www.pharmgkb.org/labelAnnotation/PA166184423	PA166184423	Annotation of Swissmedic Label for antithrombotic agents and G6PD	Swissmedic		Actionable PGx							antithrombotic agents	G6PD			The Swiss drug label for Thrombozytenaggregationshemmer, exkl. Heparin (DuoPlavin 75/100 mg) cautions about use in patients with G6PD deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166184111	PA166184111	Annotation of Swissmedic Label for atomoxetine and CYP2D6	Swissmedic		Actionable PGx							atomoxetine	CYP2D6			The Swiss drug label for atomoxetine (Srattera) states that caution should be exercised when CYP2D6 poor metabolizers take atomoxetine at the same time other cytochrome P450 inhibitors, as there is a risk of increasing the plasma concentrations of atomoxetine.
https://www.pharmgkb.org/labelAnnotation/PA166184456	PA166184456	Annotation of Swissmedic Label for glyburide and G6PD	Swissmedic		Actionable PGx							glyburide	G6PD			The Swiss drug label for glibenclamide (Daonil) states that caution should be used when treating patients with G6PD deficiency with glibenclamide as they are at increased risk for hemolytic anemia.
https://www.pharmgkb.org/labelAnnotation/PA166184223	PA166184223	Annotation of Swissmedic Label for Paracetamol, combinations excl. Psycholeptics (Vicks MediNait Sirup) and CYP2D6, G6PD	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	Paracetamol, combinations excl. Psycholeptics (Vicks MediNait Sirup)	CYP2D6; G6PD		2/28/2023	The Swiss drug label for Paracetamol (acetaminophen), combinations excl. Psycholeptics (Vicks MediNait® Sirup) states that patients with Glucose-6-phosphate dehydrogenase deficiency may have risk for hemolytic anemia and patients with CYP2D6 deficiency may have altered drug metabolism.
https://www.pharmgkb.org/labelAnnotation/PA166184428	PA166184428	Annotation of Swissmedic Label for sertindole and CYP2D6	Swissmedic		Actionable PGx							sertindole	CYP2D6			The Swiss drug label for sertindole (Serdolect) states that sertindole is extensively metabolized by the CYP2D6 and CYP3A, and sertidole concentration may be affected in patients who are CYP2D6 poor metabolizers and in patients simultaneously taking drugs that are CYP2C6 or CYP3A inhibitors.
https://www.pharmgkb.org/labelAnnotation/PA166184231	PA166184231	Annotation of Swissmedic Label for umeclidinium and CYP2D6	Swissmedic		Informative PGx							umeclidinium	CYP2D6			The Swiss drug label for umeclidinium (Incruse Ellipta) states that umeclidinium exposure is not affected by CYP2D6 genotype.
https://www.pharmgkb.org/labelAnnotation/PA166184237	PA166184237	Annotation of Swissmedic Label for Vitamin B-complex with vitamin C and G6PD	Swissmedic		Actionable PGx							Vitamin B-complex with vitamin C	G6PD			The Swiss drug label for vitamin B complex with vitamin C (Begrocit) states that overdose of vitamin C can cause hemolysis in patients with G6PD deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166184490	PA166184490	Annotation of Swissmedic Label for zuclopenthixol and CYP2D6	Swissmedic									zuclopenthixol	CYP2D6		8/29/2023	The Swiss drug label for zuclopenthixol (Clopixol) states that zuclopenthixol is metabolized by the polymorphic CYP2D6 but the clinical significance of poor metabolizer genotypes on metabolite production is not known.
https://www.pharmgkb.org/labelAnnotation/PA166184499	PA166184499	Annotation of Swissmedic Label for rosuvastatin and ABCG2, SLCO1B1	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	rosuvastatin	ABCG2; SLCO1B1	rs2231142; rs4149056	8/13/2024	The Swiss drug label for rosuvastatin (Crestor) states that genetic polymorphisms in SLCO1B1 and ABCG2 may lead to an increase in rosuvastatin exposure, a reduction in the dosage is recommended.
https://www.pharmgkb.org/labelAnnotation/PA166184434	PA166184434	Annotation of Swissmedic Label for sofosbuvir and IFNL3, IFNL4	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	sofosbuvir	IFNL3; IFNL4	rs12979860		"The Swiss drug label for sofosbuvir (Sovaldi) states that ""consideration should be given to possibly extending the duration of therapy beyond 12 weeks up to 24 weeks, in particular for subgroups with one or more of the previously identified negative predictive factors associated in the past with lower response rates to interferon-containing therapies (e.g. advanced fibrosis/cirrhosis, high initial viral load, black skin, IL28B-Non-CC genotype, earlier non-response to peginterferon alfa and ribavirin)."""
https://www.pharmgkb.org/labelAnnotation/PA166223861	PA166223861	Annotation of FDA Label for bupropion and CYP2D6	FDA	On FDA Biomarker List								bupropion	CYP2D6		8/14/2023	The FDA-approved drug label for bupropion (WELLBUTRIN) states that bupropion inhibits CYP2D6 and can increase concentrations of: antidepressants, antipsychotics, beta-blockers, and Type 1C antiarrhythmics.
https://www.pharmgkb.org/labelAnnotation/PA166223902	PA166223902	Annotation of FDA Label for alglucosidase alfa and GAA	FDA	On FDA Biomarker List	Testing Required							alglucosidase alfa	GAA		8/21/2023	The FDA label for alglucosidase alfa (LUMIZYME) states that LUMIZYME® (alglucosidase alfa) is a hydrolytic lysosomal glycogen-specific enzyme indicated for patients with Pompe disease (acid α-glucosidase (GAA) deficiency)
https://www.pharmgkb.org/labelAnnotation/PA166223941	PA166223941	Annotation of FDA Label for avapritinib and PDGFRA	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		avapritinib	PDGFRA	rs121908585	8/31/2023	The FDA label for avapritinib (AYVAKIT) states that avapritinib is a kinase inhibitor indicated for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.
https://www.pharmgkb.org/labelAnnotation/PA166224061	PA166224061	Annotation of HCSC Label for oxcarbazepine and HLA-B	HCSC		Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	oxcarbazepine	HLA-B	HLA-B*15:02	7/26/2024	The product monograph for oxcarbazepine (APO-OXCARBAZEPINE) states that based on studies, the presence of HLA-B*1502 allele may be one of the risk factors for oxcarbazepine-associated SJS/TEN in patients with Asian ancestry. HLA-B*1502 genotyping should be considered in these patients, and use of oxcarbazepine should be avoided in patients who test positive for the HLA-B*1502 allele unless the benefits clearly outweigh the risks.
https://www.pharmgkb.org/labelAnnotation/PA166127664	PA166127664	Annotation of FDA Label for ibrutinib	FDA	On FDA Biomarker List						Cancer Genome		ibrutinib			8/7/2024	Ibrutinib (IMBRUVICA) is a kinase inhibitor indicated for patients with multiple different cancer types, including those with chronic lymphocytic leukemia/small lymphocytic lymphoma with 17p deletion. The label also notes the presence of individuals with 11q deletion in clinical studies.
https://www.pharmgkb.org/labelAnnotation/PA166224361	PA166224361	Annotation of FDA Label for gemtuzumab ozogamicin and CD33	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		gemtuzumab ozogamicin	CD33		8/31/2023	The FDA-approved drug label for gemtuzumab ozogamicin (MYLOTARG) states that it is a CD33-directed antibody and cytotoxic drug conjugate indicated for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older, and treatment of relapsed or refractory CD33-positive AML in adults and pediatric patients 2 years and older.
https://www.pharmgkb.org/labelAnnotation/PA166224101	PA166224101	Annotation of FDA Label for citalopram and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							citalopram	CYP2D6		8/15/2023	The FDA-approved drug label for citalopram (CELEXA) states that citalopram steady state levels were not significantly different between CYP2D6 poor and extensive metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166224962	PA166224962	Annotation of FDA Label for isatuximab	FDA	On FDA Biomarker List						Cancer Genome		isatuximab			8/18/2023	The FDA label for isatuximab-irfc (SARCLISA) states that it is a CD38-directed cytolytic antibody indicated, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma. The label also notes in the clinical studies that the efficacy and safety of SARCLISA was evaluated in ICARIA-MM trial where 20% of patients had high-risk chromosomal abnormalities at study entry; del(17p), t(4;14) and t(14;16) were present in 12%, 8% and 2% of patients, respectively.
https://www.pharmgkb.org/labelAnnotation/PA166224961	PA166224961	Annotation of FDA Label for inebilizumab and AQP4	FDA	On FDA Biomarker List								inebilizumab	AQP4		9/28/2023	The FDA label for inebilizumab-cdon (UPLIZNA) states that UPLIZNA is a CD19-directed cytolytic antibody indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. The relationship is not with the AQP4 gene but this is the biomarker listed in the FDA table.
https://www.pharmgkb.org/labelAnnotation/PA166224121	PA166224121	Annotation of FDA Label for escitalopram and CYP2D6	FDA	On FDA Biomarker List								escitalopram	CYP2D6		10/24/2023	The FDA-approved drug label for escitalopram (Lexapro) notes information about possible drug-drug interaction through CYP2D6.
https://www.pharmgkb.org/labelAnnotation/PA166224441	PA166224441	Annotation of FDA Label for ibrutinib and MYD88	FDA	On FDA Biomarker List						Cancer Genome		ibrutinib	MYD88	rs387907272	8/18/2023	Ibrutinib (IMBRUVICA) is a kinase inhibitor indicated for patients with multiple different cancer types, including those with chronic lymphocytic leukemia with 17p deletion. The FDA label also mentions that MYD88 L265P mutations were present in 77% of patients from the INNOVATE study under the Clinical studies section.
https://www.pharmgkb.org/labelAnnotation/PA166224221	PA166224221	Annotation of FDA Label for eculizumab and AQP4, CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE	FDA	On FDA Biomarker List								eculizumab	AQP4; CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE		9/28/2023	Eculizumab (Soliris) is a complement inhibitor indicated for: 1)The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis; 2) The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy; 3) generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) antibody positive; 4) neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. The relationship is not with the AQP4 gene or protein or AchR genes or proteins but these are the biomarkers listed in the FDA table.
https://www.pharmgkb.org/labelAnnotation/PA166225161	PA166225161	Annotation of FDA Label for oliceridine and CYP2D6	FDA		Actionable PGx	Prescribing Info	Dosing Info		Other Prescribing Guidance		Prescribing	oliceridine	CYP2D6		9/25/2023	The FDA-approved drug label for oliceridine (OLINVYK) states that CYP2D6 poor metabolizers have increased plasma concentrations of olicerdine and may require less frequent dosing.
https://www.pharmgkb.org/labelAnnotation/PA166185145	PA166185145	Annotation of FDA Label for brentuximab vedotin and TNFRSF8	FDA	On FDA Biomarker List						Cancer Genome		brentuximab vedotin	TNFRSF8		8/5/2024	Brentuximab vedotin (ADCETRIS) is a CD30-directed antibody-drug conjugate indicated for treatment of patients with various lymphomas, including patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), and patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.
https://www.pharmgkb.org/labelAnnotation/PA166227321	PA166227321	Annotation of HCSC Label for amifampridine phosphate and NAT2	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	amifampridine phosphate	NAT2			The product monograph for amifampridine phosphate states that if a patient is known to be a NAT2 fast acetylator, the starting dose can be increased from 15 mg to 30 mg daily.
https://www.pharmgkb.org/labelAnnotation/PA166227161	PA166227161	Annotation of EMA Label for ramucirumab and KRAS	EMA							Cancer Genome		ramucirumab	KRAS		8/23/2023	The EMA European Public Assessment Report (EPAR) for ramucirumab states that tumor KRAS status testing was used to stratify patients in the RAISE (NCT01183780) clinical trial of ramucirumab in metastatic colorectal cancer.
https://www.pharmgkb.org/labelAnnotation/PA166227221	PA166227221	Annotation of EMA Label for amifampridine phosphate and NAT2	EMA		Informative PGx							amifampridine phosphate	NAT2			The EMA European Public Assessment Report (EPAR) for states that the clearance of amifampridine phosphate (Firdapse) is predominantly due to metabolism by N-acetylation and NAT2 acetylator phenotype has a greater effect on metabolism and elimination than renal function. In a clinical study, slow acetylators experienced more adverse reactions than the fast acetylators.
https://www.pharmgkb.org/labelAnnotation/PA166160054	PA166160054	Annotation of FDA Label for brexpiprazole and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	brexpiprazole	CYP2D6		5/1/2019	The FDA-approved drug label for brexpiprazole (REXULTI) states that known CYP2D6 poor metabolizers should have their usual dosage reduced by half, and that known CYP2D6 poor metabolizers who are also taking strong/moderate CYP3A4 inhibitors should be administered a quarter of the usual dose. However, the label does not mention genetic testing.
https://www.pharmgkb.org/labelAnnotation/PA166227101	PA166227101	Annotation of EMA Label for alglucosidase alfa and GAA	EMA		Testing Required							alglucosidase alfa	GAA		4/15/2024	The FDA label for alglucosidase alfa (Myozyme) states that Myozyme is indicated for long-term enzyme replacement therapy (ERT) in patients with a confirmed diagnosis of Pompe disease (acid α-glucosidase (GAA) deficiency)
https://www.pharmgkb.org/labelAnnotation/PA166227121	PA166227121	Annotation of HCSC Label for alglucosidase alfa and GAA	HCSC		Testing Required							alglucosidase alfa	GAA		4/15/2024	The HCSC label for alglucosidase alfa (Myozyme) states that MYOZYME is indicated for use in patients with Pompe’s Disease (GAA deficiency).
https://www.pharmgkb.org/labelAnnotation/PA166227141	PA166227141	Annotation of EMA Label for ramucirumab and EGFR	EMA		Testing Required					Cancer Genome		ramucirumab	EGFR		4/21/2024	The EMA European Public Assessment Report (EPAR) for ramucirumab (Cyrazma) states that it is indicated for first-line treatment of metastatic non-small cell lung cancer with activating EGFR mutations, among other indications.
https://www.pharmgkb.org/labelAnnotation/PA166227181	PA166227181	Annotation of EMA Label for alpelisib and ERBB2, ESR1, ESR2, PIK3CA	EMA		Testing Required					Cancer Genome		alpelisib	ERBB2; ESR1; ESR2; PIK3CA		4/15/2024	The EMA European Public Assessment Report (EPAR) for alpelisib (Piqray) states that it is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy.
https://www.pharmgkb.org/labelAnnotation/PA166227201	PA166227201	Annotation of HCSC Label for alpelisib and ERBB2, ESR1, ESR2, PIK3CA	HCSC		Testing Required					Cancer Genome		alpelisib	ERBB2; ESR1; ESR2; PIK3CA		4/15/2024	The product monograph for alpelisib (Piqray) states that it is indicated, in combination with fulvestrant, for the treatment of postmenopausal women, and men, with hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen.
https://www.pharmgkb.org/labelAnnotation/PA166234761	PA166234761	Annotation of FDA Label for simvastatin and SLCO1B1	FDA									simvastatin	SLCO1B1		8/24/2023	The FDA-approved label for simvastatin (ZOCOR) states that simvastatin acid is a substrate of the transport protein OATP1B1 (SLCO1B1) and concomitant administration of medicinal products that are inhibitors of the transport protein OATP1B1 may lead to increased plasma concentrations of simvastatin acid and an increased risk of myopathy.
https://www.pharmgkb.org/labelAnnotation/PA166235981	PA166235981	Annotation of FDA Label for pralsetinib and RET	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		pralsetinib	RET	rs74799832; rs77709286	8/13/2024	Pralsetinib is an oral receptor tyrosine kinase inhibitor FDA approved for use in adult NSCLC with RET fusions, and adult and pediatric thyroid cancer with RET fusions and adult and pediatric medullary thyroid cancer with RET mutations.
https://www.pharmgkb.org/labelAnnotation/PA166235921	PA166235921	Annotation of FDA Label for metreleptin and AGPAT2, BSCL2, LEP	FDA	On FDA Biomarker List	Testing Required							metreleptin	AGPAT2; BSCL2; LEP		8/9/2024	The FDA-approved label for metreleptin (MYALEPT) is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy, which may involve variants in genes such as AGPAT2 or BSCL2.
https://www.pharmgkb.org/labelAnnotation/PA166235361	PA166235361	Annotation of FDA Label for lumasiran and AGXT	FDA	On FDA Biomarker List								lumasiran	AGXT		8/8/2024	Lumasiran is indicated for treatment of primary hyperoxaluria type 1, an inherited disease in which oxalate builds up in the body resulting from variants in the AGXT gene.
https://www.pharmgkb.org/labelAnnotation/PA166184430	PA166184430	Annotation of Swissmedic Label for fenofibrate, simvastatin and SLCO1B1	Swissmedic		Actionable PGx							fenofibrate; simvastatin	SLCO1B1	rs4149056		The Swiss drug label for Simvastatin and Fenofibrate (Cholib) states that the decreased function of hepatic OATP transport proteins may increase systemic simvastatin exposure and the risk for myopathy and rhabdomyolysis.
https://www.pharmgkb.org/labelAnnotation/PA166184158	PA166184158	Annotation of Swissmedic Label for ombitasvir / paritaprevir / ritonavir and IFNL3, IFNL4	Swissmedic		Actionable PGx							ombitasvir / paritaprevir / ritonavir	IFNL3; IFNL4	rs12979860		The Swiss drug label for Ombitasvir/Paritaprevir/Ritonavir (Viekirax) states that IFNL3/4 (previously known as IL28B) genotypes may affect the efficacy of Viekirax.
https://www.pharmgkb.org/labelAnnotation/PA166184394	PA166184394	Annotation of Swissmedic Label for prasugrel and CYP2B6, CYP2C19, CYP2C9, CYP3A5	Swissmedic		Informative PGx							prasugrel	CYP2B6; CYP2C19; CYP2C9; CYP3A5			The Swiss drug label for prasugrel (Efient) states that genetic variations of CYP3A5, CYP2B6, CYP2C9 or CYP2C19 have no relevant effect on the pharmacokinetics of prasugrel or its inhibition of platelet aggregation.
https://www.pharmgkb.org/labelAnnotation/PA166127645	PA166127645	Annotation of HCSC Label for carbamazepine and HLA-A, HLA-B	HCSC		Testing Recommended							carbamazepine	HLA-A; HLA-B			The product monograph for carbamazepine (TEGETROL) states that the individuals with the HLA-A*31:01 and HLA-B*15:02 alleles are at risk of developing serious cutaneous adverse drug reactions when receiving the drug, and it is recommended that physicians consider HLA-A*31:01 and HLA-B*15:02 genotyping as a screening tool in genetically at-risk populations. Use of carbamazepine should be avoided in patients who test positive for the HLA-A*31:01 or HLA-B*15:02 alleles.
https://www.pharmgkb.org/labelAnnotation/PA166160718	PA166160718	Annotation of PMDA Label for methylene blue and BLVRB, G6PD	PMDA		Actionable PGx							methylene blue	BLVRB; G6PD			The PMDA package insert for methylene blue states that patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency or NADPH reductase (BLVRB) deficiency may have exacerbation of methemoglobinemia or hemolysis following administration.
https://www.pharmgkb.org/labelAnnotation/PA166160274	PA166160274	Annotation of PMDA Label for cetuximab and EGFR, KRAS	PMDA		Testing Required							cetuximab	EGFR; KRAS			The PMDA package insert for cetuximab (ERBITUX) states that it is indicated for individuals with epidermal growth factor receptor (EGFR)-positive, progressive or recurrent colorectal cancer that is refractory and inoperable. It also notes that K-Ras mutational status should be considered when selecting patients.
https://www.pharmgkb.org/labelAnnotation/PA166160711	PA166160711	Annotation of PMDA Label for everolimus and ERBB2, ESR1, ESR2	PMDA		Testing Required							everolimus	ERBB2; ESR1; ESR2			The PMDA package insert for everolimus (AFINITOR) states that it is indicated for patients with locally advanced or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer after failure of treatment with letrozole or anastrozole.
https://www.pharmgkb.org/labelAnnotation/PA166184426	PA166184426	Annotation of Swissmedic Label for tolterodine and CYP2D6, CYP3A4	Swissmedic		Actionable PGx							tolterodine	CYP2D6; CYP3A4			The Swiss drug label for tolterodine (Detrusitol) gives information on pharmacokinetic changes in CYP2D6 poor metabolizers. This did not result in any changes in safety or tolerability alone but was notable in patients receiving CYP3A4 inhibitors.
https://www.pharmgkb.org/labelAnnotation/PA166120287	PA166120287	Annotation of EMA Label for ethinyl estradiol / norelgestromin and F5, PROC, PROS1, SERPINC1	EMA		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	ethinyl estradiol / norelgestromin	F5; PROC; PROS1; SERPINC1		2/16/2023	The EMA European Public Assessment Report (EPAR) for norelgestromin and ethinyl estradiol (EVRA) states that it is contraindicated in patients with known hereditary or acquired predisposition for venous thromboembolism, including Factor 5 Leiden (F5), antithrombin-III deficiency (SERPINC1), protein C deficiency (PROC) and protein S deficiency (PROS).
https://www.pharmgkb.org/labelAnnotation/PA166163419	PA166163419	Annotation of FDA Label for rucaparib and BRCA1, BRCA2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		rucaparib	BRCA1; BRCA2		8/31/2023	Rucaparib (RUBRACA) is indicated for the treatment of patients with deleterious BRCA mutation-associated epithelial ovarian, fallopian tube or primary peritoneal cancer, metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for RUBRACA.
https://www.pharmgkb.org/labelAnnotation/PA166104915	PA166104915	Annotation of EMA Label for olanzapine and CYP1A2, CYP2D6	EMA									olanzapine	CYP1A2; CYP2D6		8/17/2023	The EMA European Public Assessment Report (EPAR) for olanzapine (Zalasta) contains information regarding the metabolism of the drug by the enzymes CYP1A2 and CYP2D6: factors that induce or inhibit CYP1A2 may alter the concentration of olanzapine and thus may require dosage monitoring. The EPAR does not mention pharmacogenetics or testing of genetic variants in these genes.
https://www.pharmgkb.org/labelAnnotation/PA166104817	PA166104817	Annotation of FDA Label for tretinoin and PML, RARA	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		tretinoin	PML; RARA		9/11/2023	Tretinoin (VESANOID) is a derivative of vitamin A (retinol) used for the treatment of skin conditions and acute promyelocytic leukemia (APL). APL is characterized by the translocation t(15;17) and PML/RAR alpha (RARA) fusion protein.
https://www.pharmgkb.org/labelAnnotation/PA166104819	PA166104819	Annotation of FDA Label for tamoxifen and ESR1, ESR2, PGR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		tamoxifen	ESR1; ESR2; PGR		9/1/2023	Tamoxifen (SOLTAMOX) is an anti-estrogen used in the treatment and prevention of breast neoplasms, including those with estrogen receptor-positive breast cancer.
https://www.pharmgkb.org/labelAnnotation/PA166104907	PA166104907	Annotation of EMA Label for eltrombopag and F5, SERPINC1	EMA		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	eltrombopag	F5; SERPINC1		8/14/2024	The EMA European Public Assessment Report (EPAR) states that caution should be taken when administering eltrombopag in patients with known risk factors for thromboembolism, including Factor V Leiden (F5 gene) and ATIII deficiency (SERPINC1 gene).
https://www.pharmgkb.org/labelAnnotation/PA166170938	PA166170938	Annotation of FDA Label for trametinib and HRAS, KRAS, NRAS	FDA	On FDA Biomarker List						Cancer Genome		trametinib	HRAS; KRAS; NRAS		8/29/2023	Trametinib (MEKINIST) is indicated for use in patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, or metastatic non-small cell lung cancer with BRAF V600E mutation, as detected by an FDA-approved test. The label also notes that dabrafenib may promote growth and development of malignancies with activitation of RAS (HRAS, KRAS, NRAS).
https://www.pharmgkb.org/labelAnnotation/PA166184560	PA166184560	Annotation of FDA Label for ramucirumab and ALK, EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		ramucirumab	ALK; EGFR		12/5/2023	The FDA-approved drug label for ramucirumab (CYRAMZA) states that it is indicated for patients with EGFR or ALK genomic tumor aberrations who have had disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. Ramucirumab is targeted against human vascular endothelial growth factor receptor 2 (VEGFR2) coded for by KDR, although any testing for variants in KDR is not discussed in the drug label. EGFR is listed on the FDA table but ALK is not.
https://www.pharmgkb.org/labelAnnotation/PA166104909	PA166104909	Annotation of EMA Label for crizotinib and ALK, ROS1	EMA		Testing Required					Cancer Genome		crizotinib	ALK; ROS1		4/16/2024	The EMA European Public Assessment Report (EPAR) for crizotinib (XALKORI) states that it is indicated for ALK-positive advanced non-small cell lung cancer (NSCLC) and ROS1-positive NSCLC.
https://www.pharmgkb.org/labelAnnotation/PA166104821	PA166104821	Annotation of EMA Label for arsenic trioxide and PML, RARA	EMA		Testing Required					Cancer Genome		arsenic trioxide	PML; RARA		4/15/2024	The EMA European Public Assessment Report (EPAR) for arsenic trioxide (TRISENOX) states that it is indicated for the induction of remission, and consolidation in adult patients with acute promyelocytic leukemia (APL) characterized by the presence of the t(15;17) translocation and/or the PML/RARα gene.
https://www.pharmgkb.org/labelAnnotation/PA166127632	PA166127632	Annotation of HCSC Label for arsenic trioxide and PML, RARA	HCSC		Testing Required					Cancer Genome		arsenic trioxide	PML; RARA		4/15/2024	The product monograph for arsenic trioxide (TRISENOX) states that is indicated for patients with acute promyelotic leukemia (APL) characterized by the presence of the t(15;17) translocation or promyelocytic leukemia-retinoic-acid-receptor alpha (PML-RARa) gene expression.
https://www.pharmgkb.org/labelAnnotation/PA166127648	PA166127648	Annotation of HCSC Label for cetuximab and EGFR, KRAS	HCSC		Testing Required					Cancer Genome		cetuximab	EGFR; KRAS		4/16/2024	The product monograph for cetuximab (ERBITUX) states that it is indicated for treatment of EGFR-expressing K-ras wild-type metastatic colorectal carcinoma.
https://www.pharmgkb.org/labelAnnotation/PA166127699	PA166127699	Annotation of HCSC Label for panitumumab and KRAS, NRAS	HCSC		Testing Required					Cancer Genome		panitumumab	KRAS; NRAS		8/12/2024	The product monograph for panitumumab (VECTIBIX) states that it is indicated for patients with metastatic colorectal carcinoma with wild-type KRAS and NRAS. Evidence of wild-type KRAS and NRAS status is required before initiating treatment.
https://www.pharmgkb.org/labelAnnotation/PA166104911	PA166104911	Annotation of EMA Label for everolimus and ERBB2, ESR1, ESR2	EMA		Testing Required					Cancer Genome		everolimus	ERBB2; ESR1; ESR2		4/16/2024	The EMA European Public Assessment Report (EPAR) for everolimus (Afinitor) states that it is indicated for hormone receptor-positive HER2/neu negative advanced breast cancer in combination with exemestane in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor, among other indications.
https://www.pharmgkb.org/labelAnnotation/PA166104919	PA166104919	Annotation of EMA Label for fulvestrant and ERBB2, ESR1, ESR2, PGR	EMA		Testing Required					Cancer Genome		fulvestrant	ERBB2; ESR1; ESR2; PGR		4/16/2024	The EMA European Public Assessment Report (EPAR) for fulvestrant (Faslodex) states that it is indicated for the treatment of estrogen-receptor positive, locally advanced or metastatic breast cancer in postmenopausal women, and, in combination with palbociclib for hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.
https://www.pharmgkb.org/labelAnnotation/PA166104926	PA166104926	Annotation of EMA Label for imatinib and ABL1, BCR, FIP1L1, KIT, PDGFRA, PDGFRB	EMA		Testing Required					Cancer Genome		imatinib	ABL1; BCR; FIP1L1; KIT; PDGFRA; PDGFRB		4/21/2024	The EMA European Public Assessment Report (EPAR) for imatinib (Glivec) contains pharmacogenetic information regarding the indication of the drug in patients with tumors positive for biomarkers including KIT (CD117), BCR-ABL (Philadelphia chromosome), PDGFR and FIP1L1-PDGFRα rearrangements.
https://www.pharmgkb.org/labelAnnotation/PA166104809	PA166104809	Annotation of FDA Label for panitumumab and KRAS, NRAS	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		panitumumab	KRAS; NRAS		8/12/2024	The FDA-approved drug label for panitumumab (Vectibix) states that it is an EGFR antagonist indicated for the treatment of wild-type RAS (defined as wild-type in both KRAS and NRAS) metastatic colorectal cancer. The absence of a RAS mutation needs to be confirmed prior to initiation of treatment with panitumumab.
https://www.pharmgkb.org/labelAnnotation/PA166120370	PA166120370	Annotation of EMA Label for glimepiride, pioglitazone and G6PD	EMA		Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	glimepiride; pioglitazone	G6PD		7/22/2024	The EMA European Public Assessment Report (EPAR) for pioglitazone and glimepiride (Tandemact) states that caution should be taken in patients with G6PD deficiency as glimepiride is a sulfonylurea agent and a non-sulfonylurea alternative should be considered.
https://www.pharmgkb.org/labelAnnotation/PA166104914	PA166104914	Annotation of EMA Label for dasatinib and ABL1, BCR	EMA		Testing Required					Cancer Genome		dasatinib	ABL1; BCR		8/26/2024	The EMA European Public Assessment Report (EPAR) for dasatinib (SPRYCEL) states that it is indicated for adults or children with Philadelphia chromosome-positive chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (Ph+ ALL).
https://www.pharmgkb.org/labelAnnotation/PA166182923	PA166182923	Annotation of EMA Label for abemaciclib and ERBB2, ESR1, ESR2, PGR	EMA		Testing Required					Cancer Genome		abemaciclib	ERBB2; ESR1; ESR2; PGR		8/26/2024	The EMA European Public Assessment Report (EPAR) for abemaciclib (Verzenios) states that it is indicated for the treatment of women with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. Verzenios in combination with endocrine therapy is also indicated for the adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive early breast cancer at high risk of recurrence.
https://www.pharmgkb.org/labelAnnotation/PA166104823	PA166104823	Annotation of EMA Label for methylene blue and BLVRB, CYB5R3, G6PD	EMA		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	methylene blue	BLVRB; CYB5R3; G6PD		2/22/2023	The EMA European Public Assessment Report (EPAR) for methylthioninium chloride Proveblue (also known as methylene blue) states that the drug is contraindicated in patients with G6PD deficiency due to risk of hemolytic anemia, and in patients with a deficiency in NADPH reductase (encoded by the BLVRB gene). The label also states that failure to respond to the drug may indicate a deficiency in cytochrome b5 reductase (CYB5R3) or G6PD.
https://www.pharmgkb.org/labelAnnotation/PA166184224	PA166184224	Annotation of Swissmedic Label for acetaminophen, acetaminophen / tramadol and G6PD	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	acetaminophen; acetaminophen / tramadol	G6PD		2/28/2023	The Swiss drug label for Paracetamol, Tramadol hydrochlorid (Tramadol plus Spirig HC) states that patients with Glucose-6-phosphate dehydrogenase deficiency may have risk for hemolytic anemia.
https://www.pharmgkb.org/labelAnnotation/PA166123527	PA166123527	Annotation of PMDA Label for arsenic trioxide and PML, RARA	PMDA		Testing Required							arsenic trioxide	PML; RARA			Arsenic trioxide is indicated for treatment of patients with relapsed or refractory acute promyelocytic leukemia (APL). The PMDA package insert for arsenic trioxide states that patients with APL should be characterized by presence of the t(15;17) translocation or PML/RAR-alpha gene expression.
https://www.pharmgkb.org/labelAnnotation/PA166123532	PA166123532	Annotation of PMDA Label for carbamazepine and HLA-A, HLA-B	PMDA		Actionable PGx							carbamazepine	HLA-A; HLA-B			The PMDA package insert for carbamazepine notes that the HLA-A*3101 allele appeared at a high frequency in Japanese patients who developed a serious drug rash when taking carbamazepine. The insert also notes that the HLA-B*1502 allele appeared in nearly all of a group of Han Chinese patients who developed Stevens-Johnson syndrome or toxic epidermal necrolysis when taking carbamazepine.
https://www.pharmgkb.org/labelAnnotation/PA166123540	PA166123540	Annotation of PMDA Label for fulvestrant and ESR1, ESR2	PMDA		Testing Required							fulvestrant	ESR1; ESR2			The PMDA package insert for fulvestrant states that it is indicated for postmenopausal women with hormone-receptor positive breast cancer, and that fulvestrant should not be used in women negative for hormone receptor.
https://www.pharmgkb.org/labelAnnotation/PA166123541	PA166123541	Annotation of PMDA Label for gefitinib and CYP2D6, EGFR	PMDA		Testing Required							gefitinib	CYP2D6; EGFR			The PMDA package insert for gefitinib (Iressa) states that patients should be tested for EGFR gene mutations prior to administration. It also discusses the role of CYP2D6 is the metabolism of gefitinib.
https://www.pharmgkb.org/labelAnnotation/PA166123542	PA166123542	Annotation of PMDA Label for imatinib and ABL1, BCR	PMDA		Testing Required							imatinib	ABL1; BCR			Imatinib is an inhibitor of the BCR-ABL tyrosine kinase that is created by the Philadelphia chromosome rearrangement. The PMDA package insert for imatinib (Glivec) contains pharmacogenetic information regarding the indication of the drug in patients with Philadelphia chromosome positive (BCR-ABL) acute lymphoblastic leukemia.
https://www.pharmgkb.org/labelAnnotation/PA166123544	PA166123544	Annotation of PMDA Label for lapatinib and ERBB2, HLA-DQA1, HLA-DRB1	PMDA		Testing Required							lapatinib	ERBB2; HLA-DQA1; HLA-DRB1			The PMDA package insert for lapatinib states that it is indicated for individuals with breast cancer whose tumors overexpress HER2. It also contains information about the risk of severe liver injury in patients with the HLA-DQA1*02:01 or HLA-DRB1*07:01 variants.
https://www.pharmgkb.org/labelAnnotation/PA166123552	PA166123552	Annotation of PMDA Label for valproic acid and CPS1, OTC	PMDA		Actionable PGx							valproic acid	CPS1; OTC			The PMDA package insert for valproic acid states that it is contraindicated in patients with known urea cycle disorders (UCDs), due to a risk for severe hyperammonemia. UCDs result from mutations in one of several genes, including ornithine transcarbamylase (OTC) deficiency and carbamoyl-phosphate synthetase 1 (CPS1) deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166127672	PA166127672	Annotation of HCSC Label for exemestane and ESR1, ESR2	HCSC		Testing Required							exemestane	ESR1; ESR2			The product monograph for exemestane states that it is an aromatase inhibitor indicated for the treatment of estrogen receptor-positive early breast cancer.
https://www.pharmgkb.org/labelAnnotation/PA166183781	PA166183781	Annotation of Swissmedic Label for mercaptopurine and NUDT15, TPMT	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	mercaptopurine	NUDT15; TPMT	TPMT*2; TPMT*3A; TPMT*3C		The Swiss drug label for mercaptopurine (Puri-Nethol, Xaluprine) states that patients with TPMT and/or NUDT15 variant genotype may have higher risk of severe adverse effects when treated with 6-mercaptopurine. Treatment should be cautious and patients should be carefully monitored for side effects.
https://www.pharmgkb.org/labelAnnotation/PA166127668	PA166127668	Annotation of HCSC Label for eltrombopag and F5, SERPINC1	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	eltrombopag	F5; SERPINC1	rs6025	7/19/2024	The product monograph for eltrombopag (REVOLADE) states caution should be used in patients with known risk factors for thromboembolism including but not limited to inherited (e.g. Factor V Leiden) or acquired risk factors (e.g. ATIII deficiency, antiphospholipid syndrome and systemic lupus erythematosus).
https://www.pharmgkb.org/labelAnnotation/PA166185190	PA166185190	Annotation of FDA Label for ospemifene and CYP2B6, CYP2C9	FDA	On FDA Biomarker List								ospemifene	CYP2B6; CYP2C9		8/23/2023	The FDA-approved drug label for ospemifene (OSPHENA) states that ospemifene is metabolized primarily by CYP3A4 and CYP2C9, and ospemifene was also suggested to be a weak inhibitor for CYP2B6, CYP2C9, CYP2C19, CYP2C8, CYP2D6 and CYP3A4 in in vitro studies.
https://www.pharmgkb.org/labelAnnotation/PA166127666	PA166127666	Annotation of HCSC Label for drospirenone / ethinyl estradiol and F5, PROC, PROS1, SERPINC1	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	drospirenone / ethinyl estradiol	F5; PROC; PROS1; SERPINC1	rs6025	7/18/2024	The product monograph for drospirenone and ethinyl estradiol (YAZ) states that the drug is contraindicated in women with Factor V Leiden mutation, antithrombin-III-deficiency, protein C deficiency and protein S deficiency (among other contraindications), due to the risk for arterial or venous thrombosis.
https://www.pharmgkb.org/labelAnnotation/PA166127726	PA166127726	Annotation of HCSC Label for valproic acid and OTC, POLG	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	valproic acid	OTC; POLG		7/19/2024	The HCSC product monograph for valproic acid states that it is contraindicated in patients with mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG) or in patients with known urea cycle disorders, particularly ornithine transcarbamylase (OTC) deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166127685	PA166127685	Annotation of HCSC Label for lapatinib and ERBB2	HCSC		Testing Required					Cancer Genome		lapatinib	ERBB2		7/23/2024	The product monograph for lapatinib (TYKERB) states that it is indicated for patients with metastatic breast cancer whose tumours overexpress HER2. Testing should be performed using an accurate and validated assay.
https://www.pharmgkb.org/labelAnnotation/PA166236241	PA166236241	Annotation of FDA Label for satralizumab and AQP4, IL6R	FDA	On FDA Biomarker List								satralizumab	AQP4; IL6R		9/28/2023	Satralizumab (ENSPRYNG) is an interleukin-6 receptor (IL6R) antagonist indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. The FDA biomarker table lists the aquaporin gene (AQP4).
https://www.pharmgkb.org/labelAnnotation/PA166182759	PA166182759	Annotation of FDA Label for chloroprocaine and CYB5R3, G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	chloroprocaine	CYB5R3; G6PD		7/23/2024	The FDA-approved drug label for chloroprocaine (Nesacaine) states that individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency or congenital methemoglobinemia may be at increased risk for treatment-induced methemoglobinemia.
https://www.pharmgkb.org/labelAnnotation/PA166129517	PA166129517	Annotation of FDA Label for isoflurane and CACNA1S, RYR1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	isoflurane	CACNA1S; RYR1		4/1/2023	The FDA-approved drug label for isoflurane (FORANE) warns that individuals with a genetic predisposition to malignant hyperthermia.
https://www.pharmgkb.org/labelAnnotation/PA166235941	PA166235941	Annotation of FDA Label for setmelanotide and LEPR, PCSK1, POMC	FDA	On FDA Biomarker List	Testing Required							setmelanotide	LEPR; PCSK1; POMC		8/22/2023	The FDA-approved drug label for setmelanotide (IMCIVREE) states that is a melanocortin 4 (MC4) receptor agonist indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).
https://www.pharmgkb.org/labelAnnotation/PA166123410	PA166123410	Annotation of EMA Label for ritonavir and CYP2D6, CYP3A4	EMA									ritonavir	CYP2D6; CYP3A4		8/22/2023	The EMA European Public Assessment Report (EPAR) for ritonavir (Norvir) does not contain pharmacogenetic information. It contains information regarding use of ritonavir as a pharmacokinetic enhancer for certain drugs to prolong their therapeutic effects. It is a potent inhibitor of CYP3A and CYP2D6-mediated biotransformation, and the EPAR provides a list of drugs contraindicated for concomitant use with ritonavir.
https://www.pharmgkb.org/labelAnnotation/PA166123551	PA166123551	Annotation of PMDA Label for tretinoin and PML, RARA	PMDA							Cancer Genome		tretinoin	PML; RARA		9/26/2023	Tretinoin is indicated for the treatment of acute promyelocytic leukemia (APL). The PMDA package insert for tretinoin (VESANOID) notes that it acts on the PML-RAR-α fusion gene, allowing immature promyelocytes to differentiate into normal mature blood cells.
https://www.pharmgkb.org/labelAnnotation/PA166105232	PA166105232	Annotation of FDA Label for quinine and CYP2D6, G6PD	FDA	On FDA Biomarker List								quinine	CYP2D6; G6PD		4/2/2024	Quinine (QUALAQUIN) is an antimalarial indicated for treatment of uncomplicated Plasmodium falciparum malaria. G6PD is mentioned in the Warnings and Precautions section of the label, while CYP2D6 is mentioned in the Drug Interactions and Clinical Pharmacology sections. However, there is no information on the label associating either gene with quinine response.
https://www.pharmgkb.org/labelAnnotation/PA166127671	PA166127671	Annotation of HCSC Label for everolimus and ERBB2, ESR1, ESR2	HCSC		Testing Required					Cancer Genome		everolimus	ERBB2; ESR1; ESR2		4/16/2024	The product monograph for everolimus (AFINITOR) states that it is indicated for treatment of hormone receptor-positive, HER2-negative breast cancer.
https://www.pharmgkb.org/labelAnnotation/PA166127682	PA166127682	Annotation of HCSC Label for imatinib and ABI1, BCR, FIP1L1, KIT, PDGFRA, PDGFRB	HCSC		Testing Required					Cancer Genome		imatinib	ABI1; BCR; FIP1L1; KIT; PDGFRA; PDGFRB		4/21/2024	The product monograph for imatinib (GLEEVEC) contains pharmacogenetic information regarding the indication of the drug in patients with tumors positive for biomarkers including Kit (CD117), BCR-ABL1 (Philadelphia chromosome), PDGFR and FIP1L1-PDGFRalpha rearrangements.
https://www.pharmgkb.org/labelAnnotation/PA166104840	PA166104840	Annotation of EMA Label for lapatinib and ERBB2, ESR1, ESR2	EMA		Testing Required					Cancer Genome		lapatinib	ERBB2; ESR1; ESR2		4/21/2024	The EMA European Public Assessment Report (EPAR) for lapatinib (Tyverb) states that it is indicated for the treatment of adult patients with breast cancer whose tumors overexpress HER2, in combination with various other drugs. This includes combination with trastuzumab for patients with hormone receptor-negative disease, and combination with an aromatase inhibitor for hormone receptor-positive disease.
https://www.pharmgkb.org/labelAnnotation/PA166105334	PA166105334	Annotation of EMA Label for nilotinib and ABL1, BCR	EMA		Testing Required					Cancer Genome		nilotinib	ABL1; BCR		4/21/2024	The EMA European Public Assessment Report (EPAR) for nilotinib (Tasigna) states it is indicated for patients who have Philadelphia chromosome-positive (presence of a BCR-ABL1 gene fusion) chronic myelogenous leukemia (CML). The label differs from that of the FDA as it does not contain any information regarding UGT1A1 genotype.
https://www.pharmgkb.org/labelAnnotation/PA166183421	PA166183421	Annotation of EMA Label for ribociclib and ERBB2, ESR1, ESR2, PGR	EMA		Testing Required					Cancer Genome		ribociclib	ERBB2; ESR1; ESR2; PGR		4/21/2024	The EMA European Public Assessment Report (EPAR) for ribociclib (Kisqali) states that it is indicated for the treatment of women with hormone receptor positive, HER2-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.
https://www.pharmgkb.org/labelAnnotation/PA166183425	PA166183425	Annotation of EMA Label for talazoparib and BRCA1, BRCA2, ERBB2	EMA		Testing Required					Cancer Genome		talazoparib	BRCA1; BRCA2; ERBB2		4/21/2024	The EMA European Public Assessment Report (EPAR) for talazoparib (Talzenna) states that it is indicated as a monotherapy for the treatment of adult patients with germline BRCA1 or BRCA2 mutations, who have HER2-negative locally advanced or metastatic breast cancer.
https://www.pharmgkb.org/labelAnnotation/PA166127695	PA166127695	Annotation of HCSC Label for ethinyl estradiol / norelgestromin and F2, F5, MTHFR, PROC, PROS1, SERPINC1	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	ethinyl estradiol / norelgestromin	F2; F5; MTHFR; PROC; PROS1; SERPINC1	rs1799963; rs1801131; rs1801133	7/25/2024	The product monograph for norelgestromin and ethinyl estradiol (EVRA) states that the drug is contraindicated in women with Factor V Leiden mutation, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinaemia due to mutations in the MTHFR gene and prothrombin mutation G20210A (among other contraindications), due to the risk for arterial or venous thrombosis.
https://www.pharmgkb.org/labelAnnotation/PA166127687	PA166127687	Annotation of HCSC Label for letrozole and ESR1, ESR2, PGR	HCSC		Testing Required					Cancer Genome		letrozole	ESR1; ESR2; PGR		8/8/2024	The product monograph for letrozole (FEMARA) states that it is indicated for the treatment of hormone-receptor positive early breast cancer.
https://www.pharmgkb.org/labelAnnotation/PA166127693	PA166127693	Annotation of HCSC Label for nilotinib and ABL1, BCR	HCSC		Testing Required					Cancer Genome		nilotinib	ABL1; BCR		8/9/2024	The product monograph for nilotinib (TASIGNA) states that it is indicated for patients with Philadelphia chromosome positive (BCR-ABL1 fusion) chronic myeloid leukemia, though individuals with the BCR-ABL T315I mutation are highly resistant to the drug. The monograph also notes that patients homozygous for the UGT1A1*28 allele (rs8175347; (TA)7) may be at risk for hyperbilirubinemia when receiving nilotinib.
https://www.pharmgkb.org/labelAnnotation/PA166127712	PA166127712	Annotation of HCSC Label for sodium phenylbutyrate and ASS1, CPS1, OTC	HCSC									sodium phenylbutyrate	ASS1; CPS1; OTC		8/13/2024	The product monograph for sodium phenylbutyrate (Pheburane) states that it is indicated for treatment of urea cycle disorders due to deficiencies of carbamylphosphate synthetase (CPS1), ornithine transcarbamylase (OTC) or argininosuccinate synthetase (ASS1).
https://www.pharmgkb.org/labelAnnotation/PA166114381	PA166114381	Annotation of EMA Label for sodium phenylbutyrate and ASS1, CPS1, OTC	EMA									sodium phenylbutyrate	ASS1; CPS1; OTC		8/13/2024	The EMA European Public Assessment Report (EPAR) for sodium phenylbutyrate (AMMONAPS) states that it is indicated as an adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase (CPS1), ornithine transcarbamylase (OTC) or argininosuccinate synthetase (ASS1).
https://www.pharmgkb.org/labelAnnotation/PA166182789	PA166182789	Annotation of EMA Label for toremifene and ESR1, ESR2	EMA							Cancer Genome		toremifene	ESR1; ESR2		8/16/2024	The EMA European Public Assessment Report (EPAR) states that toremifene (FARESTON) is a first line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients and is not recommended for patients with metastatic breast cancer who have estrogen receptor negative tumors.
https://www.pharmgkb.org/labelAnnotation/PA166127660	PA166127660	Annotation of HCSC Label for dasatinib and ABL1, BCR	HCSC		Testing Required					Cancer Genome		dasatinib	ABL1; BCR		8/26/2024	The product monograph for dasatinib (SPRYCEL) states that it is indicated for the treatment of adults with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia with resistance or intolerance to prior therapy.
https://www.pharmgkb.org/labelAnnotation/PA166240301	PA166240301	Annotation of EMA Label for avatrombopag and CYP2C9, F2, F5, PROC, PROS1, SERPINC1	EMA		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	avatrombopag	CYP2C9; F2; F5; PROC; PROS1; SERPINC1	CYP2C9*2; CYP2C9*3; rs1799963; rs6025	7/17/2024	The EMA European Public Assessment Report (EPAR) for avatrombopag (Doptelet) states that avatrombopag exposure may increase in patients with CYP2C9*2 and/or CYP2C9*3 alleles, and that increased exposure may increase the risk of clinically-relevant QTc prolongation. The label also states that potential increased thrombotic risk should be considered in patients with deficiency in Factor V Leiden (F5), prothrombin 20210A (F2), antithrombin (SERPINC1), protein C (PROC), or protein S (PROS1).
https://www.pharmgkb.org/labelAnnotation/PA166246485	PA166246485	Annotation of FDA Label for sotorasib and KRAS	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		sotorasib	KRAS	rs121913530	9/1/2023	Sotorasib is an inhibitor of the RAS GTPase family indicated for the treatment of adult patients with KRAS G12C-mutated cancer.
https://www.pharmgkb.org/labelAnnotation/PA166248801	PA166248801	Annotation of FDA Label for anakinra and IL1RN	FDA									anakinra	IL1RN		8/7/2024	The FDA-approved label for anakinra (KINERET) states that anakinra is an interleukin-1 receptor antagonist indicated for rheumatoid arthritis, cryopyrin-Associated Periodic Syndromes (CAPS) (treatment of neonatal-onset multisystemic inflammatory disease (NOMID)) and deficiency of the interleukin-1 receptor antagonist (DIRA). DIRA is an autosomal recessive monogenic autoinflammatory disease caused by mutations in the IL1RN gene leading to loss of secretion of the interleukin-1 receptor antagonist (IL-1Ra).
https://www.pharmgkb.org/labelAnnotation/PA166252901	PA166252901	Annotation of FDA Label for tepotinib and ALK, EGFR	FDA	On FDA Biomarker List						Cancer Genome		tepotinib	ALK; EGFR		8/24/2023	The FDA-approved drug label for tepotinib stated that it is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal- epithelial transition (MET) exon 14 skipping alterations. Eligible patients in the tepotinib clinical study were required to have advanced or metastatic NSCLC harboring METex14 skipping alterations, epidermal growth factor receptor (EGFR) wild-type and anaplastic lymphoma kinase (ALK) negative status.
https://www.pharmgkb.org/labelAnnotation/PA166251482	PA166251482	Annotation of FDA Label for dostarlimab	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		dostarlimab			8/31/2023	The FDA label for dostarlimab-gxly (JEMPERLI) states that it is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer (EC), as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen. Select patients based on the presence of dMMR in tumor specimens.
https://www.pharmgkb.org/labelAnnotation/PA166252881	PA166252881	Annotation of FDA Label for tepotinib and MET	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		tepotinib	MET		8/31/2023	The FDA-approved drug label for tepotinib stated that it is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal- epithelial transition (MET) exon 14 skipping alterations. Select patients for treatment with TEPMETKO on the presence of METex14 skipping.
https://www.pharmgkb.org/labelAnnotation/PA166252081	PA166252081	Annotation of FDA Label for infigratinib and FGFR2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		infigratinib	FGFR2		8/31/2023	"The FDA label for infigratinib (TRUSELTIQ) states that it is indicated for the treatment of cholangiocarcinoma with a FGFR2 fusion or other rearrangement, as detected by an FDA-approved test.
Please note that as of 9/10/2024, the marketing status of this drug is Discontinued."
https://www.pharmgkb.org/labelAnnotation/PA166251821	PA166251821	Annotation of FDA Label for evinacumab and LDLR	FDA	On FDA Biomarker List								evinacumab	LDLR		8/20/2024	The FDA-approved drug label for evinacumab-dgnb (EVKEEZA) states that it is an ANGPTL3 (angiopoietin-like 3) inhibitor indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH). Familial hypercholesterolemia is commonly caused by mutations in the LDLR gene. Low density lipoprotein receptor (LDLR) function was mentioned under the clinical studies section.
https://www.pharmgkb.org/labelAnnotation/PA166269081	PA166269081	Annotation of FDA Label for glycerol phenylbutyrate and NAGS	FDA	On FDA Biomarker List								glycerol phenylbutyrate	NAGS		8/17/2023	Glycerol phenylbutyrate (RAVICTI) is a nitrogen-binding agent indicated for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. The FDA label states that the safety and efficacy for treatment of N-acetylglutamate synthase (NAGS) deficiency has not been established for glycerol phenylbutyrate.
https://www.pharmgkb.org/labelAnnotation/PA166269121	PA166269121	Annotation of FDA Label for nateglinide and CYP2C9	FDA	On FDA Biomarker List	Informative PGx							nateglinide	CYP2C9		8/28/2024	Nateglinide is a glinide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In a table of clinically significant drug interactions with nateglinide, the FDA label states that in patients who are known to be CYP2C9 poor metabolizers, alcohol may increase both the blood-glucose-lowering effect of nateglinide and susceptibility to hypoglycemia. Dose reductions and increased frequency of glucose monitoring may therefore be required.
https://www.pharmgkb.org/labelAnnotation/PA166268901	PA166268901	Annotation of FDA Label for efgartigimod alfa and CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE	FDA	On FDA Biomarker List								efgartigimod alfa	CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE		9/28/2023	Efgartigimod alfa (Vyvgant) is a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. The relationship is not with the ACHR genes but this is the biomarker listed in the FDA table.
https://www.pharmgkb.org/labelAnnotation/PA166268923	PA166268923	Annotation of FDA Label for ropeginterferon alfa-2b and JAK2	FDA	On FDA Biomarker List	No Clinical PGx					Cancer Genome		ropeginterferon alfa-2b	JAK2	rs77375493	7/6/2022	The FDA label for ropeginterferon alfa-2b (BESREMi) states that the presence or absence of the JAK2 V617F (rs77375493) variant does not have a clinically significant effect on the pharmacokinetics of ropeginterferon alfa-2b
https://www.pharmgkb.org/labelAnnotation/PA166170052	PA166170052	Annotation of FDA Label for valbenazine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	valbenazine	CYP2D6		4/12/2022	The FDA-approved drug label for valbenazine (INGREZZA) states that dosage reduction of INGREZZA is recommended for known CYP2D6 poor metabolizers and the recommended dosage for known CYP2D6 poor metabolizers is 40 mg once daily.
https://www.pharmgkb.org/labelAnnotation/PA166269101	PA166269101	Annotation of FDA Label for glycerol phenylbutyrate and ASS1, CPS1, OTC	FDA	On FDA Biomarker List	Testing Required							glycerol phenylbutyrate	ASS1; CPS1; OTC		8/21/2023	Glycerol phenylbutyrate (RAVICTI) is a nitrogen-binding agent indicated for chronic management of patients with urea cycle disorders (UCDs) (involving deficiencies of carbamylphosphate synthetase (CPS1), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (ASS1)) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.
https://www.pharmgkb.org/labelAnnotation/PA166179878	PA166179878	Annotation of FDA Label for encorafenib and BRAF	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		encorafenib	BRAF	rs113488022	10/25/2023	The FDA-approved drug label for encorafenib (BRAFTOVI) states that it is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, or for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. It is also indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.
https://www.pharmgkb.org/labelAnnotation/PA166268902	PA166268902	Annotation of FDA Label for odevixibat and ABCB11, ATP8B1	FDA	On FDA Biomarker List								odevixibat	ABCB11; ATP8B1	rs11568372; rs72549402	8/16/2024	The FDA label for odevixibat (Bylvay) states that BYLVAY is an ileal bile acid transporter (IBAT) inhibitor indicated for Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). PFIC1 is caused by variants in the aminophospholipid flippase (ATP8B1) gene, while PFIC2 results from variants in the ABCB11 gene. Odevixibat may not be effective in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of the bile salt export pump protein.
https://www.pharmgkb.org/labelAnnotation/PA166234701	PA166234701	Annotation of FDA Label for allopurinol and HLA-B	FDA	On FDA Biomarker List	Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	allopurinol	HLA-B	HLA-B*58:01	5/23/2024	The FDA-approved label for allopurinol (ALOPRIM) states that patients who carry the HLA-B*58:01 allele, found at a higher frequency in individuals of African, Asian (e.g., Han Chinese, Korean, Thai), and Native Hawaiian/Pacific Islander ancestry, are at a higher risk of allopurinol hypersensitivity syndrome (AHS). The label recommends testing for HLA-B*58:01 in genetically at-risk populations and states that ALOPRIM is not recommended in HLA-B*58:01 positive patients unless the benefits outweigh the risks.
https://www.pharmgkb.org/labelAnnotation/PA166122592	PA166122592	Annotation of FDA Label for simeprevir and IFNL3	FDA	On FDA Biomarker List	Informative PGx							simeprevir	IFNL3	rs12979860	7/26/2024	"The FDA-approved drug label for simeprevir (OLYSIO) contains information regarding a genetic variant near the IFNL3 gene (IL28B, rs12979860, a C to T change) which is a strong predictor of response to peginterferon alfa and ribavirin treatment. Simeprevir must not be used as a monotherapy, and should be administered in combination with both peginterferon alfa and ribavirin for treatment of chronic hepatitis C genotype 1.
July 2024: Please note that simeprevir is listed as discontinued by the FDA. However, this drug is still on the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. PharmGKB has therefore decided to keep this annotation active until the drug is removed from the FDA Biomarker table."
https://www.pharmgkb.org/labelAnnotation/PA166127710	PA166127710	Annotation of HCSC Label for simeprevir and IFNL3	HCSC		Informative PGx							simeprevir	IFNL3	rs12979860	7/26/2024	"The product monograph for simeprevir (GALEXOS) contains information regarding a genetic variant near the IFNL3 gene (IL28B, rs12979860) which is a strong predictor of response to peginterferon alfa (PegIFN-alfa) and ribavirin (RBV) treatment. Simeprevir is only indicated in combination with PegIFN-alfa and RBV or with sofosbuvir, it is not indicated as a monotherapy.
Please note that as of July 2024, the HCSC database lists the marketing status of simeprevir as ""Cancelled Post Market""."
https://www.pharmgkb.org/labelAnnotation/PA166122607	PA166122607	Annotation of FDA Label for vortioxetine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	vortioxetine	CYP2D6		8/10/2023	Vortioxetine (TRINTELLIX) is indicated as a treatment for major depressive disorder. The FDA-approved drug label for vortioxetine notes that the maximum recommended dose in patients who are known CYP2D6 poor metabolizers is 10 mg/day.
https://www.pharmgkb.org/labelAnnotation/PA166182741	PA166182741	Annotation of FDA Label for articaine / epinephrine and CYB5R3, G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	articaine / epinephrine	CYB5R3; G6PD		10/24/2019	The FDA-approved drug label for articaine and epinephrine (ORABLOC) states that individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency or congenital methemoglobinemia may be at increased risk for treatment-induced methemoglobinemia.
https://www.pharmgkb.org/labelAnnotation/PA166170929	PA166170929	Annotation of FDA Label for gefitinib and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	gefitinib	CYP2D6			The FDA-approved drug label for gefinitib (IRESSA) states that it is indicated for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. The label also notes the potential clinical importance of considering CYP2D6 phenotype, though CYP2D6 testing is not mentioned.
https://www.pharmgkb.org/labelAnnotation/PA166104780	PA166104780	Annotation of FDA Label for carbamazepine and HLA-B	FDA	On FDA Biomarker List	Testing Required	Prescribing Info		Alternate Drug			Prescribing	carbamazepine	HLA-B	HLA-B*15:02	4/26/2024	The FDA-approved label for carbamazepine (TEGRETOL) states that screening of patients with ancestry in genetically at-risk populations (patients of Asian descent) for the presence of the HLA-B*1502 allele should be carried out prior to treatment due to a high risk of serious and sometimes fatal dermatologic reactions. It also notes that a moderate association has been found between HLA-A*3101 and the risk of developing hypersensitivity reactions to carbamazepine, though it does not mention testing for this allele.
https://www.pharmgkb.org/labelAnnotation/PA166104807	PA166104807	Annotation of FDA Label for fluorouracil and DPYD	FDA	On FDA Biomarker List	Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	fluorouracil	DPYD		4/19/2024	Fluorouracil is not recommended for use in patients known to have certain homozygous or compound heterozygous DPYD variants that result in complete dihydropyrimidine dehydrogenase (DPD) deficiency. Prescribers should consider testing for genetic variants of DPYD prior to initiating fluorouracil. Fluorouracil is available as both an injection and a topical cream (CARAC). These two formulations have different indications. Both FDA-approved labels contain information about the potential for severe toxicity in patients with DPD deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166246301	PA166246301	Annotation of FDA Label for acetaminophen / caffeine / dihydrocodeine and CYP2D6	FDA		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	acetaminophen / caffeine / dihydrocodeine	CYP2D6			The FDA-approved drug label for acetaminophen/caffeine/dihydrocodeine (TREZIX) states that respiratory depression and death have occurred in children who received codeine following a tonsillectomy and/or adenoidectomy and who had evidence of being CYP2D6 ultra-rapid metabolizers. The label also states that CYP2D6 ultrarapid metabolizers should not use codeine.
https://www.pharmgkb.org/labelAnnotation/PA166104839	PA166104839	Annotation of FDA Label for aripiprazole and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	aripiprazole	CYP2D6		5/9/2019	The FDA-approved drug labels for aripiprazole (ABILIFY and ABILIFY MAINTENA), provide dosage adjustments for patients who are CYP2D6 poor metabolizers (PMs). CYP2D6 PMs taking ABILIFY should receive half the usual dose, and CYP2D6 PMs taking ABILIFY MAINTENA should have their dose reduced to 300 mg from the recommended dose of 400 mg.
https://www.pharmgkb.org/labelAnnotation/PA166104838	PA166104838	Annotation of FDA Label for thioguanine and NUDT15, TPMT	FDA	On FDA Biomarker List	Testing Recommended	Prescribing Info	Dosing Info				Prescribing	thioguanine	NUDT15; TPMT		10/25/2013	The FDA-approved drug label for thioguanine (TABLOID) says to consider testing for TPMT and NUDT15 deficiency in patients who experience severe bone marrow toxicities or repeated episodes of myelosuppression. It also says to reduce initial dosage in patients known to have homozygous TPMT or NUDT15 deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166104801	PA166104801	Annotation of FDA Label for peginterferon alfa-2b and IFNL3	FDA	On FDA Biomarker List	Informative PGx							peginterferon alfa-2b	IFNL3	rs12979860	4/19/2019	The FDA-approved drug label for peginterferon alfa-2b (PEGINTRON) states that a single nucleotide polymorphism near the gene encoding interferon-lambda-3 (IL28B rs12979860) was associated with variable sustained viral response (SVR) rates. SVR rates by rs12979860 genotype were as follows: CC 66% vs. CT 30% vs. TT 22%.
https://www.pharmgkb.org/labelAnnotation/PA166278361	PA166278361	Annotation of FDA Label for dextromethorphan hydrobromide / bupropion hydrochloride and CYP2D6	FDA		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	dextromethorphan hydrobromide / bupropion hydrochloride	CYP2D6			The FDA-approved drug label for AUVELITY (dextromethorphan hydrobromide and bupropion hydrochloride) states that AUVELITY is indicated for the treatment of major depressive disorder (MDD) in adults. Dextromethorphan is a CYP2D6 substrate and bupropion is an aminoketone and CYP450 2D6 inhibitor. The recommended dosage for patients known to be poor CYP2D6 metabolizers is one tablet once daily in the morning, because these patients have higher dextromethorphan concentrations than extensive/intermediate CYP2D6 metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166170935	PA166170935	Annotation of FDA Label for rucaparib and CYP1A2, CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							rucaparib	CYP1A2; CYP2D6		10/28/2020	Rucaparib (RUBRACA) is indicated for the treatment of patients with deleterious BRCA mutation-associated epithelial ovarian, fallopian tube or primary peritoneal cancer. The label notes that rucaparib concentrations did not differ significantly based on CYP2D6 or CYP1A2 genotypes.
https://www.pharmgkb.org/labelAnnotation/PA166178750	PA166178750	Annotation of FDA Label for metoclopramide and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	metoclopramide	CYP2D6			Metoclopramide (REGLAN) is indicated as a short-term treatment for adults with gastroesophageal reflux who fail to respond to conventional therapy. The label for metoclopramide notes that elimination of the drug may be slowed in CYP2D6 poor metabolizers, potentially increasing the risk for adverse reactions, and that these patients should receive a reduced dose of the drug.
https://www.pharmgkb.org/labelAnnotation/PA166179887	PA166179887	Annotation of FDA Label for raltegravir and UGT1A1	FDA	On FDA Biomarker List	No Clinical PGx							raltegravir	UGT1A1	UGT1A1*28	4/23/2019	The FDA-approved drug label for raltegravir (ISENTRESS) states that there is no evidence that common UGT1A1 polymorphisms alter raltegravir pharmacokinetics to a clinically meaningful extent, despite UGT1A1 being the primary enzyme involved in raltegravir elimination. However, the label notes that UGT1A1 activity is negligible at birth and provides dosing information based on neonatal age that takes into account increasing UGT1A1 activity.
https://www.pharmgkb.org/labelAnnotation/PA166129519	PA166129519	Annotation of FDA Label for sevoflurane and CACNA1S, RYR1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	sevoflurane	CACNA1S; RYR1		4/1/2023	The FDA-approved drug label for sevoflurane (ULTANE) states that it should not be used in patients with known or suspected susceptibility to malignant hyperthermia. Specific variants in the RYR1 and CACNA1S genes are associated with risk of malignant hyperthermia in individuals administered potent inhalational anesthetics, including sevoflurane. The label does not mention genetic testing.
https://www.pharmgkb.org/labelAnnotation/PA166104829	PA166104829	Annotation of FDA Label for tetrabenazine and CYP2D6	FDA	On FDA Biomarker List	Testing Required	Prescribing Info	Dosing Info				Prescribing	tetrabenazine	CYP2D6		10/25/2013	The FDA-approved drug label for tetrabenazine (XENAZINE) states that patients requiring doses above 50 mg per day should be genotyped for the drug metabolizing enzyme CYP2D6 to determine if the patient is a poor metabolizer (PM) or an extensive metabolizer (EM). People with CYP2D6 poor metabolizer genotypes should be treated with lower doses.
https://www.pharmgkb.org/labelAnnotation/PA166293341	PA166293341	Annotation of FDA Label for tremelimumab and ALK, EGFR	FDA	On FDA Biomarker List						Cancer Genome		tremelimumab	ALK; EGFR		8/7/2024	Tremelimumab-actl is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated in combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC), and in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
https://www.pharmgkb.org/labelAnnotation/PA166104827	PA166104827	Annotation of FDA Label for atomoxetine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	atomoxetine	CYP2D6		5/9/2019	The FDA-approved drug label for atomoxetine (STRATTERA) recommends a dose adjustment in children or adolescents who are CYP2D6 poor metabolizers, or who are administered strong CYP2D6 inhibitors. Additionally, the label notes a number of adverse events that occurred more frequently in CYP2D6 poor metabolizers than extensive metabolizers in clinical trials. Laboratory tests are available to identify CYP2D6 poor metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166104856	PA166104856	Annotation of FDA Label for amitriptyline and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							amitriptyline	CYP2D6		7/18/2024	The FDA-approved drug label for amitriptyline contains information regarding the metabolism of tricyclic antidepressants by CYP2D6. CYP2D6 poor metabolizers may have higher than expected plasma concentrations of tricyclic antidepressants when given usual doses.
https://www.pharmgkb.org/labelAnnotation/PA166104874	PA166104874	Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD, NAT2	FDA	On FDA Biomarker List	Informative PGx							sulfamethoxazole / trimethoprim	G6PD; NAT2		10/10/2019	"Sulfamethoxazole and trimethoprim (BACTRIM) is used to prevent and treat infections caused by certain bacteria. The label warns that hemolysis may occur in G6PD deficient individuals. It also notes that patients who are ""slow acetylators"" may be more prone to idiosyncratic reactions to sulfonamides. Acetylation status of an individual can be determined by examining variants in the NAT2 gene. However, the label never mentions any specific gene with regard to acetylator status."
https://www.pharmgkb.org/labelAnnotation/PA166268861	PA166268861	Annotation of FDA Label for asciminib and ABL1, BCR	FDA	On FDA Biomarker List	Testing Required	Prescribing Info	Dosing Info			Cancer Genome	Prescribing	asciminib	ABL1; BCR	rs121913459	10/11/2023	Asciminib is indicated for treatment of patients with CML with BCR-ABL (the Philadelphia chromosome) including those with the T351I variant (rs121913459C>T).
https://www.pharmgkb.org/labelAnnotation/PA166273021	PA166273021	Annotation of FDA Label for mavacamten and CYP2C19	FDA	On FDA Biomarker List	Informative PGx							mavacamten	CYP2C19	CYP2C19*2; CYP2C19*3	12/20/2023	The FDA label for mavacamten gives information on pharmacokinetic differences in CYP2C19 poor metabolizers (PM) compared to normal metabolizers (NM), but does not give information on testing for alleles associated with PM or dose adjustments.
https://www.pharmgkb.org/labelAnnotation/PA166104879	PA166104879	Annotation of FDA Label for imipramine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							imipramine	CYP2D6		7/23/2024	The FDA-approved drug label for imipramine states that CYP2D6 poor metabolizers have higher than expected plasma concentrations of TCAs when given usual doses.
https://www.pharmgkb.org/labelAnnotation/PA166104885	PA166104885	Annotation of FDA Label for norfloxacin and G6PD	FDA		Informative PGx							norfloxacin	G6PD		4/14/2019	Norfloxacin (NOROXIN) is used to treat urinary tract infections, sexually transmitted diseases and prostatitis caused by certain microorganisms. The label reports hemolytic reactions have been seen in G6PD deficient individuals in association with this drug.
https://www.pharmgkb.org/labelAnnotation/PA166104895	PA166104895	Annotation of FDA Label for erythromycin ethylsuccinate / sulfisoxazole acetyl and G6PD	FDA	On FDA Biomarker List	Informative PGx							erythromycin ethylsuccinate / sulfisoxazole acetyl	G6PD		7/24/2024	"Erythromycin ethylsuccinate and sulfisoxazole acetyl is used to treat acute otitis media in children caused by certain strains of Haemophilus influenzae. The label warns that hemolysis may occur in G6PD deficient patients on this drug.
July 2024: Please note that erythromycin ethylsuccinate / sulfisoxazole acetyl is listed as discontinued by the FDA. However, this drug combination is still on the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. PharmGKB has therefore decided to keep this annotation active until the drug combination is removed from the FDA Biomarker table."
https://www.pharmgkb.org/labelAnnotation/PA166104795	PA166104795	Annotation of FDA Label for busulfan and ABL1, BCR	FDA	On FDA Biomarker List	Informative PGx					Cancer Genome		busulfan	ABL1; BCR		2/3/2024	The FDA-approved drug label for busulfan (MYLERAN) states it is less effective in patients with chronic myelogenous leukemia who lack the Philadelphia chromosome.
https://www.pharmgkb.org/labelAnnotation/PA166114926	PA166114926	Annotation of FDA Label for mafenide and G6PD	FDA	On FDA Biomarker List	Informative PGx							mafenide	G6PD		7/24/2024	The FDA-approved drug label for mafenide acetate mentions that fatal hemolytic anemia with disseminated intravascular coagulation has been reported following treatment with mafedine acetate, possibly related to a glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD deficiency is a condition caused by variants in the G6PD gene which can be determined by enzymatic or genetic tests. However, the drug label does not specifically mention testing.
https://www.pharmgkb.org/labelAnnotation/PA166104878	PA166104878	Annotation of FDA Label for methylene blue and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	methylene blue	G6PD		12/17/2013	The FDA-approved drug label for methylene blue (PROVAYBLUE) states that it is contraindicated in patients with G6PD deficiency due to the risks of hemolytic anemia.
https://www.pharmgkb.org/labelAnnotation/PA166160007	PA166160007	Annotation of FDA Label for lesinurad and CYP2C9	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	lesinurad	CYP2C9			The FDA-approved drug label for lesinurad (ZURAMPIC) states that exposure to the drug is increased in CYP2C9 poor metabolizers, and that caution should be used in these patients.
https://www.pharmgkb.org/labelAnnotation/PA166105058	PA166105058	Annotation of FDA Label for pazopanib and HLA-B, UGT1A1	FDA	On FDA Biomarker List	Informative PGx							pazopanib	HLA-B; UGT1A1	HLA-B*57:01; UGT1A1*28	4/19/2019	The FDA-approved drug label for pazopanib (VOTRIENT) states that patients with the UGT1A1 *28/*28 genotype had a significantly increased incidence of hyperbilirubinemia when taking pazopanib, as compared to those with the *1/*1 or *1/*28 genotype. Additionally, ALT > 3 x ULN and ALT > 5 x ULN both occurred more often in carriers of the HLA-B*57:01 allele as compared to non-carriers.
https://www.pharmgkb.org/labelAnnotation/PA166122972	PA166122972	Annotation of FDA Label for fesoterodine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							fesoterodine	CYP2D6		3/15/2017	The FDA-approved drug label for fesoterodine (TOVIAZ) notes that CYP2D6 poor metabolizers may have increased maximum plasma concentrations of the active metabolite of fesoterodine, as compared to CYP2D6 extensive metabolizers. However, the label does not comment on the clinical significance of these increased concentrations.
https://www.pharmgkb.org/labelAnnotation/PA166122971	PA166122971	Annotation of FDA Label for darifenacin and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							darifenacin	CYP2D6		7/19/2024	The FDA-approved drug label for darifenacin notes that CYP2D6 poor metabolizers may have increased maximum plasma concentrations of darifenacin, as compared to CYP2D6 extensive metabolizers. However, the label does not comment on the clinical significance of these increased concentrations.
https://www.pharmgkb.org/labelAnnotation/PA166182728	PA166182728	Annotation of FDA Label for ropivacaine and CYB5R3, G6PD	FDA	On FDA Biomarker List	Informative PGx							ropivacaine	CYB5R3; G6PD		10/17/2019	The FDA-approved drug label for ropivacaine (NAROPIN) states that patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and congenital methemoglobinemia (associated with variants in CYB5R3) are more susceptible to developing methemoglobinemia in association with use of local anesthetics.
https://www.pharmgkb.org/labelAnnotation/PA166160052	PA166160052	Annotation of FDA Label for palonosetron and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							palonosetron	CYP2D6			The FDA-approved drug label for palonosetron (ALOXI) states that there is no significant difference in clinical pharmacokinetic parameters between CYP2D6 poor and extensive metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166105195	PA166105195	Annotation of FDA Label for metoclopramide and CYB5R1, CYB5R2, CYB5R3, CYB5R4, G6PD	FDA	On FDA Biomarker List	Informative PGx							metoclopramide	CYB5R1; CYB5R2; CYB5R3; CYB5R4; G6PD		10/17/2019	Metoclopramide (reglan) is indicated as a short-term treatment for adults with gastroesophageal reflux who fail to respond to conventional therapy. The FDA-approved drug label for metoclopramide notes that patients with NADH-cytochrome b5 reductase deficiency have an increased risk of developing methemglobinemia and/or sulfhemoglobinemia when treated with metoclopramide. The label and FDA table also mention G6PD; patients with G6PD deficiency experiencing metoclopramide-induced methemoglobinemia should not be given methylene blue.
https://www.pharmgkb.org/labelAnnotation/PA166170933	PA166170933	Annotation of FDA Label for pertuzumab and ESR1, ESR2, PGR	FDA	On FDA Biomarker List	Informative PGx					Cancer Genome		pertuzumab	ESR1; ESR2; PGR		4/19/2019	Pertuzumab (PERJETA) is a targeted antibody drug designed to bind to ERBB2 (HER2). The drug label notes that the pathological complete response rate was lower in patients with hormone receptor-positive tumors compared with hormone receptor-negative tumors.
https://www.pharmgkb.org/labelAnnotation/PA166182749	PA166182749	Annotation of FDA Label for lusutrombopag and F2, F5, PROC, PROS1, SERPINC1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	lusutrombopag	F2; F5; PROC; PROS1; SERPINC1	rs1799963; rs6025	7/24/2024	The FDA-approved drug label for lusutrombopag (MULPLETA) states that the potential increased risk for thrombosis should be considered in patients with risk factors for thromboembolism, including genetic prothrombotic conditions such as Factor V Leiden (F5), Prothrombin 20210A (F2), Antithrombin deficiency (SERPINC1) or Protein C (PROC) or S (PROS1) deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166182737	PA166182737	Annotation of FDA Label for lidocaine and tetracaine and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	lidocaine and tetracaine	G6PD		10/5/2023	The FDA-approved drug label for lidocaine and tetracaine (SYNERA) states that caution should be used in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency due to the risk for methemoglobinemia. Close monitoring for symptoms and signs of methemoglobinemia is recommended in this subset of patients.
https://www.pharmgkb.org/labelAnnotation/PA166161219	PA166161219	Annotation of FDA Label for aripiprazole lauroxil and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	aripiprazole lauroxil	CYP2D6			The FDA-approved drug labels for aripiprazole lauroxil (ARISTADA and ARISTADA INITIO) provide dosing guidance for CYP2D6 poor metabolizers (PMs). CYP2D6 PMs taking ARISTADA who are taking a concomitant medicine that is a strong CYP3A4 inhibitor should have their dose reduced to 441 mg. ARISTADA INITIO should be avoided in CYP2D6 poor metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166104837	PA166104837	Annotation of FDA Label for propafenone and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							propafenone	CYP2D6		7/30/2024	The FDA-approved drug label for propafenone (RYTHMOL SR) states that administration of the drug to CYP2D6 slow and extensive metabolizers resulted in significant differences in plasma concentrations. However, the recommended dosing regimen of the drug is the same for all patients.
https://www.pharmgkb.org/labelAnnotation/PA166177514	PA166177514	Annotation of FDA Label for mirabegron and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							mirabegron	CYP2D6			Mirabegron (MYRBETRIQ) is indicated for the treatment of overactive bladder. The label notes that CYP2D6 poor metabolizers had increased concentrations of the drug as compared to CYP2D6 extensive metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166104903	PA166104903	Annotation of FDA Label for nitrofurantoin and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	nitrofurantoin	G6PD		7/23/2024	Nitrofurantion (Furadantin) is used to treat urinary tract infections caused by certain strains of bacteria. A link between nitrofurantoin-induced hemolytic anemia and G6PD deficiency is highlighted in the Warnings section.
https://www.pharmgkb.org/labelAnnotation/PA166160672	PA166160672	Annotation of FDA Label for tamsulosin and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	tamsulosin	CYP2D6			The FDA-approved drug label for tamsulosin (FLOMAX) states that it should be used with caution in CYP2D6 poor metabolizers, particularly at doses higher than 0.4 mg, due to the potential for a significant increase in exposure of the drug.
https://www.pharmgkb.org/labelAnnotation/PA166105117	PA166105117	Annotation of FDA Label for efavirenz and CYP2B6	FDA	On FDA Biomarker List	Informative PGx							efavirenz	CYP2B6	CYP2B6*6	7/18/2024	The FDA-approved drug label for efavirenz (SUSTIVA) states that efavirenz concentrations were higher in patients with the CYP2B6*6/*6 genotype as compared to the *1/*1 genotype, and that a positive relationship between increased efavirenz concentrations and QTc prologation has been observed. Some events of late-onset neurotoxicity have occurred in patients with CYP2B6 genetic polymorphisms which are associated with increased efavirenz levels despite standard dosing of SUSTIVA.
https://www.pharmgkb.org/labelAnnotation/PA166177521	PA166177521	Annotation of FDA Label for umeclidinium and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							umeclidinium	CYP2D6			Umeclidinium (INCRUSE ELLIPTA) is indicated for the treatment of patients with chronic obstructive pulmonary disease (COPD). The label notes that there was no clinically meaningful difference in exposure to the drug between patients who were CYP2D6 poor metabolizers and those who were CYP2D6 intermediate, extensive and ultrarapid metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166182747	PA166182747	Annotation of FDA Label for lorlatinib and ROS1	FDA	On FDA Biomarker List	No Clinical PGx					Cancer Genome		lorlatinib	ROS1		7/30/2024	The FDA-approved drug label for lorlatinib (LORBRENA) states that it is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). Lorlatinib has in vitro activity against ALK and ROS1 and adverse reactions observed in clinical trials consist of patients with ALK-positive or ROS1-positive metastatic NSCLC who received LORBRENA.
https://www.pharmgkb.org/labelAnnotation/PA166169912	PA166169912	Annotation of FDA Label for enflurane	FDA	Formerly on FDA Biomarker List								enflurane			11/30/2023	Enflurane (ETHRANE) is an inhalational anesthetic. The FDA-approved label warns that individuals with known or suspected genetic predisposition to malignant hyperthermia, or patients with Duchenne Muscular Dystrophy, are at greater risk of developing malignant hyperthermia, or hyperkaelemia, respectively.
https://www.pharmgkb.org/labelAnnotation/PA166104847	PA166104847	Annotation of FDA Label for venlafaxine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							venlafaxine	CYP2D6		10/25/2013	The FDA-approved drug label for venlafaxine (Effexor XR) states that CYP2D6 poor metabolizers had increased levels of venlafaxine as compared to CYP2D6 extensive metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166185156	PA166185156	Annotation of FDA Label for mivacurium and BCHE	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	mivacurium	BCHE		8/14/2024	"The FDA drug label for mivacurium chloride (MIVACRON) states that MIVACRON should be used with great caution, if at all, in patients known or suspected of being homozygous for the atypical plasma cholinesterase gene (BCHE), due to risk of prolonged neuromuscular block following administration of MIVACRON.
July 2024: Please note that mivacurium chloride is listed as discontinued by the FDA. However, this drug is still on the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. PharmGKB has therefore decided to keep this annotation active until the drug is removed from the FDA Biomarker table."
https://www.pharmgkb.org/labelAnnotation/PA166182746	PA166182746	Annotation of FDA Label for ceftriaxone and CYB5R3, G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	ceftriaxone	CYB5R3; G6PD		10/24/2019	The FDA-approved drug label for ceftriaxone (ROCEPHIN) states that individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency or congenital methemoglobinemia may be at increased risk for treatment-induced methemoglobinemia.
https://www.pharmgkb.org/labelAnnotation/PA166151882	PA166151882	Annotation of FDA Label for carbamazepine and HLA-A	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	carbamazepine	HLA-A	HLA-A*31:01	10/5/2023	The FDA-approved label for carbamazepine (TEGRETOL) states that a moderate association has been found between HLA-A*3101 and the risk of developing hypersensitivity reactions to carbamazepine, and the risks and benefits of Tegretol therapy should be weighed before considering Tegretol in patients known to be positive for HLA-A*3101. The label also states that screening of patients with ancestry in genetically at-risk populations (patients of Asian descent) for the presence of the HLA-B*1502 allele should be carried out prior to treatment due to a high risk of serious and possibly fatal dermatologic reactions.
https://www.pharmgkb.org/labelAnnotation/PA166185151	PA166185151	Annotation of FDA Label for amifampridine and NAT2	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	amifampridine	NAT2		5/10/2024	The FDA-approved drug label for amifampridine (RUZURGI) states that NAT2 poor metabolizers have higher concentrations of the drug as compared to normal metabolizers, and that the drug should be initiated at the lowest recommended starting dosage in these patients.
https://www.pharmgkb.org/labelAnnotation/PA166170934	PA166170934	Annotation of FDA Label for primaquine and CYB5R1, CYB5R2, CYB5R3, CYB5R4	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	primaquine	CYB5R1; CYB5R2; CYB5R3; CYB5R4		7/24/2024	The FDA-approved drug label for primaquine states that G6PD testing has to be performed before using the drug, and that it should not be prescribed for patients with severe G6PD deficiency. The label also notes that individuals with a family or personal history of nicotinamide adenine dinucleotide (NADH) methemoglobin reductase (CYB5R1-4) deficiency should be observed closely.
https://www.pharmgkb.org/labelAnnotation/PA166160049	PA166160049	Annotation of FDA Label for lacosamide and CYP2C19	FDA	On FDA Biomarker List	No Clinical PGx							lacosamide	CYP2C19			The FDA-approved drug label for lacosamide (VIMPAT) states that plasma concentrations of the lacosamide O-desmethyl metabolite were reduced by approximately 70% in CYP2C19 poor metabolizers (PMs) as compared to extensive metabolizers (EMs), but that there are no clinically relevant differences in lacosamide pharmacokinetics between PMs and EMs.
https://www.pharmgkb.org/labelAnnotation/PA166122970	PA166122970	Annotation of FDA Label for succinylcholine and BCHE, CACNA1S, RYR1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	succinylcholine	BCHE; CACNA1S; RYR1		4/1/2023	Succinylcholine (QUELICIN) is rapid acting, depolarizing skeletal muscle relaxant indicated as an adjunct to general anesthesia. The label warns that individuals who are carriers of the atypical variant of the plasma cholinesterase gene (BCHE) are at risk of prolonged apnea if administered succinylcholine. The label also notes the risk for malignant hyperthermia.
https://www.pharmgkb.org/labelAnnotation/PA166224341	PA166224341	Annotation of FDA Label for encorafenib and HRAS, KRAS, NRAS	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug		Cancer Genome	Prescribing	encorafenib	HRAS; KRAS; NRAS		8/14/2024	The FDA-approved drug label for encorafenib (BRAFTOVI) states that BRAFTOVI may promote malignancies associated with activation of RAS through mutation or other mechanisms. FDA recommends monitor patients receiving BRAFTOVI for signs and symptoms of non-cutaneous malignancies and discontinue BRAFTOVI for RAS mutation-positive non-cutaneous malignancies.
https://www.pharmgkb.org/labelAnnotation/PA166104897	PA166104897	Annotation of FDA Label for moviprep and G6PD	FDA	Formerly on FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	moviprep	G6PD		12/18/2013	MoviPrep, a solution containing Vitamin C, is a laxative used for colon cleansing in preparation for a colonoscopy. Because it contains Vitamin C (ascorbic acid), the label warns that hemolytic reactions are possible in those with G6PD deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166105211	PA166105211	Annotation of FDA Label for ondansetron and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							ondansetron	CYP2D6			The FDA-approved drug label for ondansetron (ZOFRAN) states that the drug is a substrate for CYP2D6 (among other CYP enzymes), but is likely that CYP2D6 genetic deficiency will result in little change in the rate of ondansetron elimination.
https://www.pharmgkb.org/labelAnnotation/PA166115362	PA166115362	Annotation of FDA Label for sodium nitrite and CYB5R3, G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	sodium nitrite	CYB5R3; G6PD		10/16/2019	Sodium nitrite is intended for sequential use with sodium thiosulfate, in order to treat acute and life-threatening cyanide poisoning. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency who are treated with sodium nitrite are at risk for a hemolytic crisis. Consideration should also be given for patients at increased risk for methemoglobinemia such as those with variants in CYB5R3.
https://www.pharmgkb.org/labelAnnotation/PA166179848	PA166179848	Annotation of FDA Label for lofexidine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	lofexidine	CYP2D6			The FDA-approved drug label for lofexidine (LUCEMYRA) states that although the pharmacokinetics of the drug have not been systematically evaluated in patients who do not express CYP2D6, it is likely that exposure to the drug would be increased in these patients.
https://www.pharmgkb.org/labelAnnotation/PA166105147	PA166105147	Annotation of FDA Label for glimepiride and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	glimepiride	G6PD		8/25/2023	The FDA-approved drug label for glimepiride (AMARYL) states that caution should be used in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency due to the risk for hemolytic anemia, and that a non-sulfonylurea alternative should be considered in this subset of patients. G6PD deficiency is a condition caused by variants in the G6PD gene which can be determined by enzymatic or genetic tests, however the drug label does not specifically mention testing.
https://www.pharmgkb.org/labelAnnotation/PA166184637	PA166184637	Annotation of FDA Label for oxymetazoline and tetracaine and BCHE, CYB5R3, G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	oxymetazoline and tetracaine	BCHE; CYB5R3; G6PD		10/24/2019	The FDA-approved drug label for Oxymetazoline and Tetracaine (KOVANAZE) states that patients with G6PD deficiency or congenital methemoglobinemia may be at increased risk for methemoglobinemia when treated with this drug. There is also a warning for pseudocholinesterase deficiency (BCHE) and risk for toxicity which is not listed on the FDA biomarker table.
https://www.pharmgkb.org/labelAnnotation/PA166104852	PA166104852	Annotation of FDA Label for citalopram and CYP2C19	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	citalopram	CYP2C19		9/22/2020	The FDA-approved drug label for citalopram (CELEXA) recommends a maximum dose of 20 mg/day of citalopram in patients who are CYP2C19 poor metabolizers, due to the risk for QT prolongation.
https://www.pharmgkb.org/labelAnnotation/PA166278181	PA166278181	Annotation of FDA Label for azacitidine and CBL, KRAS, NRAS, PTPN11	FDA	On FDA Biomarker List						Cancer Genome		azacitidine	CBL; KRAS; NRAS; PTPN11		8/5/2024	The FDA label for azacitidine includes mention of the genes CBL, PTPN11, NRAS, and KRAS when discussing the clinical studies of Juvenile Myelomonocytic Leukemia.
https://www.pharmgkb.org/labelAnnotation/PA166293201	PA166293201	Annotation of FDA Label for capecitabine and ERBB2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		capecitabine	ERBB2		8/31/2023	The FDA-approved label for capecitabine (XELODA) states that capecitabine is a nucleoside metabolic inhibitor that can be used for HER2 (encoded by gene ERBB2)-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen.
https://www.pharmgkb.org/labelAnnotation/PA166277661	PA166277661	Annotation of FDA Label for vutrisiran and TTR	FDA	On FDA Biomarker List								vutrisiran	TTR		9/28/2023	Vutrisiran is a transthyretin-directed small interfering RNA directed at TTR to prevent formation of TTR amyloidosis.
https://www.pharmgkb.org/labelAnnotation/PA166104790	PA166104790	Annotation of FDA Label for imatinib and ABL1, BCR, FIP1L1, KIT, PDGFRA, PDGFRB	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		imatinib	ABL1; BCR; FIP1L1; KIT; PDGFRA; PDGFRB		9/1/2023	The decision of whether to treat patients with imatinib (GLEEVEC) is based on the presence of genetic biomarkers, including BCR-ABL (the Philadelphia chromosome), KIT, and PDGFR gene rearrangements.
https://www.pharmgkb.org/labelAnnotation/PA166273561	PA166273561	Annotation of FDA Label for inclisiran and APOB, LDLR, PCSK9	FDA	On FDA Biomarker List								inclisiran	APOB; LDLR; PCSK9		7/23/2024	Inclisiran is FDA indicated for the treatment of heterozygous familial hypercholesterolemia (HeFH). The label does not describe testing for HeFH but tests could include screening for variants in the LDLR, APOB and PCSK9 genes (see the Genetic Test Registry for more information). Inclisiran is a small interfering RNA directed against PCSK9.
https://www.pharmgkb.org/labelAnnotation/PA166104860	PA166104860	Annotation of FDA Label for phenytoin and CYP2C19, CYP2C9, HLA-B	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	phenytoin	CYP2C19; CYP2C9; HLA-B	CYP2C9*2; CYP2C9*3; HLA-B*15:02	8/23/2023	The FDA-approved drug label for phenytoin (DILANTIN) states that the HLA-B*15:02 and CYP2C9*3 alleles may increase the risk of severe cutaneous adverse reactions in patients who are treated with phenytoin and that prescribers should consider avoiding phenytoin as an alternative to carbamazepine in these patients. It also notes that the drug is metabolized by CYP2C9 and CYP2C19 and that patients who are known to be CYP2C9 intermediate or poor metabolizers may have lower phenytoin dose requirements.
https://www.pharmgkb.org/labelAnnotation/PA166278081	PA166278081	Annotation of FDA Label for mitapivat and PKLR	FDA	On FDA Biomarker List								mitapivat	PKLR		8/9/2024	Mitapivat is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with liver and red blood cell-specific pyruvate kinase (PKLR) deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166296341	PA166296341	Annotation of FDA Label for pemetrexed and ALK, EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		pemetrexed	ALK; EGFR		8/31/2023	The FDA label for Pemetrexed (ALIMTA) states that it is a folate analog metabolic inhibitor indicated in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.
https://www.pharmgkb.org/labelAnnotation/PA166251421	PA166251421	Annotation of FDA Label for cemiplimab-rwlc and ALK, CD274, EGFR, ROS1	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		cemiplimab-rwlc	ALK; CD274; EGFR; ROS1		8/31/2023	The FDA-approved drug label for cemiplimab-rwlc (LIBTAYO) states that it is indicated for the first-line treatment of patients with with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations. PD-L1 is encoded by the CD274 gene.
https://www.pharmgkb.org/labelAnnotation/PA166278161	PA166278161	Annotation of FDA Label for lutetium (177lu) vipivotide tetraxetan and FOLH1	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		lutetium (177lu) vipivotide tetraxetan	FOLH1		9/1/2023	Lutetium (177lu) vipivotide tetraxetan is a radioligand treatment that is targeted to metastatic prostate cancer cells expressing prostate-specific membrane antigen, encoded for by FOLH1.
https://www.pharmgkb.org/labelAnnotation/PA166296361	PA166296361	Annotation of FDA Label for pemetrexed and CD274	FDA	On FDA Biomarker List						Cancer Genome		pemetrexed	CD274		9/7/2023	The FDA label for Pemetrexed (ALIMTA) states that it is a folate analog metabolic inhibitor indicated in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. The efficacy of ALIMTA was examined in Study KEYNOTE-189 (NCT02578680), a randomized, multicenter, double-blind, active-controlled trial conducted in patients with metastatic non-squamous NSCLC, regardless of PD-L1 tumor expression status, who had not previously received systemic therapy for metastatic disease and in whom there were no EGFR or ALK genomic tumor aberrations.
https://www.pharmgkb.org/labelAnnotation/PA166277841	PA166277841	Annotation of FDA Label for sacrosidase and SI	FDA	On FDA Biomarker List	Testing Required							sacrosidase	SI		8/21/2023	Sacrosidase is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID). The label recognizes that trial therapy may precede testing under some circumstances.
https://www.pharmgkb.org/labelAnnotation/PA166104846	PA166104846	Annotation of FDA Label for arsenic trioxide and PML, RARA	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		arsenic trioxide	PML; RARA		9/1/2023	The FDA-approved drug label for arsenic trioxide (TRISONEX) contains information regarding indication of the drug in patients whose acute promyelocytic leukemia (APL) is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.
https://www.pharmgkb.org/labelAnnotation/PA166234723	PA166234723	Annotation of FDA Label for atorvastatin and SLCO1B1	FDA									atorvastatin	SLCO1B1		12/4/2023	The FDA-approved label for atorvastatin (LIPITOR) states that atorvastatin exposure may be increased by drug interactions due to inhibition of CYP3A4 and/or transporters (e.g., breast cancer resistant protein (BCRP), organic anion-transporting polypeptide (OATP1B1 (SLCO1B1)/OATP1B3) and P-glycoprotein (P-gp (ABCB1))), resulting in an increased risk of myopathy and rhabdomyolysis.
https://www.pharmgkb.org/labelAnnotation/PA166234801	PA166234801	Annotation of FDA Label for tacrolimus and CYP3A4, CYP3A5	FDA									tacrolimus	CYP3A4; CYP3A5		8/29/2024	The FDA drug label for tacrolimus (PROGRAF) contains guidance on concomitant use with CYP3A inducers or inhibitors. The label states that tacrolimus blood concentrations are altered by CYP3A inhibitors and/or inducers, the risk of nephrotoxicity is increased with concomitant use of CYP3A inhibitors, and the risk of QT interval prolongation is increased by concomitant use of CYP3A4 substrates and/or inhibitors.
https://www.pharmgkb.org/labelAnnotation/PA166272961	PA166272961	Annotation of FDA Label for abrocitinib and CYP2C19	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	abrocitinib	CYP2C19		8/21/2023	The FDA label for abrocitinib gives dosing modifications for CYP2C19 poor metabolizers. It does not describe which CYP2C19 variants or tests can be used to define poor metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166278121	PA166278121	Annotation of FDA Label for nivolumab / relatlimab and BRAF, CD274, LAG3	FDA	On FDA Biomarker List						Cancer Genome		nivolumab / relatlimab	BRAF; CD274; LAG3		8/16/2023	The combination therapy of nivolumab, an antibody against CD274 (PD-L1) and relatlimab, an antibody against LAG3 is FDA approved for unresectable or metastatic melanoma. The label also mentions BRAF status for patients in one of the clinical studies but testing is not discussed or required as part of the indication.
https://www.pharmgkb.org/labelAnnotation/PA166179871	PA166179871	Annotation of FDA Label for binimetinib and UGT1A1	FDA	On FDA Biomarker List	No Clinical PGx							binimetinib	UGT1A1		10/25/2023	Binimetinib (MEKTOVI) states is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, or for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. The FDA-approved drug label also states that UGT1A1 genotype does not have a clinically important effect on binimetinib exposure.
https://www.pharmgkb.org/labelAnnotation/PA166277681	PA166277681	Annotation of FDA Label for anifrolumab and IFNAR1	FDA	On FDA Biomarker List								anifrolumab	IFNAR1		8/14/2023	Anifrolumab a monoclonal antibody that binds to subunit 1 of the type I interferon receptor (IFNAR1) and inhibits type I IFN signaling. Blockade of receptor mediated type I IFN signaling inhibits IFN responsive gene expression (gene signature) as well as downstream inflammatory and immunological processes.
https://www.pharmgkb.org/labelAnnotation/PA166293262	PA166293262	Annotation of FDA Label for adagrasib and KRAS	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		adagrasib	KRAS	rs121913530	9/1/2023	Adagrasib is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test. KRAS G12C is a protein change corresponding to a genetic change of rs121913530 G>T (see KRAS VIP) and the table in section KRAS Mutations and Testing.
https://www.pharmgkb.org/labelAnnotation/PA166252781	PA166252781	Annotation of FDA Label for fosdenopterin and MOCS1	FDA	On FDA Biomarker List	Testing Required							fosdenopterin	MOCS1		8/22/2023	The FDA-approved drug label for fosdenopterin (NULIBRY) stated that it is cyclic pyranopterin monophosphate (cPMP) indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A. Patients with MoCD Type A have mutations in the MOCS1 gene leading to deficient MOCS1A/B dependent synthesis of the intermediate substrate, cPMP.
https://www.pharmgkb.org/labelAnnotation/PA166293401	PA166293401	Annotation of FDA Label for futibatinib and FGFR2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		futibatinib	FGFR2		10/11/2023	Futibatinib is kinase inhibitor of FGFRs, FDA indicated for intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.
https://www.pharmgkb.org/labelAnnotation/PA166182786	PA166182786	Annotation of FDA Label for tolazamide and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	tolazamide	G6PD		8/25/2023	The FDA-approved drug label for tolazamide states that, due to the risk of hemolytic anemia, caution should be used when administering tolazamide to patients with G6PD deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166184561	PA166184561	Annotation of FDA Label for ramucirumab and KRAS	FDA	On FDA Biomarker List						Cancer Genome		ramucirumab	KRAS		12/5/2023	The FDA-approved drug label for ramucirumab (CYRAMZA) states that KRAS status testing was used to stratify patients in the RAISE (NCT01183780) clinical trial of ramucirumab in metastatic colorectal cancer.
https://www.pharmgkb.org/labelAnnotation/PA166268881	PA166268881	Annotation of FDA Label for belzutifan and VHL	FDA	On FDA Biomarker List								belzutifan	VHL		8/5/2024	Belzutifan is a treatment for adult patients with the autosomal von Hippel-Lindau (VHL) disease - related to mutations in the VHL gene - who require therapy for tumors than have become cancerous.
https://www.pharmgkb.org/labelAnnotation/PA166170958	PA166170958	Annotation of FDA Label for valproic acid and POLG	FDA	On FDA Biomarker List	Testing Required	Prescribing Info		Alternate Drug			Prescribing	valproic acid	POLG		8/22/2023	The FDA-approved drug label for valproic acid (Depakene) states that it is contraindicated in individuals with known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG), and suspected POLG-related disorders in children under 2 years old.
https://www.pharmgkb.org/labelAnnotation/PA166169880	PA166169880	Annotation of FDA Label for cerliponase alfa and TPP1	FDA	On FDA Biomarker List								cerliponase alfa	TPP1		8/5/2024	Cerliponase alfa (BRINEURA) is indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166236221	PA166236221	Annotation of FDA Label for risdiplam and SMN1, SMN2	FDA	On FDA Biomarker List	Testing Required							risdiplam	SMN1; SMN2		8/21/2023	The FDA-approved label for risdiplam (EVRYSDI) implies that genetic testing for SMN1 and SMN2 is required since the drug is only approved for treatment of spinal muscular atrophy. The label discusses clinical studies were for Type 1, 2 and 3 spinal muscular atrophy which involve variants in the genes SMN1 and SMN2 [Article:11791208].
https://www.pharmgkb.org/labelAnnotation/PA166184565	PA166184565	Annotation of FDA Label for tafamidis and TTR	FDA	On FDA Biomarker List								tafamidis	TTR		8/24/2023	The FDA label for tafamidis (VYNDAQEL) and (VYNDAMAX) states is it indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM).
https://www.pharmgkb.org/labelAnnotation/PA166182755	PA166182755	Annotation of FDA Label for vincristine and ABL1, BCR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		vincristine	ABL1; BCR		8/31/2023	The FDA-approved drug label for vincristine (MARQIBO) states that it is indicated for the treatment of Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.
https://www.pharmgkb.org/labelAnnotation/PA166104923	PA166104923	Annotation of FDA Label for exemestane and ESR1, ESR2, PGR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		exemestane	ESR1; ESR2; PGR		9/1/2023	Exemestane (AROMASIN) is an aromatase inhibitor indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy, or for treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
https://www.pharmgkb.org/labelAnnotation/PA166268941	PA166268941	Annotation of FDA Label for mobocertinib and EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		mobocertinib	EGFR		9/1/2023	Mobocertinib is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
https://www.pharmgkb.org/labelAnnotation/PA166159963	PA166159963	Annotation of FDA Label for blinatumomab and ABL1, BCR, CD19	FDA	On FDA Biomarker List						Cancer Genome		blinatumomab	ABL1; BCR; CD19		5/21/2024	The FDA-approved drug label for blinatumomab (BLINCYTO) states that it is indicated for treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) or relapsed or refractory B-cell precursor ALL. Blinatumomab mechanism of action is via CD19. The label notes whether patients were Philadelphia chromosome-positive (i.e. having the product of the BCR ABL1 gene fusion) or negative in the Clinical Studies section.
https://www.pharmgkb.org/labelAnnotation/PA166127662	PA166127662	Annotation of FDA Label for arformoterol and CYP2D6, UGT1A1	FDA	On FDA Biomarker List	No Clinical PGx							arformoterol	CYP2D6; UGT1A1			The FDA-approved label for arformoterol (BROVANA) states those with reduced CYP2D6 and/or UGT1A1 activity do not show changes in their systemic exposure to the drug compared to those with normal CYP2D6 and/or UGT1A1 enzymatic activities.
https://www.pharmgkb.org/labelAnnotation/PA166105010	PA166105010	Annotation of FDA Label for duloxetine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							duloxetine	CYP2D6			Duloxetine (CYMBALTA) is metabolized by CYP2D6 and CYP1A2. The FDA-approved drug label notes that concomitant administration of duloxetine and fluvoxamine (a potent CYP1A2 inhibitor) to CYP2D6 poor metabolizers resulted in a 6-fold increase in duloxetine AUC and Cmax.
https://www.pharmgkb.org/labelAnnotation/PA166268961	PA166268961	Annotation of FDA Label for zanubrutinib and MYD88, TP53	FDA	On FDA Biomarker List						Cancer Genome		zanubrutinib	MYD88; TP53	rs387907272	10/24/2023	Zanubrutinib is indicated for Mantle cell lymphoma (MCL), Relapsed or refractory marginal zone lymphoma, Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and Waldenström’s macroglobulinemia. The label describes that clinical trials included patients with Waldenström’s macroglobulinemia that had variant and reference MYD88 LEU265PRO (rs387907272), as well as patients with TP53 mutations, but no variants or mutations are included in the indication or dosage text.
https://www.pharmgkb.org/labelAnnotation/PA166177518	PA166177518	Annotation of FDA Label for sofosbuvir / velpatasvir / voxilaprevir and IFNL3	FDA	On FDA Biomarker List								sofosbuvir / velpatasvir / voxilaprevir	IFNL3		8/24/2023	VOSEVI (sofosbuvir, velpatasvir and voxilaprevir) is indicated for treatment of adult patients with chronic hepatitis C virus (HCV) infection. Within the clinical studies section, the label mentions frequency of the rs12979860 non-CC genotype.
https://www.pharmgkb.org/labelAnnotation/PA166190643	PA166190643	Annotation of FDA Label for trastuzumab deruxtecan and ERBB2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		trastuzumab deruxtecan	ERBB2		8/31/2023	Fam-trastuzumab deruxtecan-nxki (ENHERTU) is a HER2-directed antibody and topoisomerase inhibitor conjugate used for the treatment of adult patients with HER2-positive (ERBB2) cancers.
https://www.pharmgkb.org/labelAnnotation/PA166182762	PA166182762	Annotation of FDA Label for elagolix and SLCO1B1	FDA	On FDA Biomarker List	Informative PGx							elagolix	SLCO1B1	rs4149056	7/19/2024	The FDA-approved drug label for elagolix (ORILISSA) states that higher plasma concentrations of the drug have been observed in patients who have two reduced function alleles of the gene that encodes OATP 1B1 (SLCO1B1 521T>C, rs4149056 variant).
https://www.pharmgkb.org/labelAnnotation/PA166104792	PA166104792	Annotation of FDA Label for fulvestrant and ESR1, ESR2, PGR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		fulvestrant	ESR1; ESR2; PGR		9/1/2023	Fulvestrant (FASLODEX) is used to treat hormone-receptor positive breast cancer.
https://www.pharmgkb.org/labelAnnotation/PA166163439	PA166163439	Annotation of FDA Label for elbasvir / grazoprevir and IFNL3	FDA	On FDA Biomarker List								elbasvir / grazoprevir	IFNL3		9/6/2023	Elbasvir and grazoprevir (ZEPATIER) is indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 or 4 infection in adults. It is indicated for use with ribavirin in certain patient populations. Within the clinical studies section, the label mentions frequency of the rs12979860 non-CC genotype.
https://www.pharmgkb.org/labelAnnotation/PA166160005	PA166160005	Annotation of FDA Label for dasabuvir / ombitasvir / paritaprevir / ritonavir and IFNL3	FDA	On FDA Biomarker List								dasabuvir / ombitasvir / paritaprevir / ritonavir	IFNL3		9/6/2023	The FDA-approved drug label for VIEKIRA PAK (ombitasvir, paritaprevir, ritonavir, and dasabuvir) notes the percentage of subjects in clinical studies that carried the IL28B rs12979860 non-CC genotype. However, the label does not discuss the effect of this variant or genetic testing.
https://www.pharmgkb.org/labelAnnotation/PA166251501	PA166251501	Annotation of FDA Label for cabotegravir / rilpivirine and UGT1A1	FDA	On FDA Biomarker List	No Clinical PGx							cabotegravir / rilpivirine	UGT1A1		12/5/2023	The FDA label for cabotegravir / rilpivirine (CABENUVA) describes that cabotegravir is primarily metabolized by UGT1A1 but states that UGT1A1 polymorphisms did not have significant clinical effects on its pharmacokinetics.
https://www.pharmgkb.org/labelAnnotation/PA166122589	PA166122589	Annotation of FDA Label for afutuzumab and MS4A1	FDA	Formerly on FDA Biomarker List						Cancer Genome		afutuzumab	MS4A1		8/14/2023	Afutuzumab (GAZYVA; obinutuzumab) is used in combination with chlorambucil in patients with chronic lymphocytic leukemia who are previously untreated. The drug is a CD20-directed cytolytic monoclonal antibody, but there is no association with genetic variation within the coding gene, MS4A1, and therefore no mention of genetic testing in the drug label.
https://www.pharmgkb.org/labelAnnotation/PA166105012	PA166105012	Annotation of FDA Label for escitalopram and CYP2C19	FDA	On FDA Biomarker List	Informative PGx							escitalopram	CYP2C19		10/24/2023	The FDA-approved drug label for escitalopram (Lexapro) notes that escitalopram exposure under a supratherapeutic 30 mg dose is similar to the steady state concentrations expected in CYP2C19 poor metabolizers following a therapeutic dose of 20 mg.
https://www.pharmgkb.org/labelAnnotation/PA166178724	PA166178724	Annotation of FDA Label for neratinib and ESR1, ESR2, PGR	FDA	On FDA Biomarker List						Cancer Genome		neratinib	ESR1; ESR2; PGR		8/15/2023	Neratinib (NERLYNX) is indicated for the treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer. The label notes the percentages of patients in clinical studies who had hormone receptor positive disease.
https://www.pharmgkb.org/labelAnnotation/PA166182764	PA166182764	Annotation of FDA Label for emapalumab and PRF1, RAB27A, SH2D1A, STX11, STXBP2, UNC13D, XIAP	FDA	On FDA Biomarker List								emapalumab	PRF1; RAB27A; SH2D1A; STX11; STXBP2; UNC13D; XIAP		8/17/2023	Emapalumab (GAMIFANT) is indicated for hemophagocytic lymphohistiocytosis (HLH): the FDA label lists some of the genes associated with HLH in patients in the NI-0501-04 clinical study.
https://www.pharmgkb.org/labelAnnotation/PA166105070	PA166105070	Annotation of FDA Label for anastrozole and ESR1, ESR2, PGR	FDA	On FDA Biomarker List						Cancer Genome		anastrozole	ESR1; ESR2; PGR		8/6/2024	Anastrozole (ARIMIDEX) is an aromatase inhibitor indicated for use in postmenopausal women as an adjuvant treatment for hormone receptor-positive early breast cancer, as a first-line treatment for hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer, or to treat advanced breast cancer with disease progression following tamoxifen therapy.
https://www.pharmgkb.org/labelAnnotation/PA166163431	PA166163431	Annotation of FDA Label for isosorbide mononitrate and CYB5R1, CYB5R2, CYB5R3, CYB5R4	FDA	On FDA Biomarker List	Informative PGx							isosorbide mononitrate	CYB5R1; CYB5R2; CYB5R3; CYB5R4		7/30/2024	Isosorbide mononitrate (monoket) is indicated for the prevention and treatment of angina pectoris due to coronary artery disease. The FDA-approved drug label provides information about patients with cytochrome b5 reductase activity and risk for methemoglobinemia.
https://www.pharmgkb.org/labelAnnotation/PA166182742	PA166182742	Annotation of FDA Label for talazoparib and ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11, NBN, PALB2, RAD51C	FDA	On FDA Biomarker List	Testing Required							talazoparib	ATM; ATR; BRCA1; BRCA2; CDK12; CHEK2; FANCA; MLH1; MRE11; NBN; PALB2; RAD51C		8/13/2024	The FDA-approved label for talazoparib (TALZENNA) states that it is indicated for use in patients with deleterious or suspected deleterious germline BRCA mutations and HER2-negative locally advanced or metastatic breast cancer, and in combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCPRC). Select patients for the treatment with talazoparib based on the presence of alterations in genes directly or indirectly involved in HRR.
https://www.pharmgkb.org/labelAnnotation/PA166182738	PA166182738	Annotation of FDA Label for siponimod and CYP2C9	FDA	On FDA Biomarker List	Testing Required	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	siponimod	CYP2C9	CYP2C9*2; CYP2C9*3	3/7/2024	The FDA-approved drug label for siponimod (MAYZENT) states that it is indicated for treatment of relapsing forms of multiple sclerosis (MS). Siponimod is contraindicated in patients with the CYP2C9*3/*3 genotype. Patients with the CYP2C9*1/*1, *1/*2 or *2/*2 genotypes should be given a daily maintenance dose of 2mg starting on Day 6 of treatment, while patients with the *1/*3 or *2/*3 genotypes should be given a daily maintenance dose of 1mg starting on Day 5 of treatment.
https://www.pharmgkb.org/labelAnnotation/PA166160056	PA166160056	Annotation of FDA Label for cholic acid and AKR1D1, AMACR, CYP27A1, CYP7A1, DHCR7, HSD3B2	FDA	On FDA Biomarker List								cholic acid	AKR1D1; AMACR; CYP27A1; CYP7A1; DHCR7; HSD3B2		8/5/2024	The FDA-approved drug label for cholic acid (CHOLBAM) states that one of the indications of the drug is for bile acid synthesis disorders due to single enzyme defects. This includes deficiencies in the 3β-HSD (HSD3B2), AKR1D1 (AKR1D1), CYP27A1 (CYP27A1), AMACR (AMACR), and CYP7A1 (CYP7A1) enzymes.
https://www.pharmgkb.org/labelAnnotation/PA166182730	PA166182730	Annotation of FDA Label for amphetamine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							amphetamine	CYP2D6		7/26/2024	The FDA-approved drug label for amphetamine (ADZENYS XR-ODT) states that CYP2D6 is known to be involved with formation of 4-hydroxy-amphetamine. Since CYP2D6 is genetically polymorphic, population variations in amphetamine metabolism are a possibility.
https://www.pharmgkb.org/labelAnnotation/PA166184539	PA166184539	Annotation of FDA Label for paliperidone and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							paliperidone	CYP2D6			The FDA-approved drug label for paliperidone (INVEGA) states that population pharmacokinetic analyses found no difference in exposure or clearance of paliperidone between extensive metabolizers and poor metabolizers of CYP2D6 substrates.
https://www.pharmgkb.org/labelAnnotation/PA166104778	PA166104778	Annotation of FDA Label for brentuximab vedotin and ALK	FDA	On FDA Biomarker List						Cancer Genome		brentuximab vedotin	ALK		9/7/2023	Brentuximab vedotin (ADCETRIS) is a CD30-directed antibody-drug conjugate indicated for treatment of patients with various lymphomas. The Clinical Studies section of the label notes the percentage of patients who were anaplastic lymphoma kinase (ALK) negative and positive in certain trials.
https://www.pharmgkb.org/labelAnnotation/PA166225001	PA166225001	Annotation of FDA Label for lutetium (177Lu) oxodotreotide and SSTR1, SSTR2, SSTR3, SSTR4, SSTR5	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		lutetium (177Lu) oxodotreotide	SSTR1; SSTR2; SSTR3; SSTR4; SSTR5		8/8/2024	The FDA label for lutetium Lu 177 dotatate (LUTATHERA) states that LUTATHERA is a radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adult and pediatric patients 12 years and older.
https://www.pharmgkb.org/labelAnnotation/PA166114923	PA166114923	Annotation of FDA Label for lomitapide	FDA	On FDA Biomarker List								lomitapide			9/7/2023	Lomitapide (JUXTAPID) is FDA indicated for the treatment of homozygous familial hypercholesterolemia (HoFH). The FDA lists Nonspecific (Homozygous Familial Hypercholesterolemia) as the biomarker. Diagnostic testing for LDL receptor alleles or function is only mentioned in the context of clinical trials, but testing for HoFH could include screening for variants in the LDLR, APOB and PCSK9 genes (see the Genetic Test Registry for more information).
https://www.pharmgkb.org/labelAnnotation/PA166114317	PA166114317	Annotation of FDA Label for sodium phenylbutyrate and ASS1, CPS1, OTC	FDA	On FDA Biomarker List								sodium phenylbutyrate	ASS1; CPS1; OTC		8/13/2024	Sodium phenylbutyrate (BUPHENYL) is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).
https://www.pharmgkb.org/labelAnnotation/PA166293701	PA166293701	Annotation of FDA Label for levothyroxine and IRS4, NKX2-5, PAX8, TBL1X, TSHB	FDA	On FDA Biomarker List								levothyroxine	IRS4; NKX2-5; PAX8; TBL1X; TSHB		8/8/2024	The FDA table of biomarkers lists Congenital Hypothyroidism as a biomarker for levothyroxine but does not give specific genes. There are several genes associated with Congenital Hypothyroidism although not all types are responsive to levothyroxine treatment. OMIM lists PAX8, IRS4, NKX2-5, TSHB and TBL1X as genes associated with Congenital hypothyroidism where endogenous T4 is low/absent.
https://www.pharmgkb.org/labelAnnotation/PA166169882	PA166169882	Annotation of FDA Label for deutetrabenazine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	deutetrabenazine	CYP2D6		9/7/2023	Deutetrabenazine (AUSTEDO) is indicated for treatment of chorea associated with Huntington's disease. The maximum recommended dosage in poor CYP2D6 metabolizers is 36 mg per day (i.e. 18 mg twice daily).
https://www.pharmgkb.org/labelAnnotation/PA166169918	PA166169918	Annotation of FDA Label for midostaurin and FLT3	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		midostaurin	FLT3		8/31/2023	The FDA-approved label for midostaurin (RYDAPT) states that it is indicated for the treatment of adult patients with acute myeloid leukemia that is FLT3 mutation-positive as detected by an FDA-approved test.
https://www.pharmgkb.org/labelAnnotation/PA166104900	PA166104900	Annotation of FDA Label for pegloticase and G6PD	FDA	On FDA Biomarker List	Testing Required	Prescribing Info		Alternate Drug			Prescribing	pegloticase	G6PD		3/31/2023	The FDA-approved drug label for pegloticase (KRYSTEXXA) states that patients at risk for G6PD deficiency should be screened prior to starting treatment, and that the drug should not be administered to patients with G6PD deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166182961	PA166182961	Annotation of FDA Label for duvelisib	FDA	On FDA Biomarker List						Cancer Genome		duvelisib			8/15/2023	Duvelisib (COPIKTRA) is indicated for various leukemia types and the FDA label mentions that some patients had the 17p chromosomal deletion.
https://www.pharmgkb.org/labelAnnotation/PA166184636	PA166184636	Annotation of FDA Label for tipiracil / trifluridine and ERBB2, KRAS	FDA	On FDA Biomarker List						Cancer Genome		tipiracil / trifluridine	ERBB2; KRAS		8/27/2023	The FDA-approved drug label for tipiracil / trifluridine (Lonsurf) states that it is indicated for patients who have failed other targeted therapies including those for KRAS negative metastatic colorectal cancer and HER2 positive (ERBB2) metastatic gastric or gastroesophageal junction cancers. Therefore testing was required for those prior therapies.
https://www.pharmgkb.org/labelAnnotation/PA166163414	PA166163414	Annotation of FDA Label for ustekinumab and IL12A, IL12B, IL23A	FDA	On FDA Biomarker List								ustekinumab	IL12A; IL12B; IL23A		8/29/2023	The FDA-approved drug label for ustekinumab (STELARA) states that serious infections from mycobacteria, salmonella and BCG vaccinations have been reported in patients who are genetically deficient in IL-12/IL-23, and that diagnostic tests for these infections should be considered as dictated by clinical circumstances.
https://www.pharmgkb.org/labelAnnotation/PA166177486	PA166177486	Annotation of FDA Label for enasidenib and IDH2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		enasidenib	IDH2		8/31/2023	Enasidenib (IDHIFA) is an isocitrate dehydrogenase-2 (IDH2) inhibitor, indicated for the treatment of adult patients with acute myeloid leukemia with an IDH2 mutation.
https://www.pharmgkb.org/labelAnnotation/PA166123487	PA166123487	Annotation of FDA Label for eliglustat and CYP2D6	FDA	On FDA Biomarker List	Testing Required	Prescribing Info	Dosing Info		Other Prescribing Guidance		Prescribing	eliglustat	CYP2D6		8/28/2023	The FDA-approved drug label for eliglustat (CERDELGA) states that it is indicated for patients with Gaucher disease type 1. CYP2D6 intermediate and extensive metabolizers have a recommended dose of 84 mg twice daily, while poor metabolizers have a recommended dose of 84 mg once daily. The label notes that CYP2D6 ultra-rapid metabolizers may not achieve adequate concentrations of eliglustat to achieve a therapeutic effect.
https://www.pharmgkb.org/labelAnnotation/PA166177483	PA166177483	Annotation of FDA Label for desvenlafaxine and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							desvenlafaxine	CYP2D6		8/15/2023	Desvenlafaxine (PRISTIQ) is indicated for the treatment of adults with major depressive disorder. The label notes that the pharmacokinetics of the drug are similar in CYP2D6 poor metabolizers and CYP2D6 extensive metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166151878	PA166151878	Annotation of FDA Label for lapatinib and HLA-DQA1, HLA-DRB1	FDA	On FDA Biomarker List	Informative PGx							lapatinib	HLA-DQA1; HLA-DRB1	HLA-DQA1*02:01; HLA-DRB1*07:01	8/24/2020	Lapatinib (TYKERB) is indicated for patients with breast cancer whose tumors overexpress HER2 (ERBB2). The FDA-approved drug label for lapatinib notes that the HLA-DQA1*02:01 and HLA-DRB1*07:01 alleles have been associated with hepatotoxicity in individuals received the drug, but does not discuss genetic testing for these alleles.
https://www.pharmgkb.org/labelAnnotation/PA166160040	PA166160040	Annotation of FDA Label for Parathyroid Hormones And Analogues and CASR	FDA	On FDA Biomarker List								Parathyroid Hormones And Analogues	CASR		8/23/2023	The FDA-approved drug label for parathyroid hormone (NATPARA) states that it was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor (CASR) mutations.
https://www.pharmgkb.org/labelAnnotation/PA166122594	PA166122594	Annotation of FDA Label for sofosbuvir and IFNL3	FDA	On FDA Biomarker List								sofosbuvir	IFNL3	rs12979860	8/24/2023	Sofosbuvir (SOVALDI) is indicated for the treatment of chronic hepatitis C in combination with ribavirin and/or peg-interferon alfa. The FDA-approved drug label for sofosbuvir contains information regarding a genetic variant near the IFNL3 gene (IL28B, rs12979860, a C to T change). Though the sofosbuvir label itself does not discuss why this variant is relevant, literature evidence has shown that this variant is a strong predictor of response to peginterferon alfa and ribavirin treatment.
https://www.pharmgkb.org/labelAnnotation/PA166182280	PA166182280	Annotation of FDA Label for dacomitinib and EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		dacomitinib	EGFR	rs121434568	8/31/2023	The FDA-approved drug label for dacomitinib (VIZIMPRO) states that it is indicated for the treatment of patients with metastatic non-small cell lung cancer with EGFR exon 19 deletion or exon 21 L858R mutations as detected by an FDA-approved test.
https://www.pharmgkb.org/labelAnnotation/PA166179847	PA166179847	Annotation of FDA Label for ivacaftor / tezacaftor and CFTR	FDA	On FDA Biomarker List	Testing Required							ivacaftor / tezacaftor	CFTR	rs113993958; rs113993960; rs115545701; rs11971167; rs121908752; rs121908753; rs121909020; rs141033578; rs150212784; rs186045772; rs202179988; rs368505753; rs397508256; rs397508288; rs397508387; rs397508442; rs397508513; rs397508537; rs397508759; rs397508761; rs74551128; rs75039782; rs75541969; rs76151804; rs77834169; rs77932196	10/6/2023	The FDA-approved drug label for ivacaftor and tezacaftor combination (SYMDEKO) states that it is indicated for treatment of cystic fibrosis in patients age 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.
https://www.pharmgkb.org/labelAnnotation/PA166105148	PA166105148	Annotation of FDA Label for glipizide and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	glipizide	G6PD		8/25/2023	The FDA-approved drug label for glipizide (GLUCOTROL) states that caution should be used in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency due to the risk for hemolytic anemia, and that a non-sulfonylurea alternative should be considered in this subset of patients. G6PD deficiency is a condition caused by variants in the G6PD gene which can be determined by enzymatic or genetic tests, however the drug label does not specifically mention testing.
https://www.pharmgkb.org/labelAnnotation/PA166105113	PA166105113	Annotation of FDA Label for donepezil and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							donepezil	CYP2D6			The FDA-approved drug label for donepezil (ARICEPT) states that it is metabolized by the CYP2D6 and CYP3A4 enzymes, and that there are differences in clearance values among CYP2D6 poor, extensive and ultra-rapid metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166182021	PA166182021	Annotation of FDA Label for amifampridine phosphate and NAT2	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	amifampridine phosphate	NAT2		10/4/2019	The FDA-approved drug label for amifampridine phosphate (FIRDAPSE) states that NAT2 poor metabolizers have higher concentrations of the drug as compared to normal metabolizers, and that the drug should be initiated at the lowest recommended starting dosage in these patients.
https://www.pharmgkb.org/labelAnnotation/PA166170939	PA166170939	Annotation of FDA Label for trastuzumab and ESR1, ESR2, PGR	FDA	On FDA Biomarker List						Cancer Genome		trastuzumab	ESR1; ESR2; PGR		8/29/2023	Trastuzumab (Herceptin) is used for the treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. The label also notes overall survival hazard ratios based on whether patients had hormone receptor-positive disease or hormone receptor-negative disease.
https://www.pharmgkb.org/labelAnnotation/PA166191561	PA166191561	Annotation of FDA Label for nivolumab and ALK, CD274, EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		nivolumab	ALK; CD274; EGFR		8/9/2024	The FDA-approved drug label for nivolumab (OPDIVO) stated that it is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of a variety of cancers, including patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test. Nivolumab is approved as first line therapy for patients with no EGFR and ALK genomic tumor aberrations and for patients with EGFR and ALK genomic tumor aberrations who have disease progression on FDA-approved therapies. It is also approved for adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, as a single agent or in combination with ipilimumab.
https://www.pharmgkb.org/labelAnnotation/PA166160133	PA166160133	Annotation of FDA Label for palbociclib and ERBB2, ESR1, ESR2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		palbociclib	ERBB2; ESR1; ESR2		9/1/2023	The FDA-approved drug label for palbociclib (IBRANCE) states that it is indicated for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with either an aromatase inhibitor or fulvestrant.
https://www.pharmgkb.org/labelAnnotation/PA166313381	PA166313381	Annotation of FDA Label for polatuzumab vedotin and BCL2, BCL6, MYC	FDA	On FDA Biomarker List						Cancer Genome		polatuzumab vedotin	BCL2; BCL6; MYC			The FDA label for polatuzumab vedotin discusses a study where some patients had MYC, BCL2 and/or BCL6 rearrangements.
https://www.pharmgkb.org/labelAnnotation/PA166114930	PA166114930	Annotation of FDA Label for omacetaxine and ABL1, BCR	FDA	On FDA Biomarker List						Cancer Genome		omacetaxine	ABL1; BCR		8/12/2024	"The FDA-approved drug label for omacetaxine (homoharringtonine; SYNRIBO) notes that it is intended for adults with chronic or accelerated phase chronic myeloid leukemia (CML). The majority of patients with CML are positive for the Philadelphia chromosome (BCR-ABL1 gene fusion).
August 2024: Please note that omacetaxine mepesuccinate (SYNRIBO) is currently listed as Discontinued; however, the drug is still included in the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling."
https://www.pharmgkb.org/labelAnnotation/PA166314003	PA166314003	Annotation of FDA Label for odevixibat and JAG1, NOTCH2	FDA	On FDA Biomarker List								odevixibat	JAG1; NOTCH2			The FDA label for odevixibat (Bylvay) states that BYLVAY is an ileal bile acid transporter (IBAT) inhibitor indicated for Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). JAG1 and NOTCH2 mutations implicated in ALGS are mentioned in the clinical studies section.
https://www.pharmgkb.org/labelAnnotation/PA166313361	PA166313361	Annotation of FDA Label for elacestrant and ERBB2, ESR1	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		elacestrant	ERBB2; ESR1		9/27/2023	Elacestrant is FDA approved for treatment of Breast Cancer in patients who have variants in ESR1 but do not have ERBB2 variants or overexpression (HER-2 negative). The label references FDA-approved tests for detection of ESR1 mutations.
https://www.pharmgkb.org/labelAnnotation/PA166159962	PA166159962	Annotation of FDA Label for alirocumab and LDLR	FDA	Formerly on FDA Biomarker List								alirocumab	LDLR		2/8/2024	Although the alirocumab (PRALUENT) drug label does not specifically mention genetic testing, one of the indications listed is for the treatment of adults with heterozygous familial hypercholesterolemia. Familial hypercholesterolemia is commonly caused by mutations in the LDLR gene.
https://www.pharmgkb.org/labelAnnotation/PA166114921	PA166114921	Annotation of FDA Label for ibritumomab and MS4A1	FDA	Formerly on FDA Biomarker List						Cancer Genome		ibritumomab	MS4A1		9/28/2023	Ibritumomab tiuxetan (Zevalin) is used to treat patients with B-cell non-Hodgkin's lymphoma. The drug is a CD20-directed radiotherapeutic antibody, but there is no association with genetic variation within the coding gene, MS4A1, and therefore no mention of genetic testing in the drug label.
https://www.pharmgkb.org/labelAnnotation/PA166281101	PA166281101	Annotation of HCSC Label for eculizumab and AQP4, CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE	HCSC									eculizumab	AQP4; CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE		9/28/2023	"Eculizumab (SOLIRIS) is a monoclonal antibody that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9 and free C5a.
Soliris is indicated for the treatment of patients with paroxysmal nocturnal haemoglobinuria (PNH), atypical haemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive, and neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody-positive.
The presence of antibodies against the AQP4 protein and AchR proteins are biomarkers for treatment indication."
https://www.pharmgkb.org/labelAnnotation/PA166281121	PA166281121	Annotation of EMA Label for efgartigimod alfa and CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE	EMA									efgartigimod alfa	CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE		9/28/2023	Efgartigimod alfa (Vyvgart) is a neonatal Fc receptor blocker indicated as an add-on to standard therapy for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.
https://www.pharmgkb.org/labelAnnotation/PA166273541	PA166273541	Annotation of EMA Label for inebilizumab and AQP4	EMA									inebilizumab	AQP4		9/28/2023	Inebilizumab is EMA indicated for Neuromyelitis Optica spectrum disorders who test positive for anti-aquaporin-4 antibodies. The relationship is not with the AQP4 gene but this is the biomarker listed in the FDA table.
https://www.pharmgkb.org/labelAnnotation/PA166272761	PA166272761	Annotation of EMA Label for satralizumab and AQP4	EMA									satralizumab	AQP4		9/28/2023	Satralizumab is an interleukin-6 receptor (IL6R) antagonist indicated for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 IgG (AQP4-IgG) seropositive.
https://www.pharmgkb.org/labelAnnotation/PA166272123	PA166272123	Annotation of EMA Label for zanubrutinib and MYD88	EMA							Cancer Genome		zanubrutinib	MYD88		9/28/2023	Zanubrutinib is indicated for Waldenström’s macroglobulinemia, some patients with Waldenström’s macroglobulinemia have variant MYD88.
https://www.pharmgkb.org/labelAnnotation/PA166273081	PA166273081	Annotation of HCSC Label for zanubrutinib and MYD88	HCSC							Cancer Genome		zanubrutinib	MYD88		9/28/2023	Zanubrutinib is indicated for Waldenström’s macroglobulinemia, some patients with Waldenström’s macroglobulinemia have variant MYD88.
https://www.pharmgkb.org/labelAnnotation/PA166277881	PA166277881	Annotation of FDA Label for ravulizumab and CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE	FDA	On FDA Biomarker List								ravulizumab	CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE		9/28/2023	Ravulizumab-cwvz is a monoclonal antibody against complement protein C5 FDA approved for treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria, adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome and adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. The relationship is not with the AchR genes or proteins but these are the biomarkers listed in the FDA table.
https://www.pharmgkb.org/labelAnnotation/PA166182758	PA166182758	Annotation of FDA Label for goserelin and ESR1, ESR2, PGR	FDA	On FDA Biomarker List						Cancer Genome		goserelin	ESR1; ESR2; PGR		9/28/2023	The FDA-approved label for goserelin (ZOLADEX) states that it is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for 1) combination use with flutamide for the management of locally confined carcinoma of the prostate, 2) palliative treatment of advanced carcinoma of the prostate or advanced breast cancer in pre- and perimenopausal women, 3) management of endometriosis, 4) use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding.
https://www.pharmgkb.org/labelAnnotation/PA166272141	PA166272141	Annotation of EMA Label for voxelotor and HBB	EMA									voxelotor	HBB		12/11/2023	Voxelotor (Oxbryta) is indicated by the EMA European Public Assessment Report (EPAR) for the treatment of haemolytic anaemia due to sickle cell disease (SCD) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.
https://www.pharmgkb.org/labelAnnotation/PA166278621	PA166278621	Annotation of HCSC Label for satralizumab and AQP4	HCSC									satralizumab	AQP4		9/28/2023	Satralizumab is HCSC approved for treatment of neuromyelitis optica spectrum disorders (NMOSD) in adult and adolescent patients who are anti-aquaporin 4 (AQP4) seropositive. The AQP4 gene or gene product is not discussed only anti-aquaporin antibodies.
https://www.pharmgkb.org/labelAnnotation/PA166274001	PA166274001	Annotation of EMA Label for blinatumomab and ABL1, BCR, CD19	EMA							Cancer Genome		blinatumomab	ABL1; BCR; CD19		5/21/2024	The EMA-approved drug label for blinatumomab (BLINCYTO) states that it is indicated as monotherapy for the treatment of adults and pediatric patients aged 1 year or older with CD19 positive relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
https://www.pharmgkb.org/labelAnnotation/PA166316281	PA166316281	Annotation of FDA Label for trofinetide and MECP2	FDA	On FDA Biomarker List								trofinetide	MECP2			Trofinetide (DAYBUE) is indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older. Clinical studies were performed in patients with a diagnosis of typical Rett syndrome according to the Rett Syndrome Diagnostic Criteria with a documented disease-causing mutation in the MECP2 gene.
https://www.pharmgkb.org/labelAnnotation/PA166316301	PA166316301	Annotation of FDA Label for plazomicin and MT-RNR1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	plazomicin	MT-RNR1	rs267606617		"Plazomicin (ZEMDRI) is an aminoglycoside antibacterial indicated for the treatment of patients 18 years of age or older with Complicated Urinary Tract Infections (cUTI) including Pyelonephritis.
Cases of ototoxicity with aminoglycosides have been observed in patients with certain variants in the mitochondrially encoded 12S rRNA gene (MT-RNR1), particularly the m.1555A>G variant. In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies."
https://www.pharmgkb.org/labelAnnotation/PA166316321	PA166316321	Annotation of FDA Label for amikacin and MT-RNR1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	amikacin	MT-RNR1	rs267606617		"Amikacin (ARIKAYCE) is an aminoglycoside antibacterial indicated in adults who have limited or no alternative treatment options, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy.
Cases of ototoxicity with aminoglycosides have been observed in patients with certain variants in the mitochondrially encoded 12S rRNA gene (MT-RNR1), particularly the m.1555A>G variant. In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies."
https://www.pharmgkb.org/labelAnnotation/PA166316341	PA166316341	Annotation of FDA Label for tobramycin and MT-RNR1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	tobramycin	MT-RNR1	rs267606617		"Tobramycin (BETHKIS) is an inhaled aminoglycoside antibacterial indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa.
Cases of ototoxicity with aminoglycosides have been observed in patients with certain variants in the mitochondrially encoded 12S rRNA gene (MT-RNR1), particularly the m.1555A>G variant. In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies."
https://www.pharmgkb.org/labelAnnotation/PA166317541	PA166317541	Annotation of EMA Label for ganaxolone and CDKL5	EMA		Testing Required							ganaxolone	CDKL5			Ganaxolone is EMA indicated for pediatric and adult patients with CCD, cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder.
https://www.pharmgkb.org/labelAnnotation/PA166317601	PA166317601	Annotation of EMA Label for futibatinib and FGFR2	EMA		Testing Required					Cancer Genome		futibatinib	FGFR2	rs1057519045; rs1057519797	10/11/2023	Futibatinib is EMA indicated for intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements as determined by an appropriate diagnostic test.
https://www.pharmgkb.org/labelAnnotation/PA166317742	PA166317742	Annotation of EMA Label for margetuximab	EMA									margetuximab				N/A
https://www.pharmgkb.org/labelAnnotation/PA166184524	PA166184524	Annotation of FDA Label for alpelisib and ERBB2, ESR1, ESR2, PIK3CA	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		alpelisib	ERBB2; ESR1; ESR2; PIK3CA		8/31/2023	The FDA-approved drug label for alpelisib (PIQRAY) states that it is indicated for the treatment of patients with hormone receptor positive, HER-2 negative (ERBB2 negative) and PIK3CA-mutated breast neoplasms.
https://www.pharmgkb.org/labelAnnotation/PA166190261	PA166190261	Annotation of FDA Label for estradiol / progesterone and PROC, PROS1, SERPINC1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	estradiol / progesterone	PROC; PROS1; SERPINC1			Estradiol / progesterone (BIJUVA) is a combination of an estrogen and progesterone indicated in a woman with a uterus for the treatment of moderate to severe vasomotor symptoms due to menopause. It is contraindicated in patients with known protein C (PROC), protein S (PROS1), or antithrombin (SERPINC1) deficiency, or other known thrombophilic disorders.
https://www.pharmgkb.org/labelAnnotation/PA166251561	PA166251561	Annotation of FDA Label for casimersen and DMD	FDA	On FDA Biomarker List	Testing Required							casimersen	DMD		8/21/2023	Casimersen (AMONDYS 45) is FDA approved under accelerated approval for the treatment of Duchenne muscular dystrophy in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping.
https://www.pharmgkb.org/labelAnnotation/PA166251621	PA166251621	Annotation of FDA Label for viloxazine and SLCO1B1	FDA	On FDA Biomarker List								viloxazine	SLCO1B1		8/29/2023	"The viloxazine FDA label mentions that it is not an inhibitor or a substrate of ""OATP1B1*1a"". OATP1B1 is encoded by SLCO1B1 and likely OATP1B1*1a refers to the protein formed by the reference sequence of SLCO1B1, however this is not explained in the label."
https://www.pharmgkb.org/labelAnnotation/PA166182721	PA166182721	Annotation of FDA Label for erdafitinib and FGFR2, FGFR3	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		erdafitinib	FGFR2; FGFR3		8/31/2023	The FDA-approved label for erdafitinib (BALVERSA) states that it is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations and progressed during or following at least one line of prior platinum-containing chemotherapy.
https://www.pharmgkb.org/labelAnnotation/PA166159964	PA166159964	Annotation of FDA Label for olaparib and BRCA1, BRCA2, ERBB2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		olaparib	BRCA1; BRCA2; ERBB2		9/1/2023	The FDA-approved drug label for olaparib (Lynparza) states that it is indicated for treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, as well as deleterious or suspected deleterious germline or somatic BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. Lynparza is also indicated in combination with bevacizumab for the maintenance treatment of adult patients with HRD-positive Advanced Ovarian Cancer. The label also notes that patients with hormone receptor positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. It is also used as treatment for germline BRCA-mutated metastatic pancreatic adenocarcinoma and homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
https://www.pharmgkb.org/labelAnnotation/PA166251522	PA166251522	Annotation of FDA Label for cabotegravir / rilpivirine and HLA-B	FDA	On FDA Biomarker List								cabotegravir / rilpivirine	HLA-B		12/5/2023	Cabotegravir and Rilpivirine is listed with HLA-B in the Table of Pharmacogenomic Biomarkers in Drug Labeling however the only mention of HLA-B in the label is in conjunction with the FLAIR clinical trial which avoided abacavir in subjects that were HLA-B*5701.
https://www.pharmgkb.org/labelAnnotation/PA166268882	PA166268882	Annotation of FDA Label for belzutifan and CYP2C19, UGT2B17	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	belzutifan	CYP2C19; UGT2B17	CYP2C19*2; CYP2C19*3	9/28/2023	The FDA label for belzutifan has warnings that dual UGT2B17 and CYP2C19 Poor Metabolizers may be at increased risk for side effects such as anemia.
https://www.pharmgkb.org/labelAnnotation/PA166182722	PA166182722	Annotation of FDA Label for erdafitinib and CYP2C9	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	erdafitinib	CYP2C9	CYP2C9*3	10/9/2019	The FDA-approved label for erdafitinib (BALVERSA) states that it is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations and progressed during or following at least one line of prior platinum-containing chemotherapy. The label further states that erdafitinib plasma concentrations were predicted to be higher in patients with the CYP2C9*3/*3 genotype and to monitor for increased adverse reactions in patients who are known or suspected to have CYP2C9*3/*3 genotype.
https://www.pharmgkb.org/labelAnnotation/PA166316381	PA166316381	Annotation of FDA Label for gentamicin and MT-RNR1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	gentamicin	MT-RNR1	rs267606617		"Gentamicin is a water soluble antibiotic of the aminoglycoside group derived from Micromonospora purpurea.
Cases of ototoxicity with aminoglycosides have been observed in patients with certain variants in the mitochondrially encoded 12S rRNA gene (MT-RNR1), particularly the m.1555A>G variant. In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies."
https://www.pharmgkb.org/labelAnnotation/PA166316361	PA166316361	Annotation of FDA Label for streptomycin and MT-RNR1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	streptomycin	MT-RNR1	rs267606617		"Streptomycin is a bactericidal aminoglycoside antibiotic derived from Streptomyces griseus.
Cases of ototoxicity with aminoglycosides have been observed in patients with certain variants in the mitochondrially encoded 12S rRNA gene (MT-RNR1), particularly the m.1555A>G variant. In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies."
https://www.pharmgkb.org/labelAnnotation/PA166317641	PA166317641	Annotation of EMA Label for mavacamten and CYP2C19	EMA		Testing Required	Prescribing Info	Dosing Info				Prescribing	mavacamten	CYP2C19	CYP2C19*1; CYP2C19*2; CYP2C19*3	7/24/2024	Mavacamten is indicated for the treatment of obstructive hypertrophic cardiomyopathy. The EMA label requires CYP2C19 genotyping and gives dosing adjustments for metabolizer phenotypes. The label states that if genotyping results have not yet been returned that patients should follow dosing instructions for poor metabolisers.
https://www.pharmgkb.org/labelAnnotation/PA166313401	PA166313401	Annotation of FDA Label for lecanemab and APOE	FDA	On FDA Biomarker List	Testing Required							lecanemab	APOE	rs429358; rs7412	8/16/2024	The FDA label for lecanemab includes warnings that testing should be performed for ApoE E4/E4 as individuals with ApoE E4/E4 have increased risk for amyloid related imaging abnormalities (ARIA) when treated with lecanemab. The label does not give details on the E4/E4 allele.
https://www.pharmgkb.org/labelAnnotation/PA166317521	PA166317521	Annotation of EMA Label for asciminib and ABL1, BCR	EMA		Testing Required					Cancer Genome		asciminib	ABL1; BCR		8/26/2024	Asciminib is indicated for treatment of patients with Philadelphia chromosome positive CML, which has the BCR-ABL fusion, previously treated with two or more tyrosine kinase inhibitors. Activity against the T315I variant is mentioned in the Pharmacodynamic properties section but no prescribing changes are listed.
https://www.pharmgkb.org/labelAnnotation/PA166251601	PA166251601	Annotation of FDA Label for viloxazine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							viloxazine	CYP2D6			The FDA label for viloxazine mentions pharmacokinetic differences between CYP2D6 poor metabolizers and extensive metabolizers but does not state if this is clinically significant nor which genotypes were affected.
https://www.pharmgkb.org/labelAnnotation/PA166184754	PA166184754	Annotation of FDA Label for procainamide and NAT2	FDA	On FDA Biomarker List	Informative PGx							procainamide	NAT2		9/7/2023	The FDA label for procainamide states that it is metabolized by acetylation, and differences in exposure may occur between fast and slow acetylators. Acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene. However, the label never mentions any specific gene with regard to acetylator status.
https://www.pharmgkb.org/labelAnnotation/PA166235901	PA166235901	Annotation of FDA Label for margetuximab and FCGR2A, FCGR2B, FCGR3A	FDA	On FDA Biomarker List	No Clinical PGx							margetuximab	FCGR2A; FCGR2B; FCGR3A			The FDA label for margetuximab mentions that there may be interactions between the drug and FCGR3A (CD16A) and FCGR2B (CD32B) but that unspecified variant genotypes of FCGR3A (CD16A), FCGR2A (CD32A) and FCGR2B (CD32B) have no impact on clinical pharmacokinetics.
https://www.pharmgkb.org/labelAnnotation/PA166317442	PA166317442	Annotation of EMA Label for Ascorbic acid (vitamin C), plain	EMA									Ascorbic acid (vitamin C), plain				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317443	PA166317443	Annotation of EMA Label for desmopressin	EMA									desmopressin				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317444	PA166317444	Annotation of EMA Label for levothyroxine	EMA									levothyroxine				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317445	PA166317445	Annotation of EMA Label for olutasidenib	EMA									olutasidenib				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317461	PA166317461	Annotation of EMA Label for mirvetuximab soravtansine	EMA									mirvetuximab soravtansine				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317441	PA166317441	Annotation of EMA Label for adagrasib	EMA									adagrasib				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317481	PA166317481	Annotation of EMA Label for desflurane	EMA									desflurane				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317482	PA166317482	Annotation of EMA Label for isoflurane	EMA									isoflurane				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317483	PA166317483	Annotation of EMA Label for belzutifan	EMA									belzutifan				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317501	PA166317501	Annotation of EMA Label for sevoflurane	EMA									sevoflurane				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317502	PA166317502	Annotation of EMA Label for succinylcholine	EMA									succinylcholine				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317503	PA166317503	Annotation of EMA Label for escitalopram	EMA									escitalopram				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317504	PA166317504	Annotation of EMA Label for estradiol valerate	EMA									estradiol valerate				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317581	PA166317581	Annotation of EMA Label for capmatinib and MET	EMA		Testing Required					Cancer Genome		capmatinib	MET			Capmatinib is indicated for the treatment of non-small cell lung cancer (NSCLC) with variants in MET that result in exon 14 skipping as detected by a well validated test.
https://www.pharmgkb.org/labelAnnotation/PA166317741	PA166317741	Annotation of EMA Label for infigratinib	EMA									infigratinib				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317721	PA166317721	Annotation of EMA Label for casimersen	EMA									casimersen				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317701	PA166317701	Annotation of EMA Label for golodirsen	EMA									golodirsen				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317663	PA166317663	Annotation of EMA Label for fosphenytoin	EMA									fosphenytoin				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317662	PA166317662	Annotation of EMA Label for enflurane	EMA									enflurane				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317761	PA166317761	Annotation of EMA Label for metoclopramide	EMA									metoclopramide				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317762	PA166317762	Annotation of EMA Label for mivacurium	EMA									mivacurium				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317781	PA166317781	Annotation of EMA Label for mobocertinib	EMA									mobocertinib				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317782	PA166317782	Annotation of EMA Label for oliceridine	EMA									oliceridine				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317783	PA166317783	Annotation of EMA Label for oxymetazoline and tetracaine	EMA									oxymetazoline and tetracaine				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317681	PA166317681	Annotation of EMA Label for mitapivat and PKLR	EMA									mitapivat	PKLR	rs118204085	8/9/2024	Mitapivat is EMA indicated for the treatment of pyruvate kinase deficiency. The label discusses efficacy for mutation types in the PKLR gene including R479H (rs118204085).
https://www.pharmgkb.org/labelAnnotation/PA166317784	PA166317784	Annotation of EMA Label for phenytoin	EMA									phenytoin				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317801	PA166317801	Annotation of EMA Label for procainamide	EMA									procainamide				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317821	PA166317821	Annotation of EMA Label for tretinoin	EMA									tretinoin				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317841	PA166317841	Annotation of EMA Label for valproic acid	EMA									valproic acid				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317822	PA166317822	Annotation of EMA Label for viloxazine	EMA									viloxazine				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317842	PA166317842	Annotation of EMA Label for viltolarsen	EMA									viltolarsen				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317901	PA166317901	Annotation of HCSC Label for adagrasib	HCSC									adagrasib				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317902	PA166317902	Annotation of HCSC Label for Ascorbic acid (vitamin C), plain	HCSC									Ascorbic acid (vitamin C), plain				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317882	PA166317882	Annotation of HCSC Label for futibatinib	HCSC									futibatinib				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317903	PA166317903	Annotation of HCSC Label for mirvetuximab soravtansine	HCSC									mirvetuximab soravtansine				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317904	PA166317904	Annotation of HCSC Label for olutasidenib	HCSC									olutasidenib				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317905	PA166317905	Annotation of HCSC Label for pegloticase	HCSC									pegloticase				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317906	PA166317906	Annotation of HCSC Label for ganaxolone	HCSC									ganaxolone				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317883	PA166317883	Annotation of HCSC Label for mitapivat	HCSC									mitapivat				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317907	PA166317907	Annotation of HCSC Label for vutrisiran	HCSC									vutrisiran				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317884	PA166317884	Annotation of HCSC Label for casimersen	HCSC									casimersen				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317908	PA166317908	Annotation of HCSC Label for crizanlizumab-tmca	HCSC									crizanlizumab-tmca				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317941	PA166317941	Annotation of HCSC Label for lonafarnib	HCSC									lonafarnib				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317942	PA166317942	Annotation of HCSC Label for margetuximab	HCSC									margetuximab				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317961	PA166317961	Annotation of HCSC Label for mobocertinib	HCSC									mobocertinib				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317947	PA166317947	Annotation of HCSC Label for procainamide	HCSC									procainamide				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317962	PA166317962	Annotation of HCSC Label for ropeginterferon alfa-2b	HCSC									ropeginterferon alfa-2b				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317963	PA166317963	Annotation of HCSC Label for rucaparib	HCSC									rucaparib				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317949	PA166317949	Annotation of HCSC Label for viloxazine	HCSC									viloxazine				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317964	PA166317964	Annotation of HCSC Label for viltolarsen	HCSC									viltolarsen				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317950	PA166317950	Annotation of HCSC Label for voxelotor	HCSC									voxelotor				N/A
https://www.pharmgkb.org/labelAnnotation/PA166318001	PA166318001	Annotation of HCSC Label for setmelanotide and LEPR, PCSK1, POMC	HCSC		Testing Required							setmelanotide	LEPR; PCSK1; POMC			Setmelanotide is HCSC indicated for weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance.
https://www.pharmgkb.org/labelAnnotation/PA166319021	PA166319021	Annotation of FDA Label for mepolizumab and FIP1L1, PDGFRA	FDA	On FDA Biomarker List								mepolizumab	FIP1L1; PDGFRA			Mepolizumab is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa). FIP1L1 and PDGFRA are listed in the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling in the Adverse Reactions and Clinical Studies section.
https://www.pharmgkb.org/labelAnnotation/PA166294083	PA166294083	Annotation of HCSC Label for durvalumab and CD274	HCSC							Cancer Genome		durvalumab	CD274		8/15/2023	Durvalumab is HCSC indicated for NSCLC, extensive-stage small cell lung cancer, and biliary tract cancer but does not discuss biomarker status. The product monograph has information about PD-L1 (CD274) in the mechanism of action section.
https://www.pharmgkb.org/labelAnnotation/PA166317221	PA166317221	Annotation of FDA Label for rozanolixizumab and CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE, MUSK	FDA	On FDA Biomarker List								rozanolixizumab	CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE; MUSK			Rozanolixizumab-noli (RYSTIGGO), a neonatal Fc receptor blocker, is a recombinant, humanized IgG4P monoclonal antibody that is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
https://www.pharmgkb.org/labelAnnotation/PA166317281	PA166317281	Annotation of FDA Label for leniolisib and PIK3CD, PIK3R1	FDA	On FDA Biomarker List								leniolisib	PIK3CD; PIK3R1			Leniolisib (JOENJA) is a kinase inhibitor that inhibits PI3K-delta by blocking the active binding site of PI3K-delta. It is indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.
https://www.pharmgkb.org/labelAnnotation/PA166319001	PA166319001	Annotation of FDA Label for sacituzumab govitecan and BRCA1, BRCA2	FDA	On FDA Biomarker List								sacituzumab govitecan	BRCA1; BRCA2			Sacituzumab govitecan-hziy is a Trop-2-directed antibody and topoisomerase inhibitor conjugate used in the treatment of certain cancers. BRCA is listed in the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling in the Clinical Studies section.
https://www.pharmgkb.org/labelAnnotation/PA166319101	PA166319101	Annotation of FDA Label for tofersen and SOD1	FDA	On FDA Biomarker List								tofersen	SOD1		8/6/2024	Tofersen (QALSODY) is an antisense oligonucleotide indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene.
https://www.pharmgkb.org/labelAnnotation/PA166317881	PA166317881	Annotation of EMA Label for lonafarnib and LMNA, ZMPSTE24	EMA		Testing Required							lonafarnib	LMNA; ZMPSTE24		11/21/2023	Lonafarnib is EMA indicated for the treatment of processing-deficient Progeroid Laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation or homozygous or compound heterozygous ZMPSTE24 mutations.
https://www.pharmgkb.org/labelAnnotation/PA166293282	PA166293282	Annotation of FDA Label for Ascorbic acid (vitamin C), combinations, Ascorbic acid (vitamin C), plain, sodium ascorbate and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info		Other Prescribing Guidance		Prescribing	Ascorbic acid (vitamin C), combinations; Ascorbic acid (vitamin C), plain; sodium ascorbate	G6PD		5/23/2023	The FDA label for Ascorbic acid recommends that patients with G6PD deficiency do not exceed the recommended dietary allowance or daily intake due to risk of hemolysis.
https://www.pharmgkb.org/labelAnnotation/PA166317948	PA166317948	Annotation of HCSC Label for rimegepant and CYP2C9	HCSC		No Clinical PGx							rimegepant	CYP2C9	CYP2C9*2; CYP2C9*3	3/13/2024	Rimegepant is an HCSC CGRP antagonist approved for acute treatment of migraine with or without aura in adults. The pharmacogenomics section gives information on variants of CYP2C9 but these are not expected to have clinical impact.
https://www.pharmgkb.org/labelAnnotation/PA166317943	PA166317943	Annotation of HCSC Label for metreleptin and AGPAT2, BSCL2, LEP, LMNB2	HCSC		Testing Required							metreleptin	AGPAT2; BSCL2; LEP; LMNB2		8/9/2024	Metreleptin is indicated as an adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy (LD) patients. In addition to acquired lipodystrophies, the label specifies indications for confirmed congenital generalized lipodystrophy and confirmed familial partial lipodystrophy. These may involve variants in genes such as AGPAT2, BSCL2, or LMNB2.
https://www.pharmgkb.org/labelAnnotation/PA166318021	PA166318021	Annotation of HCSC Label for tremelimumab	HCSC									tremelimumab				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317981	PA166317981	Annotation of HCSC Label for mavacamten and CYP2C19	HCSC		Informative PGx							mavacamten	CYP2C19		12/20/2023	The HCSC label for mavacamten gives information on pharmacokinetic differences in CYP2C19 poor metabolizers (PM) compared to normal metabolizers (NM), but does not give information on testing for alleles associated with PM or dose adjustments.
https://www.pharmgkb.org/labelAnnotation/PA166318981	PA166318981	Annotation of FDA Label for sacituzumab govitecan and ERBB2, ESR1, ESR2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		sacituzumab govitecan	ERBB2; ESR1; ESR2			Sacituzumab govitecan-hziy is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
https://www.pharmgkb.org/labelAnnotation/PA166284042	PA166284042	Annotation of EMA Label for entrectinib and NTRK1, NTRK2, NTRK3, ROS1	EMA		Testing Required					Cancer Genome		entrectinib	NTRK1; NTRK2; NTRK3; ROS1		4/16/2024	Entrectinib is EMA indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, and for the treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.
https://www.pharmgkb.org/labelAnnotation/PA166283922	PA166283922	Annotation of EMA Label for gemtuzumab ozogamicin and CD33	EMA		Testing Required					Cancer Genome		gemtuzumab ozogamicin	CD33		4/16/2024	Gemtuzumab ozogamicin is an antibody-drug conjugate EMA indicated for de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL).
https://www.pharmgkb.org/labelAnnotation/PA166294381	PA166294381	Annotation of EMA Label for evolocumab	EMA									evolocumab			8/14/2024	Evolocumab is an antibody targeted to PCSK9, indicated for the treatment of heterozygous familial hypercholesterolemia (HeFH) or homozygous familial hypercholesterolemia (HoFH). Familial hypercholesterolemia is commonly caused by mutations in the LDLR gene, it can also be due to variants in PCSK9.
https://www.pharmgkb.org/labelAnnotation/PA166184454	PA166184454	Annotation of Swissmedic Label for galantamine and CYP2D6	Swissmedic		Informative PGx							galantamine	CYP2D6		11/13/2023	The Swiss drug label for galantamine (Reminyl) states that CYP2D6 is involved in the metabolism of galantamine but there were limited differences between CYP2D6 extensive and poor metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166283781	PA166283781	Annotation of EMA Label for givosiran and CPOX, HMBS, PPOX	EMA									givosiran	CPOX; HMBS; PPOX		11/20/2023	Givosiran is EMA indicated for the treatment of acute hepatic porphyria (AHP) in adults and adolescents aged 12 years and older. The FDA table lists the genes CPOX, HMBS and PPOX which are associated with AHP however these are not specified in the EMA label.
https://www.pharmgkb.org/labelAnnotation/PA166122907	PA166122907	Annotation of EMA Label for vandetanib and RET	EMA		Testing Required							vandetanib	RET		12/5/2023	Vandetanib (Caprelsa) is EMA indicated for RET mutant medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.
https://www.pharmgkb.org/labelAnnotation/PA166121250	PA166121250	Annotation of EMA Label for lomitapide and APOB, LDLR, PCSK9	EMA		Testing Required							lomitapide	APOB; LDLR; PCSK9		8/8/2024	The EMA European Public Assessment Report (EPAR) for lomitapide (Lojuxta) states it is indicated only for use in adult patients with homozygous familial hypercholesterolemia and that genetic confirmation should be obtained whenever possible. Genetic tests include screening for variants in the LDLR, APOB and PCSK9 genes (see the Genetic Test Registry for more information).
https://www.pharmgkb.org/labelAnnotation/PA166121252	PA166121252	Annotation of EMA Label for ofatumumab and MS4A1	EMA							Cancer Genome		ofatumumab	MS4A1		8/17/2023	The EMA European Public Assessment Report (EPAR) for ofatumumab (Arzerra) contains information regarding its mechanism of action by targeting CD20 (expressed by the MS4A1 gene).
https://www.pharmgkb.org/labelAnnotation/PA166122968	PA166122968	Annotation of EMA Label for sildenafil	EMA									sildenafil			8/24/2023	The EMA European Public Assessment Report (EPAR) for sildenafil (Viagra) contains genetic information regarding its contraindication in patients with hereditary degenerative retinal disorders. It also mentions that the drug is metabolized by CYP3A4 and CYP2C9, and that a lower dose of silenafil should be considered in patients taking CYP3A4 inhibitors concomitantly.
https://www.pharmgkb.org/labelAnnotation/PA166123388	PA166123388	Annotation of EMA Label for ruxolitinib and CYP3A4	EMA									ruxolitinib	CYP3A4		8/24/2023	The EMA European Public Assessment Report (EPAR) for ruxolitinib (Jakavi) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4 and CYP2C9, and suggests dosing adjustments and more frequent monitoring of hematology parameters if co-administered with strong CYP3A4 inhibitors or inducers, or dual inhibitors of CYP3A4 and CYP2C9.
https://www.pharmgkb.org/labelAnnotation/PA166123411	PA166123411	Annotation of EMA Label for sirolimus and CYP3A4	EMA									sirolimus	CYP3A4		8/24/2023	The EMA European Public Assessment Report (EPAR) for sirolimus (Rapamune) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4, and recommends therapeutic monitoring and dose adjustments when coadministrated with strong CYP3A inhibitors or inducers.
https://www.pharmgkb.org/labelAnnotation/PA166123413	PA166123413	Annotation of EMA Label for zonisamide and CYP3A4	EMA									zonisamide	CYP3A4		8/29/2023	The EMA European Public Assessment Report (EPAR) for zonisamide (Zonegran) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4, and recommends dose adjustments if CYP3A4 inducers are taken concomitantly.
https://www.pharmgkb.org/labelAnnotation/PA166123417	PA166123417	Annotation of EMA Label for telithromycin and CYP3A4	EMA									telithromycin	CYP3A4		8/24/2023	"Note: this medication has been withdrawn from use in the European Union.
The EMA European Public Assessment Report (EPAR) for telithromycin (Ketek) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4 and contains information regarding use of concomitant drugs that are CYP3A4 substrates, inhibitors or inducers."
https://www.pharmgkb.org/labelAnnotation/PA166123420	PA166123420	Annotation of EMA Label for fosamprenavir and CYP3A4	EMA									fosamprenavir	CYP3A4		8/17/2023	The EMA European Public Assessment Report (EPAR) for fosamprenavir (Telzir) does not contain human pharmacogenetic information, but does contain pharmacogenetic information related to the genotype of the HIV virus. Concomitant use of drugs with a narrow therapeutic window that are substrates of CYP3A4 or CYP2D6 is contraindicated.
https://www.pharmgkb.org/labelAnnotation/PA166123424	PA166123424	Annotation of EMA Label for darunavir and CYP3A4	EMA									darunavir	CYP3A4		8/15/2023	The EMA European Public Assessment Report (EPAR) for darunavir (PREZISTA) does not contain human pharmacogenetic information, but does contain pharmacogenetic information related to the genotype of the HIV virus. It contains information regarding metabolism of darunavir by CYP3A and gives information regarding the coadministration of drugs that are CYP3A substrates, inhibitors or inducers.
https://www.pharmgkb.org/labelAnnotation/PA166317885	PA166317885	Annotation of HCSC Label for fosdenopterin	HCSC									fosdenopterin				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317945	PA166317945	Annotation of HCSC Label for oliceridine	HCSC									oliceridine				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317921	PA166317921	Annotation of HCSC Label for golodirsen	HCSC									golodirsen				N/A
https://www.pharmgkb.org/labelAnnotation/PA166317946	PA166317946	Annotation of HCSC Label for oxymetazoline and tetracaine	HCSC									oxymetazoline and tetracaine				N/A
https://www.pharmgkb.org/labelAnnotation/PA166104882	PA166104882	Annotation of EMA Label for desloratadine	EMA									desloratadine			9/6/2023	The EMA European Public Assessment Report (EPAR) highlights information regarding variation in the metabolism of desloratadine in different individuals, but does not mention pharmacogenetics or genetic testing. The genes/ enzymes involved are not known.
https://www.pharmgkb.org/labelAnnotation/PA166105315	PA166105315	Annotation of EMA Label for nelfinavir and CYP3A4	EMA									nelfinavir	CYP3A4		8/15/2023	"Note: this medication has been withdrawn from use in the European Union
The EMA European Public Assessment Report (EPAR) for nelfinavir (Viracept) contains information regarding the metabolism of the drug by CYP3A4, CYP2C19 and CYP2D6, and that concomitant use of CYP3A4 substrates or inducers is contraindicated. No genetic information is included."
https://www.pharmgkb.org/labelAnnotation/PA166123529	PA166123529	Annotation of PMDA Label for atorvastatin and LDLR	PMDA									atorvastatin	LDLR		9/25/2023	The PMDA package insert for atorvastatin states that an indication for the drug is familial hypercholesterolemia, a genetically determined condition caused by mutations in the low density lipoprotein receptor gene (LDLR).
https://www.pharmgkb.org/labelAnnotation/PA166123545	PA166123545	Annotation of PMDA Label for lenalidomide	PMDA							Cancer Genome		lenalidomide			9/26/2023	The PMDA package insert for lenalidomide (Revlimid) states that it is indicated for individuals with myelodysplastic syndromes associated with a deletion of chromosome 5q.
https://www.pharmgkb.org/labelAnnotation/PA166123549	PA166123549	Annotation of PMDA Label for tolterodine and CYP2D6	PMDA		Informative PGx							tolterodine	CYP2D6		8/14/2023	Tolterodine is metabolized by CYP2D6 into the pharmacologically active and equipotent 5-hydroxymethyl metabolite (DD01). The PMDA package insert for tolterodine (Detrusitol) notes that CYP2D6 poor metabolizers have negligible concentrations of the 5-hydroxymethyl metabolite and significantly increased concentrations of tolterodine, as compared to extensive metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166123553	PA166123553	Annotation of PMDA Label for abacavir and HLA-B	PMDA		Informative PGx							abacavir	HLA-B		8/14/2023	The HLA-B*57:01 allele is associated with a high risk of experiencing a hypersensitivity reaction to abacavir in multiple populations, including Caucasians and African-Americans. However, the PMDA package insert for abacavir notes that the association between HLA-B*57:01 and risk of an abacavir hypersensitivity reaction is unknown in Japanese patients, and that the *57:01 allele has a reported prevalence of only 0.1% in the Japanese population.
https://www.pharmgkb.org/labelAnnotation/PA166120286	PA166120286	Annotation of EMA Label for esomeprazole and CYP2C19	EMA		No Clinical PGx							esomeprazole	CYP2C19		8/17/2023	The EMA European Public Assessment Report (EPAR) for esomeprazole (Nexium Control) notes that CYP2C19 poor metabolizers have higher plasma concentrations of the drug compared to extensive metabolizers, but there are no implications for dosing.
https://www.pharmgkb.org/labelAnnotation/PA166317944	PA166317944	Annotation of HCSC Label for odevixibat and ABCB11	HCSC									odevixibat	ABCB11		8/16/2024	Odevixibat (BYLVAY) is indicated for the treatment of pruritus in patients with progressive familial intrahepatic cholestasis (PFIC). PFIC type 2 results from variants in the ABCB11 gene. The product monograph for odevixibat states that it may not be effective in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of the bile salt export pump protein.
https://www.pharmgkb.org/labelAnnotation/PA166127640	PA166127640	Annotation of HCSC Label for boceprevir and IFNL3	HCSC		No Clinical PGx							boceprevir	IFNL3		7/26/2024	"The product monograph for boceprevir (VICTRELIS) contains information regarding a genetic variant near the IFNL3 gene (IL28B, rs12979860, a C to T change) which is a strong predictor of response to peginterferon alfa-2b/ribavirin treatment.
Please note that as of July 2024, the marketing status of boceprevir at HCSC is Cancelled Post Market."
https://www.pharmgkb.org/labelAnnotation/PA166119827	PA166119827	Annotation of EMA Label for dextromethorphan / quinidine and CYP2D6	EMA		No Clinical PGx							dextromethorphan / quinidine	CYP2D6		8/28/2023	The EMA European Public Assessment Report (EPAR) for dextromethorphan and quinidine (Nuedexta) does not require dose adjustment based on CYP2D6 genotype. Efficacy is not expected to be affected in CYP2D6 poor metabolizers, however adverse reactions to quinidine are possible. Dextromethorphan is rapidly metabolized in CYP2D6 ultrametabolizers, and may result in subtherapeutic concentrations. Please note that as of February 2016 dextromethorphan and quinidine (Nuedexta) has been withdrawn from use in the European Union.
https://www.pharmgkb.org/labelAnnotation/PA166123414	PA166123414	Annotation of EMA Label for dronedarone and CYP2D6, CYP3A4	EMA		No Clinical PGx							dronedarone	CYP2D6; CYP3A4		8/15/2023	The EMA European Public Assessment Report (EPAR) for dronedarone (MULTAQ) states that it is a mild inhibitor of CYP2D6, and that the effect on metoprolol and propranol exposure is much below the difference seen between poor and extensive CYP2D6 metabolisers. It also contains information regarding metabolism of by dronedarone CYP3A4, and that concomitant drugs that are potent CYP3A4 inhibitors are contraindicated and potent CYP3A4 inducers are not recommended.
https://www.pharmgkb.org/labelAnnotation/PA166123387	PA166123387	Annotation of EMA Label for axitinib and CYP2C19, UGT1A1	EMA		No Clinical PGx							axitinib	CYP2C19; UGT1A1		8/14/2023	The EMA European Public Assessment Report (EPAR) for axitinib (Inlyta) states that population pharmacokinetic analyses show no clinically relevant effects of UGT1A1 or CYP2C19 genotype.
https://www.pharmgkb.org/labelAnnotation/PA166127691	PA166127691	Annotation of HCSC Label for metoprolol and CYP2D6	HCSC		Informative PGx							metoprolol	CYP2D6		7/25/2024	The product monograph for metoprolol notes that CYP2D6 poor metabolizers exhibit higher plasma concentrations of the drug as compared to extensive metabolizers, which are associated with higher intensity of therapeutic effects, an increase in duration of action and an increase in the occurrence and severity of adverse events as compared to extensive metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166127713	PA166127713	Annotation of HCSC Label for succinylcholine and BCHE, CACNA1S, RYR1	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	succinylcholine	BCHE; CACNA1S; RYR1		4/1/2023	The product monograph for succinylcholine notes that it should be used with caution, if at all, in patients know or suspected of being homozygous for the atypical plasma cholinesterase gene (BCHE), due to the risk for prolonged muscle paralysis. It is also contraindicated in persons with personal or familial history of malignant hyperthermia, skeletal muscle myopathies, and known hypersensitivity to the drug.
https://www.pharmgkb.org/labelAnnotation/PA166160720	PA166160720	Annotation of PMDA Label for omeprazole and CYP2C19	PMDA		Informative PGx							omeprazole	CYP2C19		8/14/2023	The PMDA package insert for omeprazole states that the slower metabolism of the drug in CYP2C19 poor metabolizers is similar to that observed with other proton-pump inhibitors.
https://www.pharmgkb.org/labelAnnotation/PA166161087	PA166161087	Annotation of PMDA Label for isoniazid and NAT2	PMDA		Informative PGx							isoniazid	NAT2		8/14/2023	The PMDA package insert for isoniazid (ISCOTIN) notes that acetylation rate of isoniazid differs between individuals, and that about 10% of Japanese are slow acetylators.
https://www.pharmgkb.org/labelAnnotation/PA166183789	PA166183789	Annotation of Swissmedic Label for metabutethamine and G6PD	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	metabutethamine	G6PD		2/28/2023	The Swiss drug label for metabutethamin (Alcacyl® 500 Instant-Pulver) states that patients with G6PD deficiency may have increased risk of adverse events to metabutethamin and caution is advised.
https://www.pharmgkb.org/labelAnnotation/PA166184129	PA166184129	Annotation of Swissmedic Label for daclatasvir and IFNL3	Swissmedic		Informative PGx							daclatasvir	IFNL3		8/15/2023	The Swiss drug label for daclatasvir (Daklinza) states that response to daclatasvir is not dependent on IFNL3 (IL28B) genotype.
https://www.pharmgkb.org/labelAnnotation/PA166184380	PA166184380	Annotation of Swissmedic Label for brivaracetam and CYP2C19, CYP2C9	Swissmedic		Informative PGx							brivaracetam	CYP2C19; CYP2C9			The Swiss drug label for brivaracetam (Briviact) discusses metabolism of brivaracetam by CYP2C19 and CYP2C9 and changes in pharmacokinetics in CYP2C19 poor metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166272161	PA166272161	Annotation of EMA Label for venetoclax and FLT3, IDH1, IDH2, NPM1, TP53	EMA							Cancer Genome		venetoclax	FLT3; IDH1; IDH2; NPM1; TP53		8/29/2023	Venetoclax (Venclyxto) is EMA approved for certain patients with CLL or AML particularly those with 17p chromosome deletion or TP53 mutations. The label also notes whether mutation analyses detected mutations in the IDH1, IDH2, FLT3 and NPM1 genes.
https://www.pharmgkb.org/labelAnnotation/PA166272181	PA166272181	Annotation of EMA Label for upadacitinib and CYP2D6	EMA									upadacitinib	CYP2D6		8/29/2023	Upadacitinib (Rinvoq) is indicated for moderate to severe active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis or moderate to severe atopic dermatitis in adult patients. Upadacitinib is metabolized by CYP3A4 with a minor contribution from CYP2D6. There is no information on the label about the impact of CYP2D6 variants.
https://www.pharmgkb.org/labelAnnotation/PA166272261	PA166272261	Annotation of HCSC Label for venetoclax and FLT3, IDH1, IDH2, NPM1, TP53	HCSC							Cancer Genome		venetoclax	FLT3; IDH1; IDH2; NPM1; TP53		8/29/2023	Venetoclax (VENCLEXTA) is HCSC approved for certain patients with CLL or AML including those with 17p chromosome deletion. The label also notes whether mutation analyses detected mutations in the IDH1, IDH2, FLT3, NPM1, and TP53 genes.
https://www.pharmgkb.org/labelAnnotation/PA166272621	PA166272621	Annotation of EMA Label for tafamidis and TTR	EMA									tafamidis	TTR		8/24/2023	Tafamidis is EMA indicated for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
https://www.pharmgkb.org/labelAnnotation/PA166272681	PA166272681	Annotation of EMA Label for tipiracil / trifluridine and ERBB2, KRAS	EMA							Cancer Genome		tipiracil / trifluridine	ERBB2; KRAS		8/27/2023	Tipiracil / trifluridine (Lonsurf) is EMA indicated for patients with metastatic colorectal cancer or metastatic gastric cancer who have failed other targeted therapies including those for KRAS negative metastatic colorectal cancer and HER2 positive (ERBB2) metastatic gastric or gastroesophageal junction cancers. Therefore testing was required for those prior therapies.
https://www.pharmgkb.org/labelAnnotation/PA166272741	PA166272741	Annotation of EMA Label for ropeginterferon alfa-2b and JAK2	EMA							Cancer Genome		ropeginterferon alfa-2b	JAK2	rs77375493	8/24/2023	Ropeginterferon Alfa-2b is used as monotherapy for the treatment of polycythaemia vera in adults. Polycythaemia vera is a type of cancer in which the bone marrow produces too many red blood cells, white blood cells and platelets. Ropeginterferon Alfa-2b decreased the mutated JAK2V617F allele burden in patients with polycythaemia vera (a V617F point mutation, rs77375493G>T, in the JAK2 kinase is a hallmark of polycythaemia vera and is present in approximately 95% of patients).
https://www.pharmgkb.org/labelAnnotation/PA166273262	PA166273262	Annotation of EMA Label for ospemifene and CYP2B6	EMA									ospemifene	CYP2B6		8/23/2023	N/A
https://www.pharmgkb.org/labelAnnotation/PA166278461	PA166278461	Annotation of EMA Label for crizanlizumab-tmca and HBB, SELP	EMA									crizanlizumab-tmca	HBB; SELP		9/26/2023	Crizanlizumab (Adakveo) is a P-selectin blocker indicated for the prevention of recurrent vaso-occlusive crises (VOCs) in sickle cell disease patients aged 16 years and older. The safety of this drug was evaluated in patients with sickle cell disease (any genotype including HbSS, HbSC, HbS beta0-thalassemia, HbSbeta+thalassemia, and others).
https://www.pharmgkb.org/labelAnnotation/PA166278501	PA166278501	Annotation of EMA Label for duvelisib	EMA							Cancer Genome		duvelisib			8/15/2023	"The EMA drug label states that duvelisib monotherapy is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) after at least two prior therapies and follicular lymphoma (FL) that is refractory to at least two prior systemic therapies.
The label mentions that some patients had a documented 17p deletion and/or TP53 mutation, and others had a documented 11q deletion."
https://www.pharmgkb.org/labelAnnotation/PA166281781	PA166281781	Annotation of HCSC Label for ospemifene and CYP2B6, CYP2C9	HCSC									ospemifene	CYP2B6; CYP2C9		8/23/2023	The HCSC product monograph for ospemifene (OSPHENA) states that ospemifene is metabolized primarily by CYP3A4 and CYP2C9, and ospemifene was also suggested to be a weak inhibitor for CYP2B6, CYP2C9, CYP2C19, CYP2C8, CYP2D6 and CYP3A4 in in vitro studies. No details are given about the effects of poor metabolizer status or variants of these enzymes.
https://www.pharmgkb.org/labelAnnotation/PA166282861	PA166282861	Annotation of HCSC Label for nusinersen and SMN2	HCSC									nusinersen	SMN2		8/17/2023	Nusinersen is an antisense oligonucleotide that increases the expression of SMN2 to treat SMA, an autosomal recessive progressive neuromuscular disease.
https://www.pharmgkb.org/labelAnnotation/PA166283181	PA166283181	Annotation of HCSC Label for meloxicam and CYP2C9	HCSC									meloxicam	CYP2C9		8/15/2023	The product monograph for meloxicam discusses metabolism by CYP2C9 and drug-drug interactions but does not discuss CYP2C9 variants or metabolizer status.
https://www.pharmgkb.org/labelAnnotation/PA166283261	PA166283261	Annotation of HCSC Label for isatuximab	HCSC							Cancer Genome		isatuximab			8/18/2023	Isatuximab is listed on the FDA table with the biomarkers Chromosome 17p, 4p, 14q, 16q. The HCSC product monograph for Isatuximab mentions clinical studies where patients had high-risk chromosomal abnormalities at study entry; del(17p), t(4;14) and t(14;16) but do not discuss testing or impact of these variants.
https://www.pharmgkb.org/labelAnnotation/PA166284741	PA166284741	Annotation of HCSC Label for nivolumab and BRAF	HCSC							Cancer Genome		nivolumab	BRAF	rs113488022	9/7/2023	The HCSC product monograph for nivolumab (OPDIVO) has information about BRAF V600 variants in clinical trials and which prior drugs may have been used as part of the indication for metastatic melanoma.
https://www.pharmgkb.org/labelAnnotation/PA166277721	PA166277721	Annotation of HCSC Label for anifrolumab and IFNAR1	HCSC									anifrolumab	IFNAR1		8/14/2023	Anifrolumab a monoclonal antibody that binds to subunit 1 of the type I interferon receptor (IFNAR1) and inhibits type I IFN signaling. Blockade of receptor mediated type I IFN signaling inhibits IFN responsive gene expression (gene signature) as well as downstream inflammatory and immunological processes.
https://www.pharmgkb.org/labelAnnotation/PA166283001	PA166283001	Annotation of EMA Label for elexacaftor / tezacaftor / ivacaftor and CFTR	EMA		Testing Required							elexacaftor / tezacaftor / ivacaftor	CFTR	rs113993960	4/16/2024	Ivacaftor/tezacaftor/elexacaftor (Kaftrio) is a combination of ivacaftor, a CFTR potentiator, tezacaftor, and elexacaftor indicated for the treatment of cystic fibrosis (CF) in patients 6 years and older who have at least one F508del mutation in the cyctic fibrosis transmembrane conductance regulator (CFTR) gene. Genetic testing should be performed prior to initiating treatment to confirm the presence of at least one F508del mutation if a patient's CFTR genotype is not known.
https://www.pharmgkb.org/labelAnnotation/PA166283021	PA166283021	Annotation of HCSC Label for elexacaftor / tezacaftor / ivacaftor and CFTR	HCSC		Testing Required							elexacaftor / tezacaftor / ivacaftor	CFTR	rs113993960	4/16/2024	Elexacaftor/tezacaftor/ivacaftor (TRIKAFTA) is a combination of ivacaftor, a CFTR potentiator, tezacaftor, and elexacaftor indicated for the treatment of cystic fibrosis (CF) in patients 6 years and older who have at least one F508del mutation in the cyctic fibrosis transmembrane conductance regulator (CFTR) gene. If a patient's CFTR genotype is not known, genetic testing with an accurate and validated genotyping method should be performed prior to initiating treatment to confirm the presence of at least one F508del mutation.
https://www.pharmgkb.org/labelAnnotation/PA166284661	PA166284661	Annotation of HCSC Label for pembrolizumab and BRAF	HCSC							Cancer Genome		pembrolizumab	BRAF	rs113488022	8/23/2023	Pembrolizumab is an anti-PD-L1 (CD274) antibody HCSC indicated for a number of cancers including melanoma. BRAF V600 mutation status is mentioned in the context of prior therapies.
https://www.pharmgkb.org/labelAnnotation/PA166284701	PA166284701	Annotation of HCSC Label for regorafenib and KRAS	HCSC							Cancer Genome		regorafenib	KRAS		8/26/2024	Regorafenib is HCSC indicated for colon or rectal cancer that has spread to other parts of the body in patients who have already received other treatments (fluoropyrimidine-based chemotherapy, oxaliplatin, irinotecan, an anti-VEGF therapy, and, if RAS wild type, an anti-EGFR therapy).
https://www.pharmgkb.org/labelAnnotation/PA166272981	PA166272981	Annotation of EMA Label for abrocitinib and CYP2C19, CYP2C9	EMA		No Clinical PGx							abrocitinib	CYP2C19; CYP2C9		8/11/2023	The EMA product information for abrocitinib states that CYP2C19 or CYP2C9 genotype does not have a clinically significant effect on abrocitinib exposure. There is clinical dosing information about CYP2C19 drug-drug interactions.
https://www.pharmgkb.org/labelAnnotation/PA166273001	PA166273001	Annotation of HCSC Label for abrocitinib and CYP2C19, CYP2C9	HCSC		No Clinical PGx							abrocitinib	CYP2C19; CYP2C9		8/11/2023	The HCSC product monograph for abrocitinib states that CYP2C19 or CYP2C9 genotype does not have a clinically significant effect on abrocitinib exposure. There is clinical dosing information about drug-drug interactions.
https://www.pharmgkb.org/labelAnnotation/PA166273321	PA166273321	Annotation of EMA Label for niraparib and BRCA1, BRCA2	EMA		Informative PGx					Cancer Genome		niraparib	BRCA1; BRCA2		9/8/2023	BRCA1 and BRCA2 status is discussed in some of the trials documented in the EMA product information for niraparib but it is not required as part of the indication. In the NOVA study patients with mutated BRCA genes (gBRCAmut) had improved progression-free survival and overall survival than non-gBRCAmut.
https://www.pharmgkb.org/labelAnnotation/PA166183424	PA166183424	Annotation of EMA Label for rucaparib and CYP1A2, CYP2D6	EMA		No Clinical PGx							rucaparib	CYP1A2; CYP2D6		12/5/2023	The EMA European Public Assessment Report (EPAR) for rucaparib (Rubraca) states that no clinically relevant pharmacokinetic differences were observed among patients with different CYP2D6 or CYP1A2 phenotypes.
https://www.pharmgkb.org/labelAnnotation/PA166328921	PA166328921	Annotation of FDA Label for capivasertib and AKT1, ERBB2, ESR1, ESR2, PIK3CA, PTEN	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		capivasertib	AKT1; ERBB2; ESR1; ESR2; PIK3CA; PTEN			Capivasertib is a tyrosine kinase inhibitor, FDA indicated the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer based on the presence of PIK3CA, AKT1, and/or PTEN genetic alterations in tumor tissue.
https://www.pharmgkb.org/labelAnnotation/PA166328961	PA166328961	Annotation of HCSC Label for capivasertib and AKT1, ERBB2, ESR1, ESR2, PIK3CA, PTEN	HCSC		Testing Required					Cancer Genome		capivasertib	AKT1; ERBB2; ESR1; ESR2; PIK3CA; PTEN			Capivasertib is HCSC indicated for the treatment of hormone receptor positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, and/or PTEN genetic alterations.
https://www.pharmgkb.org/labelAnnotation/PA166328941	PA166328941	Annotation of EMA Label for capivasertib	EMA									capivasertib				N/A
https://www.pharmgkb.org/labelAnnotation/PA166329001	PA166329001	Annotation of EMA Label for eflornithine	EMA									eflornithine				N/A
https://www.pharmgkb.org/labelAnnotation/PA166329021	PA166329021	Annotation of HCSC Label for eflornithine	HCSC									eflornithine				N/A
https://www.pharmgkb.org/labelAnnotation/PA166329061	PA166329061	Annotation of EMA Label for elranatamab	EMA									elranatamab				Elranatamab is EMA indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies. The label mentions high risk cytogenetics results for patients including Chromosome 17p. Chromosome 4p;14q and Chromosome 14q;16q.
https://www.pharmgkb.org/labelAnnotation/PA166329043	PA166329043	Annotation of HCSC Label for elranatamab	HCSC							Cancer Genome		elranatamab				Elranatamab is HCSC the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy. The Clinical Trials section mentions high risk cytogenetics including Chromosome 17p. Chromosome 4p;14q and Chromosome 14q;16q.
https://www.pharmgkb.org/labelAnnotation/PA166329041	PA166329041	Annotation of FDA Label for elranatamab	FDA	On FDA Biomarker List						Cancer Genome		elranatamab				Elranatamab is FDA indicated for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. The Clinical Studies section mentions high risk cytogenetics results for patients including Chromosome 17p. Chromosome 4p;14q and Chromosome 14q;16q.
https://www.pharmgkb.org/labelAnnotation/PA166329101	PA166329101	Annotation of FDA Label for eplontersen and TTR	FDA	On FDA Biomarker List	Testing Required							eplontersen	TTR	rs28933979		Eplontersen is a transthyretin-directed antisense oligonucleotide, FDA indicated for the treatment of the polyneuropathy of hereditary transthyretin (TTR) -mediated amyloidosis in adults.
https://www.pharmgkb.org/labelAnnotation/PA166329121	PA166329121	Annotation of EMA Label for eplontersen and TTR	EMA									eplontersen	TTR			N/A
https://www.pharmgkb.org/labelAnnotation/PA166329141	PA166329141	Annotation of HCSC Label for quizartinib	HCSC									quizartinib				N/A
https://www.pharmgkb.org/labelAnnotation/PA166329221	PA166329221	Annotation of FDA Label for quizartinib and FLT3	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		quizartinib	FLT3			Quizartinib (VANFLYTA) is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test.
https://www.pharmgkb.org/labelAnnotation/PA166329241	PA166329241	Annotation of EMA Label for quizartinib and FLT3	EMA		Testing Required					Cancer Genome		quizartinib	FLT3			Quizartinib (VANFLYTA) is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by quizartinib single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3-ITD positive.
https://www.pharmgkb.org/labelAnnotation/PA166329281	PA166329281	Annotation of EMA Label for repotrectinib	EMA									repotrectinib				N/A
https://www.pharmgkb.org/labelAnnotation/PA166329301	PA166329301	Annotation of HCSC Label for repotrectinib	HCSC									repotrectinib				N/A
https://www.pharmgkb.org/labelAnnotation/PA166329322	PA166329322	Annotation of FDA Label for repotrectinib and ROS1	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		repotrectinib	ROS1			Repotrectinib (AUGTYRO) is indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). Repotrectinib is an inhibitor of proto-oncogene tyrosine-protein kinase ROS1 (ROS1) and of the tropomyosin receptor tyrosine kinases (TRKs) TRKA, TRKB, and TRKC.
https://www.pharmgkb.org/labelAnnotation/PA166329341	PA166329341	Annotation of FDA Label for pirtobrutinib and BTK, IGH, TP53	FDA	On FDA Biomarker List						Cancer Genome		pirtobrutinib	BTK; IGH; TP53			The FDA label for pirtobrutinib (JAYPIRCA) states that it is a a kinase inhibitor indicated for the treatment of Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor; and also Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor. Under clinical studies, mutation status in BTK, TP53, IGHV and deletions in chromosome 11q and 17q were mentioned in patients treated with JAYPIRCA.
https://www.pharmgkb.org/labelAnnotation/PA166329122	PA166329122	Annotation of HCSC Label for eplontersen and TTR	HCSC									eplontersen	TTR		7/5/2024	Eplontersen is a transthyretin mRNA-directed antisense oligonucleotide indicated for the treatment of polyneuropathy associated with stage 1 or stage 2 hereditary transthyretin-mediated amyloidosis (hATTR) in adults.
https://www.pharmgkb.org/labelAnnotation/PA166329401	PA166329401	Annotation of HCSC Label for zilucoplan	HCSC									zilucoplan				N/A
https://www.pharmgkb.org/labelAnnotation/PA166329441	PA166329441	Annotation of EMA Label for pirtobrutinib and BTK	EMA							Cancer Genome		pirtobrutinib	BTK			The EMA label for pirtobrutinib (Jaypirca) states that Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a Bruton’s tyrosine kinase (BTK) inhibitor.
https://www.pharmgkb.org/labelAnnotation/PA166329525	PA166329525	Annotation of FDA Label for fruquintinib and KRAS	FDA	On FDA Biomarker List						Cancer Genome		fruquintinib	KRAS			Fruquintinib is a vascular endothelial growth factor receptor inhibitor indicated for adults with metastatic colorectal cancer that have previously been reated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy. The FDA label for fruquintinib discusses RAS status in the context of which prior treatments a patient may have received and RAS status of patients in clinical trials.
https://www.pharmgkb.org/labelAnnotation/PA166329481	PA166329481	Annotation of EMA Label for fruquintinib	EMA									fruquintinib				N/A
https://www.pharmgkb.org/labelAnnotation/PA166329501	PA166329501	Annotation of HCSC Label for fruquintinib	HCSC									fruquintinib				N/A
https://www.pharmgkb.org/labelAnnotation/PA166328981	PA166328981	Annotation of FDA Label for eflornithine and MYCN	FDA	On FDA Biomarker List	No Clinical PGx					Cancer Genome		eflornithine	MYCN			Eflornithine is FDA indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma. It acts by inhibiting the enzyme ornithine decarboxylase (ODC), a transcriptional target of MYCN.
https://www.pharmgkb.org/labelAnnotation/PA166329782	PA166329782	Annotation of EMA Label for zilucoplan and CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE	EMA									zilucoplan	CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE			Zilucoplan (Zilbrysq) is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
https://www.pharmgkb.org/labelAnnotation/PA166329781	PA166329781	Annotation of FDA Label for zilucoplan and CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE	FDA	On FDA Biomarker List								zilucoplan	CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE			"Zilucoplan (ZILBRYSQ) is a complement inhibitor indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are antiacetylcholine receptor (AChR) antibody positive.
The relationship is not with the AchR genes or proteins but this is the biomarker listed in the FDA table."
https://www.pharmgkb.org/labelAnnotation/PA166330041	PA166330041	Annotation of EMA Label for nedosiran and AGXT	EMA									nedosiran	AGXT			N/A
https://www.pharmgkb.org/labelAnnotation/PA166330042	PA166330042	Annotation of HCSC Label for nedosiran and AGXT	HCSC									nedosiran	AGXT			N/A
https://www.pharmgkb.org/labelAnnotation/PA166330081	PA166330081	Annotation of EMA Label for nirogacestat and APC, CTNNB1	EMA									nirogacestat	APC; CTNNB1			N/A
https://www.pharmgkb.org/labelAnnotation/PA166330082	PA166330082	Annotation of HCSC Label for nirogacestat and APC, CTNNB1	HCSC									nirogacestat	APC; CTNNB1			N/A
https://www.pharmgkb.org/labelAnnotation/PA166330101	PA166330101	Annotation of FDA Label for nirogacestat and APC, CTNNB1	FDA	On FDA Biomarker List								nirogacestat	APC; CTNNB1			Nirogacestat is indicated for the treatment of progressing desmoid tumors in adult patients who require systemic treatment. APC and CTNNB1 are mentioned in the Clinical Studies section of the label.
https://www.pharmgkb.org/labelAnnotation/PA166278001	PA166278001	Annotation of HCSC Label for belzutifan and CYP2C19, UGT2B17	HCSC		Informative PGx							belzutifan	CYP2C19; UGT2B17			The HCSC label for belzutifan mentions that UGT2B17 and CYP2C19 polymorphisms may affect belzutifan exposure, but no dose adjustment is recommended.
https://www.pharmgkb.org/labelAnnotation/PA166277701	PA166277701	Annotation of EMA Label for anifrolumab and IFNAR1	EMA									anifrolumab	IFNAR1		8/14/2023	Anifrolumab a monoclonal antibody that binds to subunit 1 of the type I interferon receptor (IFNAR1) and inhibits type I IFN signaling. Blockade of receptor mediated type I IFN signaling inhibits IFN responsive gene expression (gene signature) as well as downstream inflammatory and immunological processes.
https://www.pharmgkb.org/labelAnnotation/PA166278581	PA166278581	Annotation of HCSC Label for siponimod and CYP2C9	HCSC		Testing Required	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	siponimod	CYP2C9	CYP2C9*1; CYP2C9*2; CYP2C9*3		The HCSC product monograph indicates siponimod for the treatment of patients with secondary progressive multiple sclerosis. Siponimod is contraindicated in patients with CYP2C9*3/*3 genotype and gives a dose adjustment table for other genotypes involving CYP2C9*1, CYP2C9*2 and CYP2C9*3.
https://www.pharmgkb.org/labelAnnotation/PA166329261	PA166329261	Annotation of EMA Label for etrasimod and CYP2C9	EMA		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	etrasimod	CYP2C9		7/25/2024	The EMA label for etrasimod has contraindications for patients who are known or suspected to be CYP2C9 poor metabolisers (< 5% of the population) and who take medicinal products that are moderate or strong inhibitors of CYP2C8 and/or CYP3A4.
https://www.pharmgkb.org/labelAnnotation/PA166329181	PA166329181	Annotation of HCSC Label for etrasimod and CYP2C9	HCSC		Informative PGx							etrasimod	CYP2C9		8/28/2024	The HCSC label for etrasimod has some recommendations to avoid drug-drug interactions in CYP2C9 poor metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166277981	PA166277981	Annotation of HCSC Label for belzutifan and VHL	HCSC									belzutifan	VHL		8/2/2024	Belzutifan is indicated as a treatment for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated non-metastatic renal cell carcinoma, not requiring immediate surgery.
https://www.pharmgkb.org/labelAnnotation/PA166330061	PA166330061	Annotation of FDA Label for nedosiran and AGXT	FDA	On FDA Biomarker List								nedosiran	AGXT		8/9/2024	Nedosiran (RIVFLOZA) is indicated for the treatment of high urinary oxalate levels in patients 9 years or older with primary hyperoxaluria type 1 (PH1). PH1 is caused by pathogenic variants in the AGXT gene.
https://www.pharmgkb.org/labelAnnotation/PA166277801	PA166277801	Annotation of HCSC Label for tebentafusp and HLA-A	HCSC		Testing Required							tebentafusp	HLA-A	HLA-A*02:01	8/14/2024	Tebentafusp is HCSC indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. Patients treated with tebentafusp must have a positive HLA-A*02:01 genotype status using a validated HLA sequencing system.
https://www.pharmgkb.org/labelAnnotation/PA166269742	PA166269742	Annotation of EMA Label for odevixibat and ABCB11	EMA									odevixibat	ABCB11		8/16/2024	Odevixibat (Bylvay) is indicated for the treatment of progressive familial intrahepatic cholestasis (PFIC). PFIC type 2 results from variants in the ABCB11 gene. The EMA label for odevixibat states that patients in whom the bile salt export pump protein encoded by ABCB11 does not function (i.e. with the BSEP3 subtype of PFIC type 2) will not respond to odevixibat.
https://www.pharmgkb.org/labelAnnotation/PA166329161	PA166329161	Annotation of FDA Label for etrasimod and CYP2C9	FDA		Informative PGx							etrasimod	CYP2C9	CYP2C9*2; CYP2C9*3	7/26/2024	The FDA label for etrasimod (VELSIPIDY) states that the impact of CYP2C9 genetic variants on the pharmacokinetics of etrasimod has not been directly evaluated. The label has a Pharmacogenomics section with information that can be used for possible drug-drug interactions in CYP2C9 poor metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166286181	PA166286181	Annotation of HCSC Label for alectinib and ALK	HCSC		Testing Required					Cancer Genome		alectinib	ALK		4/15/2024	Alectinib is HCSC indicated for ALK positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
https://www.pharmgkb.org/labelAnnotation/PA166230001	PA166230001	Annotation of EMA Label for avapritinib and PDGFRA	EMA		Testing Required					Cancer Genome		avapritinib	PDGFRA	rs121908585	4/15/2024	The EMA European Public Assessment Report (EPAR) for avapritinib (AYVAKYT) states that it is intended to treat gastrointestinal stromal tumour (GIST) that has a specific mutation (D842V) in the gene responsible for making a kinase called platelet-derived growth factor receptor alpha (PDGFRA).
https://www.pharmgkb.org/labelAnnotation/PA166278421	PA166278421	Annotation of EMA Label for cemiplimab-rwlc and ALK, CD274, EGFR, ROS1	EMA		Testing Required					Cancer Genome		cemiplimab-rwlc	ALK; CD274; EGFR; ROS1		4/16/2024	The EMA-approved drug label for cemiplimab (LIBTAYO) states that it is indicated for the first-line treatment of patients with non-small cell lung cancer whose tumors express PD-L1 in more than 50% of tumor cells, with no EGFR, ALK or ROS1 aberrations. PD-L1 is encoded by the CD274 gene.
https://www.pharmgkb.org/labelAnnotation/PA166284542	PA166284542	Annotation of HCSC Label for encorafenib and BRAF	HCSC		Testing Required					Cancer Genome		encorafenib	BRAF	rs113488022	4/16/2024	Encorafenib is HCSC indicated for unresectable or metastatic melanoma with a BRAF V600 mutation or metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test.
https://www.pharmgkb.org/labelAnnotation/PA166284282	PA166284282	Annotation of HCSC Label for gemtuzumab ozogamicin and CD33	HCSC		Testing Required					Cancer Genome		gemtuzumab ozogamicin	CD33		4/16/2024	Gemtuzumab ozogamicin is HCSC approved for the treatment of adult patients with previously untreated, de novo CD33-positive acute myeloid leukemia (AML).
https://www.pharmgkb.org/labelAnnotation/PA166334981	PA166334981	Annotation of EMA Label for fluorouracil	EMA									fluorouracil				N/A
https://www.pharmgkb.org/labelAnnotation/PA166283841	PA166283841	Annotation of HCSC Label for infigratinib and FGFR2	HCSC		Testing Required					Cancer Genome		infigratinib	FGFR2		4/21/2024	"Infigratinib is HCSC indicated for the treatment of cholangiocarcinoma (bile duct cancer) with a FGFR2 fusion or other rearrangement as assessed by a validated test.
Please note that the current status of this drug at HCSC is Cancelled Pre Market."
https://www.pharmgkb.org/labelAnnotation/PA166182954	PA166182954	Annotation of EMA Label for ivacaftor / tezacaftor and CFTR	EMA		Testing Required							ivacaftor / tezacaftor	CFTR	rs113993960; rs121908752; rs121908753; rs141033578; rs202179988; rs368505753; rs397508288; rs397508442; rs397508761; rs74551128; rs75039782; rs75541969; rs76151804; rs77834169; rs80224560	4/21/2024	The EMA European Public Assessment Report (EPAR) for ivacaftor and tezacaftor (Symkevi) states that it is indicated for the treatment of patients with cystic fibrosis aged 12 years and older who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A->G, S945L, S977F, R1070W, D1152H, 2789+5G->A, 3272-26A->G, 3849+10kbC->T.
https://www.pharmgkb.org/labelAnnotation/PA166183209	PA166183209	Annotation of EMA Label for migalastat and GLA	EMA		Testing Required							migalastat	GLA		4/21/2024	"The EMA European Public Assessment Report (EPAR) for migalastat (Galafold) states that it is for the treatment of adults and adolescents age 16 years and older with Fabry disease and an ""amenable"" GLA variant."
https://www.pharmgkb.org/labelAnnotation/PA166183243	PA166183243	Annotation of EMA Label for olaparib and BRCA1, BRCA2, ERBB2	EMA		Testing Required					Cancer Genome		olaparib	BRCA1; BRCA2; ERBB2		4/21/2024	The EMA European Public Assessment Report (EPAR) for olaparib (Lynparza) in 50 mg hard capsules states that it is indicated for treatment of BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. Olaparib (Lynparza) in 100 or 150 mg film-coated tablets is indicated for patients with germline BRCA1/2-mutations with HER2 negative breast cancer, among other indications.
https://www.pharmgkb.org/labelAnnotation/PA166282882	PA166282882	Annotation of HCSC Label for olaparib and BRCA1, BRCA2, ERBB2	HCSC		Testing Required					Cancer Genome		olaparib	BRCA1; BRCA2; ERBB2		4/21/2024	Olaparib is for treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative Breast Neoplasms, and other gBRCAm cancers including Ovarian Neoplasms, Pancreatic Neoplasms, and Prostatic Neoplasms.
https://www.pharmgkb.org/labelAnnotation/PA166284121	PA166284121	Annotation of HCSC Label for trastuzumab deruxtecan and ERBB2	HCSC		Testing Required					Cancer Genome		trastuzumab deruxtecan	ERBB2		4/21/2024	Trastuzumab deruxtecan (ENHERTU) is a HER2-directed antibody and topoisomerase inhibitor conjugate used for the treatment of adult patients with HER2-positive cancers. Trastuzumab deruxtecan should only be used in patients with documented HER2-positive or HER2-low tumor status.
https://www.pharmgkb.org/labelAnnotation/PA166335921	PA166335921	Annotation of HCSC Label for vincristine	HCSC									vincristine				N/A
https://www.pharmgkb.org/labelAnnotation/PA166335941	PA166335941	Annotation of EMA Label for vincristine	EMA									vincristine				N/A
https://www.pharmgkb.org/labelAnnotation/PA166336642	PA166336642	Annotation of HCSC Label for eliglustat and CYP2D6	HCSC		Testing Required	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	eliglustat	CYP2D6			The HCSC-approved drug label for eliglustat (CERDELGA) states that it is indicated for patients with Gaucher disease type 1. Before initiation of treatment with eliglustat, patients must be genotyped for CYP2D6 to determine their CYP2D6 metabolizer status (predicted phenotype). Eliglustat should not be used in patients genotyped as CYP2D6 ultrarapid or indeterminate metabolizers. CYP2D6 intermediate and extensive metabolizers have a recommended dose of 84 mg twice daily, while poor metabolizers have a recommended dose of 84 mg once daily.
https://www.pharmgkb.org/labelAnnotation/PA166336761	PA166336761	Annotation of EMA Label for tafenoquine	EMA									tafenoquine				N/A
https://www.pharmgkb.org/labelAnnotation/PA166335081	PA166335081	Annotation of HCSC Label for lapatinib and HLA-DQA1, HLA-DRB1	HCSC		Informative PGx							lapatinib	HLA-DQA1; HLA-DRB1	HLA-DQA1*02:01; HLA-DRB1*07:01		The product monograph for lapatinib (TYKERB) states that patients with the HLA-DQA1*02:01 or HLA-DRB1*07:01 alleles have an increased risk of lapatinib-associated hepatotoxicity. The product monograph does not comment on genotyping for these HLA alleles.
https://www.pharmgkb.org/labelAnnotation/PA166122548	PA166122548	Annotation of EMA Label for velaglucerase alfa and GBA	EMA									velaglucerase alfa	GBA		8/6/2024	The EMA European Public Assessment Report (EPAR) for velaglucerase alfa (VPRIV) states that the drug is indicated as a long-term enzyme replacement therapy for patients with type 1 Gaucher disease. Gaucher disease is caused by mutations in the GBA gene, resulting in a deficiency of the lysosomal enzyme beta-glucocerebrosidase.
https://www.pharmgkb.org/labelAnnotation/PA166273301	PA166273301	Annotation of EMA Label for nivolumab and ALK, CD274, EGFR, ERBB2	EMA		Testing Required					Cancer Genome		nivolumab	ALK; CD274; EGFR; ERBB2		8/9/2024	Nivolumab is EMA approved for several types of cancers, for some of which testing is required for PD-L1 expression (coded for by CD274) and for other types to rule out mutations in ALK, EGFR and ERBB2 (also known as HER-2).
https://www.pharmgkb.org/labelAnnotation/PA166127641	PA166127641	Annotation of HCSC Label for bosutinib and ABL1, BCR	HCSC		Testing Required					Cancer Genome		bosutinib	ABL1; BCR		8/26/2024	The product monograph for bosutinib (BOSULIF) states that it is indicated for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia.
https://www.pharmgkb.org/labelAnnotation/PA166336762	PA166336762	Annotation of HCSC Label for tafenoquine	HCSC									tafenoquine				N/A
https://www.pharmgkb.org/labelAnnotation/PA166336781	PA166336781	Annotation of EMA Label for afutuzumab and MS4A1	EMA							Cancer Genome		afutuzumab	MS4A1			Obinutuzumab (Gazyvaro; afutuzumab) in combination with certain other drugs is indicated for treatment of patients with chronic lymphocytic leukemia (CLL) or follicular lymphoma (FL). The drug is a CD20-directed cytolytic monoclonal antibody, but there is no association with genetic variation within the coding gene, MS4A1, and therefore no mention of genetic testing in the drug label.
https://www.pharmgkb.org/labelAnnotation/PA166336801	PA166336801	Annotation of EMA Label for allopurinol	EMA									allopurinol				N/A
https://www.pharmgkb.org/labelAnnotation/PA166337801	PA166337801	Annotation of HCSC Label for efgartigimod alfa and CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE	HCSC									efgartigimod alfa	CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE			Efgartigimod alfa (VYVGART) is a neonatal Fc receptor (FcRn) blocker that is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.
https://www.pharmgkb.org/labelAnnotation/PA166337821	PA166337821	Annotation of HCSC Label for duvelisib	HCSC									duvelisib				N/A
https://www.pharmgkb.org/labelAnnotation/PA166337841	PA166337841	Annotation of HCSC Label for anakinra and NLRP3	HCSC									anakinra	NLRP3			The HCSC-approved label for anakinra (KINERET) states that anakinra is indicated for treatment of, among others, Cryopyrin-Associated Periodic Syndromes (CAPS). Spontaneous mutations in the CIAS1/NLRP3 gene have been identified in a majority of patients with CAPS such as Neonatal-Onset Multisystem Inflammatory Disease (NOMID). CIAS1/NLRP3 encodes for cryopyrin, a component of the inflammasome. The activated inflammasome results in proteolytic maturation and secretion of IL-1β, which has a broad range of effects.
https://www.pharmgkb.org/labelAnnotation/PA166337881	PA166337881	Annotation of HCSC Label for avapritinib	HCSC									avapritinib				N/A
https://www.pharmgkb.org/labelAnnotation/PA166337902	PA166337902	Annotation of EMA Label for avelumab and CD274	EMA									avelumab	CD274			"The EMA-approved drug label for avelumab (Bavencio) states that it is a human monoclonal IgG1 antibody directed against the immunomodulatory cell surface ligand protein programmed death-ligand 1 (PD-L1). PD-L1 is encoded by the CD274 gene.
Avelumab is indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma, as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are progression-free following platinum-based chemotherapy, and in combination with axitinib for the first-line treatment of adult patients with advanced renal cell carcinoma."
https://www.pharmgkb.org/labelAnnotation/PA166337901	PA166337901	Annotation of HCSC Label for avelumab and CD274	HCSC									avelumab	CD274			The HCSC-approved drug label for avelumab (BAVENCIO) states that it is a programmed death ligand 1 (PD-L1) blocking antibody indicated for the treatment of unresectable locally advanced or metastatic urothelial carcinoma whose disease has not progressed following first-line platinum-based chemotherapy, metastatic Merkel cell carcinoma, and locally advanced or metastatic urothelial carcinoma. PD-L1 is encoded by the CD274 gene.
https://www.pharmgkb.org/labelAnnotation/PA166337941	PA166337941	Annotation of EMA Label for amifampridine	EMA									amifampridine				N/A
https://www.pharmgkb.org/labelAnnotation/PA166339041	PA166339041	Annotation of HCSC Label for binimetinib and BRAF	HCSC		Testing Required					Cancer Genome		binimetinib	BRAF	rs113488022		The product monograph for binimetinib (MEKTOVI) states that it is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by a validated test.
https://www.pharmgkb.org/labelAnnotation/PA166339181	PA166339181	Annotation of HCSC Label for brigatinib and ALK	HCSC		Testing Required					Cancer Genome		brigatinib	ALK			Brigatinib (ALUNBRIG) is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer. Patients treated with brigatinib must have a documented ALK-positive status based on a validated ALK assay.
https://www.pharmgkb.org/labelAnnotation/PA166339221	PA166339221	Annotation of EMA Label for erdafitinib	EMA									erdafitinib				N/A
https://www.pharmgkb.org/labelAnnotation/PA166339241	PA166339241	Annotation of HCSC Label for ibritumomab and MS4A1	HCSC							Cancer Genome		ibritumomab	MS4A1			Ibritumomab tiuxetan (ZEVALIN) is used to treat patients with B-cell non-Hodgkin's lymphoma. The drug is a CD20-directed radiotherapeutic antibody, but there is no association with genetic variation within the coding gene, MS4A1.
https://www.pharmgkb.org/labelAnnotation/PA166339262	PA166339262	Annotation of HCSC Label for cobimetinib and BRAF	HCSC		Testing Required					Cancer Genome		cobimetinib	BRAF	rs113488022		The HCSC-approved drug label for cobimetinib (COTELLIC) states that it is indicated, in combination with vemurafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Prior to initiation of treatment with cobimetinib in combination with vemurafenib, patients must have BRAF V600 mutation-positive melanoma tumor status confirmed by a validated test.
https://www.pharmgkb.org/labelAnnotation/PA166339301	PA166339301	Annotation of HCSC Label for elacestrant	HCSC									elacestrant				N/A
https://www.pharmgkb.org/labelAnnotation/PA166339321	PA166339321	Annotation of EMA Label for elacestrant and ESR1	EMA		Testing Required					Cancer Genome		elacestrant	ESR1			Elacestrant (ORSERDU) is an EMA-approved monotherapy indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation. Patients should be selected based on the presence of an activating ESR1 mutation in plasma specimens.
https://www.pharmgkb.org/labelAnnotation/PA166339442	PA166339442	Annotation of EMA Label for gilteritinib and FLT3	EMA		Testing Required					Cancer Genome		gilteritinib	FLT3			Gilteritinib (Xospata) is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. Before initiating treatment, confirmation of FMS-like tyrosine kinase 3 (FLT3) mutation (internal tandem duplication or tyrosine kinase domain) using a validated test is required.
https://www.pharmgkb.org/labelAnnotation/PA166339443	PA166339443	Annotation of HCSC Label for gilteritinib and FLT3	HCSC		Testing Required					Cancer Genome		gilteritinib	FLT3			Gilteritinib (Xospata) is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation. Before initiating treatment, a validated test is required to confirm the FLT3 mutation status of AML.
https://www.pharmgkb.org/labelAnnotation/PA166339461	PA166339461	Annotation of HCSC Label for larotrectinib and NTRK1, NTRK2, NTRK3	HCSC		Testing Required					Cancer Genome		larotrectinib	NTRK1; NTRK2; NTRK3			The product monograph for larotrectinib (VITRAKVI) states that it is indicated for the treatment of adult and pediatric patients with solid tumors that have a Neurotrophic Receptor Tyrosine Kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatment options. Treatment with VITRAKVI should be initiated following confirmation of an NTRK gene fusion in a tumor specimen using a validated test.
https://www.pharmgkb.org/labelAnnotation/PA166339462	PA166339462	Annotation of EMA Label for larotrectinib and NTRK1, NTRK2, NTRK3	EMA		Testing Required					Cancer Genome		larotrectinib	NTRK1; NTRK2; NTRK3			The EPAR for larotrectinib (VITRAKVI) states that it is indicated as monotherapy for the treatment of adult and pediatric patients with solid tumors that display a Neurotrophic Receptor Tyrosine Kinase (NTRK) gene fusion, who have disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory treatment options. The presence of an NTRK gene fusion in a tumor specimen should be confirmed by a validated test prior to initiation of treatment with larotrectinib.
https://www.pharmgkb.org/labelAnnotation/PA166339481	PA166339481	Annotation of HCSC Label for lorlatinib and ALK	HCSC		Testing Required					Cancer Genome		lorlatinib	ALK			The HCSC product monograph for lorlatinib (LORBRENA) states that it is indicated as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer. Patients treated with lorlatinib must have a documented ALK-positive status based on a validated ALK assay.
https://www.pharmgkb.org/labelAnnotation/PA166337861	PA166337861	Annotation of EMA Label for anakinra and NLRP3	EMA									anakinra	NLRP3			The EMA-approved label for anakinra (Kineret) states that anakinra is indicated for treatment of, among others, Cryopyrin-Associated Periodic Syndromes (CAPS). Spontaneous mutations in the CIAS1/NLRP3 gene have been identified in a majority of patients with CAPS. CIAS1/NLRP3 encodes for cryopyrin, a component of the inflammasome. The activated inflammasome results in proteolytic maturation and secretion of IL-1β, which has a broad range of effects including systemic inflammation.
https://www.pharmgkb.org/labelAnnotation/PA166337961	PA166337961	Annotation of FDA Label for atazanavir and CYP2C19	FDA		Informative PGx							atazanavir	CYP2C19			Atazanavir (REYATAZ) is a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. The FDA-approved drug label for atazanavir contains pharmacogenetic information related to co-treatment with voriconazole and ritonavir. The use of voriconazole in patients with a functional CYP2C19 allele and receiving atazanavir with ritonavir is not recommended unless an assessment of the benefit/risk to the patient justifies the use of voriconazole.
https://www.pharmgkb.org/labelAnnotation/PA166339061	PA166339061	Annotation of HCSC Label for binimetinib and UGT1A1	HCSC		No Clinical PGx							binimetinib	UGT1A1			The binimetinib (MEKTOVI) product monograph states is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by a validated test. It also states that UGT1A1 genotype and smoking does not have a clinically important effect on binimetinib exposure.
https://www.pharmgkb.org/labelAnnotation/PA166284642	PA166284642	Annotation of HCSC Label for pembrolizumab and ALK, CD274, EGFR, ERBB2	HCSC		Testing Required					Cancer Genome		pembrolizumab	ALK; CD274; EGFR; ERBB2		4/21/2024	The HCSC product monograph for pembrolizumab states that it is indicated for the treatment of certain cancers with documented expression of PD-L1 (CD274) and that do not have mutations in ALK, EGFR or ERBB2 (HER-2).
https://www.pharmgkb.org/labelAnnotation/PA166340121	PA166340121	Annotation of EMA Label for amphetamine	EMA									amphetamine				N/A
https://www.pharmgkb.org/labelAnnotation/PA166341882	PA166341882	Annotation of EMA Label for dostarlimab	EMA		Testing Required					Cancer Genome		dostarlimab				The EMA label for dostarlimab (JEMPERLI) states that it is indicated for the treatment of adult patients with mismatch repair deficient/microsatellite instability-high recurrent or advanced endometrial cancer, as determined by a validated test method.
https://www.pharmgkb.org/labelAnnotation/PA166336561	PA166336561	Annotation of EMA Label for teclistamab	EMA									teclistamab				N/A
https://www.pharmgkb.org/labelAnnotation/PA166336562	PA166336562	Annotation of HCSC Label for teclistamab	HCSC									teclistamab				N/A
https://www.pharmgkb.org/labelAnnotation/PA166341881	PA166341881	Annotation of HCSC Label for dostarlimab	HCSC		Testing Required					Cancer Genome		dostarlimab				The HCSC-approved label for dostarlimab (JEMPERLI) states that it is indicated for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer. Patients should be selected for treatment based on MSI-H or dMMR tumor status as determined by an accredited laboratory using validated testing methods.
https://www.pharmgkb.org/labelAnnotation/PA166340141	PA166340141	Annotation of HCSC Label for amphetamine and CYP2D6	HCSC		No Clinical PGx							amphetamine	CYP2D6			The HCSC-approved product monograph for amphetamine (TEVA-AMPHETAMINE XR) contains information about CYP2D6 and metabolism.
https://www.pharmgkb.org/labelAnnotation/PA166340161	PA166340161	Annotation of FDA Label for axitinib and CYP2C19, UGT1A1	FDA		No Clinical PGx							axitinib	CYP2C19; UGT1A1			The FDA-approved drug label for axitinib (INLYTA) states that population pharmacokinetic analyses show no clinically relevant effects of UGT1A1 or CYP2C19 genotype on the clearance of axitinib.
https://www.pharmgkb.org/labelAnnotation/PA166340181	PA166340181	Annotation of HCSC Label for axitinib and CYP2C19, UGT1A1	HCSC		No Clinical PGx							axitinib	CYP2C19; UGT1A1			The HCSC-approved product monograph for axitinib (INLYTA) states that population pharmacokinetic analyses show no clinically relevant effects of UGT1A1 or CYP2C19 genotype.
https://www.pharmgkb.org/labelAnnotation/PA166343901	PA166343901	Annotation of HCSC Label for avatrombopag and CYP2C9, F2, F5, PROC, PROS1, SERPINC1	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	avatrombopag	CYP2C9; F2; F5; PROC; PROS1; SERPINC1	CYP2C9*2; CYP2C9*3; rs1799963; rs6025	7/17/2024	The HCSC-approved product monograph for avatrombopag (DOPTELET) states that avatrombopag exposure may increase in patients with CYP2C9*2 and/or CYP2C9*3 alleles, and that increased exposure may increase the risk of clinically-relevant QTc prolongation. The label also states that potential increased thrombotic risk should be considered in patients with deficiency in Factor V Leiden (F5), prothrombin 20210A (F2), antithrombin (SERPINC1), protein C (PROC), or protein S (PROS1).
https://www.pharmgkb.org/labelAnnotation/PA166344821	PA166344821	Annotation of HCSC Label for dapsone and CYB5R3	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	dapsone	CYB5R3			The product monograph for dapsone gel (ACZONE) states that dapsone should be avoided in patients with congenital methemoglobinemia, which is associated with variants in CYB5R3.
https://www.pharmgkb.org/labelAnnotation/PA166344841	PA166344841	Annotation of HCSC Label for dolutegravir and UGT1A1	HCSC		Informative PGx							dolutegravir	UGT1A1			The product monograph for dolutegravir (TIVICAY) states that subjects with UGT1A1 genotypes that result in poor metabolism of the drug have decreased clearance and increased AUC as compared to those who have UGT1A1 genotypes that result in normal dolutegravir metabolism.
https://www.pharmgkb.org/labelAnnotation/PA166344641	PA166344641	Annotation of HCSC Label for azathioprine and NUDT15	HCSC		Testing Required	Prescribing Info	Dosing Info				Prescribing	azathioprine	NUDT15	rs116855232		The product monograph for azathioprine notes that patients with inherited mutated NUDT15 gene are at increased risk for severe 6-mercaptopurine toxicity and generally require dose reduction. Therefore, genotypic analysis of the NUDT15 genotype should be performed for all patients, including paediatric patients, prior to initiating thiopurine treatment.
https://www.pharmgkb.org/labelAnnotation/PA166278381	PA166278381	Annotation of EMA Label for bupivacaine and CYB5R3, G6PD	EMA		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	bupivacaine	CYB5R3; G6PD		7/18/2024	The EMA-approved drug label for bupivacaine (EXPAREL) states that individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency or congenital methemoglobinemia may be at increased risk for treatment-induced methemoglobinemia and recommends close monitoring for symptoms in these patients.
https://www.pharmgkb.org/labelAnnotation/PA166344721	PA166344721	Annotation of HCSC Label for bupivacaine	HCSC									bupivacaine				N/A
https://www.pharmgkb.org/labelAnnotation/PA166345022	PA166345022	Annotation of FDA Label for flibanserin and CYP2C19	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	flibanserin	CYP2C19			The FDA-approved drug label for flibanserin (ADDYI) states that CYP2C19 poor metabolizers had increased exposure to the drug as compared to extensive metabolizers, which may increase risk of hypotension, syncope, and CNS depression. The label states to increase monitoring for adverse reactions (e.g., hypotension) in patients who are CYP2C19 poor metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166345321	PA166345321	Annotation of HCSC Label for glyburide and CYP2C9	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	glyburide	CYP2C9	CYP2C9*2; CYP2C9*3		The product monograph for glyburide states that genetic polymorphisms of CYP2C9 may be associated with an increased response to glyburide, and that a lower dose regimen in poor metabolizers (CYP2C9*3 variant) should be considered.
https://www.pharmgkb.org/labelAnnotation/PA166345341	PA166345341	Annotation of HCSC Label for glimepiride and CYP2C9	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	glimepiride	CYP2C9	CYP2C9*2; CYP2C9*3		The product monograph for glimepiride states that genetic polymorphisms of CYP2C9 may be associated with an increased response to glimepiride, and that a lower dose regimen in poor metabolizers (CYP2C9*3 variant) should be considered.
https://www.pharmgkb.org/labelAnnotation/PA166122947	PA166122947	Annotation of EMA Label for ranolazine and CYP2D6	EMA		Actionable PGx	Prescribing Info	Dosing Info	Alternate Drug	Other Prescribing Guidance		Prescribing	ranolazine	CYP2D6		7/22/2024	The EMA European Public Assessment Report (EPAR) for ranolazine (Ranexa) states that CYP2D6 poor metabolizers (PMs) had higher AUC as compared to extensive metabolizers (EMs), and that the risk for increased exposure leading to adverse events is higher in PMs than EMs.
https://www.pharmgkb.org/labelAnnotation/PA166345301	PA166345301	Annotation of HCSC Label for rosuvastatin and ABCG2, SLCO1B1	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	rosuvastatin	ABCG2; SLCO1B1	rs2231142; rs4149056		The product monograph for rosuvastatin states that genetic variants in SLCO1B1 (OATP1B1) and ABCG2 (BCRP) have been shown to be associated with an increase in rosuvastatin exposure. For patients known to have the SLCO1B1 c.521CC or ABCG2 c.421AA genotype, a maximum once daily dose of 20 mg of ACH-Rosuvastatin is recommended.
https://www.pharmgkb.org/labelAnnotation/PA166344521	PA166344521	Annotation of HCSC Label for tramadol and CYP2D6	HCSC		Informative PGx							tramadol	CYP2D6			The product monograph for tramadol (Auro-Tramadol) notes that patients who are CYP2D6 ultrarapid metabolizers convert tramadol more rapidly into its more potent opioid metabolite O-desmethyltramadol, which could result in higher than expected opioid-like side effects including life-threatening or fatal respiratory depression or signs of overdose.
https://www.pharmgkb.org/labelAnnotation/PA166344801	PA166344801	Annotation of FDA Label for dapsone and G6PD	FDA	On FDA Biomarker List	No Clinical PGx							dapsone	G6PD		7/19/2024	The FDA-approved label for dapsone gel (ACZONE) states that oral dapsone treatment can result in hemolysis and hemolytic anemia, particularly in patients who are glucose-6-phosphate dehydrogenase (G6PD)-deficient. However, for this topical formulation of the drug, a study showed no clinically relevant cases of hemolysis or anemia in G6PD-deficient individuals.
https://www.pharmgkb.org/labelAnnotation/PA166273581	PA166273581	Annotation of EMA Label for inclisiran and APOB, LDLR, PCSK9	EMA									inclisiran	APOB; LDLR; PCSK9		7/23/2024	Inclisiran is EMA indicated for the treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia). The label does not describe testing for heterozygous familial hypercholesterolaemia but tests could include screening for variants in the LDLR, APOB and PCSK9 genes (see the Genetic Test Registry for more information). Inclisiran is a small interfering RNA directed against PCSK9.
https://www.pharmgkb.org/labelAnnotation/PA166345781	PA166345781	Annotation of HCSC Label for metoclopramide and CYP2D6	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	metoclopramide	CYP2D6			The product monograph for metoclopramide notes that elimination of the drug may be slowed in CYP2D6 poor metabolizers, potentially increasing the risk for adverse reactions, and that these patients should receive a reduced dose of the drug.
https://www.pharmgkb.org/labelAnnotation/PA166345921	PA166345921	Annotation of HCSC Label for primaquine and G6PD	HCSC		Testing Required	Prescribing Info	Dosing Info	Alternate Drug	Other Prescribing Guidance		Prescribing	primaquine	G6PD			The product monograph for primaquine states that due to the risk of hemolytic anemia in glucose-6-phosphate dehydrogenase (G6PD) deficient patients, G6PD testing has to be performed before using primaquine. Primaquine is contraindicated in patients with severe G6PD deficiency; in case of mild to moderate G6PD deficiency, a decision to prescribe primaquine must be based on an assessment of the risks and benefits of using primaquine.
https://www.pharmgkb.org/labelAnnotation/PA166346941	PA166346941	Annotation of HCSC Label for dabrafenib and HRAS, KRAS, NRAS	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	dabrafenib	HRAS; KRAS; NRAS			The product monograph for dabrafenib (TAFINLAR) states that it is indicated, as a single agent or in combination with trametinib, for adult patients with certain types of cancer. The label also notes that the drug may promote growth and development of malignancies with activation of RAS.
https://www.pharmgkb.org/labelAnnotation/PA166346641	PA166346641	Annotation of EMA Label for letrozole	EMA									letrozole				N/A
https://www.pharmgkb.org/labelAnnotation/PA166114482	PA166114482	Annotation of EMA Label for vemurafenib and BRAF	EMA		Testing Required					Cancer Genome		vemurafenib	BRAF		8/4/2024	The EMA European Public Assessment Report (EPAR) for vemurafenib (Zelboraf) requires testing of tumours for the BRAF V600 mutation prior to initiating treatment.
https://www.pharmgkb.org/labelAnnotation/PA166346802	PA166346802	Annotation of HCSC Label for azacitidine	HCSC									azacitidine				N/A
https://www.pharmgkb.org/labelAnnotation/PA166346841	PA166346841	Annotation of HCSC Label for cerliponase alfa and TPP1	HCSC									cerliponase alfa	TPP1			Cerliponase alfa (Brineura) is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.
https://www.pharmgkb.org/labelAnnotation/PA166338381	PA166338381	Annotation of EMA Label for dabrafenib and HRAS, KRAS, NRAS	EMA		Actionable PGx	Prescribing Info			Other Prescribing Guidance	Cancer Genome	Prescribing	dabrafenib	HRAS; KRAS; NRAS			The drug label for dabrafenib (Tafinlar) states that it is indicated, as a single agent or in combination with trametinib, for adult patients with certain types of cancer. The label also notes that the drug may promote growth and development of malignancies with activation of RAS.
https://www.pharmgkb.org/labelAnnotation/PA166346981	PA166346981	Annotation of EMA Label for denileukin diftitox	EMA									denileukin diftitox				N/A
https://www.pharmgkb.org/labelAnnotation/PA166347001	PA166347001	Annotation of HCSC Label for denileukin diftitox	HCSC									denileukin diftitox				N/A
https://www.pharmgkb.org/labelAnnotation/PA166347081	PA166347081	Annotation of HCSC Label for elosulfase alfa and GALNS	HCSC									elosulfase alfa	GALNS			Elosulfase alfa (Vimizim) is a hydrolytic lysosomal glycosaminoglycan-specific enzyme indicated for patients with mucopolysaccharidosis type IVA, also known as Morquio A syndrome. This disease results from deficiency or marked reduction of the N-acetylgalactosamine-6-sulfatase (GALNS) enzyme.
https://www.pharmgkb.org/labelAnnotation/PA166347101	PA166347101	Annotation of EMA Label for eteplirsen	EMA									eteplirsen				N/A
https://www.pharmgkb.org/labelAnnotation/PA166347121	PA166347121	Annotation of HCSC Label for eteplirsen	HCSC									eteplirsen				N/A
https://www.pharmgkb.org/labelAnnotation/PA166347141	PA166347141	Annotation of FDA Label for abemaciclib and MKI67	FDA	On FDA Biomarker List						Cancer Genome		abemaciclib	MKI67			Abemaciclib (VERZENIO) is indicated in combination with other medications or as a monotherapy for the treatment of women with hormone receptor-positive, HER2-negative breast cancer. KI-67 is mentioned in the clinical studies section.
https://www.pharmgkb.org/labelAnnotation/PA166347181	PA166347181	Annotation of FDA Label for tremelimumab and CD274	FDA	On FDA Biomarker List						Cancer Genome		tremelimumab	CD274			N/A
https://www.pharmgkb.org/labelAnnotation/PA166283881	PA166283881	Annotation of HCSC Label for glycerol phenylbutyrate and ARG1, ASL, ASS1, CPS1, OTC	HCSC		Testing Required							glycerol phenylbutyrate	ARG1; ASL; ASS1; CPS1; OTC		8/7/2024	Glycerol phenylbutyrate is indicated for adult and pediatric patients with urea cycle disorders who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. The HCSC label does not lists genes to be tested for urea cycle disorders but in Table 6 gives a list of numbers of subjects with each gene variant in a clinical trial.
https://www.pharmgkb.org/labelAnnotation/PA166272221	PA166272221	Annotation of HCSC Label for tucatinib and ERBB2	HCSC							Cancer Genome		tucatinib	ERBB2		8/16/2024	N/A
https://www.pharmgkb.org/labelAnnotation/PA166272201	PA166272201	Annotation of EMA Label for tucatinib and ERBB2	EMA							Cancer Genome		tucatinib	ERBB2		8/16/2024	Tucatinib is a tyrosine kinase inhibitor indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive (ERBB2) locally advanced or metastatic breast cancer
https://www.pharmgkb.org/labelAnnotation/PA166345821	PA166345821	Annotation of HCSC Label for metoclopramide and CYB5R1, CYB5R2, CYB5R3, CYB5R4, G6PD	HCSC		Informative PGx							metoclopramide	CYB5R1; CYB5R2; CYB5R3; CYB5R4; G6PD			The product monograph for metoclopramide notes that patients with NADH-cytochrome b5 reductase deficiency have an increased risk of developing methemglobinemia and/or sulfhemoglobinemia when treated with metoclopramide. The label also mentions G6PD; patients with G6PD deficiency experiencing metoclopramide-induced methemoglobinemia should not be given methylene blue.
https://www.pharmgkb.org/labelAnnotation/PA166347161	PA166347161	Annotation of FDA Label for anakinra and NLRP3	FDA	On FDA Biomarker List								anakinra	NLRP3		8/26/2024	The FDA-approved label for anakinra (KINERET) states that anakinra is an interleukin-1 receptor antagonist indicated for rheumatoid arthritis, cryopyrin-Associated Periodic Syndromes (CAPS) (treatment of neonatal-onset multisystemic inflammatory disease (NOMID)) and deficiency of the interleukin-1 receptor antagonist (DIRA). Spontaneous mutations in the CIAS1/NLRP3 gene have been identified in a majority of patients with cryopyrin-associated periodic syndromes such as NOMID.
https://www.pharmgkb.org/labelAnnotation/PA166345861	PA166345861	Annotation of HCSC Label for mirabegron and CYP2D6	HCSC		No Clinical PGx							mirabegron	CYP2D6			Mirabegron (MYRBETRIQ) is indicated for the treatment of overactive bladder. The label notes that CYP2D6 poor metabolizers had increased concentrations of the drug as compared to CYP2D6 extensive metabolizers, but that no dose adjustment is needed for mirabegron when administered in patients who are CYP2D6 poor metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166347361	PA166347361	Annotation of HCSC Label for gefitinib and CYP2D6	HCSC		Informative PGx							gefitinib	CYP2D6			The product monograph for gefinitib (IRESSA) states that it is indicated for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer who have activating mutations of the EGFR-TK as assessed by a well-validated test. The label also notes the potential clinical importance of considering CYP2D6 phenotype.
https://www.pharmgkb.org/labelAnnotation/PA166273441	PA166273441	Annotation of EMA Label for lumasiran and AGXT	EMA									lumasiran	AGXT		8/8/2024	Lumasiran is EMA indicated for treatment of primary hyperoxaluria type 1, an inherited disease in which oxalate builds up in the body resulting from AGXT gene mutation.
https://www.pharmgkb.org/labelAnnotation/PA166278481	PA166278481	Annotation of HCSC Label for lutetium (177Lu) oxodotreotide and SSTR1, SSTR2, SSTR3, SSTR4, SSTR5	HCSC		Testing Required					Cancer Genome		lutetium (177Lu) oxodotreotide	SSTR1; SSTR2; SSTR3; SSTR4; SSTR5		8/8/2024	The HCSC label for lutetium (177Lu) oxodotreotide (LUTATHERA)states that it is indicated for the treatment of unresectable or metastatic, well-differentiated, somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults with progressive disease. The presence of somatostatin receptor-positive tumors must be confirmed before initiating treatment.
https://www.pharmgkb.org/labelAnnotation/PA166273381	PA166273381	Annotation of EMA Label for metreleptin and AGPAT2, BSCL2, LEP, LMNB2	EMA		Testing Required							metreleptin	AGPAT2; BSCL2; LEP; LMNB2		8/9/2024	Metreleptin is EMA indicated for adjunct treatment of leptin deficiency and specifies confirmed congenital syndromes that involve the genes AGPAT2, BSCL2 (Berardinelli-Seip syndrome) and LMNB2 (Barraquer-Simons syndrome).
https://www.pharmgkb.org/labelAnnotation/PA166347601	PA166347601	Annotation of HCSC Label for midostaurin and FLT3	HCSC		Testing Required					Cancer Genome		midostaurin	FLT3			The HCSC-approved product monograph for midostaurin (RYDAPT) states that it is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML). A validated test to confirm the FLT3 mutation status is required. In addition to AML, midostaurin is also indicated for treatment of aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, or mast cell leukemia.
https://www.pharmgkb.org/labelAnnotation/PA166347622	PA166347622	Annotation of HCSC Label for migalastat and GLA	HCSC		Testing Required							migalastat	GLA			"The HCSC-approved product monograph for migalastat (GALAFOLD) states that it is indicated for the treatment of adults and adolescents aged 12 years and older with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data. The label contains a list of ""amenable GLA variants"" in Table 5."
https://www.pharmgkb.org/labelAnnotation/PA166347641	PA166347641	Annotation of HCSC Label for neratinib and ERBB2	HCSC		Testing Required					Cancer Genome		neratinib	ERBB2			Neratinib (NERLYNX) is indicated for the treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy or two or more prior anti-HER2-based regimens in the metastatic setting.
https://www.pharmgkb.org/labelAnnotation/PA166347741	PA166347741	Annotation of HCSC Label for osimertinib and EGFR	HCSC		Testing Required					Cancer Genome		osimertinib	EGFR	rs121434568; rs121434569		The product monograph for osimertinib (TAGRISSO) states that it is indicated for the treatment of patients with metastatic non-small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, or those who have EGFR T790M mutations and whose disease has progressed on or after EGFR tyrosine kinase inhibitor therapy. Validated tests to confirm the EGFR mutation-positive status are required prior to treatment.
https://www.pharmgkb.org/labelAnnotation/PA166347901	PA166347901	Annotation of FDA Label for panitumumab and EGFR	FDA	On FDA Biomarker List								panitumumab	EGFR			The FDA-approved drug label for panitumumab (Vectibix) states that it is an EGFR antagonist indicated for the treatment of wild-type RAS (defined as wild-type in both KRAS and NRAS) metastatic colorectal cancer. The absence of a RAS mutation needs to be confirmed prior to initiation of treatment with panitumumab.
https://www.pharmgkb.org/labelAnnotation/PA166273121	PA166273121	Annotation of EMA Label for pralsetinib and RET	EMA		Testing Required					Cancer Genome		pralsetinib	RET		8/13/2024	Pralsetinib is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor. Patient selection for treatment of RET fusion-positive advanced NSCLC should be based on a validated test method.
https://www.pharmgkb.org/labelAnnotation/PA166278701	PA166278701	Annotation of HCSC Label for risdiplam and SMN1, SMN2	HCSC		Testing Required							risdiplam	SMN1; SMN2		8/13/2024	The HCSC product monograph for risdiplam states that it is indicated for the treatment of spinal muscular atrophy in patients 2 months and older.
https://www.pharmgkb.org/labelAnnotation/PA166347941	PA166347941	Annotation of HCSC Label for toremifene	HCSC									toremifene				N/A
https://www.pharmgkb.org/labelAnnotation/PA166273241	PA166273241	Annotation of EMA Label for paliperidone and CYP2D6	EMA		No Clinical PGx							paliperidone	CYP2D6			The EMA product information for paliperidone states there no difference between CYP2D6 extensive metabolisers and poor metabolisers and paliperidone clearance.
https://www.pharmgkb.org/labelAnnotation/PA166122966	PA166122966	Annotation of EMA Label for darifenacin and CYP2D6	EMA		Informative PGx							darifenacin	CYP2D6		8/7/2014	The EMA European Public Assessment Report (EPAR) for darifenacin (Emselex) states that a population pharmacokinetic analysis of Phase III data showed that steady-state exposure was 66% higher in CYP2D6 poor metabolizers as compared to extensive metabolizers.
https://www.pharmgkb.org/labelAnnotation/PA166121326	PA166121326	Annotation of EMA Label for pazopanib and HLA-B	EMA		Informative PGx							pazopanib	HLA-B	HLA-B*57:01	6/5/2014	The EMA European Public Assessment Report (EPAR) for pazopanib (Votrient) states that patients who carry the HLA-B*57:01 allele have an increased risk of pazopanib-associated ALT elevations.
https://www.pharmgkb.org/labelAnnotation/PA166347921	PA166347921	Annotation of HCSC Label for tamoxifen and CYP2D6	HCSC		Informative PGx							tamoxifen	CYP2D6			The product monograph for tamoxifen states that it is indicated for treatment of early breast cancer in women with estrogen receptor positive tumors and the treatment of women with hormone responsive locally advanced / metastatic breast cancer. It also notes that individuals with low CYP2D6 activity (or using CYP2D6 inhibitors) may have reductions in plasma concentrations of the active metabolite of tamoxifen.
https://www.pharmgkb.org/labelAnnotation/PA166347961	PA166347961	Annotation of FDA Label for sulfasalazine and NAT2	FDA	On FDA Biomarker List	Informative PGx							sulfasalazine	NAT2			Sulfasalazine (Azulfidine) is used to treat and prolong remission for ulcerative colitis. The label warns that people with G6PD are susceptible to hemolytic anemia on this drug. The label also notes that acetylator status may affect metabolism of the drug and risk for adverse events; acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene. However, the label never mentions any specific gene with regard to inactivator or acetylator status.
https://www.pharmgkb.org/labelAnnotation/PA166347981	PA166347981	Annotation of HCSC Label for sulfasalazine and NAT2	HCSC		Informative PGx							sulfasalazine	NAT2			The product monograph for sulfasalazine (SALAZOPYRIN) notes that patients with glucose-6-phosphate dehydrogenase deficiency should be closely monitored for signs of hemolytic anemia when receiving the drug. The label also notes that acetylator status may affect metabolism of the drug and risk for adverse events; acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene. However, the label never mentions any specific gene with regard to acetylator status.
